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Abstract 
The herpes simplex virus (HSV) immunomodulatory protein, ICP47, conceals infected 
cells from CD8+ T cells by inhibiting the presentation of peptides on MHC class I (MHC I). 
The mechanism by which ICP47 exerts this function is by binding to the transporter 
associated with antigen processing (TAP) protein, blocking peptide transport and loading 
onto MHC I molecules in the ER. The earliest studies of ICP47 supported by biochemical 
and in vitro observations noted marked species specificity with human but not mouse TAP 
being inhibited by this protein. However, later work demonstrated that ICP47 could 
contribute to HSV-1 neurovirulence in mice. The discordance between biochemical and in 
vivo data leaves our understanding of ICP47 and its role in evading CD8+ T cells 
incomplete. Data from our laboratory suggested that ICP47 is likely to be expressed during 
the establishment and maintenance of HSV-1 latency, however, its exact function during 
these stages of infection is unknown. Therefore, in this study, we sought to re-visit the 
discrepancies discussed above and investigate the role of ICP47 during HSV-1 infection. 
We utilised different strains of HSV and mice, as well as an alternate infection model and 
unique methods to quantify the effect of ICP47 on levels of antigen presentation. 
In our mouse model, where HSV-1 is confined to the peripheral nervous system, deletion 
of ICP47 from HSV-1 KOS did not alter lesion development, virus load, spread or 
reactivation. Likewise, latency was unaffected by ICP47 deficiency as determined using a 
sensitive Cre-marking mouse model. Further observations from the Cre-marking mouse 
model revealed that unlike the ICP47 promoter inserted in an ectopic locus, native 
promoters did not induce additional neuronal marking by Cre beyond lytic infection. We 
evaluated the reasons behind the difference in marking using newly generated recombinant 
viruses. Subsequent flank infection of ROSA26R mice with these viruses showed that the 
local genomic context is also important for regulation of gene expression. 
By contrast to our in vivo pathogenesis data, we were able to show that ICP47 does inhibit 
antigen presentation significantly on HSV-infected mouse cells using in vitro antigen 
presentation assays. However, in mouse cells, antigen presentation was ablated by 44%, 
compared to an 85% reduction in human cells. As CD8+ T cells have been shown to 
recognize very few peptide-MHC I complexes on the surface of target cells, it is important 
to consider the efficiency at which ICP47 inhibits human and mouse TAP. Therefore, we 
used mass spectrometry to identify and quantify MHC I bound peptides derived from 
 viii 
HSV-1 during viral infection. We found that more peptide sequences were presented on 
mouse cells infected with ICP47 null virus compared to those infected with wild-type virus. 
We quantified the presentation of 14 of these peptides and the contribution of ICP47 to 
this process in human and mouse cells. We found that ICP47 almost entirely blocks human 
TAP-mediated peptide presentation, though the degree of inhibition was somewhat 
peptide-specific. Conversely, the effect of ICP47 on mouse TAP was far less profound, 
resulting in only up to five-fold reduction in MHC-peptide abundance. In conclusion, this 
study shows that despite significant inhibition of antigen presentation in mouse cells, 
ICP47 may not be an effective immune modulator in mice and suggests a need for re-
evaluation of suitable mouse models.  
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1 Introduction 
1.1 Herpes simplex virus 
Herpesviruses are abundant ancient viruses that co-existed with their hosts for millions of 
years. Common attributes of these viruses include: a) a large double-stranded DNA 
genome, which comprises terminal and internal reiterated sequences, b) the establishment 
of a long-term relationship with the host via generation of latent reservoirs in specific cell 
types in immunocompetent hosts and c) enveloped virions of 100 to 300 nm in size, which 
consist of an icosahedral nucleocapsid surrounding the core and an unstructured layer of 
tegument proteins beneath the lipid bilayer envelop. The family Herpesviridae comprises 
three subfamilies alphaherpesvirinae, betaherpesvirinae and gammaherpesvirinae. The key 
characteristic of alphaherpesvirinae is that they establish a lifelong latent reservoir in 
primary sensory neurons and its members infect a wide range of hosts, including mammals, 
birds and reptiles (Davison, 2010). The alpha herpesviruses, such as type 1 herpes simplex 
virus (HSV-1), type 2 herpes simplex virus (HSV-2) and varicella zoster virus (VZV) are 
among the most highly successful human pathogens. They occur worldwide and infect a 
majority of the population, across all age brackets. Availability of a protective vaccine 
against VZV along with nationwide childhood vaccination programs have greatly reduced 
the incidence of VZV disease in both developed and developing countries (Seward et al., 
2002; Oxman et al., 2005; Seward and Jumaan, 2007; Sheridan et al., 2017; Fu et al., 2017). 
Furthermore, reactivation of VZV, which typically occurs in older adults and clinically 
manifests as herpes zoster or shingles, can be limited by, Zostavax, a live attenuated herpes 
zoster vaccine. This has been shown to reduce the incidence of shingles from 51.3 % in 
people aged over 60 years (Oxman et al., 2005). However, for HSV-1 and 2 no such 
licensed vaccines are available yet. Globally, 67% of people under the age of 50 are 
estimated to be seropositive for HSV-1 (Looker et al., 2015a) and 11.3% are seropositive 
for HSV-2 (Looker et al., 2015b). Most seropositive individuals experience episodic viral 
shedding, which aids in viral transmission, with a small proportion also showing symptoms 
of recurrent HSV disease (Kaufman et al., 2005; Ramchandani et al., 2016). Lack of a 
preventative or therapeutic vaccine for HSV and high incidence of disease imposes an 
enormous global public health burden. 
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1.2 HSV disease 
HSV-1 and 2 cause a spectrum of clinical disease from mild mucocutaneous lesions, such 
as oral herpes, to severe systemic manifestations like neonatal herpes. The majority of 
initial HSV-1 infections occur during childhood and present as a local ulcerative lesion 
often associated with fever. The oro-mucosal HSV infection allows virions to enter and 
establish latency in neurons of the trigeminal ganglia (TG). HSV-1 reactivation in the 
ophthalmic branch of the TG may lead to herpetic eye diseases, such as herpes epithelial 
keratitis and herpes stromal keratitis (HSK) (Shimeld et al., 1990a, 1990b; Rowe et al., 
2013). With frequent recurrences of HSK, active viral replication together with potent 
immune response in the cornea, may eventually lead to irreversible corneal scarring and 
blindness (Darougar et al., 1985; Babu et al., 1996; Thomas et al., 1997; Gangappa et al., 
1999; Deshpande et al., 2001; Jiang et al., 2015). Globally, 40,000 people are estimated to 
have severe visual impairment or blindness as a result of HSV-1 infection (Farooq and 
Shukla, 2012). Additionally, it costs approximately 17.7 million USD per annum to treat 
HSV related eye diseases in the United States alone (Lairson et al., 2003). It is typically 
thought that Genital herpes is caused by HSV-2 infection in the genital mucosa.  However, 
recent studies demonstrate an increased incidence of genital herpes disease caused by HSV-
1, which may be attributed to an alteration in sexual practices among young adults and a 
reduction in exposure to HSV-1 during early childhood (Looker et al., 2015a, 2017). 
Genital herpes is one of the most common sexually transmittable diseases globally and has 
also been implicated in increases in both the acquisition and sexual transmission of human 
immunodeficiency virus (HIV) (Nahmias et al., 1990; McClelland et al., 2002; Corey et al., 
2004; Looker et al., 2015b). Apart from mucosal infections, HSV-1 is able to mediate 
cutaneous infections in other body parts. For example, eczema herpeticum in individuals 
with atopic dermatitis (Wollenberg et al., 2003) and herpes gladiatorum among young 
athletes involved in contact sports (Selling and Kibrick, 1964; Becker et al., 1988; Anderson, 
2003) are well recognized HSV-1 diseases.  
In rare instances, HSV-1 can lead to more debilitating diseases. When the virus spreads 
trans-synaptically from the peripheral nervous system (PNS) to the central nervous system 
(CNS), it can lead to herpes encephalitis (HE) (Zarafonetis and Smadel, 1944; Esiri, 1982; 
Kramer and Enquist, 2013). HSV is the leading cause of sporadic fatal encephalitis 
especially in western countries (Hjalmarsson et al., 2007; Mailles et al., 2009; Trung et al., 
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2012; Boucher et al., 2017). Despite the frequency of HE is being low (1 case in 1,000,000 
annually), the mortality rate is very high if there is a failure in the administration of antiviral 
drugs. Even with rapid treatment, the long-term outlook after a HE incidence is poor 
(Utley et al., 1997; Whitley, 2006; Jouan et al., 2015). Similar to HE, neonatal herpes is a 
rare but serious incapacitating HSV disease of infants (Kimberlin, 2004). Such infection 
occurs from exposure to HSV-1 or HSV-2 in the genital tract of an infected mother. 
Globally, 10 cases of neonatal infection per 100,000 live births are recorded each year 
(Looker et al., 2017). Although the exact cost involved in the diagnosis, treatment and 
long-term disability care is not known, because a large proportion of the global population 
is harbouring HSV, these diseases are a significant economic burden (Stanberry et al., 2000; 
Fisman et al., 2002). 
1.3 HSV-1 genome  
HSV-1 is a large double-stranded DNA virus. The 152 kbp genome of this virus consists of 
long (UL) and short (US) unique regions, each flanked by inverted repeat regions (Figure 
1.1). In addition, a short repeat region of approximately 400 bp is present at each terminus 
of the genome and exists as an inverted repeat at the junction between long and short 
regions (McGeoch et al., 1985, 1986, 1988; Perry and McGeoch, 1988; Wadsworth et al., 
1975). The genome also accommodates two functional origins of replications with OriL 
located within the UL region and two identical copies of OriS present in short repeat 
regions (Stow, 1982). The HSV-1 genome has 84 single copy open reading frames in total 
and the majority of the protein-coding genes are located in the unique region of the 
genome (Rajcáni et al., 2004). The genes ICP0, ICP34.5 and the latency-associated 
transcripts (LATs) are located in the repeat regions and therefore, maintained as two copies 
within the genome. Several non-coding RNA transcripts are expressed in the HSV-1 
genome both in the unique and the repeat region. The virus expresses 27 mature 
microRNAs of which the majority of them are proximal to or within the LAT locus, 
however, some can be found throughout the genome (Jurak et al., 2010; Piedade and 
Azevedo-Pereira, 2016).  
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Figure 1.1 Schematic representation of the HSV genome. UL denotes unique long 
sequence, US denotes unique short sequence, TRL and IRL are inverted repeat sequences 
flanking UL, TRS and IRS are inverted repeat sequences flanking US and a and a 
represents short inverted repeats. 
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1.4 Experimental mouse models of HSV-1 infection 
Animal species such as mice, rabbits, rats, guinea pigs, cotton rats, owl monkeys and rhesus 
macaques have been utilized in experimental model systems to understand different aspects 
of the human disease (Kollias et al., 2015a). Of these species, mice and rabbits are 
commonly used as models of HSV-1 latency, reactivation and recurrence. Both species 
have specific advantages and disadvantages. Spontaneous reactivation is attainable in 
rabbits infected with specific strains of HSV-1, whereas mouse models do not display 
efficient reactivation (Shimeld et al., 1990b; Hill et al., 2012). Limited availability of inbred 
strains and transgenic animals in addition to the expensive housing make rabbit models a 
less preferred choice. Mouse models are predominantly used in HSV research due to the 
availability of inbred and useful transgenic strains, extensive genetic and immunological 
characterisation and a myriad of useful molecular reagents available for research. HSV-1 
reproducibly establishes latency in mice and reactivation can be induced by various means. 
Nevertheless, the susceptibility outcome of infection in mouse model varies based on the 
virus strain, infection dose, host genetics, the age of the animal and the route of infection. 
Several infection models have been used for HSV-1 infection such as corneal scarification 
(Stulting et al., 1985), footpad inoculation (Cook and Stevens, 1973a), lip infection 
(Kastrukoff et al., 1982), the zosteriform model (Blyth et al., 1984), as well as intranasal 
(Kern et al., 1986), intracerebral, intraperitoneal and intravenous infection (Zawatzky et al., 
1982). Each of these infection models has strengths and limitations, pertaining to the 
experimental system as a whole.  
Although most HSV-1 strains can grow efficiently in cultured cells, as well as peripheral 
infection sites and neural tissues in mice, they exhibit differences in the severity of 
symptoms (Dix et al., 1983). Typically, HSV infection and replication occurs in cells at the 
primary infection site and in primary sensory neurons that innervate the corresponding 
dermatome. The symptoms are generally self-limiting, however, in some cases, depending 
on the virus strain, route of infection and mouse strain, the virus can invade CNS leading 
to debilitating disease. In this thesis, the term “neurovirulence” is referred to the ability of 
the virus to cause neurologic disease due to the invasion of the CNS after a peripheral 
infection. Among widely used laboratory passaged HSV-1 strains, McKrae, SC16 and 17 
syn+ are highly neurovirulent; F and RE are mildly virulent compared to KOS, which is a 
non-neurovirulent strain (Dix et al., 1983; Stevens et al., 1987b; Kollias et al., 2015b). Even 
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two HSV-1 strains from same source individual, KOS63 and KOS79, showed dramatic 
difference in virulence after footpad and intra-cerebral infection of BALB/c mice; KOS79 
is a highly neuroinvasive and neurovirulent strain compared to KOS63 (Dix et al., 1983). A 
recent study has demonstrated that KOS79 and KOS63 are genetically distinct, providing a 
possible explanation for the difference in virulence (Bowen et al., 2016). Viral genes, 
including UL34.5 (Bolovan et al., 1994), thymidine kinase (Gordon et al., 1984), 
ribonuclease reductase (Cameron et al., 1988), US12 (Goldsmith et al., 1998), and US3 
protein kinase (Kurachi et al., 1993) have all been linked to neurovirulence.  
Besides virus strain variability, the host’s genetic background and the infection route also 
influence the virulence. For example, in C57BL/6 mouse, HSV-1 McKrae appears to 
replicate in the brain and brainstem, following a corneal infection, however, such 
neurovirulence does not occur after an intra-vaginal infection. However, infected BALB/b 
mice display enhanced viral replication in the brain after both corneal and intra-vaginal 
infection routes (Wang et al., 2013a). Another study performed by Cavellero and colleagues 
demonstrated that with the same level of inoculum, corneal scarification of BALB/c mice 
with HSV strain SC16 resulted in severe morbidity and mortality compared to lip injection. 
Whilst in the same study, corneal scarification with HSV-1 KOS caused epithelial lesions 
but had no effect on the survival of mice (Cavallero et al., 2014). HSV-1 KOS is generally 
considered non-neurovirulent. However, in BALB/c mice, hind footpad inoculation of 
HSV-1 KOS resulted in paralysis of more than 80% of mice by 14 days after infection (Orr 
et al., 2005). Of the commonly used mouse strains, C57BL/6 mice limits virus spread in 
the periphery, restricts virion entry into the CNS (Metcalf and Michaelis, 1984; Sprecher 
and Becker, 1987; Kastrukoff et al., 2012a) and allows efficient establishment of latency in 
the peripheral sensory neurons (Cavallero et al., 2014; Price and Schmitz, 1978). On the 
other hand, CBA, Swiss-Webster, BALB/c and A/J mice are more susceptible to severe, 
acute infection in peripheral tissues, and can succumb more easily to encephalitis driven by 
virulent HSV-1 strains (Kastrukoff et al., 1982, 2012a; Metcalf and Michaelis, 1984). Host 
immunity, governed by CD8+ T cells, CD4+ T cells and cytotoxic natural killer (NK) cells, 
plays a major role in determining the susceptibility of a mouse to HSV infection (Simmons 
and Tscharke, 1992; Leib et al., 1999; Kastrukoff et al., 2010, 2015; Sheridan et al., 2009).  
Often the selection of a model depends on the question to be addressed by the proposed 
research (reviewed in Simmons et al., 1992). Some infection routes bear little resemblance 
Introduction 
9 
to the human HSV-1 infection, however, they are useful to study specific aspects of HSV-1 
pathogenesis. For example, intracranial infection of mice provides insight into the role of a 
selected viral gene in CNS infection (Dix et al., 1983). However, to study the natural history 
of infection and pathogenesis of HSV-1 disease, it is important to consider whether the 
route of inoculation is natural and faithfully represent human infection.   
1.5 Overview of HSV-1 infection 
HSV-1 infection can be categorised into three distinct stages: primary infection, latency, 
and reactivation (reviewed in Whitley and Roizman, 2001) (Figure 1.2). The primary 
infection occurs when HSV-1 is transmitted from an infected individual to the uninfected 
host by direct exposure of virus to the abraded skin or mucosal surface. A majority of the 
primary infections are sub-clinical and therefore unrecognised (Lafferty et al., 1987; Fillet, 
2002; Brady and Bernstein, 2004). However, in some cases, the infected individual develops 
vesiculo-ulcerative lesions and other clinical symptoms, which typically subside within 10-
14 days (Greenberg, 1996; Whitley et al., 1998; Simmons, 2002; Stoopler et al., 2003). 
Following initial infection, the virus enters sensory nerve endings that innervate the 
infection site and virions are transported to the neuronal nuclei through retrograde axonal 
transport (Goodpasture and Teague, 1923; Goodpasture, 1925; Cook and Stevens, 1973b). 
The progeny virus from the ganglion also undergoes anterograde transportation via the 
axons to the periphery (Walz et al., 1974; Norgren et al., 1992; Penfold et al., 1994). This 
process continues until viral replication is terminated by the cell-mediated immune 
response (Simmons and Tscharke, 1992; Koelle et al., 1994a, 1994b, 1998; Manickan and 
Rouse, 1995). Despite the elimination of replicating virus, the viral genome is sequestered 
in the nucleus of some primary sensory neurons for the life of the host. This non-
replicative state is known as latency. From the quiescent state, HSV-1 reactivates in the 
ganglia periodically. This results in the generation of new infectious virions, which can be 
transported along the axons and released from nerve endings to the skin or mucosa. Viral 
replication at the epidermal cells can then result in discrete shedding episodes, which are 
commonly subclinical but in some cases present as recrudescent disease, characterised by 
visible ulcers and vesicles (Spruance, 1984; Darougar et al., 1985; Kameyama et al., 1988; 
Scott et al., 1997; Rowe et al., 2013; Ramchandani et al., 2016). Asymptomatic shedding is 
thought to be a potential risk for transmission of the virus (Koelle, 2000). Each of the 
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stages of HSV-1 infection, including primary infection, latency and reactivation are 
elaborated at the cellular and molecular level in the following sections. 
1.5.1 Lytic infection in epithelium and neurons  
Initial HSV-1 infection occurs mainly through epithelial cells or mucosal surfaces (Whitley 
and Roizman, 2001). Immediately following infection, HSV DNA attains a circular form in 
the nucleus of the host cell (Strang and Stow, 2005) and becomes associated with histones 
(Kent et al., 2004). It was established in cell culture that HSV follows a temporal cascade of gene 
expression and based on this, HSV genes are chronologically grouped as immediate early (IE), early 
(E) and late (L) genes (Honess and Roizman, 1974, 1975). A general consensus is that the initiation 
of transcription of viral genes requires VP16-inducing complex (VIC) (Post et al., 1981; Campbell 
et al., 1984; Triezenberg et al., 1988; Sadowski et al., 1988). VIC is a multi-protein transactivation 
complex comprising viral tegument protein VP16 and two cellular proteins, including host cell 
factor (HCF) and octamer binding transcription factor (OCT-1) (Wysocka and Herr, 2003). VIC 
binds to VP16-responsive element (TAATGARAT) in the promoter region of IE genes. This 
interaction initiates the viral gene expression cascade by inducing the expression of IE genes 
(O’Hare, 1993). Having noted this main paradigm, models using HSV-1 mutants lacking 
VP16 transcription activation function suggest that VIC-independent gene transcription 
pathways may also exist (Ace et al., 1989; Tal-Singer et al., 1999). 
There are five IE gene products, of which, ICP0, ICP4, ICP22 and ICP27 are involved in 
controlling the initiation of gene expression at the transcriptional or post-transcriptional 
levels (Honess and Roizman, 1974, 1975). The last IE protein, ICP47, has not been shown 
to take part in transcription regulation, but it participates in immune evasion (Honess and 
Roizman, 1974, 1975; York et al., 1994). IE protein synthesis is followed by the expression 
of early genes, which mainly encode enzymes essential for replication of viral DNA, and 
transactivation of late gene expression. While late gene products are largely structural 
proteins of virions, some of them are also involved in virion assembly and egress. Late 
genes are further classified as leaky late and true late genes, where the latter are expressed 
strictly after the viral DNA replication. Collectively, these genes are referred to as “lytic 
genes” since they are expressed abundantly during lytic infection both at the peripheral 
infection site as well as in neurons. 
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Figure 1.2 Overview of HSV-1 infection. Initial HSV-1 infection typically occurs at the 
periphery, where the virus enters via damaged epithelium and starts replicating. Some 
virions enter the nerve endings, innervating the infection site, and travel in a retrograde 
manner to the neuronal cell bodies or soma. The virus replicates in epithelial cells and 
neurons resulting in the production of progeny virus. This phase is known as “lytic 
infection”. Some viruses persist in neuronal nuclei in the form of non-integrating genomes, 
during which infectious virus is absent. This stage is termed “latency”. Latency is disrupted 
sporadically with the production of infectious virus particles in neurons, which travel in an 
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anterograde direction, along the axon to the periphery. This phase is known as 
“reactivation”. 
1.5.2 Establishment and maintenance of latency in sensory neurons 
While in some infected neurons, HSV enters lytic infection, others retain viral genomes as 
circular, non-replicating episomes in the nucleus (Stevens and Cook, 1971a; Cook et al., 
1974; Efstathiou et al., 1986a; Mellerick and Fraser’, 1987; Simmons et al., 1992b). Studies 
by Efstathiou’s group demonstrated that lytic gene expression takes place in a majority of 
neurons prior to the establishment of latency (Proença et al., 2008, 2011, 2016). This 
suggests that the establishment of latency is not compromised by the expression of lytic 
genes. Latency is characterised by the absolute lack of infectious virus, however, viral 
transcripts can be still found at this stage. The most abundant of these transcripts are the 
so called “latency-associated transcripts” (LATs) which are non-coding overlapping 
transcripts of 1.5 and 2.0 Kbp in size (Stevens et al., 1987b; Spivack et al., 1991). Various 
genetic mutants have been generated to understand the role of LATs in the establishment 
and maintenance of latency. Currently all evidence suggest that LATs are not essential for 
the establishment of latency (Javier et al., 1988; Steiner et al., 1989, 1989). However, these 
transcripts were shown to promote and maintain latency presumably by the suppression of 
viral lytic gene expression via post-transcriptional or epigenetic mechanisms (Chen et al., 
1997; Garber et al., 1997; Wang et al., 2005a; Umbach et al., 2008; Cliffe et al., 2009). Other 
functions associated with LAT expression include aiding reactivation (Leib et al., 1989; Hill 
et al., 1990; Perng et al., 1994a; Chen et al., 1997; Watson et al., 2018), protection from 
neuronal cell death (Bloom, 2004) including apoptosis (Perng, 2000; Ahmed et al., 2002; 
Branco and Fraser, 2005) and protection from CD8+ T-cell killing (Chentoufi et al., 2011; 
Jiang et al., 2011). At least six miRNAs transcribed from the LAT locus were also reported 
to be present in significant amounts in the ganglia of latently infected mice (Du et al., 2015; 
Umbach et al., 2008). The exact role of these miRNAs is still being investigated and is 
suspected to interfere with lytic gene expression (Umbach et al., 2008; Tang et al., 2008, 
2009).  
The lytic transcripts are found at relatively low levels during latency and can only be 
detected using highly sensitive techniques. Whilst earlier studies reported on the expression 
of a few specific lytic transcripts in latently infected ganglia (Deatly et al., 1987; Gordon et 
al., 1988; Feldman et al., 2002a; Maillet et al., 2006; Kramer and Coen, 1995), contemporary 
studies at the single neuron level have further illuminated the dynamics of gene expression 
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during latency. The single-cell transcriptome analysis by Ma and colleagues showed that at a 
given time, genes from at-least one kinetic class were expressed in two-thirds of neurons 
while a third remained transcriptionally silent (Ma et al., 2014). Later, an investigation by 
Russell and Tscharke showed that representative HSV-1 promoters of each kinetic class of 
the temporal cascade can be expressed prior to, during and after the establishment of 
latency (Russell and Tscharke, 2016). However, whether the expression of lytic genes 
during latency is a result of abortive replication or residual gene expression is not yet clear, 
nor is the significance of such gene expression.  Moreover, factors that trigger HSV-1 to 
enter the latent state are yet to be fully defined. It appears that a complex interplay of viral 
and cellular factors determines the switch between productive and latent infection. Four 
important pathways that may lead to the establishment of latency are discussed below:  
a) Failure to initiate productive infection due to lack of formation of the VIC in neurons 
has been proposed as an underlying mechanism behind the establishment of latency. In 
neurons the formation of this complex may be hindered due to insufficient transport of 
VP16 from axonal terminus to neuronal nucleus (Hafezi et al., 2012), sequestration of 
HCF in cytoplasm (Kristie et al., 1999) or the inhibition of OCT-1 from binding to IE 
promoters by other cellular proteins (Latchman, 1999). It was suggested that such 
failure to form VP16 induced complex could restrict the activation of IE gene 
expression (Efstathiou and Preston, 2005; Thompson et al., 2009). The evidence that 
VP16 is dispensable for latency establishment also supports this hypothesis (Steiner et 
al., 1990).  
b) Epigenetic regulation of viral gene expression is a key characteristic of HSV latency. 
The naked viral DNA associates with histones immediately after being released from 
virion capsid into the nucleus (Cereghini and Yaniv, 1984). Histones associate with the 
HSV genome at the lytic stage and in latency. However, during productive infection, 
the lytic gene promoters are sparsely associated with histones and are enriched with 
active euchromatin markers, such as activating tri-methylation of lysine 4 of H3 
(H3K4me3) and acetylation of lysines 9 and 14 of H3 (H3K9ac and H3K14ac, 
respectively) (Herrera and Triezenberg, 2004; Kent et al., 2004). Conversely, the latent 
genome is characterised by ordered nucleosomes (Deshmane and Fraser, 1989). During 
latency, lytic gene promoters are associated with histones containing silencing 
heterochromatin markers such as H3K9me2, whereas, at LAT promoter, histones 
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mainly accumulate euchromatin markers (Kubat et al., 2004; Wang et al., 2005b). This 
is consistent with the accumulation of LAT mRNA during latency and its ability to 
promote repressing heterochromatin markers on the HSV genome (Cliffe et al., 2009). 
Furthermore, emerging evidence suggests that the HSV genome is separated into 
transcriptionally active and repressed domains. For example, CCCTC and CTCCC 
motifs that bind CTCF (CCCTC binding factor) proteins are clustered throughout the 
HSV-1 genome (Amelio et al., 2006). In the dorsal root ganglia (DRG) and TG of mice, 
CTCF proteins were found to be enriched on CTCF clusters during latency (Amelio et 
al., 2006; Ertel et al., 2012) and application of reactivation stimuli significantly 
diminished CTCF proteins from those clusters (Ertel et al., 2012). In addition, CTCF 
motifs clustered around the LAT promoter/enhancer region block the extension of 
enhancer activity to ICP0 expression, thus functioning like an insulator (Amelio et al., 
2006; Chen et al., 2007). Such partitioning of the genome into active and repressed 
regions emphasises the role of epigenetic regulation in the switch between lytic and 
latent infection. Chromatin repressor complexes such as 
REST/CoREST/LSD1/HDAC complex (Roizman, 2011) and polycomb repressor 
complexes were also suggested to be involved in the control of latency (Kwiatkowski et 
al., 2009; Cliffe et al., 2013a). 
c) Neuronal intrinsic factors such as neuronal subtypes, growth factors and neuron-
specific signalling pathways also influence the establishment of latency. In mice, HSV-1 
specifically establishes latency in A5+ neurons, which are the nociceptive neurons that 
express a marker identified by the A5 monoclonal antibody (Margolis et al., 2007; Yang 
et al., 2000). A5+ neurons constitute only 11% of the neurons in the TG. In vitro, A5+ 
neurons are non-permissive for productive replication whereas KH10+ neurons, 
another subtype that express KH10 marker, readily allowed HSV-1 lytic infection 
(Bertke et al., 2011). A5+ neurons respond to nerve growth factor (NGF) and express 
the NGF receptor called tropomysin kinase receptor (TrkA), whereas, KH10+ neurons 
respond to a glial cell-derived neurotrophic factor (GNDF) (Bennett et al., 1998). 
Furthermore, TrkA receptor blockade allowed rapid reactivation of the virus 
(Camarena et al., 2010). Similarly, suppression of mammalian target of rapamycin 
complex 1 (mTORC1) kinase, which acts downstream of NGF-TrkA-mediated 
phosphatidylinositol 3-kinase (PI3-K)/Akt signalling pathway also leads to the 
reactivation of the virus (Kobayashi et al., 2012). Although these data suggest that the 
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NGF signalling pathways contribute to the establishment of latency, the exact 
mechanisms remain to be explored. Neuron-specific microRNA, miR138, targets ICP0 
directly downregulating its expression and consequently the expression of other lytic 
genes. An HSV-1 lacking the miR138 target site showed enhanced virulence in mice 
and the TG of these mice showed increased lytic gene expression both during and after 
the establishment of latency (Pan et al., 2014). Together, these studies indicate the 
importance of neuronal factors in the control of latency. 
d) Latency can be established efficiently in immunodeficient mice lacking T and B 
lymphocytes, gamma interferon (IFNγ) or NK cells as in immunocompetent mice 
(Ellison et al., 2000). Thus, host immunity is not required for establishment of HSV 
latency. However, components of both innate (Kodukula et al., 1999; Liu et al., 2001; 
Nandakumar et al., 2008) and adaptive immune system (Ghiasi et al., 2000; Manickan 
and Rouse, 1995; Simmons et al., 1992a) are vital for limiting productive infection and 
may help to maintain the virus in the latent state. The role of the host immune system 
during different stages of HSV infection will be discussed in detail in the later sections. 
1.5.3 Reactivation and productive infection 
From latency, HSV periodically re-enters the lytic phase of infection to form the infectious 
virus. This process is known as reactivation. Many physiological stress factors can trigger 
reactivation (Margolis et al., 1992; Cunningham et al., 2006; Wilson and Mohr, 2012a). In 
humans, reactivation may lead to painful recrudescent lesions or can result in asymptomatic 
recurrent shedding, leading to transmission of the virus (Scott et al., 1997; Wagner and 
Bloom, 1997). The molecular mechanisms behind latency and reactivation have been 
studied using animal models (mouse, rat, guinea pigs and rabbit) and in vitro cultured 
neurons (Wagner and Bloom, 1997). In mice, reactivation is most commonly studied using 
explanted ganglia (Sawtell and Thompson, 2004; Stevens and Cook, 1971b). Other 
methods used to induce reactivation in mice include depletion of NGF, axotomy, heat 
shock, UV irradiation and application of systemic stimuli using pharmacological agents 
(Blyth et al., 1976; Halford et al., 1996; Hill et al., 1978; Sawtell and Thompson, 1992; 
Wilcox and Johnson, 1987) Such stress stimuli can activate the c-Jun N-terminal kinase 
(JNK) signalling pathway, which then mediates the phosphorylation of histone 3 on lytic 
promoters, allowing the expression of previously repressed lytic genes (Cliffe et al., 2015). 
The initial phase of reactivation involving transcription and translation of viral genes has 
Chapter 1 
16 
been termed animation (Kim et al., 2012a). It has been suggested that at the early phase of 
animation, transcription of lytic genes from the repressed state depends neither on VP16 
nor on a temporal gene expression cascade. In this case, genes from all kinetic classes are 
expressed independently of protein synthesis (Tal-Singer et al., 1997; Thompson and 
Sawtell, 2006; Du et al., 2011; Kim et al., 2012a). At the later stage of animation, gene 
expression resembles the orderly cascade that occurs during acute infection of cultured 
cells (Kim et al., 2012a). This is followed by DNA replication, packaging of virions and 
anterograde transport of virion components via axons to the peripheral tissues resulting in 
productive infection (Wilson and Mohr, 2012b). Although not required for animation, lack 
of viral genes such as VP16 or ICP0 can result in inefficient reactivation, where the 
provision of either of these in trans can trigger successful reactivation (Halford and Schaffer, 
2001; Thompson et al., 2009). In the rabbit ocular infection model, spontaneous shedding 
of the virus was reduced in a LAT mutant-infected sample compared to wild-type virus, 
suggesting a role for LAT in reactivation (Perng et al., 1994b). In addition to viral gene 
products, the host immune system can also influence reactivation. Stress stimuli induce 
glucocorticoid and interleukin (IL)-6 levels and greatly reduces the number of IFN 
producing immune cells, including macrophages, NK cells and CD8+
 
T cells in latently 
infected ganglia (Noisakran et al., 1998; Cantin et al., 1999; Freeman et al., 2007a; Huang et 
al., 2011). Such compromise in immune functions might ultimately lead to the complete 
reactivation of the virus.  
Studies have shown that only a subset of neurons undergo productive reactivation in a 
latently infected ganglion. Bertke et al. using dissociated adult mouse TG neurons 
demonstrated that certain neuronal subtypes are non-permissive for productive infection. 
For instance, HSV-1 preferentially establishes latency in A5+ neurons due to their inability 
to support viral gene expression and productive infection (Bertke et al., 2011).  Besides 
neuronal heterogeneity, other factors such as the amount of viral genomes in a latently 
infected neuron also determines the efficiency of reactivation. Using in vivo hyperthermia 
induced reactivation model, Sawtell and Thompson showed that on average, only 1–3 
neurons per TG reactivate (Sawtell and Thompson, 1992) and that the probability of 
reactivation is correlated to the number of neurons containing the latent genome as well as 
the number of copies of viral DNA present in those neurons (Sawtell, 1997; Proença et al., 
2016). Even though multiple copies of viral genome can enter a single neuronal cell, all are 
not equally capable of entering into productive infection (Kobiler et al., 2010). The main 
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take home from these studies is that the virus and its host neuron together can impose a 
significant degree of control over HSV-1 lifecycle.  
1.6 An overview of the immune system  
The immune system enables the host to recognise and effectively eliminate invading 
pathogens, minimise damage to self and establish an immunological memory to protect 
from re-infection. The mammalian immune system has a variety of mechanisms to defend 
against invading pathogens. Broadly, the host immune response is composed of two arms: 
the innate and the adaptive. However, in practice, the two components are integrated, with 
both contributing to shaping the immune response to infection. Here, I provide a general 
overview of the immune system to help understand the specifics of an immune response to 
HSV-1 infection outlined in section 1.7.  
1.6.1 Innate immunity 
The innate immune system is important for rapidly detecting incoming pathogens and is 
essential for activating adaptive immune cells. Host cells at the infection site, both immune 
and non-immune, are equipped with pattern recognition receptors (PRRs) that recognise 
pathogen-associated molecular patterns (PAMPs), which are conserved motifs derived 
from pathogens (reviewed by Kawai and Akira, 2009). PRRs such as Toll-like receptors 
(TLRs) and C-type lectin receptors (CLRs) are located in the cell membrane or membranes 
of the endosomes and lysosomes. Other PRRs, including NOD-like receptors (NLRs), 
retinoic acid-inducible gene- (RIG-) I-like receptors (RLRs) and AIM2-like receptor (ALR) 
reside in intracellular compartments (Ting et al., 2008; Yoneyama and Fujita, 2008; Gray et 
al., 2016). Examples of PAMPs include bacterial lipopolysaccharides, peptidoglycans, 
mannose-rich oligosaccharides, flagellin and pathogen-derived nucleic acid components, 
such as DNA and single or double-stranded RNA (Janeway, 1989). The stimulation of 
PRRs by appropriate PAMPs results in signal transduction leading to the synthesis and 
secretion of type I interferon (IFN), pro-inflammatory cytokines and chemokines. The type 
I IFNs act in a cell-intrinsic way, inducing expression of hundreds of genes that together 
interfere with every stage of viral replication cycle and sensitises cells for apoptosis 
(reviewed by Stetson and Medzhitov, 2006). The cytokines and chemokines further recruit 
and activate innate immune cells, such as macrophages, neutrophils, dendritic cells (DCs), 
mast cells, basophils, eosinophils and NK cells. Together, the innate immune cells perform 
two main functions. One is to directly eliminate invading pathogens by phagocytosis, 
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production of type II interferon, secretion of anti-microbial components and induction of 
apoptosis (reviewed by Medzhitov, 2007). The other function is to promote antigen-
specific adaptive immunity by presenting processed antigens derived from pathogens to T 
and B cells, whilst concurrently providing necessary signals for their activation.  
1.6.2 Adaptive immunity 
The adaptive immune system is equipped with two arms: humoral immunity and cell 
mediated immunity. The humoral immunity is responsible for the production of antibodies 
by B cells (Mitchell and Miller, 1968; Nossal et al., 1968; Roitt et al., 1969; Ryser and 
Vassalli, 1974) and the cell-mediated immunity, in which T cells, specifically CD4+ and 
CD8+ subsets (Roitt et al., 1969; Bevan, 1977; Zinkernagel, 1982), play a central role. 
Although temporally delayed, the adaptive immune system protects the host from 
pathogens through more specific responses than innate immunity. This is facilitated by the 
presence of unique receptors on the surface of adaptive immune cells. The specific 
recognition of foreign antigens by B cells and T cells is mediated by the B cell receptors 
(BCRs) and T cell receptors (TCRs), respectively. The diverse repertoire of receptors is 
generated in each individual through genetic recombination and other additional 
mechanisms (Petrie, 1995). This allows adaptive immune cells to recognise almost any 
pathogenic invasion in a specific manner.  
Mature, naïve B and T cells circulate through peripheral lymphoid organs, such as lymph 
nodes and spleen, where an adaptive immune response is elicited if these cells meet their 
corresponding antigens. The B cell receptors can directly recognise free antigens, which can 
be derived from proteins or carbohydrates. B cells also recognise antigens presented by 
professional antigen presenting cells (APCs) with the help of CD4+ T cells (Tony and 
Parker, 1985). Following antigen engagement and activation, B cells expand and 
differentiate to plasma cells that synthesise antibodies, and long-term memory B cells. By 
binding to specific epitopes, antibodies can confer viral immunity in four ways: bind to and 
neutralise pathogens, opsonise pathogens leading to their elimination, activation of the 
complement system and mediation of antibody-dependent cell-mediated cytotoxicity 
(reviewed by LeBien and Tedder, 2008).  
Unlike with B cells, TCRs recognise peptides derived from foreign antigens only when they 
are presented on the surface of cells by special host glycoproteins called major 
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histocompatibility complex (MHC) molecules. CD8+ T cells recognise peptides presented 
in the context of MHC I whilst CD4+ T cells recognise peptides presented by MHC II 
(Reinherz et al., 1999; Babbitt et al., 2005; Wucherpfennig, 2010). APCs such as DCs and 
macrophages that take up the antigen from peripheral tissues reach the lymph node or 
spleen via the lymph or blood, respectively. In these lymphoid organs, APCs present 
antigen to the naïve T cells. This process is initiated by the binding of a cell adhesion 
molecule called CD2 expressed on APCs, to an integrin protein called lymphocyte function 
associated antigen-3 (LFA-3) expressed on T cells. Another T cell integrin, namely LFA-1, 
synergistically binds to the intercellular adhesion molecules ICAM-1 and ICAM-2 on APCs. 
These transient interactions provide an opportunity for the TCR to sample peptide-MHC 
(pMHC) molecules on APCs. Recognition of a specific pMHC complex by the TCR 
stabilises the association between the T cell and the APC and provides the primary signal 
for T cell activation (Dustin, 1987; Staunton et al., 1989; Simmons, 1995; Dustin et al., 
1997). The second signal for activation is provided by ligation of the co-stimulatory 
molecule, CD28, on T cells to CD80/CD86 on APCs. The third signal is driven by the 
cytokine IL-2, produced by T cells as a result of the pMHC-TCR interaction. After these 
early activation events, several subsequent co-stimulatory signals complete the activation 
process and aid in the survival, proliferation and differentiation of T cells. The activation of 
naïve T cells by APCs is also known as “priming” (reviewed by Smith-Garvin et al., 2009).  
Depending on the cytokine environment, naïve CD4+ T cells can differentiate into 
different subsets, including CD4+ T helper (Th1 or Th2) cells, Th17 cells, regulatory T cells 
(Tregs) and follicular T cells (Tfh) (reviewed in O’Garra, 1998; Zhu and Paul, 2008). The 
differentiated T cell subsets, in turn, secrete different cytokines and chemokines that 
determine their immune response. CD4+ T cells are important for coordinating immune 
responses against a variety of pathogens, boosting antibody production, enhancing and 
maintaining responses of CD8+ T cells, regulating macrophage function, and manipulating 
general immune responses (Sakaguchi et al., 1995; Abbas et al., 1996; Asano et al., 1996; 
Breitfeld et al., 2000; Schaerli et al., 2000). After activation, naïve CD8+ T cells function as 
effector cells that are capable of recognising and killing the infected cells by secretion of 
cytolytic granules and cytokines (Lowin et al., 1994; Guidotti et al., 1996; Slifka et al., 1999; 
Harty et al., 2000; Trapani and Smyth, 2002). The primed CD8+ T cells travel from the 
lymphoid tissues to the infection sites with the help of infection-associated cell adhesion 
molecules (ICAMs) expressed on the blood vessels and several other chemotactic factors 
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(reviewed by von Andrian and Mackay, 2000). At the infection site, the activated CD8+ T 
cells bind transiently via cell adhesion receptors such as LFA-1 to their respective ligands 
(ICAMs) on the infected target cell (Anikeeva et al., 2005). This interaction facilitates the 
recognition of the specific pMHC by the TCR and subsequent release of effector molecules. 
Activation and effector function of CD8+ T cells is depicted in Figure 1.3 and Figure 1.4. 
A key feature of the adaptive immune system is the development of memory B and T cells. 
Memory B cells are derived from naïve B cells that have undergone CD4+ T cell-dependent 
antigen stimulation (Jacob et al., 1991). After re-exposure to even low dose antigens, 
memory B cells proliferate and differentiate to plasma cells, which produce large quantities 
of high-affinity antibody (reviewed by McHeyzer-Williams and McHeyzer-Williams, 2005). 
Unlike B cells, in the case of CD4+ and CD8+ T cells, memory cells are derived from 
effector T cells. After pathogen elimination during primary infection, most effector T cells 
die, however, a small number of cells survive to become long-lived memory T cells. The 
memory T cell class comprises different sub-populations. This includes circulating memory 
T cells, which enter the lymph node and recirculate into the blood, and the tissue-resident 
memory T (TRM) cells, which are locally confined at the site of previous pathogen 
encounter (Sallusto et al., 1999; Masopust, 2001; Reinhardt et al., 2001; Mueller and Mackay, 
2016). Owing to clonal expansion during primary infection, relatively large numbers of 
antigen-specific memory T cells persist in immune individuals (reviewed by Ahmed and 
Gray, 1996). Furthermore, these memory cells can undergo rapid expansion and exhibit 
accelerated effector functions. Thus, once immunological memory has been created in an 
individual, either because of primary pathogen encounter or by immunisation, adaptive 
immunity ensures that the individual is protected against future challenges with the same 
pathogen. Whilst in normal settings, memory CD8+ T cells become quiescent without 
losing the effector capacity, during chronic viral infections and cancer, long-term antigenic 
stimulation can result in functional exhaustion of CD8+ T cell function (Hashimoto et al., 
2018). CD8+ T cell exhaustion is typically characterized by gradual loss of IL-2, IFN, 
TNF and granzyme expression, acquisition of inhibitory receptors such as programmed 
cell death protein 1 (PD-1), and production of immunosuppressive cytokines such as IL10 
(Wherry, 2011). Ultimately, this can result in CD8+ T cell control of infections and cancer. 
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Figure 1.3 CD8+ T cell priming. For activation, it is important that the pMHC-I 
complexes on APCs are recognised by the cognate TCR on the naïve CD8+ T cells. To 
become fully activated, additional, antigen-independent stimulation by APCs is essential. 
This stimulation occurs as a result of binding of co-stimulatory molecules such as CD80 or 
CD86 on APCs to the receptor, CD28, on CD8+ T cells. Further, the initial TCR – pMHC-
I interaction stimulates APCs to secrete cytokines such as IL-2 and type I IFNs that drive 
robust CD8+ T cell activation, proliferation and functioning. Adapted from Thaiss et al., 
2011. 
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Figure 1.4 Functioning of activated CD8+ T cells. After recognising pMHC-I on target 
cells, CD8+ T cells use various mechanisms to deliver effector molecules. First, CD8+ T 
cells secrete cytokines such as IFN and tumour necrosis factor  (TNF), which have 
anti-viral and anti-microbial properties. Second, CD8+ T cells produce and secrete cytolytic 
granules that contain perforin and granzymes. Whilst perforins form pores on the target 
cell membrane, granzymes use these pores to enter the target cells. Granzymes are serine 
proteases that cleave cytoplasmic proteins and ultimately trigger the apoptotic pathway. 
Finally, CD8+ T cells express FasL, the ligands that bind to Fas receptors expressed on the 
surface of target cells. The Fas-FasL interaction leads to downstream signalling that 
activates caspase-mediated apoptotic cell death pathway. Adapted from Barry and Bleackley, 
2002. 
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1.6.3 Antigen presentation to CD8+ T cells 
1.6.3.1 MHC I  
The major function of MHC I molecules is to display a large number of antigenic peptides 
on the cell surface. Any given TCR specifically recognises a unique combination of a 
peptide and the surrounding  chain residues of MHC I (Garboczi et al., 2010; Rudolph et 
al., 2006). The canonical MHC I molecules are heterodimeric glycoproteins composed of a 
heavy  chain and a light  chain (Madden, 1995) (Figure 1.5). The extracellular portion of 
the heavy chain is folded into three-immunoglobulin domains, termed 1-3. The 
interface between the 1 and 2 forms a shallow peptide-binding groove (Figure 1.5) 
(Garrett et al., 1989; Matsumura et al., 1992; Madden, 1995). At both ends of the groove 
are clusters of conserved amino acid residues, which form hydrogen bonds with the 
residues at the amino (N) and carboxy (C) termini of peptides. The peptides are anchored 
to so-called peptide binding pockets interspaced along the groove. Complementary binding 
occurs between the side chains of amino acids at a particular position in a peptide, known 
as anchor residues, and the specialised pockets of MHC I. The main anchor residues are 
often placed in the second and the last position from the N-terminus of the peptide 
(Fremont et al., 1992; Madden, 1995). This interaction restricts the length of the peptides 
that bind MHC I to 8-10 residues. However, peptides longer than 10 amino acids are 
sometimes accommodated in this region. In this case, the peptides bulge out of the groove 
due to kinks in the middle section of the peptide backbone (Guo et al., 1992; Chen et al., 
1994; Urban et al., 1994; Tynan et al., 2005). The amino acid residues that line the peptide-
binding groove of MHC I in the 1 and 2 domains are highly variable (Madden, 1995). 
The 3 domain of heavy chain, as well as the  chain of MHC I, also known as -2 
microglobulin, are relatively conserved. These domains provide support and stability to the 
MHC I molecule. Furthermore, trans-membrane helices of the heavy chain anchor the 
MHC I molecule in the membrane (Figure 1.5).  
MHC I is polygenic. In humans, the genes that encode the classical MHC I are called 
human leukocyte antigen (HLA) genes. There are three MHC I  chain genes in humans, 
which encode the HLA-A, -B and -C molecules, respectively (Degli-Esposti et al., 1992; 
Horton et al., 2008). In mice, these genes are known as H-2 -K, -D and -L (Ozato et al., 
1980). Each MHC I allele is polymorphic, and the anchor residues are different for every  
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Figure 1.5 Diagrammatic representation of MHC I. MHC I is comprised of a heavy α 
chain and a light non-covalently bound β-2 microglobulin. The heavy chain forms three 
immunoglobulin domains α1, α2 and α3. The α1 and α2 domains interact with peptide via 
the peptide-binding groove. The α3 contains the transmembrane region that binds the 
whole MHC I to the membrane. Adapted from Mak and Jett, 2014. 
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allele. The polygenic and polymorphic nature of this system contributes to the high 
variability of peptides presented by MHC I (Lawlor et al., 1990).  
1.6.3.2 Antigen processing and generation of peptides  
The majority of the peptides that bind MHC I are generated due to proteolytic degradation 
of proteins or polypeptides, which occurs as a part of the cellular protein turnover 
machinery. Unwanted proteins, such as misfolded or damaged proteins and defective 
ribosomal products (DRiPs), form the major source of the peptides (Watts, 1997; Yewdell, 
2007; Apcher et al., 2011; Bassani-Sternberg et al., 2015). DRiPs are thought to be 
generated as a result of a) pre-mature termination of transcription or translation, b) use of 
an alternate reading frame, c) delay or failure in the assembly of polypeptides into a protein 
complex or d) alterations in ubiquitin modification (reviewed by Yewdell, 2011). The source 
proteins of antigenic peptides may be self-proteins expressed at abnormal levels in cancer 
cells or foreign peptides derived from intracellular pathogens following infection. Recently, 
interest has been drawn to spliced peptides, where two peptide fragments generated by 
proteolytic degradation are re-ligated to form a new peptide sequence suitable for 
presentation by MHC I (Spivack et al., 1991; Vigneron et al., 2004; Liepe et al., 2016).  
A bulk of these peptide precursors are then degraded by cellular proteasomes (reviewed in 
Goldberg and Rock, 1992; Pamer and Cresswell, 1998; Rock and Goldberg, 1999) (Figure 
1.6). The 26S proteasome is a highly sophisticated, multi-catalytic protease composed of a 
20S catalytic core that is capped at each end by the 19S regulatory complex (Walz et al., 
1998). The 20S catalytic core is comprised of four symmetrical hetero-heptameric rings. 
The two outer rings are composed of -subunits whilst the inner rings are composed of -
subunits, each containing seven similar subunits. The -subunits act as a proteolytic 
chamber in which the catalytic activity is restricted to the inside of the core. Although 
proteasomes can sometimes act on substrates in a ubiquitin-independent manner (Grune et 
al., 2003), peptide precursors tagged with a poly-ubiquitin chain serve as the principal 
substrate (Ciechanover, 1998). It is the 19S complex that recognises the ubiquitin-tagged 
protein substrates and unfolds them for entry into the core catalytic chamber. Here, the -
subunits mediate proteolytic cleavage at specific sites, which results in a heterogeneous 
population of peptides ranging from 4-30 amino acids. Isoforms of the proteasome, called 
immunoproteasomes, are generated when cells are exposed to immunomodulatory 
cytokines, particularly IFN (Cerundolo et al., 1995). These immunoproteasomes have 
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specialised catalytic subunits with altered cleavage properties for efficient antigen 
processing and generation of diverse peptide repertoires for MHC I presentation (reviewed 
by McCarthy and Weinberg, 2015). Some proteasome cleaved products can be transported 
directly into the endoplasmic reticulum (ER) without further processing. Whereas, longer 
peptides are further trimmed by other peptidases such as cytosolic aminopeptidase, thimet 
oligopeptidase (TOP) and leucine aminopeptidase in the cytoplasm before entering into ER 
(Beninga et al., 1998; Mo et al., 1999; Portaro et al., 1999). The N-terminally extended 
peptide intermediates that enter ER are processed by the ER amino-peptidases, ERAP-1 
and ERAP-2, to yield the final peptides for MHC I presentation (Serwold et al., 2002).   
1.6.3.3 MHC I-mediated antigen presentation  
The pathway that involves the processing and presentation of endogenous antigen is called 
the classical or direct MHC I presentation pathway (Figure 1.6) and it takes place in all 
nucleated cells. In this pathway, the peptides generated in the cytosol are transported into 
the lumen of the ER in order for antigen presentation to continue. This process is 
facilitated by the transporter associated with antigen processing (TAP), a member of the 
ATP binding cassette family of transporters (reviewed by Townsend and Trowsdale, 1993) 
(Figure 1.6). The TAP complex is a heterodimeric complex consisting of TAP1 and TAP2 
(Figure 1.7). Each of these subunits contains a cytosolic nuclear binding domain (NBD), a 
transmembrane domain (TMD) and an N-terminal transmembrane domain (TMD0) 
(Schmitt and Tampé, 2002). The binding of peptide and ATP to the NBD at the cytosolic 
interface induces dimerization of NBDs. This is followed by a conformational switch of 
TMDs that enables movement of peptides from the cytoplasm into the ER (Oldham et al., 
2016a). The influx of peptide into the ER results in ATP hydrolysis, which resets the TAP 
complex back to the pre-translocation state.  
MHC I proteins are synthesised on membrane-bound ribosomes and delivered into the ER, 
where their assembly and folding is aided by the peptide loading complex (PLC) (Figure 
1.6). The PLC is a macromolecular assemblage of different protein subunits comprising 
TAP, the MHC I heterodimer, the oxidoreductase ERp57, and ER-resident chaperones, 
such as tapasin and calreticulin, that co-ordinate loading of peptides onto the peptide 
receptive MHC I (Cresswell et al., 1999; Ortmann et al., 1997; Sadasivan et al., 1996; Blees 
et al., 2017) (Figure 1.6). The peptide loaded MHC I molecules dissociate from the PLC 
followed by exit from ER perhaps with the help of transport receptors (Spiliotis et al., 
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2000). Subsequently, the stable pMHC-I complexes are translocated to the cell surface via 
the Golgi apparatus. MHC I molecules devoid of peptides or that bind low-affinity 
peptides often fail to reach the cell surface (Ljunggren et al., 1990). Thus, only peptides of 
reasonable affinity for MHC I get displayed for presentation. The ER is also the site of 
initiation of post-translational glycosylation of MHC I. The most prominent glycans on 
MHC I are N-linked. N-glycosylations play a role in proper folding and trafficking of these 
proteins to cell surface in addition to the assembly of peptide-MHC I complex (Barbosa et 
al., 1987; Ryan and Cobb, 2012). Initially, the N-glycans on MHC I are susceptible to 
release by endoglycosidase H (endo H) digestion. However, as the pMHC-I moves through 
the Golgi, the glycoproteins undergo extensive processing giving rise to complex glycans 
that are resistant to endo H cleavage. The resistance of MHC I to endo H is often used as 
evidence of passage through the Golgi apparatus (Townsend et al., 1989; York et al., 1994).  
Another pathway exists where exogenous antigens are internalised by cells and presented 
on MHC I. This is referred to as the cross-presentation pathway (reviewed by Huang et al., 
1996; Heath and Carbone, 2001; Rock and Shen, 2005; Cresswell et al., 2005; Basta and 
Alatery, 2007, 2007; Neefjes et al., 2011; Joffre et al., 2012). The major cell types that cross-
present antigens to the TCR are the professional APCs, which mainly consist of specific 
subsets of DCs. These cells have the ability to take up the antigen from extracellular milieu 
through various processes, including phagocytosis, endocytosis and macropinocytosis 
(reviewed by Blum et al., 2013). Phagocytosis is a regulated process that helps internalise 
particulate antigens, apoptotic or necrotic cells, and pathogens via phagosomes (Shen et al., 
1997). Endocytosis, on the other hand, captures membrane components and solubilised 
macromolecules in endosomes. During macropinocytosis, macromolecules, extracellular 
materials and pathogens are captured in large quantities within vesicles known as 
pinosomes, which eventually fuse with lysosomes (Norbury et al., 1995). The internalised 
antigens may access the cytosol through the vesicular compartments, where they are 
processed by proteasomes and the resultant peptides enter the TAP-mediated antigen 
presentation pathway. However, antigen processing and peptide loading can also occur in 
the endocytic compartment independent of TAP. This idea is further supported by the 
detection of MHC I molecules in phagosomes and endosomes (Ackerman et al., 2003; 
Guermonprez et al., 2003). Cross-presentation is essential for the initiation of a CD8+ T 
cell response against pathogens that do not infect DCs.  
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Figure 1.6 Schematic representation of classical MHC I antigen presentation 
pathway. The nascent heavy chain and -2 microglobulin of MHC I are delivered into the 
ER lumen during protein synthesis via ribosomes. In the ER, the MHC I components fold 
and assemble together with the help of chaperone molecules calnexin, calreticulin, BiP and 
ERp57. Concurrently, the peptides generated by proteasomal degradation in the cytosol are 
transported into ER lumen by TAP. These peptides are loaded on the empty MHC I by the 
peptide loading complex, which includes TAP, tapasin, calreticulin, ERp57 and MHC I. 
Subsequently, the peptide-MHC I complexes are translocated to the surface of cells via the 
Golgi apparatus. Adapted from Schölz and Tampé, 2005. 
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Figure 1.7 Structural model of TAP. TAP is a heterodimeric subunit complex made up 
of TAP1 and TAP2. Each subunit is comprised of a transmembrane domain (TMD) and a 
nuclear binding domain (NBD). The N-terminal four transmembrane helix bundle of 
TMD is referred to as TMD0. A TAP complex without TMD0, called core TAP, is 
sufficient for translocation of peptides into ER. Modified from Lehnert and Tampé, 2017. 
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1.7 Immune response to HSV-1 infection 
With the overview of the innate and adaptive immune system outlined above, the following 
sections focus on detailed review of the immune response against HSV-1 infection, with a 
particular focus on the CD8+ T cell-mediated immunity and the ability of HSV-1 to evade 
detection by CD8+ T cells. 
1.7.1 Innate immune cells 
The immune recognition of HSV-1 infection begins at the level of infected epithelial cells 
and neurons (Sato and Iwasaki, 2004; Jin et al., 2007; Lucinda et al., 2017). PRRs are 
strategically placed at multiple cellular locations to maximize the chance for recognition of 
a viral infection. For example, TLR2 recognises the infecting viral particles at the cell 
surface (Kurt-Jones et al., 2004), TLR9 interacts with viral DNA released via endosomes in 
the cytoplasm (Krug et al., 2004), cytosolic viral DNA is also recognised by receptors such 
as DNA-dependent activator of interferon regulatory factor (DAI) (Takaoka et al., 2007), 
interferon gamma inducible protein 16 (IFI16) (Conrady et al., 2010), RNA polymerase III 
and retinoic inducible gene RIG-I (Chiu et al., 2009); and finally, transcription 
intermediates such as double-stranded RNA are recognised by melanoma associated 
differentiation gene 5 (MDA5) in the cytoplasm (Melchjorsen et al., 2010) and TLR3 in the 
endosome (Zhou et al., 2009; Lafaille et al., 2012). In fact, it has been demonstrated that a 
deficiency in TLR2, TLR9 or TLR3 leads to severe consequences during HSV infection 
(Kurt-Jones et al., 2004; Lima et al., 2010; Mørk et al., 2015; Zhou et al., 2009). Following 
cellular recognition of PAMPs, cells activate the type I and type III interferon pathways 
which drive production of pro-inflammatory cytokines. Consequently, circulating immune 
cells, including  T cells, macrophages, NK cells and DCs are recruited to the epithelial 
and ganglionic infection sites where they infiltrate and then become further activated by 
inflammatory signals (Liu et al., 1996; Donaghy et al., 2009; Melchjorsen et al., 2010; 
Shimeld, 1995; Lucinda et al., 2017). These immune cells can directly function as effector 
cells by releasing anti-viral molecules, as well as orchestrate an anti-viral response by 
recruiting the adaptive immune components to the infection site. 
Macrophages are multifunctional; they can phagocytise virus particles and infected cells, 
present processed antigen to adaptive immune cells (Unanue, 1984; Ramirez and Sigal, 
2002) and release anti-viral cytokines (Scieux, 1997; Kodukula et al., 1999). Additionally, 
Introduction 
31 
they are intrinsically resistant to HSV infection (Hirsch et al., 1970; Stevens and Cook, 
1971a; Lopez and Dudas, 1979), and provide extrinsic resistance by releasing anti-viral 
factors, which inhibit viral replication in other infected cells (Morahan et al., 1980; 
Benencia and Courreges, 1999). In particular, within the TG of HSV-1 infected mice, 
infiltrating macrophages secrete anti-viral factors such as TNF, regulated on activation 
normal T cell expressed and secreted (RANTES), IL-12 and inducible nitric oxide synthase 
(iNOS) (Kodukula et al., 1999; Melchjorsen et al., 2002; Mott et al., 2007). In line with this, 
depletion of macrophages, TNF or inhibition of nitric oxide production favours early 
viral replication in HSV-1 infected mice (Benencia and Courreges, 1999; Kodukula et al., 
1999), although the kinetics of virus control is comparable between the macrophage-
depleted mice and wild-type mice (Sciammas et al., 1997; Kodukula et al., 1999; Cheng et 
al., 2000). In addition, macrophages do not affect HSV-1 latency, as determined by the 
level of LAT expression in latently infected mice (Mott et al., 2007). These findings suggest 
that macrophages are involved in controlling initial viral replication but do not contribute 
to the clearance of the infectious virus. 
DCs, that are tissue-resident or tissue infiltrating, can detect HSV-1 invasion through PRRs 
and inflammatory cytokines secreted at the site of infection. Activated DCs secrete type-I 
interferon and release cytokines such as IL-12, IL-15 and IL-18. These cytokines, 
specifically IL-12 and IL-15, have been shown to play a role in NK cell activation (Ferlazzo 
et al., 2004). For instance, DCs were critical for optimal IFN production by an NK cell 
subset in the popliteal lymph node of mice following footpad infection with HSV-1 
(Kassim et al., 2009). In addition, corneal resident dendritic cells recruited circulating NK 
cells to the site of infection (Frank et al., 2012). Besides boosting the innate immune 
response via NK cells, DCs are efficient APCs due to their elevated expression of major 
histocompatibility complex (MHC I and II) and co-stimulatory molecules. Together these 
help to prime naïve T cells and secrete IL-12, which leads to the activation and 
differentiation of CD4+ T cells and CD8+ T cells (Banchereau and Steinman, 1998; Sato and 
Iwasaki, 2004; Henry et al., 2008).  
DCs are heterogeneous in their phenotype, location and function. For example, epidermal 
Langerhans cells (LCs) are located in the basal epidermal layer of skin and are among the 
first immune cells to encounter HSV. Depletion of LCs in mice enhances viral replication 
in the skin suggesting that these cells provide local immunity to HSV-1 (Sprecher and 
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Becker, 1989). HSV-1 counteracts this process by inducing apoptotic cell death of infected 
LCs (Bosnjak et al., 2005a). Curiously, in further studies, these cells were shown to neither 
participate directly in presenting antigen to CD8+ T cells (Allan et al., 2003) nor deliver 
HSV-1 antigens from the peripheral infection site to lymphoid organs for priming as 
determined using cutaneous infection model (Whitney et al., 2017). Nevertheless, in lymph 
nodes HSV-1-derived peptides are presented to naïve CD8+ T cells specifically by the 
lymph-node resident CD8+ DCs in the initial stages of acute cutaneous infection in mice 
(Allan et al., 2003; Jirmo et al., 2009) and predominantly by the migratory dermal CD103+ 
DCs during the later stages (Bedoui et al., 2009). Kim and colleagues (2015) made similar 
observations in human in situ models. Using the human foreskin explant and HSV-1 
infected penile skin biopsy models, they showed that HSV infected LCs undergo apoptosis 
and migrate to the dermal layer, where the dermal DCs take up the infected LCs, 
suggesting the possibility that the dermal DCs might relay HSV antigens from the infection 
site for antigen presentation (Kim et al., 2015). While the lymph-node resident DCs were 
the main APCs during cutaneous infection of mice, Lee et al., showed using vaginal 
infection model that, in addition to lymph nodes resident CD8+ DCs, migratory DCs, but 
not Langerhans cells, also present antigen and contribute to the priming of CD8+ and 
CD4+ T cells (Lee et al., 2009). Another subset of DCs, known as plasmacytoid dendritic 
cells (pDCs), are also capable of secreting high amounts of type I IFNs and respond 
against HSV-1 infection in a TLR9-dependent manner (Lund et al., 2003; Krug et al., 2004; 
Sato et al., 2006). However, the participation of pDCs in antigen presentation was shown 
to be unlikely in a vaginal infection model (Lee et al., 2009). Together, these studies 
indicate that different DC subsets display a differential role in priming of CD8+ T cells and 
overall, DCs play a predominant role in linking the innate and adaptive immune system to 
primary HSV infection.  
NK cells are heterogeneous in their expression of cell surface receptors, phenotypic 
markers and their cytolytic activity. It is well established that NK cells can become 
activated directly after being exposed to interferons (IFN ,  or ) or interleukins such as 
IL-12, IL-15 and IL-18 (Biron et al., 1984; Biron, 1997; Ahmad et al., 2000). In addition to 
cytokine-mediated recognition, NK cells also employ receptor-mediated detection of 
pathogens, such as in the context of murine cytomegalovirus (MCMV) infection. NK cells 
use two kinds of receptors: activating receptors which induce cytolysis after engaging an 
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appropriate ligand on virus-infected cells (Diefenbach and Raulet, 2001) and inhibitory 
receptors which recognise MHC I on the cell surface to provide a protective signal and 
suppress the cytolytic activity of NK cells (Kärre et al., 1986; Storkus et al., 1987). Use of 
such receptors for recognising HSV infected cells is under-explored. Analysis of NK cell 
recognition of HSV infected cells at the clonal level indicated that both activating and 
inhibitory receptors might be involved (Pietra et al., 2000). HSV (type 1 and 2) infection 
down-modulates the MHC I on the cell surface using an infected cell protein (ICP) 47 
(York et al., 1994; Hill et al., 1995). In particular, an NK cell clone bearing an inhibitory 
receptor was able to lyse ICP47 expressing cells in vitro (Huard and Früh, 2000) suggesting 
that the loss of inhibitory signal stimulated the NK cell cytolytic activity. Conversely, in 
another study, neither infection with an ICP47 deletion virus nor the blocking of inhibitory 
receptors on NK cells abolished the killing of HSV-1 infected target cells (Chisholm et al., 
2007). The effects of down-modulation of MHC I on NK cell recognition of HSV-1 
infected cells, therefore, remains unresolved. Regardless, earlier reports have documented 
that human patients lacking NK cell activity become extremely susceptible to HSV 
infection (Lopez et al., 1983; Biron et al., 1989) highlighting the important protective role 
of NK cells. These cells perform their anti-viral cytolytic function by releasing IFN, 
cytotoxic granules containing perforin and several granzymes, tumour necrosis factor and 
other cytokines upon recognition of viral invasion (Smyth et al., 2005). Besides the cytolysis 
of infected cells, emerging evidence indicates that NK cells might be involved in linking 
innate and adaptive immunity. In HSV-2-induced lesions in humans, the activated NK cells 
were shown to be in contact with plasmacytoid DCs (Donaghy et al., 2009) and they also 
formed an immunological synapse with CD4+ T cells (Kim et al., 2012b). The up-regulation 
of TLR-2 and MHC II on NK cells upon stimulation with HSV antigens in vitro suggests 
that NK cells may also serve as APCs (Kim et al., 2012b). The functional significance of 
such interaction between DCs, NK cells and T cells remain to be elucidated.  
1.7.2 Adaptive immune cells 
The initial infiltration of innate immune components is later replaced by adaptive immune 
cells, which are essential for complete clearance of the infectious virus. All arms of the 
adaptive immune system, including B cells, CD4+ T cells and CD8+ T cells have been 
shown to infiltrate the infection sites (Liu et al., 1996) and function against acute HSV 
infection (Minagawa et al., 1988).  
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1.7.2.1 Humoral immunity against HSV infection 
Many earlier studies using mouse models tested the efficacy of passive immunisation with 
HSV-specific antibodies in controlling primary HSV disease. Following flank infection of 
BALB/c mice, passive immunisation with a high dose of neutralising antibody prevented 
the formation of secondary skin lesions, indicating that the antibody neutralised the 
extracellular virus released from nerve endings (Simmons and Nash, 1985). Similarly, 
passive immunisation of mice prior to HSV-1 infection by corneal scarification significantly 
reduced the herpetic eye disease and the incidence of mortality (Shimeld et al., 1990a). 
Studies in B cell-deficient mice also support a role for humoral immunity against HSV 
infection. Beland and colleagues (1999) demonstrated that B cell-deficient, but not control 
mice (C57BL/6), developed encephalomyelitis due to viral spread to the CNS after intra-
peritoneal injection of HSV-1 strain KOS. Further, the survival of HSV-1 infected B cell-
deficient mice was improved after administration of HSV-specific hyper immune serum 
(Beland et al., 1999). These studies emphasise that neutralising antibody ameliorates disease 
in experimentally infected mice, possibly by limiting the spread of the virus at early stages 
of infection. Even though these experiments reveal the value of immunisation, the 
functional role of B cells in natural infection is not well defined. 
Other mouse studies, however, challenge the significance of antibody-mediated protection 
against HSV infection. Dudley et al. (2000) observed that, although there is a slight delay, 
B-cell deficient MT mice clear HSV-2 infection efficiently as their immunocompetent 
counterparts after vaginal infection. Furthermore, prior immunisation of wild-type mice did 
not provide adequate resistance against HSV-2 in the absence of T cells (Dudley et al., 
2000). In another study, intranasal immunisation of mice with recombinant vaccinia virus 
expressing HSV glycoproteins gB or gD failed to prevent primary vaginal epithelial 
infection with HSV-1. This was despite the induction of a high titre of antigen-specific 
antibodies (Kuklin et al., 1998). Furthermore, depletion of CD4+ T cell in these immune 
mice leads to increased viral replication in the vaginal tract (Kuklin et al., 1998).  
The role of B cells in control of human HSV infection has been the subject of extensive 
investigation. Compelling evidence of the protective function of antibodies comes from 
neonatal infection, where the transfer of maternal antibodies to neonates reduces the risk 
of acquiring neonatal herpes. For example, trans-placental transfer of neutralising antibody 
from mother to infants provides a various degree of protection against neonatal herpes 
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disease, including complete neutralisation of the virus in some infants (Yeager et al., 1980; 
Brown et al., 1991, 1997). Furthermore, a recent study demonstrated that virus-specific 
maternal antibodies can infiltrate and persist in uninfected human foetal TG and are 
capable of protecting neonates from fatal HSV infection (Jiang et al., 2017). In adults, 
HSV-1 infection elicits humoral immune responses, with neutralising antibodies against 
viral glycoproteins, gB and gD, being detected (Bravo et al., 1996; McClements et al., 1997; 
Wang et al., 2016). However, the recombinant glycoprotein subunit vaccines failed large-
scale human clinical trials and interestingly, levels of neutralising antibody did not correlate 
with the disease outcome (Corey et al., 1999). It appears that antibodies play a supporting 
role rather than providing primary protection against HSV disease. 
Together, the above findings indicate that antibodies are potentially useful in controlling 
the early spread of the virus and protect against lethal viral challenge, likely by neutralising 
the free virus. However, antibody responses alone are not sufficient to provide complete 
protection against acute as well as recurrent HSV infection. Instead, a vigorous T cell 
response is required. 
1.7.2.2 Cell-mediated immunity against HSV-1 
The evidence that T cells contribute significantly to the defense against HSV infection 
came from early studies utilising congenitally athymic nude mice, which lack both their 
CD4+ T cells and their CD8+ T cells. Athymic mice in a BALB/c genetic background 
typically die as a result of HSV-1 infection, irrespective of the route of infection (Nagafuchi 
et al., 1979; Kapoor et al., 1982; Metcalf and Michaelis, 1984). Passive transfer of 
splenocytes from previously infected mice to HSV-infected athymic mice protected these 
mice from mortality (Nagafuchi et al., 1979). However, depletion of T cells from the 
splenocytes prior to transfer, or infusion with HSV-1 specific antibody, did not provide 
resistance against HSV-1 in the athymic mice (Nagafuchi et al., 1979). Additionally, 
compared to immunocompetent mice, athymic mice had significantly more infectious virus 
at the peripheral infection site, ganglia, spinal cord and brain, demonstrating a progressive 
spread of the virus to the CNS which resulted in the death of the animal (Walz et al., 1976; 
Kapoor et al., 1982). The above reports in mice indicate that T cells are indispensable for 
the control of HSV infection. Subsequent studies showed that a large number of CD4+ T 
cells and CD8+ T cells infiltrate infection sites during both the initial HSV-1 infection (Liu 
et al., 1996) and reactivation (Shimeld et al., 1996a, 1996b) in mice. Similarly, in humans, 
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both HSV-2 specific CD4+ T cells and CD8+ T cells have been isolated from genital lesions 
(Koelle et al., 1994a, 1994b, 1998; Posavad et al., 2000; Hosken et al., 2006). The relative 
importance of each of these subsets has been argued, with some proposing that CD4+ T 
cells play a primary role in anti-HSV immunity (Kuklin et al., 1998; Manickan and Rouse, 
1995; Ghiasi et al., 2000; Milligan et al., 2005; Mott et al., 2016), whilst others favour the 
importance of CD8+ T cells (Simmons and Tscharke, 1992; Koelle et al., 1998; Posavad et 
al., 2000; Khanna et al., 2003a). Despite these incongruities, various groups have 
demonstrated that the effector activity of at least one of the T cell subsets, whether CD4+ 
or CD8+ T cells, are strictly required and sufficient to clear infectious virions from the 
epithelial, mucosal and neural mouse tissues (Nash et al., 1987; Ghiasi et al., 2000; van Lint 
et al., 2004a; Johnson et al., 2008a).  
The functionality of CD4+ T cells during acute infection is critical for the development of 
an effective adaptive immune response. CD4+ T cells are the predominant source of IFN, 
which has been shown to suppress HSV-2 replication in mucosal epithelial tissues (Iijima et 
al., 2008). In addition to this, CD4+ T cells secrete chemokines, such as CXCL9 and 
CXCL10, at the local infected tissue (Nakanishi et al., 2009). Through IFN, CXCL9 and 
CXCL10, CD4+ T cells enable the migration of effector CD8+ T cells to the site of 
infection (Nakanishi et al., 2009). By secreting IL-2 and enhancing the provision of co-
stimulatory signals by DCs, CD4+ T cells assist CD8+ T cells in activating, expanding and 
mounting a response against infection (Smith et al., 2004; Wilson and Livingstone, 2008). 
Consistently, HSV-1 infected CD4+ T cell-deficient mice contained less virus-specific 
CD8+ T cells. However, the remaining CD8+ T cells were fully functional, producing 
perforin and granzyme B at levels equivalent to wild-type mice (Rajasagi et al., 2009; Frank 
et al., 2010). As a result, the CD4+ T cell depleted mice were able to clear HSV-1 and 
maintain latency similar to that of the infected wild-type mice (Frank et al., 2010). This 
suggests that CD8+ T cells can function efficiently in the absence of CD4+ T cells. Despite 
the lack of evidence suggesting CD4+ T cells do not play a direct role in the establishment 
and maintenance of latency, they reside in the TG, next to neurons expressing LATs (van 
Velzen et al., 2013a) and help prevent CD8+ T cells from functional exhaustion (Frank et 
al., 2010).  
The role of CD8+ T cells during both the acute HSV-1 infection and the latency are 
elaborated below. 
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1.7.3 How do CD8+ T cells recognise and respond to HSV-1 infection? 
CD8+ T cells play a predominant role in eliminating actively replicating HSV-1 virions by 
initiating a series of steps, which precede the mounting of an effective immune response. It 
appears that within hours of infection, migratory DCs acquire HSV antigens from the site 
of infection and reach the draining lymph nodes, where antigens are delivered to resident 
DCs. These cells then present the viral peptides in the context of MHC I to circulating 
naïve CD8+ T cells (Mueller et al., 2002; Bosnjak et al., 2005a; Jirmo et al., 2009). The 
different DC subtypes that might be involved in cross-presentation of HSV-1 peptides to 
CD8+ T cells are described in Section 1.7.1. After optimal priming, CD8+ T cells undergo 
rapid clonal expansion and gain effector functions within the lymph node (Coles et al., 
2002). The mobilisation of activated effector cells from the lymph node to infection sites is 
likely to depend on chemokines, such as CXCL9 and CXCL10, that operate through the 
CXCR3 receptor on CD8+ T cells (Araki-Sasaki et al., 2006; Thapa et al., 2008; Nakanishi 
et al., 2009). Consistent with this, CXCL9 and CXCL10 levels were shown to be elevated in 
the neural and epithelial tissue of mice, after infection with HSV-2 (Thapa et al., 2008). The 
activated effector CD8+ T cells leave the lymphoid organs and reach the infected epithelial 
and neural tissues within 5 days of HSV-1 infection in mice (van Lint et al., 2004a; Lang 
and Nikolich-Zugich, 2005). 
At the infection site, when the TCR on infiltrating effector CD8+ T cells re-engages with 
the pMHC presented on the infected cells, CD8+ T cells are usually stimulated to secrete 
effector molecules such as IFN, TNF and lytic granules containing perforin and 
granzymes (Harty et al., 2000; Lucinda et al., 2017). Smith et al. (1994) suggested that an 
antiviral mechanism that is common to both CD4+ and CD8+ T cells, such as IFN, is 
primarily responsible for curtailing viral replication. Consistent with this hypothesis, 
antibody-mediated neutralisation of IFN after HSV-1 infection in mice resulted in 
increased viral replication in the skin and delayed virus clearance (Smith et al., 1994). 
Concordantly, one study previously suggested that IFN also enhanced antigen 
presentation on virus-infected cells, improving the chance of recognition by CD8+ T cells 
(Wallach et al., 1982). Alternatively, Dobbs et al. offer a more complex interpretation to 
Smith et al. (1994), suggesting that IFN alone cannot provide complete protection against 
replicating virus, but requires the function of perforin and granzymes (Dobbs et al., 2005). 
Perforin is secreted to bind and oligomerize on the plasma membrane of infected cells, 
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resulting in the formation of cell membrane pores, through which granzymes enter, leading 
to the fragmentation of cellular proteins triggering apoptotic cell death pathway (Trapani 
and Smyth, 2002). Granzymes belong to the serine protease family and are capable of 
inducing apoptosis (reviewed by Trapani, 2001). There are five types of granzymes in 
human and eight in mice. Granzyme -A and -B are shown to be primarily involved during 
HSV infection. Granzyme A induces apoptosis in a caspase-independent manner by 
cleaving single-stranded DNA and by hydrolysing histone proteins (Zhang et al., 2001; Fan 
et al., 2003; Lee et al., 2016). Granzyme A can also induce apoptosis by activating IL-1, 
which can function as a positive mediator of cell death (Irmler et al., 1995). Granzyme B 
induces caspase-dependent apoptotic pathway (Metkar et al., 2003) and it is the 
predominant type of granzyme expressed by HSV-1 specific CD8+ T cells that infiltrate the 
infection sites during lytic phase (van Lint et al., 2004a). Adoptive transfer of antigen-
specific CD8+ T cells from TCR transgenic mice to HSV-2 infected recipient mice resulted 
in efficient control of viral replication, whereas, transfer of antigen-specific CD8+ T cells 
deficient in IFN or perforin resulted in impaired resolution of genital infection (Dobbs et 
al., 2005).  
After the elimination of the infectious virus, a distinct population of memory CD8+ T cells, 
termed CD8+ TRM cells, establish residence at antigen-challenged peripheral skin tissues 
(Ariotti et al., 2012; Gebhardt et al., 2009, 2011; Zhu et al., 2007, 2013a). Ariotti and 
colleagues used intra-vital imaging to understand the function of these epidermal CD8+ TRM 
cells in mice challenged by intra-epidermal injection with a gB498-505 epitope-encoding DNA 
vaccine and exposed to a transfer of gB498-505 epitope-specific CD8
+ T cells (Ariotti et al., 
2012). They found that the CD8+ TRM cells possess a dendritic-shaped morphology and 
steady-state slow migration compared to effector CD8+ T cells in the epidermis of HSV 
infected mice (Ariotti et al., 2012). Whether the morphology and migration of CD8+ TRM 
cells in ganglia are similar to that of the epidermis is not known. Interestingly, when they 
used a mouse model in which only a small fraction of epidermal cells were allowed to 
express gB498-505 epitope, the CD8
+ TRM cells were capable of recognising these antigen 
presenting cells and attain morphological configuration of effector CD8+ T cells (Ariotti et 
al., 2012). Further, transcriptome analysis of these cells showed that HSV challenge can 
rapidly induce IFN expression, which subsequently up-regulates expression of antiviral 
transcripts in the neighbouring skin cells (Ariotti et al., 2014). Further, these virus-specific 
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skin-resident CD8+ T cells was shown to be capable of providing protection against local 
re-infection with HSV-1 (Gebhardt et al., 2009). From the above data, it is evident that the 
CD8+ T cells patrol both the ganglia and skin during latency and can rapidly attain an 
effector state upon cognate antigen recognition. Subsequent secretion of IFN may also 
induce a tissue-wide pathogen alert, activate innate immune cells and stimulate further 
recruitment of circulating memory T cells.  
Consistent with the results obtained from mouse models, Zhu and colleagues have shown 
that CD8+ T cells may be crucial for controlling recurrent HSV-2 infections in the human 
female genital tract. They analysed biopsies taken at regular intervals from human patients 
who experienced recurrent genital lesions and demonstrated that CD8+ T cells, both 
antigen-specific and non-specific cells, infiltrate infected tissues in large numbers during 
productive HSV-2 infection (Zhu et al., 2007). The CD8+ T cells isolated from these 
recurrent lesions were functional as they induced cytolytic killing of the target cells (Zhu et 
al., 2007). In addition, after complete resolution of the recurrent lesions, a long-term 
residence of CD8+ T cells was observed at the dermal-epidermal junctions (Zhu et al., 
2007). Later they demonstrated that these CD8+ T cells, at the site of previous reactivation, 
expressed genes involved in CD8+ T cell activation and produced perforin as shown by 
immunofluorescent staining (Zhu et al., 2013a). In biopsies displaying asymptomatic viral 
shedding, CD8+ T cells containing perforin granules were found clustered around HSV-2 
infected cells (Zhu et al., 2013a). Furthermore, an inverse correlation was drawn between 
the duration of viral shedding and CD8+ T cell density in the human genital tract, 
suggesting that the CD8+ T cells established during prior infection at peripheral site are a 
major factor in control and containment of infection, as well as the severity of reactivation 
(Schiffer et al., 2010). The long-term persistence of virus-specific CD8+ T cells in dermal-
epidermal junctions of recurrent infection site and their physical interaction with the HSV-
2 infected cells imply that CD8+ T cells may provide surveillance at the cutaneous infection 
site during latency and are equipped to contain the virus shedding from nerve endings 
during reactivation.  
1.7.4 Role of CD8+ T cells in maintaining HSV latency 
Investigations using mouse models led to findings related to the significance of CD8+ T cells during 
latent infection in the ganglia. In C57BL/6 mouse model, a large fraction of HSV-1-specific CD8+ 
T cells recognizes a single epitope gB498-505, while the remainder of the cells recognise at least 18 
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sub-dominant epitopes in varying frequency (St Leger et al., 2011). Khanna and colleagues 
showed that a stable population of HSV-1 specific CD8+ T cells existed proximally to 
latently infected neurons (Khanna et al., 2003a). These CD8+ T cells had an activated 
phenotype, as indicated by expression of markers for recent (CD69) and memory (CD44) 
activation, as well as granzyme B expression (Khanna et al., 2003a; van Lint et al., 2005; 
Verjans et al., 2007). This subset of virus-specific non-migrating CD8+ T cells is 
distinguished from circulating memory cells by the expression of CD103 (also known as 
integrin E) and persist in the ganglia and the skin long after the establishment of latency 
(Gebhardt et al., 2009; Himmelein et al., 2011). In addition, many HSV-1 specific CD8+ T 
cells persist in a functional state during latent infection as indicated by IFN- production 
and presence of lytic granules (Khanna et al., 2003b; Knickelbein et al., 2008; Mackay et al., 
2012). In addition to mice, similar observations have been reported following examination 
of latently infected human trigeminal ganglion (Theil et al., 2003; Verjans et al., 2007; van 
Velzen et al., 2013b) and other human cranial ganglia such as geniculate and vestibular 
ganglia, where HSV-1 can establish latency (Arbusow et al., 2010). Furthermore, it was 
observed that neurons are not lost due to CD8+ T cell-mediated cytolysis nor reactivation 
despite the presence of functional CD8+ T cells in latent ganglia (Pereira et al., 2000; 
Decman et al., 2005; Knickelbein et al., 2008). Mice lacking granzyme B or perforin show 
an exacerbation of reactivation in the latently infected TG, as illustrated by a dramatic 
increase in viral genome copy number. Regardless, these mice cleared the infectious virus 
with the same kinetics as the wild-type mice (Knickelbein et al., 2008). Additionally, using 
immunostaining, it was shown that granzyme B-containing CD8+ T cells are juxtaposed to 
latently infected neurons that lack activated caspases (Knickelbein et al., 2008). Together 
these observations imply that granzyme B and perforin participate in controlling viral 
replication in ganglia using a caspase-independent, non-cytolytic mechanism. In another 
study, Pereira and colleagues found that granzyme A can restrict the inter-neuronal spread 
of virus without inducing cytolysis (Pereira et al., 2000). However, the participation of 
granzyme A after the establishment of latency has not been shown. Collectively, the above 
studies imply that both lytic granules and IFN released from CD8+ T cells act 
synergistically to rapidly eliminate the infectious virus and possibly, help maintain latency. 
Although there is no direct evidence to show that ganglia-resident CD8+ T cells help maintain 
latency and prevent full-blown reactivation, the following data from mouse studies support this 
hypothesis. Antibody-mediated depletion of CD8+ T cells or depletion of IFN in explant cultured 
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TG of mice resulted in enhanced reactivation of the virus (Liu et al., 2000, 2001). Other work has 
also shown that CD8+ T cell depletion of mice harbouring latent HSV-1 resulted in increased HSV-
1 DNA load and protein synthesis in the latently infected ganglia compared to untreated mice 
(Freeman et al., 2007b; Hoshino et al., 2007). Upon reactivation, the ganglion resident CD8+ T cells 
were capable of proliferation. This was evidenced by explanting latently infected DRG from gB498-
505 epitope specific TCR transgenic mice to under the kidney capsule of naïve syngeneic recipients 
(Mackay et al., 2012). Moreover, TRM cells are also capable of secreting multiple effector molecules 
upon reactivation of the virus (Mackay et al., 2012). The ability of TRM cells to proliferate and 
secrete effector molecules suggests that upon reactivation of the virus in the ganglia, these cells are 
capable of mounting a rapid local response. While gB-specific cells retained their function, 
some have speculated that CD8+ T cells specific to sub-dominant epitopes undergo 
functional exhaustion in ganglia during latency (Treat et al., 2017). This idea is based on 
studies that showed increased PD1 expression on gB-non-specific CD8+ T cells and IL-10-
mediated inhibition of proliferation of subdominant CD8+ T cells in mouse TG (Jeon et al., 
2013; St Leger et al., 2013). Currently, there is no apparent explanation for the difference in 
the functionality of gB-specific and -non-specific CD8+ T cells. 
1.7.5 Do neurons present HSV antigens to CD8+ T cells? 
For many years the nervous system was thought to be functionally immune-privileged, 
displaying a complete lack or delayed infiltration of immune cells (Barker and Billingham, 
1977; Lampson, 1995). However, this perception is no longer widely held. It is now well 
documented that CD8+ T cells can enter the CNS or PNS upon viral infection of neurons 
and in a range of autoimmune CNS diseases, CD8+ T cells are involved in mediating 
neuronal destruction (Babbe et al., 2000; Zhang et al., 2008; Aye et al., 2009; Varadkar et al., 
2014). CD8+ T cell-mediated neuronal destruction depends on interactions with MHC I 
molecules, which have been recently found on neuronal cells. For example, experiments 
performed on mouse hippocampal neurons showed that electrically-silenced neurons of the 
CNS can express MHC I on the cell surface in the presence of pro-inflammatory cytokine 
IFN (Neumann et al., 1995). Concurrently, Pereira and colleagues, using northern blot 
analysis and in situ hybridization, found that the MHC I transcripts were up-regulated in 
neurons of the PNS during acute HSV-1 infection of mice (Pereira et al., 1994; Pereira and 
Simmons, 1999). However, these transcripts were undetectable during HSV-1 latency 
(Pereira et al., 1994). Furthermore, mice infected intra-cranially with mouse hepatitis virus 
(MHV), but not sham-infected mice, displayed expression of MHC I proteins in neurons, 
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oligodendrocytes and microglia (Redwine et al., 2001). While the above studies indicate that 
MHC I is expressed in neurons only during injury or infection, later investigations using 
more sensitive techniques to detect mRNA and protein have demonstrated that MHC I is 
present in normal healthy neurons of both the developing and adult nervous system 
(Corriveau et al., 1998; Huh et al., 2000; Elmer and McAllister, 2012; Ma et al., 2014; Tyler 
and Boulanger, 2014). Indeed, MHC I molecules are crucial for synaptic plasticity, memory 
and learning (Tyler and Boulanger, 2014). However, the immune function of MHC I in 
neurons have yet to be explored in detail.  
Although direct evidence to show the participation of neurons in presenting antigen to 
CD8+ T cells is lacking, there are sufficient data to suggest that cognate antigen recognition 
by CD8+ T cells occurs in the nervous system. A number of studies demonstrated that 
CD8+ T cells are essential for clearing neurotropic viruses, such as HSV (Nash et al., 1987; 
Simmons, 1989; Simmons and Tscharke, 1992), murine cytomegalovirus (Cheeran et al., 
2005), West Nile virus (Shrestha and Diamond, 2004; Shrestha et al., 2006) and mouse 
hepatitis virus (MacNamara et al., 2005) from the nervous system (CNS or PNS) during 
acute infection. Moreover, it has been demonstrated that CD8+ T cells form and maintain a 
stable contact with infected neurons until the infected cells are subsequently destroyed 
(Khanna et al., 2003a; Chevalier et al., 2011). Notably, during HSV-1 latency, virus-specific 
CD8+ T cells reside long-term in the ganglia in an activated state forming an immunological 
synapse with neurons containing latent genomes (Khanna et al., 2003a; Theil et al., 2003; 
Verjans et al., 2007; Gebhardt et al., 2009). The reason for the lack of MHC I transcripts 
during latency in earlier studies (Pereira and Simmons, 1999) could be due to the method 
employed and the sensitivity of detection. This is contrasted by acute infection where 
inflammatory cytokines could have driven up-regulation of MHC I expression to a 
detectable level. Together, the MHC I expression in healthy neurons and preferential 
presence of CD8+ T cells in ganglia, suggests that these neurons not only express surface 
MHC I, but, may also present virus-specific epitopes to CD8+ T cells. Only a small number 
of pMHC-I is thought to be required for a CD8+ T cell to respond (Sykulev et al., 1996), 
hence determining if there is even a low-level synthesis of MHC I would be of paramount 
importance to understanding elements of neuronal HSV-1 infection. 
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1.8 Immune evasion by HSV 
HSV is remarkable in its ability to subvert both the innate and the adaptive immune system 
by interfering with several anti-viral pathways.  
HSV evades host innate sensing of viral PAMPs at a very early stage of infection. For 
example, HSV-1 US3 protein kinase reduces TLR3 expression, which ultimately results in 
reduced type I IFN response (Peri et al., 2008). HSV-1 immediate early protein ICP0 was 
shown to reduce the levels of myeloid differentiation primary response protein (MyD88) 
and MyD88-adapter like (MAL) protein, which are involved in TLR2 mediated 
inflammatory response (van Lint et al., 2010). The virion host shut-off (vhs) protein 
counteracts the cytosolic DNA-sensing pathway by degrading the transcripts of a key DNA 
sensor called cyclic GMP-AMP synthase (cGAS) (Su and Zheng, 2017). Other HSV 
proteins, ICP27 and vhs, induce global shut-off of host protein synthesis by inducing 
degradation of cellular mRNA or by repressing transcription and splicing (Smiley, 2004). 
Proteins including, ICP0, ICP27, vhs, US3, VP16 and UL36, interfere with type I and type 
II interferon anti-viral pathways (reviewed by Paladino and Mossman, 2009; Su et al., 2016). 
Additionally, ICP0 was shown to interfere with the synthesis of interferon-stimulated genes 
(ISG) by blocking interferon regulatory factors, IRF3 and IRF7 (Lin et al., 2004). Finally, 
ICP27 was shown to dampen interferon secretion by interfering with activation of IRF3 
and signal transducer and activator of transcription 1 (STAT1) (Melchjorsen et al., 2006; 
Johnson et al., 2008b).  
HSV has the capacity to inhibit apoptosis, a critical innate immune mechanism that limits 
viral replication and spread. The HSV-1 proteins US3 protein kinase and glycoprotein J 
inhibit Fas- or caspase-dependent apoptotic pathway, both of which are utilised by CD8+ T 
cells to kill virus-infected cells (Jerome et al., 1999). Additionally, other HSV proteins such 
as ICP4, ICP27, ICP24, glycoprotein D and UL14 are shown to be involved in protection 
of infected cells against apoptosis. Anti-apoptotic function of LATs has been demonstrated 
both in cultured cells and in vivo animal studies (Perng, 2000; Henderson et al., 2002; 
Branco and Fraser, 2005). Necroptosis is an alternate cell death pathway to apoptosis that 
can be activated by TNF family death receptors, Toll-like receptors and interferon 
receptors (Nailwal and Chan, 2019). HSV-1 protein ICP6 interacts with caspase 8 and 
supresses necroptosis in human cells (Guo et al., 2015). In mouse cells, HSV-1 lacking 
ICP6 failed to trigger necroptosis indicating that ICP6-mediated evasion of necroptosis is 
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specific to human cells (Huang et al., 2015; Wang et al., 2014). The exact mechanism 
behind this species specificity is not clear. 
HSV-1 proteins can also specifically dampen the adaptive immune response. For example, 
glycoproteins gE and gI form heterodimeric receptor complexes and bind the Fc portion 
of the IgG antibody (FcR) (Johnson et al., 1988). Such interactions between FcR and the 
HSV antibody subsequently blocks complement activation and NK cell-mediated antibody-
dependent cellular cytotoxicity (ADCC), thereby increasing the severity of the disease 
(Lubinski et al., 2011). HSV being a large DNA virus encodes 84 unique proteins during 
productive infection, which will generate a large number of peptides for presentation to 
CD8+ T cells. This will render the infected cells more susceptible to elimination by the 
virus-specific CD8+ T cells. As a countermeasure, HSV has evolved various evasion 
mechanisms that can hamper different processes that elicit a CD8+ T cell response. For 
example, when HSV-1 penetrates CD8+ T cells following contact with infected fibroblast 
cells, the viral proteins can alter tyrosine phosphorylation equilibrium and negatively 
regulate TCR signalling (Sloan et al., 2006). An early-late protein, ICP34.5 is capable of 
inhibiting type I IFN production in DCs and also can suppress DC maturation, leading to 
attenuation of CD4+ T cell activation (Jin et al., 2009). As CD8+ T cells play a prominent 
role in clearing replicating virus, HSV has co-evolved mechanisms to evade CD8+ T cell 
recognition using ICP47, a viral protein that abrogates the MHC I antigen presentation 
pathway (York et al., 1994; Früh et al., 1995; Hill et al., 1995). The next section will focus 
on ICP47, its mechanism of action and will address some caveats in the previous in vitro 
and in vivo studies in determining the functional significance of ICP47. 
1.8.1 Infected cell protein 47 
To escape from CD8+ T cells, HSV utilises an efficient strategy driven by the ICP47 
protein, which is able to bind the peptide binding site of TAP and prevent the formation of 
peptide-MHC complex in the lumen of the endoplasmic reticulum (ER) (York et al., 1994; 
Früh et al., 1995; Hill et al., 1995; Ahn et al., 1996) (Figure 1.8). ICP47 is a relatively small 
protein, comprising 88 amino acids with a minimal active site mapped to the amino 
terminus (amino acid position 3-34) of the protein (Galocha et al., 1997; Neumann et al., 
1997). It was demonstrated that ICP47 by itself is not transported into ER lumen, but 
binds to TAP with higher affinity than peptide substrates (Tomazin et al., 1996). For 
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effective ICP47 functioning, binding to the TMD domains of both the subunits of TAP is 
required (York et al., 1994; Hill et al., 1995). 
Beinert and colleagues found that the protein did not attain a specific conformation in 
solution, but in a lipid environment a more refined α-helical conformation was noticed 
(Beinert et al., 1997). Later, Aisenbrey and colleagues resolved the structure of ICP47 using 
solid-state nuclear magnetic resonance (NMR) spectroscopy and found that ICP47 attains 
helix-loop-helix conformation (Aisenbrey et al., 2006). The structure of ICP47 was further 
refined using cryo-electron microscopy by Oldham and colleagues (2016) (Figure 1.9). 
According to their model, at the peptide receptive stage, TAP is in an inverted “V” shaped 
conformation with the N-terminus of TMDs close to each other and NBD domains placed 
apart. When bound to TAP, ICP47 attains a hairpin-like structure with the two helices 
running anti-parallel to each other connected by a linker. The N-terminal part of ICP47 
was found to form physical contacts with the inner surface of the TMD of TAP1 and 
TAP2 (Oldham et al., 2016a). A short conserved motif “50PLL52” within the middle part of 
ICP47 is needed for the freezing of TAP in the inactive state (Matschulla et al., 2017). This 
specific interaction between ICP47 and TAP holds the transporter in an inactive state that 
is incapable of binding and transporting peptides. In contrast, the conserved C-terminal 
part of ICP47 was shown to be required for the stability of ICP47 (Herbring et al., 2016). 
When associated with TAP, ICP47 attains a stable conformation, which blocks the binding 
and translocation of peptides into ER lumen (Oldham et al., 2016a).  
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Figure 1.8 ICP47 targets and blocks TAP-mediated antigen presentation pathway. 
The HSV-1 protein ICP47 binds, with high affinity, to TAP1 and TAP2 on the cytosolic 
side of the ER membrane and blocks the transport of peptides into the ER lumen. 
Interaction of ICP47 with TAP ultimately results in the blockade of TAP-mediated 
presentation of peptides on the cell surface. Adapted from Schölz and Tampé, 2005.  
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Figure 1.9 Structure of ICP47-TAP complex. The ribbon structure shown in blue 
represents TAP1 and in yellow represents TAP2. The transmembrane and nucleotide 
binding domains in TAP1 and TAP2 are labelled. ICP47 bound to TAP is shown in 
magenta. Modified from Oldham et al., 2016.  
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In past murine models of HSV-1 infection, most experiments were performed using 
deletion viruses containing mutations in one or more genes in addition to ICP47. For 
instance, intra-peritoneal injection of an ICP47 deletion mutant that also lacks US9, US10, 
US11 and US12, showed that viral replication was not significantly different to the virulent 
parent strain, Patton, various organs tested, including brain tissues. However, despite 
normal replication, there was a delayed invasion into the spinal cord and brain (Nishiyama 
et al., 1993). Similarly, when HSV-1 strain F, containing a deletion of ICP47 and a part of 
the US11 gene, was introduced in the cornea (Meignier et al., 1988) or injected 
intravenously (Burgos et al., 2006), the virus displayed a significant reduction in virulence in 
the CNS. Furthermore, the titre of the deletion virus was recovered to wild-type levels in 
TAP-deficient mice, indicating a specific function which is provided by the TAP-ICP47 
interaction (Burgos et al., 2006). Unlike above studies, Goldsmith and colleagues (1998) 
generated a single gene deletion mutant with a deletion of just ICP47 sparing the 
neighbouring genes in neurovirulent strain F. With this virus, they tested the effect of 
ICP47 on viral pathogenesis using an ocular mouse model. Although viral replication was 
unaltered in the cornea of the infected mice, they found a reduction in neurovirulence in 
the absence of ICP47. Furthermore, depletion of CD8+ T cells in mice rescued the 
virulence phenotype when mice were infected with the ICP47 deletion mutant, suggesting 
that ICP47 has a role in combating the CD8+ T cell-mediated protection to HSV 
(Goldsmith et al., 1998). Although these findings are consistent with the above studies, it is 
not clear if this dampened neurovirulence of the ICP47 mutant is exclusively due to its 
inability to block antigen presentation to CD8+ T cells. Given that HSV infection 
commonly occurs via damaged skin or mucous membranes, the virus becomes restricted to 
dermatomes and therefore, to the peripheral nervous system in an immunocompetent host. 
Using models that invariably cause encephalitis in mice cannot exemplify a typical HSV 
disease. Such infection models are not well suited to investigate the function of ICP47 
during latency. Moreover, the impact of ICP47 on resistance to CD8+ T cell recognition 
has not been tested in other infection models or using non-neuroinvasive HSV-1 strains.  
An important yet unresolved dispute while using HSV mouse models is the species-specific 
binding of ICP47 to TAP. Evidence from biochemical studies indicates that ICP47 binds 
to human TAP with 100 fold more affinity compared to murine TAP (Ahn et al., 1996; 
Tomazin et al., 1996; Jugovic et al., 1998). Cytotoxic T cell killing assays further supported 
this as ICP47 inhibited the recognition of human cells but not mouse cells by HSV-specific 
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CD8+ T cells (York et al., 1994). Subsequently, this led some researchers to argue that 
ICP47 is entirely non-functional in mice. The in vivo and biochemical data are difficult to 
reconcile, and this leaves our understanding of ICP47 and its role in evading CD8+ T cells 
incomplete. Additionally, spontaneous reactivation and viral shedding are rare in mice 
(Tullo et al., 1982; Shimeld et al., 1990b) but occur periodically in humans. This has been 
attributed to the poor binding of ICP47 to mouse TAP (Liu et al., 2000; Leger and 
Hendricks, 2011). Attempts were made to mimic the function of ICP47 by using 
recombinant HSV with human cytomegalovirus (HCMV) US11 or murine cytomegalovirus 
(MCMV) m152, whose expression inhibits MHC I -mediated antigen presentation 
efficiently in mice (Wiertz et al., 1996; Ziegler et al., 2000; Orr et al., 2005). It was shown 
that infection of BALB/c mice with the above recombinant HSV showed an increase in 
viral replication in the spinal cord and enhanced disease progression. The phenotype was 
reversed in TAP-deficient mice or in mice depleted of CD8+ T cells (Orr et al., 2005). In 
the relatively HSV-resistant mouse strain C57BL/6, ocular infection with recombinant 
HSV-1 expressing HCMV US11 or MCMV m152, but not the control virus, increased the 
frequency of reactivation in TG. This was shown using an in vitro explant reactivation 
model and in vivo reactivation model via UV irradiation (Orr et al., 2007). Consistently, 
depletion of CD8+ T cells induced the reactivation of control virus similar to that of the 
recombinant HSV-1 (Orr et al., 2007). However, these experiments are not always simple 
to interpret as they involve the use of non-HSV genes and promoters. Nonetheless, these 
studies by Orr and colleagues reinforce the idea that CD8+ T cells may provide immune 
surveillance during latency.  
1.9 Cre-reporter mouse model  
The spatiotemporal evaluation of HSV-1 gene expression during latency proved to be 
challenging to researchers for decades. In recent years, the development of single cell-based 
detection systems has engendered a significant shift in the understanding of gene 
expression during latency (Ma et al., 2014). While, single-cell transcriptome analysis 
provides a snap-shot of transcriptional events at a given time, tracking of lytic gene 
expression in neurons from initial infection to throughout the life of the animal has only 
recently become possible due to the ROSA26R reporter mouse model (Russell and 
Tscharke, 2016). 
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ROSA26R transgenic mice contain the lacZ reporter gene under the control of the ROSA 
promoter (Figure 1.10). However, the synthesis of a lacZ gene product is muted by the 
presence of a loxP-flanked stop element between the reporter gene and the ROSA 
promoter (Soriano, 1999). The expression of Cre recombinase induces removal of the stop 
element by recombination between loxP-sites and allows the synthesis of -galactosidase 
enzyme (Figure 1.10). In the event of this recombination, the cell is permanently marked by 
-galactosidase, which can be visualised at a later time point by staining with a 
chromogenic substrate such as X-Gal. By infecting ROSA26R reporter mice with 
recombinant HSV-1, which contains Cre recombinase under the control of a selected 
HSV-1 promoter, the transcriptional history of that promoter can be studied at any time 
during the life of the mouse. This tracking method depends on the activation of the 
selected viral promoter, which when occurs, leads to Cre-mediated recombination taking 
place and driving constitutive reporter gene expression.  
Recombinant HSV-1, engineered to express Cre from the cytomegalovirus IE (CMV IE) 
promoter, triggers Cre expression in every infected cell regardless of its fate leading to the 
permanent marking of that cell (Arthur et al., 2001; Proença et al., 2008; Wakim et al., 
2008). While the CMV IE promoter marks all neurons, it had been noted from previous 
studies that native HSV-1 promoters are regulated such that only a proportion of the 
infected neurons are marked by -galactosidase expression during lytic infection (Proença 
et al., 2008; Russell and Tscharke, 2016). Further, using this model, Russell and Tscharke 
(2016) found that lytic gene expression also occurs during and after the establishment of 
latency. They generated HSV-1 expressing Cre under the control of ICP0, ICP47, ICP6 or 
gB promoters. By infecting ROSA26R mice with these recombinant viruses, they made 
several interesting findings. First, Cre-mediated marking by lytic promoters occurred 
beyond the initial lytic infection, indicating that the virus spread after the peak of acute 
infection. Secondly, the lytic promoters ICP47, ICP6 and gB, were active during latency 
suggesting the possibility that these proteins might be expressed during latency. Finally, the 
ICP47 promoter, unlike other lytic promoters tested, was active during the establishment 
phase of latency. The authors suggested that ICP47 might be involved in promoting 
neuronal survival. 
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Figure 1.10 Schematic diagram of ROSA26R/Cre reporter mouse model. The 
ROSA26R reporter constructs consists of a ROSA promoter, which drives a loxP flanked 
coding sequence of the lacZ gene. Following Cre-mediated recombination between the two 
loxP sites, the stop element gets excised and the ROSA promoter can now constitutively 
drive the expression of the lacZ gene leading to the synthesis of -galactosidase. ROSA26 
mice infected with recombinant HSV-1 that express Cre display permanent -galactosidase 
synthesis in infected cells in which Cre is expressed. These cells can be tracked later by 
staining the tissue using X-Gal. 
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1.10 Aims of this thesis 
The ability of HSV-1 to modulate CD8+ T cell recognition is of clinical significance in 
human recrudescent disease. Equally, the ability of the host to recognise and respond to 
HSV-1 infection is of paramount importance to control the primary infection and 
reactivation. Over the past two decades, our knowledge on the CD8+ T cell immunity to 
HSV-1 infection has substantially increased with the use of mouse models. However, there 
is still a discrepancy in the HSV-1 field on the functionality of the immunomodulatory 
protein ICP47 in mice. On the one hand, in vitro assays and biochemical studies suggest a 
poor inhibition of mouse TAP by ICP47, but on the other, in vivo mouse studies suggests 
that ICP47 enhances HSV-1 neurovirulence in mice. The overall aim of my PhD study was 
to improve our understanding of the role of ICP47 by bridging the current gap between 
the available in vitro biochemical data and the in vivo pathogenesis data.  
The first aim of the thesis was to investigate the role of ICP47 during different facets of 
HSV-1 infection in mice. For this, I generated ICP47 mutant and appropriate control 
viruses and analysed the ability of ICP47 to inhibit antigen presentation in mouse cells by 
an in vitro flow cytometry-based assay. Then, I assessed the influence of ICP47 on viral 
pathogenesis, establishment of latency, stability of latency and reactivation of the virus in 
mice using a zosteriform infection model (Chapter 3). The results from this chapter lead to 
the subsequent aims of this thesis. 
The second aim was to investigate the basis of the difference in Cre-mediated neuronal 
marking by the ICP47 promoter when placed in different regions of HSV-1 genome using 
ROSA Cre reporter mouse model (Chapter 4).  
The third aim was to assess the efficiency at which ICP47 block antigen presentation in 
human cells and mouse cells by an absolute quantification of MHC I bound peptides 
presented on cells infected with wild-type virus or ICP47 null mutant (Chapter 5). 
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2 Materials and Methods 
2.2 Materials 
2.2.1 Media, buffers, and solvents 
2.2.1.1 Cell culture media 
Dulbecco’s Modified 
Eagle Medium 
(DMEM) 
 Dulbecco’s Modified Eagle Medium (DMEM); high glucose 
with phenol red (Invitrogen™); was supplemented with 2 
mM L-glutamine. Heat inactivated foetal bovine serum 
(FBS) was added at a concentration of 2% v/v (D2) or 10% 
v/v (D10). Media without FBS was referred to as D0. 
Minimum essential 
medium (MEM) 
 MEM with phenol red (Invitrogen™) was supplemented 
with 4 mM L-glutamine, 5mM HEPES buffer 
(Invitrogen™) and 50 M -mercaptoethanol. Heat-
inactivated FBS was added at a concentration of 2% v/v 
(M2) or 10% v/v (M10). Media without FBS was referred 
to as M0. 
Foetal bovine serum 
(FBS) 
  
CMC-MEM  0.4% (w/v) Carboxymethyl cellulose in M2. 
 
2.2.1.2 Media for bacterial culture 
Luria Bertani (LB) 
media 
 10 g/L Tryptone (Bacto), 5 g/L yeast extract (Bacto), 10 
g/L sodium chloride (Merck) in deionised water. 
LB agar   1.5% (w/v) Agar (Bacto) in liquid LB media. 
 
2.2.1.3 Buffers and solutions   
FBS-PBS  PBS (Sigma Aldrich) supplemented with 2% (v/v) FBS. 
Red cell lysis buffer  0.14 mM Ammonium chloride (Sigma Aldrich) and 19 
mM Trizma base (Sigma Aldrich) in deionised water, pH 
7.2. The buffer was sterilised by autoclaving and stored at 
4C. 
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 RSB buffer  10 mM Trizma base, 10 mM potassium chloride (Sigma 
Aldrich) and 1.5 mM magnesium chloride (Ajax 
FineChem) in deionised water. 
0.5 M EDTA  0.5 M Ethylenediaminetetraaceticacid (EDTA) (Sigma-
Aldrich) in deionised water, pH adjusted to 8.0 with 
sodium hydroxide pellets. 
Tris-Acetate-EDTA 
(TAE) buffer 
 40 mM Trizma base (Sigma-Aldrich), 20 mM glacial acetic 
acid (Univar) and 1 mM EDTA in deionised water. 
Tris-EDTA (TE) 
buffer 
 10 mM Trizma base and 1 mM EDTA in deionised water. 
Crystal violet solution  0.1% (w/v) of crystal violet (Sigma Aldrich) and 15% 
(v/v) ethanol in deionised water. 
Avertin   12.5 mg/mL 2, 2, 2 – tribromoethanol (Sigma Aldrich) 
and 2.5% (v/v) 2-methyl-butanol dissolved in sterile 
water and filter sterilised. Stored in the dark at 4C for no 
more than 14 days. 
Fixative for DRG  2% (v/v) Paraformaldehyde (PFA) (COM) and 0.5% 
glutaraldehyde (Sigma Aldrich) in PBS. 
X-Gal permeabilisation 
buffer 
 2 mM Magnesium chloride, 0.01% (w/v) sodium 
deoxycholate (Sigma-Aldrich), 0.02% (v/v) IGEPAL® 
CA-630 (Octyl phenoxy poly (ethyleneoxy) ethanol) 
(Sigma-Aldrich), 5 mM potassium ferrocyanide (Sigma-
Aldrich) and 5 mM potassium ferricyanide (Sigma-
Aldrich) in deionised water. 
X-Gal staining solution  X-Gal permeabilisation buffer with 1 mg/mL 5-bromo-4-
chloro-indolyl--D-galactopyranoside (X-Gal). 
50% Glycerol  50% (w/v) Glycerol (Sigma-Aldrich) in PBS. 
Trioxsalen  1 g/L Trioxsalen (Sigma-Aldrich) in PBS. 
6× DNA gel loading 
buffer 
 50% (w/v) Glycerol, 0.25% (w/v) Bromophenol blue 
(Merck) and 0.25% (w/v) xylene cyanol (Sigma-Aldrich) 
in deionised water.   
Saponin  5% (w/v) Saponin (Fluka) in deionised water. 
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2.2.1.4 Buffers and solutions used for mass spectrometry 
DPM crosslinker  40 mM Dimethyl pimelimidate (Sigma D8388) in 
Triethanolamine (0.2 M, pH 8.2). The pH of the solution 
was adjusted to 8.3 using NaOH. 
1× Lysis buffer  0.5% (v/v) IGEPAL CA-630 from Sigma, 50 mM Tris-HCl 
(pH 8.0), 150 mM sodium chloride, cOmplete™ protease 
inhibitor cocktail (Sigma-Aldrich) in Milli-Q water. 
Wash buffer 1  0.005% (v/v) NP-40, 50 mM Tris-HCl (pH 8.0), 150 mM 
sodium chloride, 5 mM EDTA, 100 M phenyl methyl 
sulfonyl fluoride (stored at -20C as 0.1 M stock in absolute 
ethanol), 1 g/mL pepstatin A (stored at -20C as 1 
mg/mL in isopropanol) and Milli-Q water. The buffer was 
freshly prepared and stored on ice. 
Wash buffer 2  50 mM Tris-HCl (pH 8.0), 150 mM sodium chloride in 
Milli-Q water. The buffer was freshly prepared and stored 
on ice. 
Wash buffer 3  50 mM Tris-HCl (pH 8.0), 450 mM sodium chloride in 
Milli-Q water. Freshly made and stored on ice. 
Wash buffer 4  50 mM Tris-HCl (pH 8.0) in Milli-Q water. The buffer was 
freshly made and stored on ice. 
Elution buffer  10% (v/v) Acetic acid (Sigma ACS grade) in Milli-Q water. 
HPLC fractionation 
buffer A  
 0.1% (w/v) Trifluoroacetic acid (Sigma-Aldrich) in Milli-Q 
water. 
HPLC fractionation 
buffer B 
 0.1% (w/w) Trifluoroacetic acid and 80% (v/v) acetonitrile 
(Sigma-Aldrich) in Milli-Q water. 
Borate buffer pH 8  50 mM Boric acid, 50 mM potassium chloride and 3.97 mM 
sodium hydroxide in Milli-Q water. Filter sterilized through 
a 0.22 m syringe filter. 
Citrate buffer pH 3.0  0.1 M Citrate (Sigma-Aldrich), pH 3.0. Filter sterilized 
through a 0.22 m syringe filter. 
MS buffer A  0.1% (v/v) Formic acid (Sigma-Aldrich) in Milli-Q water. 
MS buffer B  95% (v/v) Acetonitrile (Sigma-Aldrich) and 0.1% (v/v) 
formic acid in Milli-Q water. 
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2.2.2 Antibodies 
The antibodies used for this study are listed in Table 2.1. 
Table 2.1 Summary of the antibodies used in this thesis 
Antibody Species Clone Source 
Anti-mouse-H-2Kb Mouse Y-3 Purcell lab* 
Anti-mouse-H-2Db Mouse 28-14-8S Purcell lab* 
Anti-mouse-CD8-Phycoerythrin Rat 53.6.7 Biolegend
® 
Anti-mouse-IFN-Allophycocyanin Rat XMG1.2 Biolegend
® 
Anti-mouse-SIINFEKL bound to 
H-2Kb-Allophycocyanin 
Mouse 25-D1.16  Biolegend® 
Fluorescein isothiocyanate (FITC) - 
conjugated goat anti-mouse F(ab)2 
(Polyclonal) 
Goat --- Agilent Dako 
Anti-MVA hyperimmune serum Rabbit --- Institute of Medical 
and Veterinary 
Science, South 
Australia# 
*Antibody produced in-house in the Purcell laboratory, Monash University, Victoria 
#The hyperimmune serum was generated by immunising rabbit at three weekly intervals 
with 107 focal forming units of VACV strain MVA. The serum was collected two weeks 
after the last immunisation at Institute of Medical and Veterinary Science, South Australia# 
--- Not applicable. 
 
2.2.3 Chemicals and Reagents 
DNA markers (100 bp and 1.0 Kbp)  New England Biolabs 
1 Kbp DNA extension ladder  Invitrogen™  
UltraPure Agarose  Life Technologies 
BigDye terminator for Sanger 
sequencing 
 Biomolecular resource facility, John Curtin 
School of Medical Research 
5× reaction buffer for Sanger 
sequencing 
 Biomolecular resource facility, John Curtin 
School of Medical Research 
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Deoxyribonucleotide triphosphate 
(dNTP) mix (10 mM) 
 Bioline 
10 µg/mL Proteinase K   Roche 
Cycloheximide   100 mg/mL cycloheximide (Sigma-Aldrich). 
Actinomycin D   20 mg/mL in methanol (Life Technologies). 
Ampicillin   100 μg/L in deionised water (Sigma-Aldrich). 
Kanamycin  50 μg/L in deionised water (Sigma-Aldrich). 
Penicillin Streptomycin (Pen Strep)   100× concentrated solution contains 5000 
units/mL of penicillin and 5000 µg/mL of 
streptomycin. (Thermo Fisher Scientific). 
Sodium dodecyl sulfate   20% (w/v) in deionised water (Sigma-Aldrich). 
0.4% (v/v) Trypan blue solution   Invitrogen™ 
Phenol – chloroform – isoamyl 
alcohol mixture (25:24:1)  
 Sigma-Aldrich 
 
2.2.4 Plasmids 
The plasmids generated in this study and the parent vectors are listed in the Table 2.2. The 
CRISPR Cas-9/guide plasmids and homology directed repair (HDR) templates were used 
for the generation of recombinant HSV-1.  
Table 2.2 Summary of plasmids used in this thesis 
Plasmid  Description  Viruses 
px330 icp47  A plasmid with Cas-9/guide sequence targeting 
ICP47 gene. 
 HSV-1 Ka47Δ 
  HSV-1 GKa47Δ 
  HSV-1 Ka47inΔ 
px330 
icp47del 
 A plasmid with Cas-9/guide sequence targeting 
ICP47 region in HSV-1 Ka47Δ. 
 HSV-1 Ka47R 
  HSV-1 GKa47R 
pxUL26/7  A plasmid with Cas-9/guide sequence targeting 
intergenic region between UL26 and UL27 
genes. 
 HSV-1 
Ka47rescue 
  HSV-1 UL27-
pa47min 
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Plasmid  Description  Viruses 
pxUL3/4 A plasmid with Cas-9/guide sequence targeting 
intergenic region between UL3 and UL4 genes. 
HSV-1 UL3-
pa47 
    HSV-1 UL3-
pa47ΔoriS 
pUC 
ICP47del 
 ICP47 deletion region and left homology arm 
amplified from HSV-1 Ka47Δ and cloned into 
the unique HindIII site of RF_CP47_HIII. 
Used as homology-directed repair (HDR) 
template. 
 HSV-1 GKa47Δ 
pT CMV IE 
eGFP Cre 
 DNA template to amplify EGFP Cre BGH 
PolyA fusion gene for cloning (Russell et al., 
2015). 
 HSV-1 Ka47inΔ 
pICP47 
eGFPCrePol
yA 
 eGFP Cre BGH PolyA and ICP47 left 
homology arm cloned into the unique HindIII 
site of RF_CP47_HIII. Used as HDR template. 
 HSV-1 Ka47inΔ 
pU26/7 
pI47 
 A plasmid containing ICP47 promoter without 
oriS flanked by UL26 and UL27 region of 
HSV-1 KOS (Tiffany Russell, unpublished). 
 Plasmid: 
pUL26\7 
pICP47eGC 
BGH PolyA 
pUL26/27 
ICP47 SV40 
PolyA 
 This plasmid was constructed in two steps. 
First, the ICP47 coding sequence was amplified 
from HSV-1 KOS genomic DNA and cloned 
into the unique SpeI site of pU26/7 pI47. 
Then, the sequence corresponding to SV40 
PolyA signal was amplified from pT CMV IE 
eGFP Cre and cloned into the unique EcoRV 
site downstream of the ICP47 coding sequence. 
Used as HDR template. 
 HSV-1 
Ka47rescue 
pUL26/7 
pICP47eGC 
BGH PolyA 
 eGFP Cre BGH PolyA amplified from pT 
CMV IE eGFP Cre and cloned into NotI site 
of pU26/7 pI47. Used as HDR template. 
 HSV-1 UL27-
pa47min 
mnpICP47 
eGC 
 A plasmid containing eGFP Cre BGH PolyA 
placed under the full-length ICP47 promoter 
with mutated oriS site flanked by right and left 
homology arms from UL3-UL4 region. Used as 
HDR template. Synthesised by GenScript. 
 HSV-1 UL3-
pa47ΔoriS 
npICP47 
eGC 
 A plasmid containing eGFP Cre BGH PolyA 
placed under the full-length ICP47 promoter 
flanked by right and left homology arms from 
UL3-UL4 region. Used as HDR template. 
Synthesised by GenScript. 
 HSV-1 UL3-
pa47 
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2.2.5 Oligodeoxynucleotides 
The oligonucleotides listed in Table 2.3 were synthesized by Sigma-Aldrich. 
Table 2.3 Summary of oligonucleotides used in this thesis 
Oligo  Sequence 5′ to 3′  Use 
ICP47 Seq Fwd  CAGAGACTCGGGTGATGGTCG  To amplify the ICP47 coding region.  
ICP47R2  GTTGCGTGGACCGCTTC  To amplify HSV-1 KOS or HSV-1 Ka47Δ. 
ICP47mR  GGGCCCTGAAGCTTTGAC  Specific reverse primer to screen for recombinant HSV-1 
Ka47Δ. 
ICP47wR  GCCCTGGAAATGGCGGAC  Specific reverse primer to screen for HSV-1 KOS. 
ICP47wR2  TGTCGTGGGCCCTGGAAA  Specific reverse primer to screen for HSV-1 KOS. 
ICP47revRP  GGAAAAGCATGTCGTGGGCTCTA  Specific reverse primer to screen for Ka47R. 
47_EGFPCreBGH_FP*  GGAAGGTGTCCGCCAAAGAACTAGCTGCTA
TTGTCTT 
 To amplify EGFP Cre BGH PolyA signal from pT CMV 
eGFP Cre plasmid for the construction of the plasmid, 
pICP47eGFPCrePolyA. 
 
rf47_egfpcre RP*  TCGGGGGGAAAAGCTATGGTGAGCAAGGG
CGAG 
 
LF_FP infusion*  TGATTACGCCAAGCTTGGTCCGCGGGCAAC
ATCAC 
 Forward primer to amplify left homology arm from ICP47 
region for the construction of the plasmid, 
pICP47eGFPCrePolyA. 
LFpBII_EGFPCreBGH_R
P* 
 TAGCAGCTAGTTCTTTGGCGGACACCTTCC
TGGACAA 
 
icp47 LF seq FP  CAACATGGCCCCTGTAGCCG  To confirm the insertion site in HSV-1 Ka47in. 
Cre Lf Seq  CACGACCAAGTGACAGCAAT 
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Oligo  Sequence 5′ to 3′  Use 
Cre Rf Seq  TGGCAATTTCGGCTATACGT  Sequencing primer that binds the Cre coding sequence. 
BGH Seq Fwd  AAGCCTTCGACGTGGAGG  Sequencing primer. 
pUS12UL26_27 infusion F*  GAAAGATATCGCGGCCTCAACGGGTTACCG
GATTAC 
 
Primers to amplify the ICP47 coding sequence for the 
construction of the plasmid, pUL26/27 ICP47 SV40 PolyA. pUS12UL26_27 infusion R*  GGCACTAGTGCGGCCATGTCGTGGGCCCT
GGAAATG 
 
SV40 F*  TTGTTGGGTACCAGCCAGACATGATAAGAT
ACATTG 
 Forward primer to amplify SV40 PolyA signal. 
SV40 R*  CCCGGCTGTGATAGAACTTGTTTATTGCAG
C 
 Reverse primer to amplify SV40 PolyA signal. 
ICP47F  GTTCTTCGATGTGCCACACC  PCR primer used to screen for HSV-1 Ka47rescue. It was 
paired with ICP47wR2. 
UL26inF  AGGCGGGTAGCTTTACAATGCAAAAG  PCR primers used to plaque purify HSV-1 Ka47rescue and 
UL27-pa47min. 
UL27R  AAGTTCCCAACAAAGACGGTGACG 
 
UL4 Seq Rev  CGTCGTCAACACCAACATCA  Primer pair to confirm the insertion site in HSV-1 UL3-pa47 
and HSV-1 UL3-pa47ΔoriS. 
BGHr  CTGTGCCTTCTAGTTGCCAG 
 
UL3_Seq_Fwd  GCCGTCAAGAACTGTTATCC  Primer pair to confirm the insertion site in HSV-1 UL3-pa47 
and HSV-1 UL3-pa47ΔoriS 
pICP47_Seq_Rev  ACGCCGGGACCAACGGG 
 
ptracer UL3 Lf  TTACACGCGATCTTCGGACG  Primer pair used to plaque purify HSV-1 UL3-pa47 and 
HSV-1 UL3-pa47ΔoriS. 
ptracer UL4 Rf  CGCGGACACCATTTACATCA 
 
Seq_RevpEGFPN1  CTCGACCAGGATGGGCAC  Sequencing primer that binds the eGFP coding sequence. 
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Oligo  Sequence 5′ to 3′  Use 
ICP47 seq2  CGCACTTCGCCCTAATAAT  Sequencing primer that binds the ICP47 promoter region. 
Tomato_BGH_rev*  CGCCCTTGCTCACCATGCGGCCGCACTAGT
G 
 
Primers to amplify eGFP Cre BGH PolyA for the 
construction of the plasmid pUL27-pa47min. UL7pICP47eGC inf*  AGATATCGCGGCCGCTGCTATTGTCTTCCC
AATCC 
 
HSVgB_p4  GAGTACGGCGGCTCCTTCCGAT  Used with pICP47_Seq_Rev for screening HSV-1 UL27-
pa47min. 
M13 Rev+  CAGGAAACAGCTATGAC  Used with an appropriate guide oligo for the screening of the 
corresponding CRISPR associated protein 9 (Cas9)/guide 
sequence containing plasmid. 
*Oligos used for generating PCR fragments compatible for In-Fusion cloning. The underlined nucleotides are complementary to a linearised vector end or 
an adjacent PCR fragment.  
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2.2.6 Cell lines 
All cell lines were handled in a class II biosafety cabinet and maintained in a humidified 
incubator at 37C and 5% CO2. All cell lines used in this study were sub-cultured twice a 
week. Table 2.4 provides the list of cell lines used for this study. 
Table 2.4 Summary of cell lines used in this thesis 
Cell line  Origin   Media Used for 
Veros  African green monkey 
kidney epithelial cells 
 M10 a. Purification of 
recombinant HSV-1 
b. Plaque assay 
c. Preparation of HSV-1 
stocks  
d. Cycloheximide reversal 
assay 
293A  Primary human 
embryonic kidney cells 
transformed with human 
adenovirus 5 DNA 
 D10 Generation of recombinant 
HSV-1 
MC57G  A cell line derived from 
Methylcholanthrene 
induced fibrosarcoma in 
C57BL/6J mice 
 D10 a. Quantification of surface 
H-2Kb using QIFIKIT 
b. In vitro antigen 
presentation assay 
c. Mass spectrometry based 
discovery and 
quantification of MHC I 
bound peptides 
293KbC2  293A cells that stably 
express H-2 Kb under 
cytomegalovirus 
promoter (Tscharke et 
al., 2005) 
 D10 a. Quantification of surface 
H-2Kb using QIFIKIT 
b. In vitro antigen 
presentation assay 
c. Mass spectrometry based 
discovery and 
quantification of MHC I 
bound peptides 
293DbA5  293A cells that stably 
express H-2 Kb under 
cytomegalovirus 
promoter (Tscharke et 
al., 2005) 
  Quantification of surface H-
2Kb using QIFIKIT 
BHK-21  Syrian gold hamster 
kidney fibroblast 
 M10 Preparation of MVA stocks 
and plaque assay 
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2.2.7 Viruses 
The wild-type HSV-1 strain KOS used throughout this thesis was a gift from Dr. F. R. 
Carbone (University of Melbourne, Australia). The recombinant HSV-1s were generated on 
the background HSV-1 strain KOS. Recombinant vaccinia viruses and recombinant HSV-1 
viruses used in this study are listed in Table 2.5 and Table 2.6. 
Table 2.5 Summary of recombinant HSV-1 made for this study 
Virus  Description 
HSV-1 Ka47Δ  HSV-1 ICP47 null mutant generated by introducing a stop codon 
downstream of the ICP47 translation initiation site in HSV-1 
KOS. 
HSV-1 Ka47R  Revertant of HSV-1 Ka47Δ, capable of encoding functional 
ICP47. 
HSV-1 Ka47in  HSV-1 ICP47 null mutant generated by inserting eGFP Cre in 
place of ICP47 gene in HSV-1 KOS. The native ICP47 promoter 
drives the expression of the fusion gene. 
HSV-1 
Ka47rescue 
 
 Rescuant of Ka47in that encodes functional ICP47. ICP47 
coding sequence placed downstream of the modified ICP47 
promoter (without oriS) was inserted into the intergenic region 
between UL3 and UL4 genes. The virus was generated using 
HSV-1 Ka47in as the background.  
HSV-1 GKa47Δ  HSV-1 ICP47 null mutant generated by introducing a stop codon 
downstream of the ICP47 translation initiation site in HSV-1 
pCMV IE eGFP Cre.  
HSV-1 GKa47R  Revertant of HSV-1 GKa47Δ that encodes functional ICP47. 
HSV-1 UL27-
pa47min 
 HSV-1 that expresses eGFP-Cre fusion gene under the control of 
a minimal ICP47 promoter without oriS. The reporter cassette 
was inserted into the intergenic region between the UL26 and 
UL27 genes. 
HSV-1 UL3-pa47  HSV-1 that expresses eGFP-Cre fusion gene under the control of 
a full-length ICP47 promoter. The reporter cassette was inserted 
into the intergenic region between the UL3 and UL4 genes. 
HSV-1 UL3-
pa47ΔoriS 
 HSV-1 that expresses eGFP-Cre fusion gene under the control of 
a full-length ICP47 promoter. The reporter cassette was inserted 
into the intergenic region between the UL3 and UL4 genes. The 
oriS site in the full-length ICP47 promoter was modified to stop 
the function of the ectopic oriS. 
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Table 2.6 Recombinant viruses already available for this study 
Virus  Description  Reference 
HSV-1 pCMV 
IE eGFP Cre 
 HSV-1 expressing eGFP-Cre fusion gene 
driven by CMV IE promoter.  
 Ma et al., 2014 
HSV-1 UL3-
pa47min 
 HSV-1 expressing eGFP-Cre fusion gene 
driven by the modified ICP47 promoter 
(without oriS). Originally, this virus was 
referred to as HSV-1 pICP47_eGC. 
 Russell and 
Tscharke, 2016 
MVA ES mini 
OVA* 
 MVA with the ER-targeted OVA257-264 mini 
gene inserted in the TK locus and driven by 
VACV p7.5 promoter. 
 Generated by 
YC Wong in 
Tscharke Lab 
MVA mini 
OVA* 
 MVA with the OVA257-264 mini gene inserted 
in the TK locus and driven by VACV p7.5 
promoter. 
 Generated by 
YC Wong in 
Tscharke Lab 
MVA mini Flu 
PR8 PB1F2(62-
70)* 
 MVA with the PR8 PB1F262-70 mini gene 
inserted in the TK locus and driven by 
VACV p7.5 promoter. 
 Generated in 
Tscharke Lab 
*Modified Vaccinia virus Ankara (MVA) is an attenuated vaccinia virus derived from the 
parental strain chorioallantois vaccinia virus Ankara (CVA) by multiple laboratory passages 
in chicken embryo fibroblast.  
  
2.2.8 Mice 
Six weeks old pathogen-free female C57BL/6 mice or B6.129S4-Gt(ROSA)26Sortm1So/J 
(ROSA26R; Soriano, 1999) mice were obtained from the Australian Phenomics Facility 
(Canberra, Australia). ROSA26R mice were a kind gift from Dr. F. R. Carbone (University 
of Melbourne, Australia), housed and bred at the Australian Phenomics Facility. Mice were 
housed and all experiments were conducted according to the ethical requirements under 
approvals A2014/025 and A2017/39 from the Australian National University Animal 
Ethics and Experimental Committee. 
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2.3 Methods 
2.3.1 Polymerase chain reaction (PCR) 
Standard Taq Polymerase (NEB) was used for performing colony PCR and screening for 
isolation of recombinant virus. Phusion® High fidelity DNA polymerase (NEB) was used 
for the amplification of DNA fragments for molecular cloning and amplification of 
recombinant viral DNA for sequencing. PCR was performed using Eppendorf 
Mastercycler or ABI Veriti 96-well thermocycler. PCR was set up according to 
manufacturer’s protocol in a volume of 20 L or 50 L on ice.  
PCR using Taq polymerase (NEB) was performed in a reaction mix consisting of 1× 
ThermoPol buffer, 200 M dNTPs, 0.2 μM each of forward primer and reverse primer, an 
appropriate amount of DNA template and 1 unit of Taq polymerase enzyme in sterile 
deionised water. The PCR conditions were as follows: initial denaturation at 95C for 30 
sec, 30 cycles of denaturation (95C, 15 sec), annealing (appropriate temperature for the 
primer pair, 30 sec), extension (68C, 1 minute/kb), and the final extension at 68C for 5 
minutes. The reaction was placed on hold at 16C until subsequent use. 
PCR using Phusion® High fidelity DNA polymerase (NEB) was done using 1 unit of the 
enzyme, 1× Phusion GC buffer, 200 M dNTPs, and 0.5 μM each of forward primer and 
reverse primer, 3% (v/v) DMSO and approximately 10 ng of DNA template in sterile 
deionised water. The thermocycling condition for PCR included initial denaturation at 
98C for 30 sec, 30 cycles of denaturation (98C, 10 sec) followed by annealing 
(appropriate temperature for the primer pair, 30 sec) then extension (72C, 15 sec/kb). The 
final extension was performed at 72C for 10 minutes. Again, the reaction was placed on 
hold at 16C until subsequent use. 
2.3.1.1 Preparation of DNA template for PCR 
The DNA template for colony PCR generally came from a small portion of a recently 
transformed bacterial colony that was resuspended in 10 L of deionized water and boiled 
at 95C for 5 minutes. After heat treatment, the cell debris was pelleted using a 
microcentrifuge and 2 L of the clear supernatant was used for conducting PCR.  
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For screening of plaque picks during the isolation of recombinant virus (see section 
2.3.5.4), DNA template was prepared from virus grown in Vero cells in a 96-well plate. 
Briefly, Vero cells were inoculated with the virus from a plaque pick and allowed to grow 
for 48 hours at 37C and 5% CO2. The inoculum was removed, and the cells were washed 
with PBS. To each well, 100 L of 10 g/mL of proteinase K in 1× ThermoPol PCR 
buffer was added, the plate was freeze-thawed once and then, incubated at 56C for 20 
minutes. Proteinase K was heat inactivated by incubating the plate at 85C for 15 minutes. 
Subsequently, for PCR screening 2 L of the DNA preparation was used as a template. 
Extraction of viral DNA from seed stock was performed as described previously by mixing 
10 L of seed stock with 1 g/mL proteinase K in 1× ThermoPol PCR buffer, incubating 
at 56C for 20 minutes followed by heat killing proteinase K at 85C for 15 minutes. For 
PCR, 10 L of this solution was used as a template. In some cases, purified plasmid DNA 
or viral genomic DNA were used as a template for PCR. 
2.3.2 DNA sequencing 
Automated Sanger sequencing was carried out to confirm and verify the desired 
modification introduced into the plasmid DNA or viral genomic DNA. The sequencing 
reaction was performed in a volume of 20 L and contained 1 L of Big Dye Terminator, 
3.2 pmol of the sequencing primer, 1× sequencing buffer and an appropriate amount of 
DNA template. Generally, 200 ng of plasmid or 10 ng of PCR amplified product was used 
for sequencing. The thermocycling conditions for PCR were: 
Step Temperature Duration Cycle 
Initial denaturation 94C 5 min 1 
Denaturation 96C 10 sec 
 
30 
Annealing 50C 5 sec 
Extension 60C 4 min 
Hold 4C 
 
The sequencing reaction was subjected to ethanol/sodium acetate precipitation and air-
drying prior to submission for sequencing to ACRF Biomolecular Resource Facility, ANU. 
The sequencing data was analysed using CLC Main Workbench (version 7.6.2). 
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2.3.3 Restriction enzyme digestion 
Restriction enzyme digestion was carried out to a) produce linearised plasmids for cloning 
(section 2.3.4.1), b) produce linearised plasmids for the generation of HDR template 
(section 2.3.5.1) and for the restriction digestion analysis of genomic DNA of the 
recombinant HSV-1 (section 2.3.7.2). Restriction digestion reactions were carried out using 
NEB restriction enzymes and corresponding reagents according to the manufacturer’s 
instructions. 
2.3.4 Molecular cloning and bacterial transformation 
2.3.4.1 Ligation cloning  
Linear double-stranded DNA fragments were obtained either by annealing of 
complementary oligonucleotides (section 2.3.5.2) or by PCR amplification. The resulting 
products were cloned into vectors previously linearised by restriction digestion reaction. 
The purified DNA fragments containing complementary overhanging sequences were 
ligated together using NEB ligase enzyme according to the manufacturer’s protocol. 
2.3.4.2 In-Fusion cloning 
The In-Fusion cloning system involves the insertion of multiple DNA fragments into a 
linearised vector based on a 15 bp homologous overlapping segments in the adjacent 
fragments. This facilitates directional cloning of multiple fragments into the desired vector. 
The inserts used in this thesis were generated by PCR amplification using viral DNA or 
plasmid DNA as a template and high-fidelity DNA polymerase. The backbone vector was 
linearised by restriction enzyme digestion at a unique recognition site. The purified DNA 
fragments were subsequently cloned using the In-Fusion PCR cloning kit (Clontech) 
according to the manufacturer’s protocol. Briefly, a 10 µL reaction mix consisting of 5× In-
Fusion HD enzyme premix, linearized vector, purified PCR fragments and deionised water 
was incubated at 50ºC for 15 minutes, before being cooled on ice and transformed into -
select gold competent cells (Bioline) or One Shot™ Stbl3™ chemically competent E. coli 
cells (Invitrogen™) cells.  
2.3.4.3 Transformation and plasmid isolation 
For purification of plasmids after cloning competent E. coli cells were transformed using 
the manufacturer’s protocol. Briefly, an appropriate amount of plasmid, ligation mix or In-
Fusion PCR reaction was added to a vial of competent cells. After gentle mixing, the 
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transformation mix was incubated on ice for 30 minutes, followed by 45 sec of heat shock 
at 42ºC in a water bath. The tube was then immediately cooled on ice for 2 minutes with 
the subsequent addition of 1 mL of pre-warmed LB media. The tubes were incubated for a 
further 60 minutes in a shaking incubator set to 37ºC and 250 rpm. For each 
transformation, 100 L of the transformed cells was inoculated onto agar plates by 
spreading and the plates were incubated overnight at 37C. The following day, individual 
colonies were screened by colony PCR. The correct clone was cultured in 5 mL of LB 
broth overnight at 37C in a shaking incubator. Following this, plasmid DNA was 
extracted using the AxyPrep plasmid miniprep kit (Axygen Biosciences). The sequence of 
the DNA insert was verified by Sanger sequencing (section 2.3.2).   
2.3.5 Generation of recombinant HSV-1 
To study the role of ICP47 during HSV-1 infection and to study the activation of the 
ICP47 promoter during latency establishment and maintenance, nine recombinant HSV-1 
were generated in this study (Table 2.5). The steps involved in the construction of the 
recombinant viruses are: a) the generation of homology-directed repair (HDR) templates 
that incorporated the desired modification or contained an insert, b) the generation of 
plasmids that could express Cas9 protein and an appropriate guide RNA c) the co-
transfection of HDR template and CRISPR Cas9 plasmids into 293A cells, iv) infection of 
transfected cells at a low plaque forming units (pfu)/cell) with an appropriate HSV-1 
parent virus that could serve as the backbone of the recombinant virus and v) isolation of 
the recombinant virus.  
2.3.5.1 Generation of HDR template 
For the construction of HSV-1 Ka47, HSV-1 Ka47R and HSV-1 GKa47R, long single-
stranded oligo dideoxynucleotides (ssODN) were used as the repair templates. These oligos 
incorporated modification of a few nucleotides in the ICP47 coding sequence. Regions 
composed of 75 bp DNA arms, which flanked the nucleotide modification site, helped to 
direct the homology-based repair of the HSV-1 genome. The sequence information of the 
ssODNs used in this study can be found in Table 2.7. Instead of using ssODN, for the 
construction of HSV-1 GKa47Δ linearized plasmid pUC ICP47del was used. This plasmid 
contained appropriate nucleotide modifications in the ICP47 coding sequence flanked by 
DNA homologous to sequences flanking the desired modification site in the HSV-1 
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genome. Similarly, for the construction of recombinants HSV-1 Ka47in, HSV-1 
Ka47rescue, HSV-1 UL27-pa47min, HSV-1 UL3-pa47 and HSV-1 UL3-pa47ΔoriS, 
linearised plasmid DNA was used as the HDR template (See Table 2.2).  
Table 2.7 List of ssODNs used for the construction of recombinant HSV-1 
Name Sequence 5′ to 3′  Virus 
*cp47 
ttattgatctcatcgcgtacgtcggcgtacgtcctgggcccaacccgcatgttgtcc
aggaaggtgtccgccacgtcaAAGCTTcagggcccacgacatgcttttcc
ccccgacgagcaggaagcggtccacgcaacggtcgccgccggtcgcctcgacg 
 HSV-1 Ka47Δ 
#rev_cp
_47 
ttattgatctcatcgcgtacgtcggcgtacgtcctgggcccaacccgcatgttgtcc
aggaaggtgtccgccattTCTAGAgcccacgacatgcttttcccgacgagc
aggaagcggtccacgcaacggtcgccgccggtcgcctcgacgagggcgtt 
 HSV-1 Ka47R 
HSV-1 
GKa47R 
*The nucleotide substitutions compared to wild-type HSV-1 KOS sequence are shown in 
bold. 
#The restriction enzyme recognition sites introduced for verification of the recombinants 
are shown in uppercase letters. 
2.3.5.2 The CRISPR-Cas9 plasmid 
Single expression vector, pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene plasmid # 
42230, a gift from Feng Zhang), that has both a chimeric single guide RNA driven by the 
U6 promoter and a human-codon optimised spCas9 gene driven by the CBh promoter was 
used as backbone for the construction of all the recombinant viruses described in this 
thesis (Cong et al., 2013). The guide DNA sequences for construction of various CRISPR-
Cas9 plasmids used in this study are listed in Table 2.8. For guide RNA plasmid 
construction, the protocol described by Ran et al. (2013) was followed. Briefly, the 
nucleotide sequence of 20 bases located 5 to an NGG motif was chosen in close proximity 
to the desired genome modification site. A guanine residue was appended at the 5 end of 
the guide sequence if not already present. The complementary guide DNA oligos (Sigma) 
were designed such that the annealed oligos have overhangs compatible for cloning into 
the backbone vector. The oligo pairs were mixed at the equimolar ratio and annealed by 
incubating at 95C for 5 minutes, followed by slow cooling at room temperature. The 
annealed oligo was cloned into the px330 vector, which had been previously linearised 
using BbsI. The ligated vector was transformed into One Shot Stbl3 chemically 
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competent E. coli as per the manufacturer’s instruction. The clones were selected using 100 
g/mL ampicillin-containing LB media and screened for the presence of insert by colony 
PCR. The inserted guide DNA sequence was further verified by Sanger sequencing.  
Table 2.8 Guide DNA sequences used to induce double-stranded break at the 
target region of the HSV-1 genome 
Name of the 
oligo 
 Sequence  Target location Plasmid 
sgRNA_icp47 
top 
 CACCGGAAGGTGTCC
GCCATTTCC 
 
ICP47 region in 
HSV-1 KOS 
px330 icp47 
sgRNA_icp47 
bottom 
 AAACGGAAATGGCG
GACACCTTCC 
 
sgRNA_icp47
r top 
 CACCGTCCGCCACGT
CAAAGCTTC 
 
ICP47 region in 
HSV-1 Ka47Δ 
px330 
icp47del sgRNA_icp47
r bottom 
 AAACGAAGCTTTGAC
GTGGCGGAC 
 
px330UL26\7 
T 
 CACCTTTGTCACGGG
AAAGGAAAG 
 Intergenic region 
between the UL26 
and UL27 genes in 
HSV-1 KOS 
pxUL26/27 
px330UL26\7 
B 
 AAACCTTTCCTTTCCC
GTGACAAA 
 
pxul3\4F  CACCTGGTTGTTTGT
TGTCTTTAA 
 Intergenic region 
between the UL3 
and UL4 genes in 
HSV-1 KOS 
pxUL3/4 
pxul3\4R  TTAAAGACAACAAAC
AACCACAAA 
 
2.3.5.3 Transfection and infection 
The day before transfection, 293A cells were seeded on to a 6-well plate and incubated at 
37C and 5% CO2. The monolayer of cells in each well was transfected with a total of 3 g 
of DNA comprising an equimolar amount of the HDR template and the CRISPR-Cas9 
plasmid. Transfection was carried out using Lipofectamine 2000 (Invitrogen™) according 
to the manufacturer’s instructions. Transfected cells were incubated for 5 hours at 37C 
and 5% CO2. Subsequently, the transfected cells were infected with 0.01 pfu/cell of HSV-1 
in a volume of 1 mL of D0. After two hours of incubation, the inoculum was removed and 
replaced with fresh D2 after which the cells were incubated to allow recombination and 
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virus replication. After 72 hours, the cells and supernatants were collected and stored at      
-80C until further use. 
2.3.5.4 Isolation of recombinant virus 
Five-fold dilutions of the above-harvested transfection/infection mix were made, and 
appropriate dilutions were used to infect confluent Vero cells in a 6-well plate. After 2 
hours of incubation at 37C and 5% CO2, the virus inoculum was removed, and cells were 
overlayed with 2 mL of CMC-MEM. The plate was incubated for 48 hours at 37C and 5% 
CO2.  The individual plaques were marked and 10 l of cells with the medium from this 
marked region was aspirated using a micropipette and transferred to 500 L of D2. This 
virus inoculum is referred to as “plaque pick”. The plaque picks were then subjected to 
three freeze-thaw cycles before infecting individual wells of a 96-well plate with confluent 
Vero cells. A range of PCR primers were used to confirm the presence of the recombinant 
virus and detect the parental virus. Multiple rounds of plaque purification were carried out 
until the stock was free of the parental virus. The genome modification and insertion sites 
were verified by Sanger sequencing (section 2.3.2) and restriction fragment length 
polymorphism (RFLP) analysis (section 2.3.7.2). 
2.3.5.5 Preparation of HSV-1 stocks 
For the preparation of seed stock, the virus from the purified plaque was added to a 25 cm2 
flask with confluent Vero cells. The virus was allowed to grow for 72 hours followed by a 
collection of both the adherent cells and the supernatant with the help of a cell scraper (BD 
Biosciences). The infected cells were centrifuged at 524 g for 10 minutes at 4C. The 
supernatant was discarded, and the cell pellet was resuspended in 500 l of M2, which 
formed the seed stock. After freeze-thawing three times, 100 l of the seed stock was 
inoculated into a T75 flask containing confluent Vero cells and incubated at 37C and 5% 
CO2. After 72 hours, the infected cells were collected with the culture medium with the aid 
of a cell scraper (BD Biosciences). The cell suspension was centrifuged for 10 minutes at 
524 g. The supernatant was collected and subjected to ultracentrifugation for 90 minutes at 
12,000 rpm and 4C. In this step, the centrifugation was performed in Beckmann Coulter 
Optima™ L-90K ultracentrifuge using the SW32Ti rotor. Subsequently, the supernatant 
was discarded, and the pellet was resuspended in M2. This became the supernatant virus. 
The cell-associated virus was harvested by resuspending the cell pellet in M0, sonicating the 
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cells thrice for 20 sec each, followed by centrifugation at 524 g for 5 minutes. This step was 
repeated an additional time and the supernatants from the two rounds of centrifugation 
were pooled to obtain the cell-associated virus. The cell-associated virus and the 
supernatant virus were then pooled, mixed by pipetting and used as the master stock. For 
working stock, the confluent Vero cells in five T175 flasks were inoculated with 0.01 
pfu/cell of master stock and incubated at 37C and 5% CO2 for 72 hours. After this, the 
stock was prepared following the same procedure as the master stock. The centrifugation 
was performed using Beckmann coulter AllegraX-15R benchtop centrifuge unless specified 
otherwise. 
2.3.6 Plaque assay 
Plaque assays were used to estimate the virus titre (Russell, 1962) of the newly prepared 
stocks, samples from the growth curve and tissue homogenates. For virus stocks, 10-fold 
dilutions of the stock were prepared in duplicate in M0. The culture media from 6-well 
plate containing confluent Vero cells was removed and replaced with 500 L of the 
inoculum from the appropriate viral dilutions. The plates were incubated at 37ºC and 5% 
CO2 for 90 minutes with rocking every 15 minutes to allow even spread of the inoculum. 
After the incubation step, the inoculum was removed and replaced with 2 mL of CMC-
MEM. The plates were incubated at 37ºC and 5% CO2 for 48 hours. To visualise the 
plaques, the culture medium was removed, and 1 mL of crystal violet staining solution was 
added to each well. After 10 minutes, the staining solution was removed and the number of 
plaque forming units was enumerated under the microscope. The virus titre was calculated 
based on the average number of plaques formed in an appropriate dilution between 
duplicates. When the values differed more than two-fold between the duplicates or 
dilutions within a replicate, the outcome was rejected, and the assay was repeated. For 
tissue homogenates, 10-fold dilutions were prepared as described previously and the assay 
was conducted without duplicates. In this case, less than two-fold difference between the 
dilutions was tolerated and the titre was calculated appropriately. The virus titre is 
presented as a number of pfu per mL or per mouse.  
2.3.7 Characterisation of newly constructed recombinant viruses 
The newly generated recombinant viruses were compared with their parent virus or 
unmodified KOS for their ability to grow in cell culture and its virulence in mice. Further, 
to test if the recombination affected the overall structure of the HSV-1 genome, an RFLP 
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analysis was performed. The revertant and rescuant viruses serve as a control for any 
unintended random mutation that could occur during the virus purification process. 
2.3.7.1 Multi-step growth assay 
The growth characteristics of the newly constructed recombinant HSV-1 were determined 
by infecting Vero cells at 0.01 pfu/cell in a 6-well tissue culture plate and incubated at 37ºC 
and 5% CO2. The infections were carried out in triplicates. After 1 hour, the inoculum was 
removed, and the cells were washed with 2 mL of warm FBS-PBS twice to remove the un-
adsorbed virus. Then, 2 mL of warm M2 was added to each well. This point was 
considered as 0 hours post-infection (hpi). At this time, the cells were immediately scraped 
into the media using cell lifters (Corning Costar), harvested and stored at -80ºC. The 
remaining plates were incubated at 37ºC and 5% CO2. At 6, 24, 48 and 72 hpi, the cells and 
the supernatant were harvested together using cell-lifters. The samples from all five time 
points after infection were subjected to three freeze-thaw cycles before determining the 
virus titre.  
2.3.7.2 Isolation of HSV-1 genomic DNA and RFLP analysis 
Confluent Vero cells in a T175 flask were infected with wild-type or recombinant HSV-1 at 
0.1 pfu/cell and incubated at 37ºC and 5% CO2 for 24 hours or until full cytopathic effect 
(CPE) was observed. The cells were harvested along with the media with the aid of a cell 
scraper (BD Biosciences) and centrifuged at 524 g for 10 minutes at 4ºC (Beckmann 
coulter AllegraX-15R). The supernatant was separated and stored on ice until further 
processing. The cell pellet was resuspended in 10 mL of cold RSB buffer and incubated for 
10 minutes on ice. The lysate was centrifuged at 524 g for 10 minutes at 4ºC. The 
supernatant was collected and stored on ice. The pellet was lysed again as described above. 
All of the supernatants were pooled and subjected to centrifugation at 12, 000 rpm for 90 
minutes at 4ºC (Beckmann Coulter Optima™ LE-90K Ultracentrifuge, SW32Ti rotor). 
The supernatant was discarded, and the pellet was resuspended in TE buffer containing 50 
g/mL proteinase K and 0.5% (w/v) SDS. After 5 minutes of incubation at room 
temperature, an equal volume of phenol:chloroform (24:1 mixture) was added to the 
aqueous mixture and mixed gently. The mixture was then centrifuged at 13,523 g for 10 
minutes using Eppendorf 5454 Benchtop Centrifuge. The aqueous phase was separated 
and subjected to phenol: chloroform extraction twice more. Finally, the aqueous phase, 
containing the DNA, was treated with 0.1 volume of 3 M sodium acetate and three 
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volumes of 100% (v/v) ethanol. The DNA was isolated by centrifugation at 13,523 g for 20 
minutes and washed using 70% (v/v) ethanol. After drying, the DNA was resuspended in TE 
buffer.  
The genome structure of newly generated recombinant viruses was compared with the wild-
type or the parent virus by performing restriction enzyme digestion of the purified genomic 
DNA. The DNA fragments were then analysed by agarose gel electrophoresis. 
2.3.8 Cycloheximide reversal assay 
Vero cells grown to confluency in a 24-well plate were pre-treated with 100 g/mL of 
cycloheximide in M2 for 1 hour at 37ºC and 5% CO2. Later, the media was removed, and 
the cells were infected with wild-type or recombinant HSV-1 at 5 pfu/cell in M0 with 
added cycloheximide. The virus was adsorbed for 1 hour at 37ºC. Then, the inoculum was 
removed and replaced with fresh M2 containing cycloheximide. The plate was incubated 
for 6 hours at 37ºC and 5% CO2. The media containing cycloheximide was then removed 
and the cells were washed with media containing actinomycin D at a concentration of 5 
g/mL. The infection was allowed to proceed in the presence of actinomycin D for a 
further 4 hours, after which, the cells were washed with PBS and harvested by 
trypsinisation. Similarly, control samples were prepared for each virus by following the 
above steps in the absence of cycloheximide and actinomycin D. After neutralisation of 
trypsin, the cells were transferred to individual wells of a 96-well plate (U bottomed plate, 
Falcon) and centrifuged at 524 g (Beckmann coulter AllegraX-15R) for 5 minutes at 4ºC. 
The cell pellets were resuspended in 150 L of PBS and centrifuged again. Then, the cells 
were fixed using 50 L of 1% (v/v) PFA (in PBS) for 20 minutes and washed three times 
with FBS-PBS. To wash the cells, the cell pellets were dislodged by gentle vortexing, 
followed by addition of 150 L of FBS-PBS to each well and centrifugation at 931 g 
(Beckmann coulter AllegraX-15R) for 3 minutes. Subsequently, the cells were resuspended 
in an appropriate volume of FBS-PBS and analysed by flow cytometry. 
2.3.9 Functional verification of genome modification in the newly 
generated recombinant viruses 
The function of ICP47 in various recombinant viruses generated in this study was tested 
using the following two assays. 
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2.3.9.1 Quantitative analysis of MHC I using QIFIKIT 
To assess the effect of ICP47 on the cell surface expression of H-2Kb, 106 MC57G, 
293KbC2 or 293DbA5 cells were infected with the wild-type HSV-1 (strain KOS), ICP47 
null mutant (HSV-1 Ka47) or revertant (HSV-1 Ka47R) at 5 pfu/cell in 200 L D0. 
Uninfected cells were used as a control. The infection was carried out in a 4 mL tube 
(Sarstedt). For infection, the cells were first incubated at 37ºC water bath for 3 minutes 
with intermittent shaking. Then the tubes were transferred to 37ºC shaking incubator at 
250 rpm. After 30 minutes, the cells were transferred to a 15 mL tube containing 9.75 mL 
of pre-warmed D2 and incubated at 37ºC and 5% CO2 in a MACSmix
TM tube rotator. After 
5.5 hours of incubation, the cells were harvested by centrifugation at 524 g (Beckmann 
coulter AllegraX-15R) and 4ºC for 5 minutes. The cells were washed using FBS-PBS, 
transferred to individual wells of a 96-well U-bottom tissue culture plate (BD Biosciences). 
Afterward, 50 L of anti-H-2Kb (Y-3 clone) diluted to a concentration of 200 µg/mL was 
added to the wells and the plate was incubated for 30 minutes at 4ºC. The cells were then 
washed three times by resuspending in FBS-PBS and centrifuging at 524 g (Beckmann 
coulter AllegraX-15R), 5 minutes, 4ºC, followed by staining with a saturating concentration 
of FITC-conjugated goat anti-mouse F(ab)2 fragments provided in the QIFIKIT (Dako, 
Glostrup, Denmark). After incubating for 45 minutes at 4ºC in dark, the cells were washed 
using PBS thrice and fixed using 1% (v/v) PFA. At this stage, the calibration beads 
provided were washed using FBS-PBS and stained using the FITC-conjugated antibody as 
per the manufacturer’s instructions. The cells and the beads were washed using FBS-PBS at 
least three times and analysed for FITC flourescence using flow cytometer. The 
photomultiplier tube (PMT) voltages were set up according to the manufacturer’s 
instruction. The calibration beads consist of five populations, each coated with a defined 
number of antibody binding sites per bead (Figure 2.1 A). The fluorescence data from each 
of the five-bead populations were used for the construction of the standard calibration 
curve by relating the mean fluorescence intensity to the antibody binding capacity (ABC) of 
the beads (Figure 2.1 B). The mean fluorescent intensity (MFI) of samples was interpolated 
on to the standard curve to obtain the ABC of the samples (Figure 2.2). The actual number 
of H-2Kb molecules was calculated by subtracting the ABC of negative control from the 
ABC of the desired sample. 
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Figure 2.1 Generation of a standard curve using QIFIKIT calibration beads. (A) 
Calibration bead populations (B to F) were gated to obtain MFI. A different population of 
beads shown in the figure bind to a specified amount of antibody also known as antibody 
binding capacity (ABC) (B) A linear regression curve was plotted using the MFI and the 
corresponding ABC of different bead populations.  
 
 
 
A 
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Figure 2.2. Computation of total cell surface H-2Kb molecules using the calibration 
curve. Mock-treated or infected cells were incubated with anti- H-2Kb antibody, followed 
by staining with the FITC-conjugated secondary antibody. The ABC of each sample was 
obtained by interpolating the MFI into the standard curve constructed using QIFIKIT 
calibration beads.  
 
 
 
 
Y=22.69X+0 
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2.3.9.2 Flow cytometry-based antigen presentation assay 
293KbC2 or MC57G cells were infected with 10 pfu/cell of HSV-1 KOS, HSV-1 Ka47Δ, 
HSV-1 Ka47R, HSV-1 Ka47inΔ, HSV-1 Ka47rescue, HSV-1 GKa47Δ or HSV-1 GKa47R. 
Briefly, 3 to 6 × 106 cells were added to appropriate tubes. This was followed by addition 
of the virus in an appropriate volume of D0. Uninfected cells were used as a control. The 
tubes were incubated at 37ºC in a water bath for 3 minutes with intermittent shaking. The 
tubes were then transferred to 37ºC shaking incubator at 250 rpm. After 30 minutes, the 
cells were shifted to a 15 mL tube containing 9.5 mL of pre-warmed D2 and incubated at 
37ºC and 5% CO2 for 2.5 hours in a MACSmix
TM tube rotator. The cells were pelleted by 
centrifugation at 524 g for 5 minutes and resuspended in D0. An appropriate number of 
cells was transferred to 15 mL tube for infection with MVA mini OVA, MVA ES mini 
OVA or MVA mini Flu. Cells not infected with HSV-1 were separated into 5 tubes for 
infection with MVA mini OVA, MVA ES mini OVA or MVA mini Flu, incubating with 
10-7 mM OVA (SIINFEKL) peptide or to serve as an uninfected control. Infection with 
MVA was performed at 10 pfu/cell. The treatments were performed in a total volume of 
500 µL of D0. The tubes were incubated at 37ºC water bath for 3 mins with intermittent 
shaking, followed by incubating for 30 minutes in 37ºC shaking incubator (250 rpm). After 
incubation, 9.5 mL of warm D2 was added to each tube and incubated at 37ºC and 5% 
CO2 in the MACSmix
TM tube rotator. After 5.5 hours of incubation, the cells were pelleted 
by centrifugation at 524 g for 5 minutes. The cells were resuspended in 150 µL of cold 
FBS-PBS and transferred to individual wells of a U-bottomed 96-well plate (BD 
Biosciences). The cell pellets obtained after centrifugation at 524 g for 5 minutes were 
resuspended in cold FBS-PBS. This washing step was repeated one more time before 
staining the cells using 50 µL of allophycocyanin-conjugated monoclonal antibody specific 
to H-2Kb/SIINFEKL complex (clone 25D.1.16) at a 1/200 dilution in cold FBS-PBS. The 
cells were incubated for 1 hour on ice followed by 3 wash steps as described above. They 
were then fixed using 50 µL of 1% (v/v) PFA (in PBS) for 20 minutes at room temperature 
and subsequently washed twice using cold FBS-PBS. Finally, the cells were resuspended in 
cold FBS-PBS and the fluorescence was measured using flow cytometry. Uninfected cells, 
uninfected cells pulsed with SIINFEKL peptide and cells infected with HSV-1 or MVA 
alone were used as controls. 293KbC2 is a stably transfected clone of 293A, a human 
embryonic kidney cell line (Tscharke et al., 2005). This cell line was used to validate 
recombinant HSV-1 ICP47 null mutants by testing their function, which is to inhibit TAP 
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mediated antigen presentation. The species specificity of ICP47 was assessed by comparing 
the level of Kb-SIINFEKL complex between 293KbC2 and MC57G. A diagrammatic 
representation of this assay is displayed in Figure 3.5. 
2.3.10 In vivo analysis of HSV-1 infection using a mouse model 
2.3.10.1 HSV-1 infection model and pathogenesis  
Female C57BL/6 mice aged 8 weeks or more were inoculated with HSV-1 using a flank 
infection model (Russell et al., 2015). In brief, mice were anesthetized using Avertin (1, 1, 
1-tribromoethanol in 2-methyl-2-butanol) at 250 mg per kilogram weight of mice, fur was 
clipped and depilated from upper to lower midline on the left flank. A 25 mm2 area was 
marked, using the tip of the spleen as a landmark for tattooing. The marked area was 
tattooed using a round shader needle immediately after dipping in 108 pfu/mL virus stock. 
After removing the excess inoculum, the mice were wrapped in tissue and monitored 
throughout the anaesthesia to manage potential complications such as hypothermia. 
Following infection, the progress of the HSV-1 induced skin lesion was monitored from 
the day when the primary lesion appeared until resolution. Additionally, mice were 
examined for signs of generalised systemic illness based on posture, activity and fur texture 
and scored according to the criteria provided in Table 2.9. Grades 0, 1, and 2 were given a 
score of 0, 1 and 2 respectively. The scores from different criteria were summed to obtain a 
total score. A total score of less than 3 was considered mild, 3 to 5 was considered 
moderate and a score of 6 was considered to be indicative of severe clinical symptoms.  
Table 2.9 Scoring criteria for systemic illness 
Criteria Grade 0 Grade 1 Grade 2 
Posture Normal Hunching noted only at rest Severe hunching impairs 
movement 
Activity Normal Mild to moderately decreased Stationary unless stimulated 
Fur texture Normal Mild to moderate ruffling Severe ruffling/poor 
grooming 
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2.3.10.2 Assessment of virus growth in mice  
Amounts of virus from skin and DRG were quantified using plaque assay. For this, skin 
tissue that was 0.8 cm wide from upper to lower midline of the infected dermatome was 
excised in 800 µL of D2. Similarly, DRG from spinal levels T5 to L1 were collected. After 
harvesting, the tissues were frozen using dry ice and stored at -80ºC until further 
processing. The tissues were later homogenised using a 1 mL tissue grinder. The amount of 
virus in the homogenates was determined using a plaque assay (see section 2.3.6) and 
plotted as pfu/mouse. 
2.3.10.3 Analysis of reactivation competence  
Reactivation of HSV-1 can be induced in latently infected ganglia by removing them from 
mice and culturing as explant in D2 (Price and Schmitz, 1978). For assessing the 
reactivation efficiency between the wild-type HSV-1 (strain KOS), HSV-1 Ka47 or HSV-
1 Ka47R, mice were tattoo-infected at least 30 days prior to performing the reactivation 
assay. Once latency was established (>30 days post-infection), mice were culled and their 
DRG corresponding to thoracic level T4 to T13 and lumbar level L1 to L3 were excised. 
The DRGs were placed individually in each well of a 96-well plate (U bottomed, BD) 
containing 100 µL of M10 with Pen-Strep. The explanted DRG were cultured for 5 days in 
the culture media at 37ºC and 5% CO2, homogenized and the homogenates were assessed 
for the presence of the infectious virus on Vero cell monolayers. Differences in percentage 
of reactivation were compared on the level of individual mice, or at the spinal level. 
In other experiments, where the ability of the recombinant viruses to reactivate from 
latency was tested, DRG were excised from thoracic level T4 to T13 and lumbar level L1 to 
L3 of the latently infected mice. The harvested tissues were pooled per mouse in D2 and 
cultured for five days at 37ºC and 5% CO2. After this culture period, the DRG were 
homogenised using a 1 mL tissue grinder. The homogenate was assessed for infectious 
virus by inoculating the Vero cells in a 6-well plate and incubated at 37ºC and 5% CO2 for 
two days. For the recombinant viruses that experessed eGFP, the plaques were tested for 
the expression of GFP by fluorescence microscopy (Olympus CKX41). 
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2.3.10.4 Intracellular cytokine staining for IFNγ 
The CD8+ T cell response following infection in mice was measured using the intracellular 
cytokine staining (ICS) assay. The technique used in this study involved ex vivo stimulation 
of splenocytes using synthetic peptides in the presence of Brefeldin A and antibody 
staining for CD8 and IFNγ followed by analysis using flow cytometry (Flesch et al., 2012).  
Previously infected mice were euthanized using CO2 and their spleens were collected in 1 
mL of D10 and stored on ice until further processing. Splenocytes were prepared by 
crushing the spleens using plungers from 1 mL syringes and passing them through cell 
strainers using PBS. The isolated splenocytes were pelleted by centrifugation at 524 g for 5 
minutes (Beckman coulter AllegraX-15R) and resuspended in 5 mL of red cell lysis buffer. 
After incubating for 3 minutes, the reaction was stopped by adding 30 mL of PBS. The 
cells were centrifuged at 524 g at 4ºC for 5 minutes (Beckman coulter AllegraX-15R). The 
cell pellet was resuspended in 5 mL of D10. After staining with trypan blue solution, viable 
splenocytes were enumerated using haemocytometer. The number of splenocytes in each 
sample was adjusted to 107 cells/mL using D10. From this, 100 µL of cells were transferred 
to each well of a 96-well plate (U-bottom, BD Biosciences) for ICS assay. To the cells, 100 
µL of 0.2 µM synthetic peptide (in D0) or 100 µL of D0 (control) was added and incubated 
for 1 hour at 37ºC and 5% CO2. Afterward, 20 µL of 50 µg/mL Brefeldin A was added to 
each well and incubated for further 3 hours. The cells were then spun down at 524 g at 4ºC 
for 5 minutes (Beckman coulter AllegraX-15R) and resuspended in 50 µL of anti-CD8-
PE clone 53-6.7 at a 1/150 dilution in FBS-PBS. The staining was done in dark for 30 
minutes on the ice after which the cells were washed three times by resuspending in PBS. 
After washing, the cells were fixed using 1% (v/v) PFA (in PBS) for 20 minutes at room 
temperature followed by washing thrice using FBS-PBS. Next, for intracellular staining, the 
cells were resuspended in 50 µL of anti-IFN-APC diluted 1/200 in FBS-PBS containing 
0.25% (w/v) saponin, and then incubated at 4C overnight. The following day, the cells 
were washed thrice using FBS-PBS and analysed by flow cytometry. The magnitude of 
peptide-specific responses was reported as a percentage of IFN+ of CD8+ cells. The gating 
strategy can be seen in Figure 2.3. 
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Figure 2.3 Gating strategy to identify HSV-1 specific CD8+ T cells. Splenocytes from 
C57BL/6 mice previously infected with HSV-1 KOS were treated exogenously with HSV-1 
gB498-505 synthetic peptide (A) or left untreated (B). Then, the cells were stained for surface 
expression of CD8α and intracellular expression of IFNγ. The events were first selected 
according to the forward scatter (FSC) and side scatter (SSC) parameters. Then, doublet 
exclusion was performed using width and area parameters of FSC and then SSC 
accordingly. The singlet events were then gated using CD8α × SSC (area) to detect CD8+ T 
cell events. Finally, IFNγ+ events were gated from the CD8+ T cell events on a CD8 × 
IFNγ plot. 
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2.3.11 X-Gal staining of DRG 
ROSA26R mice were infected with a recombinant HSV-1 that expresses Cre recombinase. 
Mice were euthanized using CO2 at 5, 10, 20, 40 and 100 days after infection. DRG 
ipsilateral to the site of infection from T4 to L1 were excised and added to individual wells 
of a 96-well plate (U bottomed, BS) containing 50 L of fixative (2% (v/v) PFA and 0.5% 
(v/v) Glutaraldehyde in PBS). DRG were incubated in the fixative for at least 1 hour on ice. 
After this, they were washed twice using 200 L of cold PBS. PBS was later replaced with 
50 L of X-Gal permeabilisation buffer and incubated for 15 minutes on ice. The 
permeabilisation buffer was then replaced with 50 L of X-Gal staining solution (1 mg/mL 
X-Gal) and the plate was incubated overnight at 4ºC. The following day, the X-Gal staining 
solution was removed, the DRG were rinsed twice using PBS and then, stored in 50% 
(w/v) glycerol. Prior to imaging, the DRG were whole mounted on microscopic slides 
using glycerol as a mounting medium and photographed using an Olympus CKX41 
microscope.  
2.3.12 Mass spectrometry-based peptide identification and quantification 
2.3.12.1 HSV-1 infection of in vitro cultured cells for mass spectrometry 
Cells (2 × 108 or 5 × 107) were grown in D10 in T175 flasks to confluency. The cells were 
trypsinized and infected at 5 pfu/cell with HSV-1 KOS, Ka47∆ or Ka47R in D0. First, 
cells were mixed with the appropriate virus in a 15 mL round bottom polypropylene tubes 
in a total volume of 2 mL and incubated in 37C shaking incubator at 250 rpm for 30 
minutes. Later, the contents were transferred to a 50 mL tube containing 38 mL of pre-
warmed D2 and incubated at 37C with continuous rotation using MACSmixTM tube 
rotator for 5 hours and 30 minutes. After infecting the cells for a total of 6 hours, viable 
cells were counted post-staining with trypan blue. The cells were then centrifuged at 524 g 
for 5 minutes and the resultant cell pellets were washed using 10 mL of cold PBS. For 
peptide discovery, the cell pellet was resuspended in 1 L/mL of Trioxsalen and UV 
inactivated for 20 minutes on ice with intermittent mixing every 5 minutes (Fischer et al., 
2007; Schneider et al., 2015). The virus-inactivated cells were resuspended in 10 mL of cold 
PBS, transferred to a 15 mL tube and centrifuged at 524 g for 5 minutes. The supernatant 
was removed, and the resultant cell pellet was snap frozen using dry-ice ethanol bath and 
stored in a freezer at -80C until lysis.  
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2.3.12.2 Solubilising AQUA peptides  
AQUA peptides were solubilised in 100% (v/v) DMSO to a concentration of 5 mM. The 
volume of DMSO added to each peptide was calculated based on a) the molecular weight 
of each peptide and b) the synthesised weight of the respective peptide as indicated by the 
manufacturer. Since the purity of the peptides were less than 100%, the exact concentration 
of the solubilised peptides was subsequently determined using a Direct Detect 
spectrophotometer (EMD Millipore) following the manufacturer’s instruction. Based on 
this data, the peptides were diluted to 5 pmoles/L using MS buffer A.  
2.3.12.3 Generation of cell lysate 
For cell lysis, 1 mL of ice-cold 2× concentrated lysis buffer was added to the frozen cell 
pellet and mixed gently to disrupt the pellet. Then, 2 mL of 2× concentrated lysis buffer 
and 2 mL of Milli-Q water were added to the resuspended pellet and mixed end-over-end 
for 1 hour at 4ºC with gentle rotation. The lysate was centrifuged (Beckman coulter 
AllegraX-15R) at 3724 g for 10 minutes at 4C. The supernatant was transferred to three 2 
mL polypropylene (Eppendorf) tubes and centrifuged for a further 10 minutes at 15,871 g 
at 4C. Cleared lysates were collected and stored on ice prior to immunoprecipitation with 
protein A-crosslinked MHC-specific antibodies. 
2.3.12.4 Preparation of cross-linked immunoaffinity column 
Poly-prep Chromatography column (BioRad) was first conditioned for crosslinking by 
incubating the column with 10 mL of 10% (v/v) acetic acid for 20 minutes. The column 
was rinsed once again with 10% (v/v) acetic acid and finally rinsed with Milli-Q water to 
remove traces of acetic acid before air-drying. Protein A sepharose was supplied as 50% 
slurry in 20% (v/v) ethanol. The slurry was thoroughly mixed before transferring to the 
capped column. The protein A sepharose was rinsed and equilibrated with 10 column 
volumes (CV) of PBS to remove ethanol. Antibody diluted with PBS was mixed with the 
resin at a concentration of 10 mg antibody to 1 mL protein A in a 50 mL tube. The mixture 
was incubated for 1 hour at 4°C with gentle rotation, then transferred back to the column. 
Any unbound antibody was removed by washing the column with 10 CV of borate buffer, 
followed by equilibrating the resin with 10 CV of 0.2 M Triethanolamine, pH 8.0. The 
bound antibody was cross-linked to protein A sepharose using 40 mM DMP cross-linker 
for 1 hour at room temperature. Cross-linking was terminated by the addition of ice-cold 
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0.2 M Tris, pH 8. The column was then washed using 10 CV 0.1 M citrate buffer, pH 3 
followed by 10 CV borate buffer. The column containing antibody cross-linked to protein 
A sepharose was then stored at 4C in PBS prior to use. The cross-linked antibody was 
used within 4 days of preparation.  
2.3.12.5 Immunoaffinity purification of peptide-MHC I complexes 
Immunoaffinity purification of pMHC-I was carried out as specified by Dudek et al. (2016). 
For each sample, 1.5 mg of antibody cross-linked protein A sepharose slurry was 
transferred to a clean poly-prep column. The affinity column was equilibrated with 10 CV 
of Wash buffer 1. The cell lysate was initially passed through a pre-column containing 
protein A sepharose without the cross-linked antibody to remove any contaminants that 
non-specifically bind to protein A. The flow-through from this pre-column was dripped 
directly onto an immunoaffinity column containing anti-H-2Kb covalently bound to protein 
A sepharose. To maximise the binding of pMHC I to the antibody, the lysate was mixed 
with the slurry and incubated for 5 minutes. The lysate was then allowed to pass through 
the column by gravity flow, collected, and then passed over a second time. Flow-through 
from this second pass was dripped directly onto an anti-H-2Db column. After resuspension 
and 5 minutes incubation, the flowthrough was collected by gravity flow and passed again 
through the anti-H-2Db column. Two mL of the final flowthrough from the anti-H-2Db 
column was collected and stored for proteomics analysis. Each immunoaffinity column was 
then washed using 20 CV of a sequential series of buffers from Wash buffer 1 to Wash 
buffer 4, in order to remove unbound material, detergent, non-specifically bound 
components and salt, respectively. Finally, antibody-bound pMHC-I was eluted using 2 mL 
(5 CV) of 10% (v/v) acetic acid from both the columns separately. For MRM-MS peptide 
quantification experiments, 50 fmoles of AQUA peptides were added to the eluate at this 
stage.  
2.3.12.6 HPLC Purification, fractionation and concentration of peptides 
The above acid eluate, containing peptides, MHC I heavy chain and -microglobulin, was 
fractionated using reverse-phase high-performance liquid chromatography (HPLC) using a 
C18 column (Chromolith high-resolution RP-18 endcapped, Merck) on an ÄKTAmicro 
HPLC system (GE Healthcare). The mobile phase buffer system used in the column 
consisted of HPLC fractionation buffer A and HPLC fractionation buffer B at a flow rate 
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of 1 mL/min. The peptides were separated across a gradient of HPLC fractionation buffer 
B from 2% to 45% over the course of 20 minutes. This process separates the peptides 
from free MHC I heavy chain and -2 microglobulin. Peptide fractions (500 µL) were 
collected in LoBind Eppendorf tubes, vacuum concentrated and pooled via a 
concatenation strategy to reduce the complexity of any given pool. Specifically, pool 1 
consisted of fractions A3, A4, A8, A12, B15; pool 2 consisted of A5, A9, A13, B14; pool 3 
consisted of A6, A10, A14, B13; and pool 4 consisted of A7, A11, and A15. The pooled 
fractions were vacuum concentrated using a Labconco Centrivac concentrator (Thermo 
Fisher Scientific) and equalised to a final volume of 12 L using MS buffer A. Custom 
synthesised standard indexed retention time (iRT) peptide mix was added to pooled 
fractions, followed by sonication for 10 minutes and centrifugation at 15,871 g for 10 
minutes (Escher et al., 2012). 10 L of the supernatant was transferred to mass 
spectrometer autosampler vials and stored at 4C until analysis. For targeted MS analysis, 
iRT peptides were not included but the pooled fraction was sonicated and centrifuged as 
described above before transferring to the mass spec vials. 
2.3.12.7 LC-MS/MS and peptide identification 
For the identification of MHC I restricted HSV-1 peptides, a Q Exactive hybrid 
quadrupole-Orbitrap MS (Thermo Scientific) coupled to UltiMate 3000 RSLCnano HPLC 
(Thermo Scientific) was used. Each sample was loaded by an autosampler via a trap 
column (100 m × 2 cm NanoViper PepMap100 (Thermo Scientific) at a flow rate of 15 
L/min in MS buffer A on to the analytical nanocolumn (75 m × 50 cm PepMap100 C18 
3 mm, 100 Aº; Thermo Scientific). Peptides were separated by liquid chromatography using 
an increasing linear concentration gradient of MS buffer B at 250 nL/min flow rate for 90 
minutes. Up to 12 MS/MS most intense spectra were acquired per cycle with dynamic 
exclusion at the level of MS1 for 15 seconds to exclude re-sequencing of the exact same 
peptide and improve the repertoire of peptides identified.  
2.3.12.8 Optimisation of MRM transition conditions 
To improve the efficiency of detection of target peptides using MRM-MS, the MS 
acquisition parameters such as collision energy need to be optimised for selected MRM 
transitions. For initial selection of precursor ions, collision energy (CE) and the fragment 
ions, 500 fmoles of each AQUA peptide was loaded onto a SCIEX QTRAP® 6500 mass 
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spectrometer as a mixture and operated in enhanced MS mode followed by enhanced 
product ion scan with an m/z ranging from 80 to 1000.  The dominant precursor ion and 
its corresponding predicted collision energy (calculated by the QTRAP instrument) for 
each AQUA peptide were determined from the LC-MS/MS analysis. A set of 6 to 9 of the 
most intense product ions was then selected for MRM transitions. A targeted MRM 
method was then used to refine the collision energy for each individual MRM transition by 
injecting 500 fmoles of each AQUA peptide. MRM ion pairs corresponding to the 5 most 
intense peaks were selected for creating an optimised MRM method. For each transition 
pair, three CE values, in 4 eV increments, above or below the previously assigned 
(predicted) values were used to refine the analysis in order to obtain an optimal CE per 
transition per peptide (Lange et al., 2008; Sherwood et al., 2009). Finally, the MRM assay 
was validated in the triple-quadruple instrument SCIEX QTRAP® 6500. For determining 
the optimal concentration of AQUA peptides to add to the endogenous sample, a series of 
10-fold dilutions of the pooled peptide mix were made and injected from 500 fmoles down 
to 5 amoles into the SCIEX QTRAP® 6500 instrument. A standard curve was constructed 
for each peptide by plotting the peptide concentration against its sum peak area (Figure 
5.13). From this analysis, 50 fmoles for each deemed within a suitable linear range of 
detection. The final MRM assay method (Table 5.2) included a transition list of each 
precursor m/z and its corresponding selected product ions and associated collision energy 
values; matching transition m/z values were also incorporated for the unlabelled (i.e. non-
isotopic) peptides.  
2.3.12.9 Estimation of peptide copies 
The area under each MRM transition peak was calculated using Skyline Targeted Mass Spec 
Environment application (MacCoss Lab Software) (MacLean et al., 2010; Schilling et al., 
2012). The area of all MRM transitions for a peptide was combined to obtain the sum peak 
area. The estimated copy number of a detected endogenous peptide was calculated by 
taking the ratio between the peak areas of the peptide with that of its corresponding 
AQUA peptide. It was then possible to determine the amount of endogenous peptide 
detected by multiplying the ratio by that of the moles of AQUA peptide spiked into the 
sample (i.e. 50 fmoles of AQUA, or 5x10-14 moles). Moles were converted to molecules by 
multiplying by Avogadro’s number, and then dividing the number of molecules by the total 
number of cells for the sample arrives at a copy number for the peptide. The following 
equation summarises this: 
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2.3.13 Statistical analysis 
Statistical comparisons were made using GraphPad Prism 7 for Windows (version 7.04). 
For comparison of means of two groups, two-tailed unpaired t-test was performed. For 
comparison of means of more than two groups one-way or two-way ANOVA was used 
with an appropriate multiple comparisons post-hoc test. In all cases, p value less that 0.05 
was considered statistically significant.  
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3 Effect of ICP47 during HSV-1 infection in mice 
3.1 Introduction 
The HSV-1 protein ICP47 targets the MHC I antigen presentation pathway by interfering 
with the TAP-mediated transport of peptides into the ER lumen (York et al., 1994; Früh et 
al., 1995). The high affinity binding of ICP47 to the inner surface of the TAP1 and TAP2 
transmembrane helices, precludes peptide binding and freezes TAP in an inactive 
conformation, thus inhibiting the peptide transport into the ER lumen (Oldham et al., 
2016a). The lack of peptides in the ER lumen lead to a substantial reduction in the surface 
MHC I expression and presentation of HSV-1 peptides (York et al., 1994). As a 
consequence, HSV infected human cells show a remarkable level of resistance to CD8+ T 
cell-mediated specific lysis in vitro (York et al., 1994). Interestingly, while this holds true for 
human cells, mouse cells are susceptible to CD8+ T cell killing (York et al., 1994; Jugovic et 
al., 1998). In addition, earlier biochemical studies proposed that ICP47 does not function in 
mice because a competitive binding assay conducted using insect microsomes 
demonstrated that ICP47 had 100-fold lower binding affinity towards murine TAP 
compared to human TAP (Ahn et al., 1996; Tomazin et al., 1996). The biochemical analysis 
was performed in buffered salt solution in ambient conditions. So, these solutions lack 
various biological components present in the cytoplasmic milieu that can have significant 
effects on the binding behavior of peptides and proteins. Further, by resolving the 
structure of ICP47-TAP complex, Oldham et al. (2016) showed that the inactive, closed 
conformation of TAP1/TAP2 complex induced as a result of stable binding of ICP47 is 
the critical reason for blocking of peptide transport, rather than competitive inhibition. 
Thus, an assay that directly quantifies the antigen presentation on HSV-1 infected cells 
might overcome the difficulties associated with the biochemical assay and improve our 
understanding of species specificity of ICP47. 
Even though the aforementioned in vitro studies cast doubt over the relevance of using 
mouse models in studying the CD8+ T cell immunity to HSV infection, other in vivo studies 
have shown that ICP47 enhances the neurovirulence of HSV-1 in mice (Goldsmith et al., 
1998; Burgos et al., 2006). Due to the inherent low-level antigen-presenting capacity of 
neurons, the authors postulated that even a modest inhibition of TAP function by ICP47 is 
sufficient to affect CD8+ T cell recognition of infected neurons. This study reveals an 
apparent discrepancy between the data obtained from the in vitro assay system and the 
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biologically relevant in vivo model. However, these studies used models that permit the virus 
to enter the central nervous system (CNS) and induce encephalitis-mediated mortality in 
most of the infected mice. Accordingly, the neurovirulence model is not conducive to 
study the establishment of latency and reactivation, which are typical of natural HSV 
infection. 
It is well understood both from human and mouse studies that acute HSV-1 infection 
elicits a large CD8+ T cell response (Posavad et al., 1997; Koelle et al., 1998; Hosken et al., 
2006). This response is important in acute infection as depletion of CD8+ T cells in mice 
led to prolonged HSV-1 replication and delayed viral clearance in neurons after the initial 
primary infection (Simmons and Tscharke, 1992). Besides curtailing the acute infection, 
CD8+ T cells containing markers for functional activation were observed in close proximity 
to the latently infected neurons suggesting that they may play a role in immune surveillance 
in ganglia during latency (Khanna et al., 2003a; Theil et al., 2003; Verjans et al., 2007). 
Incidentally, ICP47 promoter was found to be active in a subset of neurons long after the 
clearance of infectious virus (Ma et al., 2014; Russell and Tscharke, 2016). The above 
observations prompted us to ask, if CD8+ T cells have a role in latency as well as in acute 
infection, then what is the consequence of expression of ICP47 and CD8+ T cell evasion 
during HSV infection? Therefore, we thought it would be timely to revisit the discrepancy 
between the biochemical and in vivo data and re-examine the role of ICP47 using a model 
where the virus is contained to the PNS as is similar of natural HSV-1 infection.  
To investigate the impact of ICP47 during HSV infection we a) generated a new set of 
ICP47 null mutants in the HSV-1 strain KOS background, b) developed an assay to 
measure directly the ICP47-mediated inhibition of antigen presentation in a human and a 
mouse cell line, c) examined in vivo role of ICP47 using a flank model of HSV-1 infection in 
C57BL/6 mouse strain and d) used ROSA26R reporter mouse system to track the 
influence of ICP47 upon HSV-1 latency. HSV-1 KOS was selected because it can infect 
and establish latency in neurons without the demise of mice. Also, since CD8+ T cell-
mediated response to HSV-1 has been thoroughly examined in C57BL/6 mice in the past, 
by utilizing this mouse model, we could better understand the impact of ICP47 mediated 
evasion from CD8+ T cells. With these new set of tools, we set out to study the 
consequence of inhibition of MHC I mediated antigen presentation by ICP47 on HSV-1 
pathogenesis, latency, and reactivation in mice. 
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3.2 Results 
3.2.1 Generation and verification of recombinant ICP47 null mutant and 
revertant viruses 
A recombinant ICP47 null virus containing nucleotide sequence modifications that would 
prevent the synthesis of ICP47 and an appropriate revertant virus were generated using 
CRISPR-Cas9 genome editing technology. Given the possibility that the selection marker 
may interfere with the expression of neighbouring open reading frames (ORFs), any 
alterations in the viral genome were kept to a minimum. The steps taken to generate 
recombinant HSV-1 are described in detail in the methods section and the modifications 
introduced in the genome are shown diagrammatically in Figure 3.1. Amino acid residues 3 
to 34 on the N-terminal of ICP47 are sufficient and critical for the inhibition of TAP 
function (Galocha et al., 1997; Neumann et al., 1997). To generate an ICP47 null mutant 
virus, we introduced a stop codon and a restriction enzyme recognition sequence after the 
sixth codon of ICP47, such that it would abruptly curtail the translation of a full-length 
protein (Figure 3.1). The sequence modification at this position of ICP47 gene means that 
the cis-regulatory elements of the neighbouring and overlapping ORFs will not be disrupted. 
The resultant ICP47 null mutant virus was named as HSV-1 Ka47. The mutation of 
ICP47 in Ka47 was then repaired in the revertant virus Ka47R so that the virus could 
synthesize a functional ICP47 (Figure 3.1). For ease of screening and verification, a 
restriction enzyme recognition site was introduced by silent substitution mutation in the 
genome of the revertant virus. 
The sequence modifications in the recombinant viruses, Ka47 and Ka47R, were 
confirmed by sequencing of the corresponding DNA fragment (data not shown) and by 
analysing the whole genome using restriction fragment length polymorphism (Figure 3.2). 
While the modification to the HSV-1 genome was kept to a minimum, the in vitro growth 
characteristics of the engineered viruses were monitored to evaluate the impact of gene 
modification on the virus replication. Multi-step growth analysis was performed in Vero 
cells over 72 hours and found that the growth kinetics of the recombinant viruses HSV-1 
Ka47 and HSV-1 Ka47R is like that of the HSV-1 KOS (Figure 3.3). This suggests that 
the virus replication was unaffected by either nucleotide modification or loss of ICP47 
function. 
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Figure 3.1 Schematic representation of recombinant HSV-1 with modification in the 
ICP47 coding sequence. (A) Diagram of the HSV-1 genome with the location of unique 
and repeat regions shown. (B), (C) and (D) Diagram indicates the region of nucleotide 
modification in the US12 coding sequence. In HSV-1 Ka47, a stop codon was introduced 
upstream of AUG start codon shown in red bar and in HSV-1 Ka47R, the blue bar 
represents silent substitutions used to create a restriction enzyme recognition site. (E) 
Sequence alignment between HSV-1 KOS, HSV-1 Ka47 and HSV-1 Ka47R is shown. 
The modified nucleotides are indicated in red and the gaps are shown in hyphens. The blue 
boxes represent the HindIII recognition sequence in Ka47 and XbaI recognition 
sequence in Ka47R. Amino acid sequence translation is provided immediately below the 
nucleotide sequence. The asterisk symbol in the amino acid sequence of Ka47 represents 
the stop codon.  
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Figure 3.2 Characterisation of the recombinant viruses by RFLP analysis. (A) The 
genome of wild-type HSV-1 (strain KOS) and HSV-1 Ka47Δ were analysed by restriction 
digestion using enzymes BamHI or HindIII. (B) The wild-type HSV-1 and HSV-1 Ka47R 
DNA were analysed by restriction digestion using enzymes BamHI, HindIII or XbaI. Blue 
arrows in (A) and (D) indicate the characteristic DNA fragments that were obtained with 
the recombinant viruses but not with wild-type HSV-1. Yellow arrowheads indicate sizes of 
the relevant fragments of molecular markers. 
A 
B C D 
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Figure 3.3 ICP47 does not affect virus replication in vitro.  Vero cells were infected 
with the wild-type HSV-1, Ka47Δ or Ka47R at 0.01 pfu/cell. After adsorption for 1 hour, 
the media containing virus inoculum was removed and replaced with 2 mL of serum 
containing culture media. The virus was then harvested in the culture medium at indicated 
time points and virus titre was determined using a plaque assay on Vero monolayers. Data 
are from triplicate measurements and are expressed as mean ± standard deviation (SD) 
(error bars). In some cases, the error bars are obscured by the symbols. 
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3.2.2 Deletion of ICP47 has a major effect on down-regulation of MHC I in 
human, but not mouse cells 
As ICP47 interferes with TAP-mediated peptide transport and prevents the translocation 
of fully assembled pMHC-I complexes to the cell surface, it has been reported that ICP47 
down-modulates the overall surface MHC I in HSV-1 infected cells (York et al., 1994; Ahn 
et al., 1997). To functionally validate the ICP47 null mutant and the revertant viruses, the 
number of surface MHC I molecules were quantified on the infected cell surface using a 
flow-cytometry based indirect immunofluorescence assay. The assay was performed on 
293KbC2 cells, a human fibroblast cell line that stably expresses mouse H-2Kb (Tscharke et 
al., 2005) and MC57G cells, a mouse fibroblast cell line derived initially from the C57BL/6 
strain. These cell lines allowed us to quantify MHC I H-2Kb here, and later measure antigen 
presentation (see section 3.2.3). Briefly, quantification was done after infecting the cells 
with 5 pfu/cell of the recombinant or wild-type HSV-1 for 6 hours, followed by incubation 
with the anti-H-2Kb antibody (clone Y3) and then stained with F(ab’)2 fragment of FITC-
conjugated goat anti-mouse antibody. Computation of total surface H-2Kb molecules is 
described in the methods section 2.3.9.1 and represented in Figure 2.2. Compared to the 
wild-type virus and the revertant viruses, the ability of Ka47 to induce down-regulation of 
MHC I was substantially attenuated in 293KbC2 cells (Figure 3.4 A, C & E). These data are 
consistent with our understanding since Ka47 does not produce ICP47, whereas a 
functional ICP47 protein is made from the revertant HSV-1 Ka47R. In MC57G cells, 
infection with ICP47 null mutant showed a slight increase in the level of MHC I compared 
to the wild-type and the revertant control, but the difference was not statistically significant 
(Figure 3.4 B, C & D).  Together, our data show that ICP47 down-modulates surface MHC 
I in human but not in mouse cells, which is indeed consistent with previous findings. 
Because a substantial number of MHC I were detected on the surface of infected mouse 
cells, it appears as though ICP47 does not inhibit mouse TAP. However, measurement of 
the level of surface MHC I does not discriminate between the pMHC-I complexes that are 
newly assembled after infection and the pre-existing stable pMHC-I on the cell surface. 
Given that a) only about half of the Kb-bound peptides that reach the cell surface are stably 
presented for more than 20 hours (Su and Miller, 2001), and b)  ICP47 has relatively weak 
binding affinity towards mouse TAP (Tomazin et al., 1998), it is possible that the impact of 
ICP47 on mouse TAP was not shown in its entirety using this assay. Thus, a more sensitive 
assay that measures the pMHC-I assembled after HSV-1 infection is required.  
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Figure 3.4 ICP47 down-regulates the surface MHC I on human cells but not on 
mouse cells. The 293KbC2 cells and MC57G cells were infected with 5 pfu/cell of 
appropriate HSV-1 for 6 hours followed by incubation with the anti-H-2Kb antibody (clone 
Y3). The cells were subsequently stained using the FITC conjugated goat anti-mouse 
secondary antibody and then analysed by flow-cytometry. The histograms show the 
fluorescence level on 293KbC2 (A) or MC57G cells (B) infected by the HSV-1 KOS, 
Ka47 or Ka47R. In the same flow cytometry experiment, calibration beads from the 
QIFIKIT were stained separately with the secondary antibody to calculate the specific 
antigen binding capacity (SABC), which reflects the absolute numbers of MHC I on the 
cell surface. (C) The data shown in the bar graph denotes the number of surface H-2Kb 
molecules per cell in MC57G and 293KbC2 cells under different conditions. The data from 
four independent experiments are shown. Error bars represent the mean  SEM. (D and E) 
The scatter plots show the level of H-2Kb relative to mock-treated samples of MC57G (D) 
and 293KbC2 (E) cell lines. Data from four independent experiments are shown. Error 
bars represent the mean ± SD. The statistical significance was calculated using one-way 
ANOVA with Tukey’s multiple comparison post-test. **p < 0.01. 
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3.2.3 ICP47 can inhibit TAP mediated antigen presentation effectively in 
mouse cells 
To measure the presentation of pMHC-I newly made at the time of infection, we designed 
a novel antigen presentation assay (see materials and methods, section 2.3.9.2) (Figure 3.5). 
In this assay, the surface Kb-SIINFEKL complex was measured after super-infection of the 
HSV-1 infected cells with recombinant vaccinia virus (strain MVA) expressing ovalbumin 
peptide SIINFEKL, termed MVA mini OVA (Figure 3.5). The cells were infected with 
HSV-1 for three hours before infection by MVA mini OVA to ensure that ICP47 will be 
present when the SIINFEKL peptide is first translated. As a positive control, MVA ES 
mini OVA expressing SIINFEKL peptide fused with ER targeting signal was used for 
infection instead of MVA mini OVA. The SIINFEKL peptide produced by this virus will 
bypass TAP mediated translocation and directly enter the ER lumen, hence evading ICP47 
influence on TAP. Recombinant MVA expressing influenza A virus (IAV) strain PR8 
PB1F262-70 peptide, termed MVA mini Flu, was used as a negative control since the 
antibody used in this assay cannot detect MHC I Kb – PB1F262-70 peptide complex. 
When 293KbC2 cells were infected with HSV-1 wild-type virus or revertant control and 
then super-infected with MVA mini OVA, the level of detection of H-2Kb–SIINFEKL 
complexes on the cell surface was similar to that of the cells super-infected with MVA mini 
Flu (Figure 3.6). In contrast, when the cells were infected with Ka47Δ and then MVA mini 
OVA, the surface Kb–SIINFEKL complexes were at a similar level to that of the Ka47Δ 
infected cells superinfected with MVA ES mini OVA (Figure 3.6). These data confirmed 
the presence of functional ICP47 in Ka47R and the lack of ICP47 in Ka47Δ. Expressing 
the data from our antigen presentation assay as fold increase in MFI over negative control 
allowed direct comparison of levels of Kb–SIINFEKL across viruses and cell types. 
Comparisons were made between the cells infected with HSV-1 KOS, Ka47 Δ and Ka47R, 
each superinfected with MVA mini OVA. In 293KbC2 cells, antigen presentation was 
significantly higher in the absence of ICP47 compared to the cells containing the functional 
protein (Figure 3.8 A). These data suggest that ICP47 significantly blocks the presentation 
of newly generated pMHC-I complex in human cells. 
Interestingly, the level of antigen presentation in MC57G samples infected with HSV-1 
KOS or Ka47R and MVA mini OVA was significantly lower compared to the ICP47 null 
virus and MVA mini OVA-infected cells (Figure 3.7 and Figure 3.8 B). This data 
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demonstrates that ICP47 can certainly impair antigen presentation in mouse cells. However, 
the level of MHC I Kb–SIINFEKL on HSV-1 KOS or Ka47R infected cells appeared 
considerably higher than the negative control (Figure 3.7 and Figure 3.8 B). Therefore, a 
direct comparison of the degree of inhibition exhibited by ICP47 between 293KbC2 and 
MC57G cell lines was made (Figure 3.8 C&D). The results show that the presence of 
ICP47 caused a significant reduction in the surface MHC I Kb–SIINFEKL complex in 
293KbC2 cells compared to the mouse cells (Figure 3.8 C). However, no significant 
difference was observed between 293KbC2 and MC57G cells infected with Ka47 and 
MVA mini OVA (Figure 3.8 D).  
Together, the above findings demonstrate that ICP47 can function in mouse cells, although 
to a lesser extent compared to human cells. These data suggest that the direct biochemical 
comparison of ICP47 binding to human and mouse TAP exaggerated the species 
difference and as a result, the potential impact of ICP47 in mice was underestimated. This 
later has borne out in the in vivo mouse studies. 
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Figure 3.5 Diagrammatic representation of the antigen presentation assay to 
measure the inhibition of antigen presentation by ICP47. 293KbC2 or MC57G cells 
were infected with wild-type HSV-1, ICP47 null mutant or revertant virus at 10 pfu/cell 
for three hours, followed by infection of HSV-1 infected cells with MVA expressing mini 
OVA at 10 pfu/cell. After 6 hours, the cells were fixed and then stained using 25D.1.16 
antibody. Fluorescence was later analysed using flow cytometry. Infection of a cell with 
wild-type HSV-1 would result in the synthesis of ICP47, which was expected to block TAP. 
During subsequent infection with MVA mini OVA, SIINFEKL peptides will be produced 
and in the absence of TAP function the peptides are expected to remain in the cytoplasm. 
This, in turn, will prevent the presentation of MHC I Kb-SIINFEKL complex on the cell 
surface. Conversely, the HSV-1 ICP47 null mutant will not be able to block the antigen 
presentation, which will be detected by specific antibody staining.  
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Figure 3.6 ICP47 blocks antigen presentation on human cells. The human cell line 
293KbC2 was infected with HSV-1 KOS, Ka47 or Ka47R at 10 pfu/cell. After 
incubation for 3 hours, the cells were superinfected with MVA expressing OVA peptide 
SIINFEKL tagged to ER targeting signal (MVA ES mini OVA), MVA expressing 
SIINFEKL without the ER targeting signal (MVA mini OVA) or MVA expressing IAV 
PR8 PB1F262-70 (MVA mini Flu) at 10 pfu/cell for 6 hours. Then the cells surface 
expression of Kb-SIINFEKL complex was analysed using flow cytometry as described 
previously. The histograms show the level of fluorescence detected due to staining by APC 
conjugated antibody (clone 25D.1.16) as a measure of H-2Kb-SIINFEKL complex. The 
data are representative of five independent experiments. 
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Figure 3.7 ICP47 blocks antigen presentation on mouse cells. The mouse cell line 
MC57G was infected with HSV-1 KOS, Ka47 or Ka47R at 10 pfu/cell. After incubation 
for 3 hours, the cells were superinfected with MVA expressing OVA peptide SIINFEKL 
tagged to ER-targeting signal sequence (MVA ES mini OVA), MVA expressing 
SIINFEKL without the targeting sequence (MVA mini OVA) or MVA expressing IAV 
PR8 PB1F262-70 (MVA mini Flu) at 10 pfu/cell for 6 hours. The cells surface expression of 
Kb-SIINFEKL complex was then analysed using flow cytometry as described previously. 
The histograms show the level of fluorescence detected due to staining by APC conjugated 
antibody (clone 25D.1.16) as a measure of H-2Kb-SIINFEKL complex. The data are 
representative of 4 independent experiments. 
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Figure 3.8 Quantification of cell surface expression of Kb-SIINFEKL complex in 
HSV-1 infected 293KbC2 and MC57G cells. (A) 293KbC2 and (B) MC57G cells were 
assessed for the cell surface expression of  Kb-SIINFEKL complex using an antigen 
presentation assay. The cells were infected with HSV-1 KOS, Ka47 or Ka47R and 
superinfected with MVA mini OVA as described previously. The cells infected with HSV-1 
KOS and superinfected with MVA mini Flu was used as the negative control. The fold 
change in mean fluorescence intensity (MFI) relative to the negative control is shown for 
indicated cell lines as a box-and-whisker plot. Statistical significance was calculated by 
comparing means using one-way ANOVA with Tukey’s multiple comparisons test 
(***p<0.001, **p<0.01, *p<0.05). C and D show a comparison of  Kb-SIINFEKL 
presentation between the human cell line (293KbC2) and the mouse cell line (MC57G) for 
indicated viruses. Box plots show the median (horizontal line) and the interquartile range; 
whiskers indicate the minimum and maximum values. The dashed line shows the baseline 
of detection. Statistical significance was calculated by comparing means using unpaired t-
test with Welch’s correction (***p<0.001, **p<0.01, *p<0.05) and ns indicates that the data 
are not significantly different. Error bars represent standard deviation (n = 4 to 5).  
A B 
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3.2.4 Does inhibition of antigen presentation by ICP47 affect HSV-1 
infection in mice? 
Our antigen presentation assay revealed that ICP47 inhibit TAP-mediated peptide 
presentation in mouse cells. However, the biological implication of this inhibition in mice 
in vivo during HSV infection is not fully known. To investigate the role of ICP47 during 
different stages of HSV-1 infection, we compared the viral pathogenesis, establishment of 
latency, stability of latency and reactivation of ICP47 null mutant viruses using a mouse 
flank infection model.  
The zosteriform model otherwise called the flank infection model typically involves 
scarification of depilated skin on the mouse flank, followed by infection using a defined 
amount of virus (Blyth et al., 1984; Simmons and Nash, 1984). As the virus is unable to 
penetrate intact skin, a productive infection necessitates physical trauma induced to the 
skin (Blyth et al., 1984). Instead of scarifying the skin, we introduce the virus by tattooing it 
on the mouse flank (Russell and Tscharke, 2016). Our modified method leaves no visible 
mark on the skin immediately after tattooing and a lesion starts developing as early as two 
days post infection at the site of initial infection. After infection of the skin, the virus 
travels to the sensory neurons of the dorsal root ganglia (DRG), where it undergoes brief 
replication and spread before returning to the skin of the same neurodermatome. As a 
result, approximately four days after inoculation of the virus, a series of secondary lesions 
develop which progresses to a vesicular ulcerous band in the corresponding dermatome 
(Figure 3.9). The appearance of the lesion is similar to that typical of herpes zoster, hence 
the name “zosteriform” being used to describe the model.  
Flank infection models have been previously utilised to show the critical importance of 
CD8+ T cell immunity to HSV-1 infection by curtailing acute infection of the nervous 
system (Simmons and Nash, 1984; Simmons and Tscharke, 1992). Furthermore, employing 
a flank infection model to track promoter activation in ROSA26R mice has previously 
provided novel insights into the promoter activity that occurs during latency and a better 
understanding of the fate of neurons after lytic infection (Proença et al., 2008, 2011; Russell 
and Tscharke, 2016).  
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Figure 3.9. Flank infection model. The virus was tattoo infected on to the skin of mice. 
The virus replicates in the skin and some virus enters the innervating nerve fibres, and 
travels in a retrograde direction to the neuronal cell body in the DRG. The virus after 
replicating in the DRG travels back in the anterograde direction to the skin resulting in the 
secondary skin lesion. (A) The tip of the spleen visualised through the skin is used to 
position the site of tattoo infection. The progression of the infection-induced lesion is 
shown. A primary lesion begins to appear from two days and the secondary lesion starts to 
emerge from four days after infection. Red arrows indicate the primary lesion and the 
yellow arrow shows the secondary lesion on designated days after infection. (B) The 
diagrammatic representation of the anatomical location of dorsal root ganglion. 
A 
B 
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3.2.4.1 Severity and resolution of lesions are independent of ICP47 expression 
The flank infection model is ideal for tracking the progression of infection by measuring 
virus titre in the primary and secondary infection sites on the skin and the ganglia in 
addition to monitoring skin lesion size. Age and sex-matched mice were infected with wild-
type HSV-1, ICP47 null mutant (Ka47) or the revertant (Ka47R) virus. A zosteriform 
lesion was observed on all mice infected in all groups between days four and five after 
infection, and the lesions resolved in all infected groups by day 14. As shown in (Figure 
3.10 A), the lesion size was comparable between the ICP47 null mutant and the control 
viruses. Mice never progressed beyond a clinical score of three (see materials and methods, 
Table 2.9) and remained healthy throughout the experiment.  
3.2.4.2 ICP47 does not alter virus replication in mice  
It had been previously shown using a flank infection model that the level of infectious virus 
is at its peak four days post infection and replication is curtailed after seven days of 
infection in both the skin and the DRG of HSV-1 infected mice (Speck and Simmons, 
1998; van Lint et al., 2004a). Coinciding with the cessation of virus replication, activated 
CD8+ T cells infiltrate both the initial infection site and DRG as early as five days after 
infection on the flank of mice (van Lint et al., 2005).  
Infection of mice with the ICP47 null virus, in theory, allows increased antigen 
presentation, which might lead to more rapid and efficient clearance of the infectious virus 
by HSV specific CD8+ T cells. We tested this hypothesis by measuring the levels of 
infectious virus in the homogenates of skin and DRG of mice at four and six days after 
infection using plaque assay (Figure 3.10 B & C). No difference in virus titre was expected 
on day 4, but on day 6 a decrease in virus titre was expected for Ka47-infected mice, 
based on the kinetics of CD8+ T cell infiltration at the infection site. However, the amount 
of virus in skin and DRG were similar among cohorts of mice infected with wild-type, 
ICP47 null mutant (Ka47) and the revertant (Ka47R) virus at the two time points. These 
findings show that the loss of ICP47 function neither affects virus replication in infected 
tissues in mice nor supports early clearance of the virus.  
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Figure 3.10 ICP47 does not affect the severity of skin lesion or virus replication in 
mice. (A) Groups of  mice were tattoo infected with HSV-1 KOS, HSV-1 Ka47 or HSV-1 
Ka47R and lesion development was monitored over several days until resolved. Shown are 
the representative images of  skin lesion taken seven days post-infection. (B and D) In 
another experiment, the virus titre in skin and DRG was measured four days after infection 
(B) and six days after infection (C). The data shown are pooled from two independent 
experiments with n=3-4 for each group. Each symbol represents the virus titre in one 
mouse and the error bars represent mean ± SEM. The means of  virus titre were compared 
between the groups using one-way ANOVA with Tukey’s multiple comparison post-test. 
No statistically significant differences were found between the three viruses at any time or 
site. 
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3.2.4.3 ICP47 does not affect the size of CD8+ T cell response in mice infected 
with HSV-1 
Considering that CD8+ T cell response is vital for the clearance of the acute HSV-1 
infection, we examined whether lack of ICP47 mediated inhibition of antigen presentation 
can influence the total HSV-1 specific CD8+ T cell response. The gB498-505 peptide-specific 
CD8+ T cell accumulation in the spleen was monitored from 5 days to 9 days after flank 
infection of C57BL/6 mice with HSV-1 strain KOS. Consistent to previous studies (Coles 
et al., 2002), we found that the proportion of gB498-505 peptide-specific CD8
+ T cells in 
spleen reached a maximum on 8 days after infection and fell considerably afterward (Figure 
3.11 A). Next, the size of splenic CD8+ T cell response to the immunogenic HSV-1 
peptides gB498-505, RR1822-829, ICP8171-178 and UL28629-637 was determined 7 days after infection 
with HSV-1 KOS, Ka47Δ or Ka47R (Figure 3.11 B). No statistically significant difference 
was observed between the groups of mice infected with the virus lacking ICP47 and the 
control viruses suggesting that ICP47 does not hinder the generation of CD8+ T cell 
responses to HSV infection in mice. 
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Figure 3.11 Peptide-specific CD8
+
 T cell response to HSV-1 infection is not 
increased in the absence of  the TAP-inhibitor, ICP47. (A) Groups of  5 mice were 
infected with HSV-1 KOS. On indicated days after infection, splenocytes were dispersed 
into single cell suspension and stimulated using immunogenic HSV-1 peptides for 4 hours, 
followed by surface staining for CD8+ T cells and intracellular staining for IFN. Bars 
represent the mean ± SEM percentage of  CD8
+
 T cells that secrete IFN (B) Groups of  
three mice were infected with HSV-1 KOS, HSV-1 Ka47 or HSV-1 Ka47R. The 
percentage of  IFN+ CD8+ T cells in spleen after stimulation by immunogenic HSV-1 
peptides on day 7 post-infection is shown. The experiment was repeated four times and the 
pooled data are shown in box and whiskers plot. Box plots show the median (horizontal 
line) and the interquartile range; whiskers indicate the minimum and maximum values. The 
means were compared by two-way ANOVA and Tukey’s multiple comparison post-test. 
The difference between the groups was not statistically significant. 
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3.2.4.4 Does ICP47 affect the establishment or maintenance of latency in mice? 
Previously, Russell and Tscharke (2016) had found that the number of neurons marked by 
ICP47 promoter increased swiftly from 10 to 20 days after infection. Further, a continued 
increase in the marking from 20 to 100 days was observed, which suggests that some 
neurons had experienced ICP47 expression during the establishment of latency and during 
latency (Russell and Tscharke, 2016). Further, our finding that ICP47 can reduce antigen 
presentation in mouse cells has opened questions such as a) whether the ICP47 expression 
in neurons promotes the establishment of latency?, b) whether ICP47 expression helps in 
the spread of the virus?, c) does ICP47 affect the stability of latency?, and d) what is the 
fate of neurons that do not express ICP47? To answer the above questions, I generated 
two sets of Cre expressing ICP47 null mutant and control viruses, which were used to 
infect ROSA26R reporter mouse followed by analysis of neuronal marking. 
3.2.4.4.1 Generation and characterisation of Cre recombinase encoding ICP47 
null mutant and control viruses 
To study the overall effect of ICP47 on infected neurons, an ICP47 null mutant was 
constructed on the HSV-1 pC_eGC background, which is a recombinant virus that 
expresses an eGFP-Cre fusion gene driven by a CMV IE promoter in UL3-UL4 region 
(Ma et al., 2014; Russell and Tscharke, 2016). The resultant virus was named HSV-1 
GKa47. A revertant virus, called HSV-1 GKa47R, capable of expressing ICP47 was later 
generated from HSV-1 GKa47. Therefore, both HSV-1 GKa47 and GKa47R can 
express Cre controlled by the CMV IE promoter (Figure 3.12). The strategy used for 
generating the above viruses was identical to that used for constructing Ka47 and Ka47R, 
respectively (see section 3.2.1). 
To investigate the effect of ICP47 on the fate of those neurons that express ICP47, a null 
virus encoding an eGFP-Cre fusion protein under the control of the native ICP47 
promoter was generated by replacing the ICP47 coding sequence with eGFP-Cre. This 
virus was named Ka47in. The ICP47 gene was rescued in Ka47in background by 
inserting an ICP47 gene cassette into the intergenic region between UL26 and UL27 and 
the resultant virus was named HSV-1 Ka47rescue. In Ka47rescue, a minimal ICP47 
promoter previously characterised by Russell and Tscharke (2016) was used to control the 
expression of ICP47. This modification in the ICP47 promoter was shown not to affect the 
kinetic class or gene expression in the previous study (Russell and Tscharke, 2016).  Of 
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note, Ka47rescue also expresses eGFP-Cre from ICP47 regions similar to the parent virus 
Ka47in. Schematic representation of ICP47 insertion-deletion mutant and the control 
rescuant virus is shown in Figure 3.14 A&B. The Cre-expressing recombinant HSV-1 
viruses generated for this chapter is listed in Table 3.1. 
The genomic structure of all recombinants was confirmed by PCR and restriction enzyme 
digestion analysis as shown in Figure 3.13 and Figure 3.15. The sequence modification 
introduced in the recombinants did not affect their replication and growth kinetics in vitro 
(Figure 3.16). The recombinant viruses were functionally characterised by using the antigen 
presentation assay described in section 3.2.3. Our antigen presentation assay showed that in 
293KbC2 cells, GKa47 and Ka47in allowed the presentation of SIINFEKL from MVA 
mini OVA to a level similar to that of presentation from MVA ES mini OVA (Figure 3.17 
A&B) suggesting that these recombinant viruses do not express functional ICP47. In 
contrast, the revertant GKa47R and the rescuant Ka47rescue inhibited the presentation to 
levels similar to that of the wild-type virus (Figure 3.17 A&B), confirming the expression of 
functional ICP47 in these cells.  
In mice, the amount of viruses found in the skin and DRG during the acute phase of 
infection were comparable between the recombinant viruses and the wild-type strain KOS 
(Figure 3.18 A&B). Likewise, the lesion induced by flank infection was resolved in both 
recombinant and the parent viruses almost at a similar rate (data not shown). An explant 
reactivation assay indicated that all recombinant viruses generated in this study were able to 
reactivate from latency (Figure 3.19). These data suggest that the recombinant viruses are 
phenotypically similar to the wild-type virus, confirming the previous observation that 
ICP47 deficiency does not affect the replication and pathogenesis of the virus in vivo.  
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Figure 3.12 Schematic representation of ICP47 null mutant and revertant viruses 
that express eGFP-Cre driven by the constitutive CMV IE promoter. (A) Diagram of 
HSV-1 pCMV eGFP-Cre genome with the location of eGFP-Cre expression cassette in the 
UL segment is indicated. The position of US12 gene in the US segment of the genome is 
also indicated in the diagram. The arrow points to the orientation of the gene. In HSV-1 
GKa47, a stop codon was introduced upstream of AUG start codon shown in red bar 
and in HSV-1 GKa47R, the blue bar represents silent substitutions used to create a 
restriction enzyme recognition site. These modifications are the same as made on the wild-
type KOS to generate Ka47 and Ka47R. (B) Sequence alignment of a relevant ICP47 
region of HSV-1 KOS, HSV-1 GKa47 and HSV-1 GKa47R is shown. The modified 
nucleotides are indicated in red, and the gaps are shown in dashes. HindIII recognition 
sequence in GKa47 and XbaI recognition sequence in GKa47R are represented by the 
blue boxes. Amino acid sequence translation is provided immediately below the nucleotide 
sequence. Here, the asterisk symbol represents the stop codon.  
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Figure 3.13 Characterisation of the recombinant viruses by RFLP analysis. The 
genome of wild-type HSV-1 (strain KOS), HSV-1 GKa47Δ and GKa47R were analysed by 
restriction digestion using enzymes BamHI, HindIII and XbaI. Blue arrows indicate the 
characteristic DNA fragments that were obtained due to the introduction of recognition 
sites for HindIII or XbaI in the genome of the recombinant viruses but not in the wild-
type HSV-1. Green arrowheads indicate the DNA fragment generated from the cleavage of 
the pCMV IE eGFP-Cre cassette. Yellow arrowheads indicate sizes of the relevant 
fragment of the molecular markers. 
 
 
 
Chapter 3 
118 
 
 
 
Figure 3.14 Schematic overview of recombinant ICP47 null mutant and rescuant 
viruses expressing eGFP-Cre controlled by the ICP47 promoter. (A) The depiction of 
the ICP47 null mutant is shown. The top line represents the prototypic arrangement of the 
HSV genome, with the green line representing the region of eGFP Cre polyA cassette 
inserted into the genome. Shown below is the expanded genomic region showing the 
location of insertion of the fusion gene. In the Ka47in, the first 19 bp from the 5 region 
of the ICP47 coding sequence was deleted and replaced by eGFP-Cre fusion gene with 
BGH polyA termination signal. (B) The depiction of the ICP47 rescuant virus is shown. 
The top line represents the HSV-1 Ka47rescue genome with the location of  eGFP-Cre 
fusion gene indicated by the green line and the position of  rescued ICP47 gene indicated 
by the blue line. Shown below is the expanded region of  the ICP47 gene cassette 
containing ICP47 coding sequence followed by SV40 polyA termination signal controlled 
by the modified ICP47 promoter. 
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Figure 3.15 Analysis of genomic DNA from the recombinant viruses HSV-1 Ka47in 
and HSV-1 Ka47rescue by RFLP. DNA from the recombinant viruses was isolated and 
digested with BamHI or EcoRI and electrophoresed on an agarose gel. There are two 
EcoRI recognition sequences in the eGFP Cre polyA cassette. Blue arrows indicate the 
characteristic DNA fragments that were obtained after restriction digestion with EcoRI. 
Yellow arrowheads indicate sizes of the relevant fragment of the molecular markers.  
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Figure 3.16 In vitro growth properties of parental and recombinant viruses. Vero 
cells were infected with the indicated viruses at 0.01 pfu/cell. After adsorption for 1 hour, 
the virus inoculum was removed and replaced with FBS-containing medium. The cells were 
then harvested in the culture medium at indicated time points and virus titre was 
determined by plaque assay. Comparisons were made between the recombinant viruses and 
their respective parental viruses. Data are from triplicate measurements and are expressed 
as mean ± SD (error bars). In some cases, the error bars are obscured by symbols showing 
means. 
B 
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Figure 3.17 Verification of recombinant viruses using antigen presentation assay. 
The human cell line 293KbC2 was infected with the wild-type HSV-1 or indicated 
recombinant viruses at 10 pfu/cell. After incubation for 3 hours, the cells were 
superinfected with MVA expressing OVA peptide SIINFEKL tagged to ER-targeting 
signal sequence (MVA ES mini OVA), MVA expressing SIINFEKL without the targeting 
sequence (MVA mini OVA) or MVA expressing Flu peptide (MVA mini Flu) at 10 
pfu/cell for 6 hours. Then the cells surface expression of Kb-SIINFEKL complex was 
analysed using flow-cytometry. (A and B) Histograms of Kb-SIINFEKL complex detected 
by APC conjugated primary anti- Kb-SIINFEKL –mAb (clone 25D.1.16) on infected cells 
is shown.  
 
A 
B 
Chapter 3 
122 
 
 
 
Table 3.1 List of recombinant HSV-1 to assess the influence of ICP47 using 
ROSA26R/Cre reporter system 
Recombinant 
HSV-1 
 ICP47  Promoter 
driving 
eGFP-Cre 
 Location of eGFP-
Cre 
 +/−  Location  
  
GKa47Δ 
 
− 
 
NA 
 
CMV IE 
 Between UL3 and 
UL4 
GKa47R 
 
+ 
 
Native position 
 
CMV IE 
 Between UL3 and 
UL4 
Ka47inΔ 
 
− 
 
NA 
 Native ICP47 
promoter 
 ICP47 gene locus 
Ka47rescue 
 
+ 
 Between UL26 
and UL27  
 Native ICP47 
promoter 
 ICP47 gene locus 
Note: 
+ ICP47 gene encode a functional protein 
− ICP47 gene does not encode a functional protein 
NA – Not applicable 
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Figure 3.18 In vivo growth characteristics of Cre expressing ICP47 null mutant and 
control viruses. To test the in vivo growth characteristics of recombinant viruses, groups of 
mice were infected with the indicated viruses and virus titres were determined from skin 
and DRG by plaque assay. The amount of virus found in skin and DRG were comparable 
between mice infected with HSV-1 pCeGC, HSV-1 GKa47 and HSV-1 GKa47R both 
after 4 days (A) and after 6 days (B) of infection. Similarly, comparison of the average virus 
titre after 5 days of infection between mice infected with wild-type (KOS), HSV-1 Ka47in, 
HSV-1 Ka47rescue shows no statistically significant difference (C). Each symbol represents 
virus titre in a single mouse and error bars represent mean ± SEM for 4 mice per time 
point. The means were tested by one-way ANOVA with Tukey’s multiple comparisons 
post-test and no groups were found to be statistically significant. 
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Figure 3.19 Reactivation of Cre expressing ICP47 null mutant and control viruses in 
explanted DRG. Mice infected with the GKa47, GKa47R, Ka47in or HSV-1 
Ka47rescue were euthanised 50 days after infection. DRG from spinal levels T5 to L1 were 
excised and incubated in culture media at 37ºC with 5% CO2 for 5 days. The DRG were 
then homogenised and assessed for infectious virus on Vero cell monolayers. After two 
days, the plaques were examined by fluorescence microscopy for eGFP expression. 
Representative plaques formed by recombinant viruses after ex vivo reactivation are shown. 
The top row shows photomicrographs taken using phase-contrast microscopy and the 
bottom row shows the detection of eGFP by fluorescent microscopy. The images were 
captured at 100× magnification. The scale bar (150 µm) is shown in the top left 
photomicrograph. 
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3.2.4.4.2 ICP47 does not affect establishment and maintenance of latency in 
mice 
The influence of ICP47 on HSV-1 latency was studied using the ROSA26R reporter mouse 
system so that the frequency of cell marking in the presence or absence of ICP47 could be 
compared. For this, cohorts of ROSA26R mice were infected with GKa47Δ and GKa47R. 
DRG from spinal level T5 to L1 were excised at different time points after infection, 
stained using X-Gal after which the number of neurons producing β-galactosidase were 
counted as a measure of historic CMV IE promoter activation. No difference in the 
number of β-gal positive neurons was observed when DRG from GKa47Δ and GKa47R 
infected mice were examined 5, 10, 20, 40 and 100 days after infection (Figure 3.20 A). 
Similar to marking by the parent virus HSV-1 pC_eGC virus (Russell, 2015; Ma et al., 
2014), infection by GKa47Δ and GKa47R, resulted in the number of β-galactosidase 
positive neurons rising from 5 day to 10 days post-infection (dpi) followed by a rapid fall 
until 20 days and thereafter, being numerical stability in both the null mutant and in the 
revertant viruses. The comparable level of marking during lytic infection (5 and 10 dpi) by 
viruses lacking ICP47 and control viruses is consistent with the similar level of virus titre 
observed in DRG on four and six days after infection. Further, the comparable number of 
neurons marked on days 20, 40 and 100 after infection suggests that ICP47 does not play a 
significant role during the establishment or maintenance of latency.  
In our infection model, the virus is tattooed on the flank of mice, which allows the virus 
primarily to infect the neurons innervating the same dermatome. However, during 
subsequent rounds of replication, the virus spreads to spinal ganglia not directly innervating 
the initial infection site (Simmons and Nash, 1984; Speck and Simmons, 1991). Based on 
the enumeration of β-gal positive neurons in DRG across the spinal levels using ROSA26R 
mouse model, Russell and Tscharke (2016) have shown that the virus spreads to multiple 
DRGs along the spine after the peak of acute infection and during the establishment phase 
of latency (10 to 20 days). In the current study, infection of ROSA26R mice with GKa47Δ 
or HSV-1 GKa47R showed that a similar number of DRG experienced Cre mediated β-gal 
marking at different times examined (Figure 3.20 B). This finding implies that the loss of 
ICP47 has no effect on the virus spread to DRG distal to those that directly innervate the 
cutaneous site of infection.  
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Based on the assumption that ICP47 can be expressed in some neurons during the 
establishment of latency (Russell and Tscharke, 2016), we examined the fate of those 
neurons by employing ICP47 null mutant and rescuant viruses in which the ICP47 
promoter controls Cre expression. ROSA26R mice were infected with HSV-1 Ka47in or 
HSV-1 Ka47rescue and their DRG were examined for β-gal expression on 5, 10, 20, 40 
and 100 days after infection. The results presented in Figure 3.21 A show that the number 
of neurons marked was similar between the null virus and the control viruses at all time 
points examined, except on day 10 after infection. Further, the number of DRG with 
marked neurons was comparable between the viruses (Figure 3.21 B). The lack of 
difference in the number of neurons marked on days 20, 40 and 100 suggests that ICP47 
expression neither influences the ability of HSV-1 to establish and maintain latency nor 
affects the survival of infected neurons.  
On day 10, the number of neurons marked by Ka47in was significantly lower than the 
marking by the control virus Ka47rescue. By analysing virus titre, we found a similar 
reduction in infectious virus in the DRG from 4 to 6 days of infection by the ICP47 null 
mutant (Ka47 or GKa47) and control viruses (wild-type, Ka47R or GKa47R) (Figure 
3.10 B, C and Figure 3.17). Similar titres on day 6 indicate that the virus is cleared at the 
same pace regardless of the presence of ICP47. Consistent with this, the difference in the 
amount of infectious virus detected on 5 dpi by the wild-type, Ka47in or Ka47rescue is 
not statistically significant. Further, a similar level of β-gal marking of neurons observed 
from 20 to 100 days post-infection indicates that the lack of ICP47 does not impair the 
ability of the virus to enter latency. Since, viral gene expression can occur beyond acute 
infection in neurons (Steiner et al., 1990; Margolis et al., 1992; Kramer et al., 1998; Russell 
and Tscharke, 2016), our result cannot rule out the possibility that ICP47 prolongs virus 
activity at the molecular level or perhaps increase the survival of the neurons until 10 days 
after infection. However, these possibilities were not explored further in this thesis.  
In contrast to the previous finding by Russell and Tscharke (2016), the ICP47 promoter in 
our study did not induce additional β-gal marking during the establishment phase. Instead, 
the numbers dropped from 5 to 20 days after infection and then remained stable during 
latency. The basis of this difference is examined in detail and the results are presented in 
the next chapter. Collectively, the data from ROSA26R reporter mice infected with the 
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different Cre expressing ICP47 null mutants suggest that the lack of ICP47 did not affect 
the spread of the virus in the ganglia or across the spinal levels. Further, ICP47 deficiency 
neither impacted the establishment of latency nor the stability of latency.  
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Figure 3.20 Historical marking of neurons by CMV IE promoter activation reveals 
that ICP47 does not affect the establishment of latency or the stability of latency. 
Groups of ROSA26R mice were infected with GKa47 or GKa47R on the flank. DRG 
from T5 to L1 were excised from each mouse on 5, 10, 20, 40- and 100-days post-infection, 
DRG were stained with X-Gal, mounted intact and large blue cells were counted. (A) The 
graph shows the number of neuronal cells marked by X-Gal staining per mouse. (B) The 
graph shows the number of DRG containing at least one -gal synthesising neuron per 
mouse. Each symbol represents a mouse and bars represent mean  SEM. Data shown are 
pooled from two experiments. The comparison of cell marking or spread of the virus 
between the viruses GKa47 and GKa47R was not significantly different based on two-
way ANOVA and Sidak’s multiple comparisons test. 
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Figure 3.21 Historical marking of  neurons by HSV-1 ICP47 promoter activation 
reveals that ICP47 does not affect the establishment of  latency or the stability of  
latency. Groups of  ROSA26R mice were infected with HSV-1 Ka47in or HSV-1 
Ka47rescue on the flank. DRG from T5 to L1 were excised from each mouse on 5, 10, 20, 
40- and 100-days post infection. DRG were stained with X-Gal, mounted intact and large 
blue cells were counted. (A) The graph shows the number of  neuronal cells marked by X-
Gal staining per mouse. (B) The graph shows the number of  DRG containing at least one 
-gal synthesising neuron per mouse. Data shown are pooled from two experiments. Each 
symbol represents a mouse and bars represent mean ± SEM. Statistical significance was 
calculated by comparing means using two-way ANOVA and Sidak’s multiple comparison 
test (**p<0.01). Except for day 10, the number of  -gal marked neurons was not different 
at other time points between the groups. The spread of  the virus between DRG across 
spinal level was not significantly different. 
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3.2.4.5 Reactivation ability of the virus is not affected by the loss of ICP47 
function of the virus 
Co-localization of activated HSV-specific effector memory CD8+ T cells and latently 
infected neurons has been reported both in human (Theil et al., 2003; Verjans et al., 2007) 
and in mouse studies (Shimeld et al., 1990b; Simmons and Tscharke, 1992; Khanna et al., 
2003a). Mackay and colleagues have shown that CD8+ T cells retained in the ganglia of 
HSV-1 infected mice are actively involved in recognition of latently infected cells and 
respond by the production of granzyme B (Mackay et al., 2012). Convincingly, the addition 
of HSV-specific CD8+ T cells to cell suspension of latently infected mouse ganglia 
prevented reactivation of the virus in an MHC I-dependent manner (Khanna et al., 2003a; 
Orr et al., 2007). These studies indicate a possible protective role of CD8+ T cells during 
latency. However, it is not yet clear whether the inhibition of MHC I-mediated antigen 
presentation by ICP47 contributes to the reactivation of the virus in mice. Therefore, the 
role of ICP47 in reactivation from latently infected sensory neurons was explored in this 
project using an explant reactivation assay (see materials and methods, section 2.3.10.3).  
In this assay, DRG from thoracic level 4 (T4) to lumbar level 3 (L3) were excised from 
latently infected mouse, explant cultured in vitro for 5 days and then assayed for infectious 
virus. We found that the percentage of ganglia with reactivated virus from each mouse and 
percentage of ganglia with the reactivated virus from individual spinal level was comparable 
amongst groups of mice infected with HSV-1 KOS, Ka47Δ or Ka47R (Figure 3.22 A and 
B). These data show that ICP47 did not alter reactivation ability of the virus nor curtail the 
reactivation in the absence of ICP47 in an ex vivo condition.  
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Figure 3.22 ICP47 does not influence reactivation of HSV-1 from DRG of mice. 
Groups of six mice were infected on the flank with HSV-1 KOS, HSV-1 Ka47 or HSV-1 
Ka47R. DRG from spinal levels T4 to L3 were excised after 30 days of infection. 
Reactivation was induced in vitro by explant culture as described in methods section. (A) 
Percentage of DRG with the infectious virus was calculated from each mouse. Data were 
pooled from 3 independent experiments. Each symbol represents a mouse and data from 
different experiments are color-coded. The error bar represents mean ± SEM. Ordinary 
one-way ANOVA with Tukey’s multiple comparisons test was used to analyse the 
statistical difference amongst the groups. (B) Percentage of DRG with the infectious virus 
was calculated for each spinal level (T4 to L3). The data from 3 experiments are plotted. 
The error bar represents mean ± SEM. The difference between the viruses is not 
statistically significant according to one-way ANOVA and Newman-Keuls multiple 
comparisons test 
B 
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3.3 Discussion  
HSV, compared to other herpesviruses, has an advantage as a model virus as it can 
productively infect mice and therefore understanding the in vivo significance of TAP 
inhibition by ICP47, at least in principle is possible. Previous in vivo findings suggest that 
inhibition of TAP by ICP47 is critical for virus spreading from PNS to CNS (Goldsmith et 
al., 1998; Burgos et al., 2006). However, the role of ICP47 in mouse models apparently 
contradicted in vitro studies that demonstrated the lack of ICP47 functioning in mouse cells 
(Ahn et al., 1996; Tomazin et al., 1996; Jugovic et al., 1998; Berger et al., 2000; Easterfield 
et al., 2001; Radosevich et al., 2003). Here, we attempted to resolve the disparity between 
the in vitro and in vivo findings by using new assays and infection models in conjunction with 
alternate virus strain and mouse strain. In the discussion that follows, we attempted to 
derive a global insight into the relevance of ICP47 during different stages of HSV-1 
infection in mice. 
Consistent with published data, in our study the ability of HSV-1 to down-modulate total 
surface MHC I was seen in infected human cells but not in mouse cells. While down-
modulation of total surface MHC I reflects the function of ICP47 on suppressing antigen 
presentation, the full extent of inhibition in mouse cells may have been underestimated due 
to the persistence of baseline pMHC-I that were present pre-infection. Therefore, ICP47 
mediated inhibition of presentation in mouse cells might not be revealed by merely 
determining surface MHC I levels. Using a super-infection-based antigen presentation assay, 
we were able to expose the influence of ICP47 on the presentation of newly synthesised 
peptides. We found that in human and mouse cells infected with wild-type HSV-1, 
followed by infection with SIINFEKL expressing MVA, the level of H-2Kb-SIINFEKL 
complexes on the cell surface was significantly reduced compared with cells infected with 
Ka47Δ. While in human cells, ICP47 showed inhibition of antigen presentation to near 
background levels, in mouse cells there was significant, but relatively reduced inhibition. 
Nevertheless, our antigen presentation assay indicates that ICP47 functions in mouse cells 
and it might be sufficient for evasion of CD8+ T cells by HSV-1 in neuronal cells that 
inherently express less MHC I in an in vivo setting as has been suggested previously 
(Corriveau et al., 1998; Redwine et al., 2001). 
While ICP47 was shown to enhance the neurovirulence in a lethal encephalitis model 
(Goldsmith et al., 1998; Burgos et al., 2006), whether this outcome is due to the defect in 
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the generation of HSV-1 specific CD8+ T cells was not tested. Our finding demonstrates 
that the magnitude of the CD8+ T cell response mounted against HSV-1 during acute 
infection is similar irrespective of ICP47. Similarly, Orr and colleagues (2005) found that 
footpad infection with recombinant HSV-1 viruses expressing potent inhibitors of antigen 
presentation, despite inducing neurological disease, did not alter the size of the CD8+ T cell 
response. This suggests that the total virus-specific CD8+ T cell response during lytic 
infection is unaltered in spite of an efficient inhibition of antigen presentation. The above 
data fit with the idea that the initial priming of naïve CD8+ T cells in the lymphoid organs 
occur mainly through the cross-presentation of HSV-1 antigens by uninfected CD8+ 
DCs (Bosnjak et al., 2005a; Bedoui et al., 2009; Whitney et al., 2017).  
Another scenario where ICP47-mediated inhibition of antigen presentation would be of 
relevance is in infected cells that are targets for activated CD8+ T cells. Transcription of 
ICP47 begins soon after infection in the human fibroblast cells and mouse neuronal culture 
(Harkness et al., 2014). The kinetics of its expression raises the possibility that ICP47 plays 
an essential role in favouring the survival of HSV infected cells against the CD8+ T cell 
response leading to the better establishment of initial infection. The in vivo experiments 
described in this chapter show that following flank infection of C57BL/6 mice with HSV-1, 
lack of ICP47 resulted in no difference in the virus replication in the skin and DRG on 
four and six days after infection. Others have also made a similar observation in corneal 
epithelia using the corneal scarification model (Goldsmith et al., 1998). The lack of 
measurable difference in viral replication in the skin could be due to other more dominant 
or redundant immune responses. Accordingly, CD4+ T cells and IFN have been shown to 
be critical for the elimination of infectious virus in mice (Smith et al., 1994; Manickan et al., 
1995). IFN expression by epidermal cells and infiltrating immune cells can partially 
overcome ICP47 mediated down-regulation of MHC I, increasing their prospect of being 
recognised by activated CD8+ T cells (Mikloska et al., 1996; Radosevich et al., 2003).  
Therefore, it can be argued that TAP inhibition by ICP47 is unlikely to have a significant 
impact on virus replication in the skin in an immunocompetent host. However, in the 
peripheral sensory neurons, CD8+ T cells have a significant role in curtailing virus 
replication with limited neuronal cell death (Simmons and Tscharke, 1992). Additionally, 
Orr and colleagues found that inhibition of antigen presentation by m152 provided a 
replication advantage to HSV-1 in the eye and TG of mice during acute infection, 
Chapter 3 
134 
suggesting that effective inhibition of antigen presentation would result in improved viral 
fitness in the nervous system. Therefore, a possible explanation for the comparable level of 
infectious virus in the infected tissues could be that ICP47 does not reduce the antigen 
presentation sufficiently during acute infection to impact the visibility of infected cells to 
CD8+ T cells. 
HSV-1 replication at the peripheral site is not a prerequisite for the establishment of 
neuronal latency in mice (Efstathiou et al., 1989). Likewise, virus lacking immediate early 
genes, including ICP47, can enter latency in mouse neurons (Meignier et al., 1988; 
Nishiyama et al., 1993). HSV-1 DNA can be detected as early as 8 hours post-infection 
(Wakim et al., 2008) and the infectious virus can be recovered by 32 hours in sensory 
ganglia of mice following infection with HSV-1 (Kramer et al., 1998). However, it takes a 
few days for the HSV-1 specific CD8+ T cells to be primed, expand and appear at the 
infection site (Coles et al., 2002). Given the rapidity at which the virus travels from the skin 
to the sensory neurons, it is unlikely that CD8+ T cells can prevent the establishment of 
latency during HSV-1 infection. Consistent with these data, we found that similar to wild-
type and revertant viruses, ICP47 null mutant viruses establish latency in all infected mice 
infected as measured by their ability to reactivate after 30 days of infection.  
From mouse studies, it is apparent that stable latency in the absence of any productive 
infection is established many days after the detection of infectious virus, typically 28 to 34 
days after the initial infection (Miller et al., 1998). During this latency establishment phase, 
some neurons tolerate lytic gene expression and virus spread (Lachmann et al., 1999; 
Arthur et al., 2001; Feldman et al., 2002a; Proença et al., 2008, 2011; Russell and Tscharke, 
2016). As a consequence, viral antigens will be present in at least a proportion of these 
neurons at this time. Moreover, virus infection in neural tissues induces the expression of 
MHC I and various other components of the antigen processing pathway (Neumann et al., 
1995; Pereira and Simmons, 1999; Kimura and Griffin, 2000; Chevalier et al., 2011). 
Additionally, mouse studies suggest ongoing stimulation of CD8+ T cells in ganglia well 
beyond the termination of lytic infection (Cantin et al., 1995; Khanna et al., 2003a). With 
the absence of professional APCs in the ganglia during latency, neurons are considered to 
be responsible for presenting viral antigens to CD8+ T cells (van Lint et al., 2005). Taken 
together, the above observations suggest that neurons present antigen during and after the 
establishment of latency. We hypothesised that the primary function of ICP47 might not 
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be to ensure the establishment of latency per se, but it may help seed a larger latent pool by 
decreasing the ability of the CD8+ T cells to respond against infected neurons. In theory, 
an HSV-1 virus lacking ICP47 would permit presentation of an increased number of viral 
epitopes on neurons, hence increasing the chances of their elimination by CD8+ T cells. 
This effect could be reflected by a reduction in the number of neurons entering latency. On 
the contrary, in our study ICP47 did not impact the number of neurons marked by CMV 
IE promoter or HSV-1 ICP47 promoter activity during the latency establishment phase. 
Similarly, the latency of ICP47 null mutant and control viruses was stably maintained as 
indicated by the similar level of marking at different times examined during latency. In this 
study, we based our assumptions on our data that showed ICP47 can block antigen 
presentation in mouse fibroblast cells and predicted that ICP47 influences latency. 
However, we lack knowledge of the abundance of peptide epitopes presented on HSV-1 
infected mouse cells. CD8+ T cells are highly sensitive in sensing low-levels of cognate 
antigen presentation, at least under ideal conditions in vitro (Valitutti et al., 1995; Purbhoo et 
al., 2004; Hogan et al., 2014). Hence, if the antigen presentation in neurons was not 
completely inhibited by ICP47 during the latency establishment phase, then infected-
neurons will still be eliminated by CD8+ T cells, leading to a similar number of marked 
neurons. If this proves not to be the case, different factors will need to be considered, such 
as whether immunogenic antigens are abundantly expressed in neurons for presentation 
after lytic infection and whether the spatial and temporal expression of ICP47 coincides 
with or precedes the expression of antigenic proteins.  
Another explanation for the lack of difference in a number of β-gal+ neurons between 
ICP47 null virus and control viruses is that CD8+ T cells may control HSV replication by 
using non-cytolytic mechanisms in neurons. In that case, the removal of ICP47 will not 
have any effect on the maintenance of latently infected neurons. Antiviral cytokines 
produced by CD8+ T cells, such as IFN or TNF, can stimulate intracellular pathways 
that inhibit the expression of essential viral genes required for viral replication (Decman et 
al., 2005). Similarly, in the TG of infected mice, granzyme B was able to curtail virus 
reactivation without inducing caspase-mediated apoptotic cell death. Instead, the control of 
virus replication was thought to be due to granzyme B mediated-degradation of ICP4, an 
immediate early gene essential for the expression of early genes (Knickelbein et al., 2008). 
Consistently, in human cadaveric TG, CD8+ T cells containing granzyme B were clustered 
close to neurons expressing LAT and showed limited neuronal destruction (Verjans et al., 
Chapter 3 
136 
2007). In addition, a large body of evidence indicates that LATs, which are the most 
abundant viral transcripts made during latency, interfere with apoptotic pathways directly 
or by blocking granzyme B from activating caspase-3 (Ahmed et al., 2002; Henderson et al., 
2002; Branco and Fraser, 2005; Jiang et al., 2011). Perhaps if the CD8+ T cells implement 
one or more of these mechanisms to protect neurons presenting HSV peptides, then lack 
of ICP47 will not have any visible effect on the number of neurons after the establishment 
of latency. Although such a complicated explanation cannot be excluded, the incomplete 
TAP inhibition by ICP47 or redundancy in immune control is the most plausible 
explanation for the data presented in this thesis. 
Goldsmith and colleagues found that the deletion of ICP47 resulted in the reduced spread 
of the virus to the CNS following ocular infection of BALB/c mice in a CD8+ T cell-
dependent manner suggesting that ICP47 enhances neurovirulence in mice by inhibiting 
TAP-mediated peptide transport (Goldsmith et al., 1998). The capacity of the virus to enter 
the CNS depends on multiple factors that often act in combination (Kollias et al., 2015a). 
First, the genetic composition of the virus is critical in determining the severity of infection 
(Dix et al., 1983; Bergström et al., 1990). Second, genetic and immunological factors of a 
mouse strain may determine the resistance to CNS infection (Kastrukoff et al., 2012b). 
Third, the route of infection also determines the ease of travel of the virus to the CNS 
(Simmons and La Vista, 1989; Wang et al., 2013b). In a susceptible mouse model, ocular 
infection, intranasal inoculation or lip injection of virulent HSV can readily permit CNS 
infection, where the virus travels via the olfactory or trigeminal route (Esiri, 1982; Esiri and 
Tomlinson, 1984; Menendez and Carr, 2017). A recent study showed that following corneal 
scarification of C57BL/6 mice with a neurovirulent HSV-1, the virus travelled via 
trigeminal ganglia to the olfactory bulb (OB) and established latency. More importantly, 
IFN producing HSV-1 specific CD8+ T cells were found in the OB of the infected mice 
during latency suggesting that CD8+ T cells could be relevant in preventing virus 
dissemination to the CNS (Menendez and Carr, 2017). In the flank infection model, the 
virus first infects the DRG that directly innervate the site of infection followed by spread 
to adjacent DRG likely via inter-neuronal synapse formed in the spinal column (Lachmann 
et al., 1999; Speck and Simmons, 1991). CNS infection was not expected to be infected in 
our mouse model, which employs C57BL/6 mice and the avirulent HSV-1 (KOS) strain 
(Thompson et al., 1986; Goel et al., 2002). However, given that CD8+ T cells can access 
sites such as spinal cord (Lang and Nikolich-Zugich, 2005; Lundberg et al., 2008), we 
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predicted that these cells would curtail the spread of the virus to adjacent spinal DRG that 
are not innervating the site of infection in the absence of ICP47. However, our experiment 
using the ROSA26R Cre model shows that this was not the case. Instead, both the ICP47 
null mutants and the control viruses showed a comparable level of marking at all the 
examined time points at neuron level and at the level of DRG implying that ICP47 does 
not influence the spread of the virus. 
Only a fraction of latently infected neurons in a ganglion express ICP47 at a detectable 
level at any given time (Ma et al., 2014; Russell and Tscharke, 2016), therefore it is not 
expected that ICP47 would completely block antigen presentation in ganglia during latency. 
Therefore, the antigenic stimulation and activation of memory CD8+ T cells seen by others 
are not surprising. In terms of their function, an inverse correlation was established 
between the number of ganglionic CD8+ T cells and the rate of reactivation (Hoshino et al., 
2007). Consistently others have shown that the depletion of CD8+ T cells from ganglia 
favours HSV-1 reactivation and supplementing ganglionic cultures with activated CD8+ T 
cells reduced the reactivation efficiency (Liu et al., 2000; Decman et al., 2005; Sheridan et 
al., 2009). Presence of armed CD8+ T cells in ganglia means that they may be able to reduce 
the probability of reactivation when it occurs at molecular level even before viral DNA 
replication is initiated and infectious virus is assembled. In the face of the change in gene 
expression cascade during reactivation (Tal-Singer et al., 1997), the removal of ICP47 was 
thought to enhance the probability of antigen recognition by ganglionic virus-specific 
CD8+ T cells resulting in the termination of reactivation. In our study, ICP47 showed no 
influence on the reactivating ability of the virus using our explant reactivation model. 
However, when Orr and colleagues infected C57BL/6 mice with recombinant HSV-1 
expressing MCMV glycoprotein gp40 (gene m152) or HCMV US11, CD8+ T cell control 
of HSV-1 reactivation was impaired as demonstrated by the frequent recovery of infectious 
virus from the eyes and ganglia of UV exposed mice (Orr et al., 2007). MCMV gp40 
interferes with the transport of pMHC-I to cell surface by retention in the ER and Golgi 
compartments (Pinto and Hill, 2005; Janßen et al., 2016), whereas HCMV US11 directs 
newly synthesised MHC I molecules from ER to cytosol where they undergo proteosomal 
degradation (Wiertz et al., 1996). The mechanism by which these two proteins down-
regulate MHC I differ from that of ICP47 is not known, however, they function relatively 
efficiently in a mouse model. While it is convincing that CD8+ T cells can inhibit 
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reactivation, it appears that ICP47 does not provide an absolute blockade of antigen 
presentation and therefore, there is no effect on reactivation.  
Where we failed to find a phenotype for our ICP47 null virus during different stages of 
HSV-1 infection, there was a significant decrease in the number of neurons marked by Cre 
on day 10 in Ka47inΔ-infected ROSA26R mice compared to Ka47rescue-infected mice. A 
similar but statistically insignificant trend was observed for the number of DRG with Cre 
marked neurons on this time point. It is possible that this difference was not apparent 
when CMV IE promoter induced Cre marking as it drives Cre expression in an extensive 
number of neurons in DRG of mice (i.e., in most of the live infected neurons). 
Comparatively, more marked neurons in Ka47rescue-infected mice allude to the 
association of ICP47 with survival of infected neurons. However, such an interpretation 
remains speculative because the difference in number of Cre marked neurons between the 
two viruses vanished on day 20 and the numbers remained stable until 100 days after 
infection. This suggests that the additionally marked neurons on day 10 did not continue to 
survive until the establishment of latency. If ICP47 enhances neuronal survival during lytic 
infection, it may result in the production of more infectious virus in DRG. Although the 
virus titre in DRG was similar on days 4, 5 or 6, and disease resolution occurred at a similar 
rate, it is possible that a small amount of infectious virus is present beyond this time in 
neurons expressing ICP47. Virus titre and viral genome copy number should be 
determined for an extended time in future studies in the DRG of infected mice to elucidate 
if ICP47 enhances survival of infected neurons and consequently results in an increase in 
the amount of infectious virus. 
Overall, our in vivo study using mouse model showed that ICP47 does not affect lytic 
infection, establishment and maintenance of latency or reactivation of the virus. Our new in 
vitro antigen presentation assay demonstrated that the inhibition of antigen presentation by 
ICP47 is less efficient in mouse cells compared to human cells, which is consistent with 
other published in vitro findings. Together, the above findings suggest that the lack of 
discernible phenotype for ICP47 in our mouse model is most likely due to the partial 
inhibition of MHC I mediated antigen presentation by ICP47 in mice. However, the 
question remains, “how much peptide presentation is inhibited by ICP47 in human than 
mouse?” The abundance of HSV peptides in infected human and mouse cells is explored in 
chapter 5. 
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4 Characterisation of ICP47 promoter using ROSA26R/Cre 
reporter mouse system 
4.1 Introduction 
Recombinant HSV-1 has been used extensively as a research tool. For this purpose, genes 
from a variety of sources have been inserted into viral genomic regions non-essential for 
virus growth in culture and virulence in mice. Typically, a viral promoter 5′ to the inserted 
sequence, another HSV-1 promoter or a heterologous promoter is used to control the 
expression of inserted genes. Of the insertion sites, the intergenic regions between UL3 
and UL4, UL26 and UL27, and UL50 and UL51 have been previously confirmed as 
suitable for reporter gene expression without altering the efficiency of viral replication in 
cell culture and in mice (Balliet et al., 2007; Morimoto et al., 2009; Russell et al., 2015). In 
particular, the UL3-UL4 locus had often been utilised by others to generate recombinant 
viruses and insertion at this site does not impair viral replication in vitro or in vivo nor does it 
affect the establishment and maintenance of latency (Baines and Roizman, 1991; Cocchi et 
al., 1998; Menotti et al., 2002; Tanaka et al., 2003, 2004; Taylor et al., 2007; Morimoto et al., 
2009; Bedadala et al., 2014; Miyagawa et al., 2015; Russell et al., 2015). Further, insertion at 
this location is not thought to affect the expression of adjacent genes as UL3 and UL4 are 
both orientated towards the intergenic region, and no cis-elements have been mapped to 
this region (Morimoto et al., 2009). Russell and Tscharke (2016) utilised the intergenic 
region between UL3 and UL4 to introduce various HSV-1 lytic gene promoters to drive 
the expression of Cre. Testing these viruses in the previously described ROSA26R/Cre 
reporter system revealed that the promoters of lytic genes (ICP47, ICP6 and gB) induced a 
detectable level of Cre expression in a subset of neurons during latency. In particular, 
ICP47 promoter induced Cre activity in a significant proportion of neurons during the 
establishment of latency (Russell and Tscharke, 2016). However, this seems not to be the 
case for the ICP47 promoter at the native location (Figure 3.21). Intriguingly, after the lytic 
phase, Cre activity driven by native ICP47 promoter in HSV-1 Ka47in and Ka47rescue 
viruses differed drastically from Cre activation by ICP47 promoter in HSV-1 pICP47_eGC, 
used in the previous study (Russell and Tscharke, 2016). The recombinant virus HSV-1 
pICP47_eGC will be referred to as HSV-1 UL3-pa47min in this thesis. 
In the experiment shown in Figure 3.21, UL3-pa47min was included for direct comparison, 
but not shown in the figure with an intension to highlight the role of ICP47. All viruses are 
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now shown in Figure 4.1. In brief, the following observations were made. First, the 
neuronal marking driven by all three viruses was comparable during lytic infection (5 dpi). 
Further in a previous study Russell (2015) confirmed that the strength of the native ICP47 
promoter was not significantly different to the ectopic version in UL3-pa47min as 
demonstrated by the similar amount of Cre and ICP47 transcripts found during lytic 
infection in mice infected with HSV-1 UL3-pa47min (Russell, 2015). Second, while the Cre 
mediated marking of neurons was similar during lytic infection between HSV-1 Ka47in or 
Ka47rescue and HSV-1 UL3-pa47min, it appeared to be differentially regulated between 
these viruses especially during the latency establishment and latency. Unlike HSV-1 UL3-
pa47min, the viruses generated in this study (HSV-1 Ka47in and Ka47rescue) did not 
mark new neurons beyond lytic infection, instead the number of labeled neurons dropped 
and ultimately became stable as latency established (Figure 4.1 A). Finally, the number of 
DRG with β-gal marked neurons increased from 5 to 100 days in UL3-pa47min-infected 
mice, however, no new marking was visualised beyond ten days in mice infected with 
Ka47in or Ka47rescue (Figure 4.1 B). So far, it remains undetermined whether the lack of 
β-gal staining means no Cre activity or insufficient Cre expression to mediate the genetic 
recombination, but it is clear that the activity of the promoter driving Cre differs between 
these viruses.  
Two main differences between the viruses used in the current and the previous study could 
account for the differential Cre marking during latency. Firstly, while in the present study 
eGFP-Cre fusion gene is driven from the native ICP47 location, Russell and Tscharke 
(2016) introduced an eGFP-Cre fusion gene cassette in the intergenic region between the 
genes UL3 and UL4 (Figure 4.2). Although the reporter gene expression from UL3-UL4 
locus and the native locus are similar during acute infection in mice, the possibility that the 
UL3-UL4 locus might be relatively permissive for gene expression during latency cannot be 
ruled out. Likewise, it is possible that the insertion of a transgene cassette into the ICP47 
locus, which is located close to the TRS, might have affected the promoter activation 
during latency. Second, the promoter that Russell and Tscharke used differed from the 
native ICP47 promoter having a 62 bp deletion to remove the origin of replication (oriS), 
and the omission of the 5' untranslated region and an intron that occurs between the 
ICP47 promoter and coding sequence (Figure 4.3). Potential regulatory elements that likely 
occur in this missing region are reviewed below.  
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Figure 4.1 Comparison of -gal marking of neurons by the ICP47 promoter in HSV-
1 UL3-pa47min, HSV-1 Ka47in and HSV-1 Ka47rescue. The transcriptional history of 
the ICP47 promoter was analysed in ROSA26R mice in the previous chapter and 
compared to another virus, UL3-pa47min, here. (A) Data represent the number of neurons 
marked by -gal in ROSA26R mice infected with HSV-1 UL3-pa47min, HSV-1 Ka47in 
and HSV-1 Ka47rescue on different days after infection. (B) Data represent the number of 
DRG containing at least one -gal+ cell per mouse previously infected with HSV-1 UL3-
pa47min, HSV-1 Ka47in or HSV-1 Ka47rescue at different days after infection. (A&B) 
The data shown are pooled from 3 independent experiments with overlapping time points. 
Box plots show the median (horizontal line) and the interquartile range; whiskers indicate 
the minimum and maximal values. Means were compared using two-way ANOVA 
combined with Bonferroni’s multiple comparisons post-test (**p<0.01, ***p<0.001, 
***p<0.0001).
Ka47in 
Ka47rescue 
UL3-pa47min  
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Figure 4.2 Location of the reporter gene insertion and position of ICP47 in the HSV-1 genome. Two loci commonly used for heterologous gene 
expression in HSV-1 are the intergenic region between the genes UL3 and UL4 and between UL26 and UL27. A diagrammatic representation of the HSV-1 
genome with unique regions and repeat regions is shown above. Below, the locations of relevant genes are annotated. Arrows in magenta indicate the 
location and orientation of UL3 and UL4 genes. Blue arrows indicate the location and orientation of UL26 and UL27 genes. Yellow lines flanking the unique 
short (US) region indicate ICP47 promoter on the right and ICP22 promoter on the left. The ICP47 promoter is in the terminal repeat TRS, and pICP22 is 
in the internal (inverted) repeat IRS, which makes these promoter sequences similar. The orange arrowhead represents the location and orientation of ICP47 
gene in the US region of the HSV-1 genome. Being in the repeat region, the LAT gene is duplicated (purple arrows), located proximal to either end of the 
UL segment. 
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4.1.1 The ICP47 locus contains several cis-acting regulatory proteins 
binding motifs  
The regulation of HSV-1 IE gene expression during lytic infection is well-studied in vitro. In 
order to define the cis-acting elements that mediate IE gene expression, promoter regions 
were cloned upstream of a reporter gene whose activity was then assessed following 
transfection of the various constructs into infected cells. It is well-established that all 
immediate early genes possess in their promoter region a reiterated cis-acting inducible 
element, with consensus sequence 5 TAATGARAT 3, that is bound by the Oct-
1/VP16/HCF-1 transactivation complex (Mackem and Roizman, 1982; Gaffney et al., 
1985; Preston et al., 1988; Roizman et al., 1988; Hagmann et al., 1995). Binding of VP16 
transactivation complexes induces IE gene transcription by interacting with various host 
transcription factors and RNA polymerase II (Batterson and Roizman, 1983; Campbell et 
al., 1984). The regulatory domains of IE gene promoters also contain TATA box and 
binding sites for other cellular transcription factors such as stimulator protein 1 (Sp1), a 
member of the zinc finger/krupple family proteins, and GABP binding factors (Jones and 
Tjian, 1985). Together, these binding sites form the basis for the “core IE promoter,” and 
have been shown to up-regulate IE gene transcription in cell culture. However, although 
these regulatory elements are required for efficient virus replication, they were 
demonstrated to be dispensable for the establishment of HSV latency or reactivation in 
mice (Davido and Leib, 1996). The above cis-acting regulatory elements in the core 
promoter are preserved in the modified ICP47 promoter used in the previous study.  
Of note, the promoter of the IE genes, ICP47 and ICP22, are situated in the repeat 
sequences that flank the unique short region of the HSV genome, hence they have identical 
nucleotide sequences (Barklie et al., 1977; Murchie and Mcgeoch, 1982; Gelman and 
Silverstein, 1987). Several transcription factors and cis-acting elements that potentially 
regulate ICP22 gene expression were also discovered in the regions flanking the core 
promoter. Since the ICP47 promoter region is identical to that of ICP22, it is reasonable to 
assume that binding of the regulatory factors to these cis elements is likely to influence the 
expression of ICP47. Greco and colleagues evaluated the 5ʹ-untranslated region (UTR) of 
ICP22 mRNA for the presence of regulatory element using mutants with progressive 
deletions within that region and in vitro chloramphenicol acetyltransferase (CAT) assays. 
They found that the region within the first exon of ICP22 mRNA is sufficient to induce 
high-level CAT activity (cis-element is localised in the 5ʹ UTR but not in the intron) (Greco 
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et al., 1994). Later, Gelman and Silverstein found a region downstream of the ICP22/47 
core promoter that represses gene expression significantly from the basal level (Gelman 
and Silverstein, 1987). Despite the knowledge of possible regulatory elements located 
downstream of the ICP22/47 promoter, it is unclear under what conditions the regulatory 
proteins bind and control the promoter activity. Likewise, the regulatory proteins that bind 
to this region are unknown. Another study conducted by Bedadala and colleagues 
discovered the presence of five copies of the early growth response (Egr1) transcription 
factor binding element to the intron of the ICP22 gene (Bedadala et al., 2007). Egr-1 is a 
multifunctional zinc finger DNA binding protein involved in regulating inflammation, cell 
proliferation and apoptosis (Virolle et al., 2003; Cho et al., 2006; Yu et al., 2007). HSV-1 
infection induces Egr-1 expression in epithelial cells after which Egr1 is recruited to the 
ICP22 promoter (Bedadala et al., 2011). How Egr-1 regulates the ICP22 promoter, and the 
consequence of Egr-1 activity is controversial, with studies divided as to whether Egr-1 
positively or negatively regulates IE gene expression (Tatarowicz et al., 1997; Bedadala et al., 
2007; Chen et al., 2008; Yao et al., 2012; Hsia, 2013). Additionally, while Egr1 is expressed 
in the nervous system, whether and how this protein controls gene expression in HSV-1 
infected neurons is currently unknown (Beckmann and Wilce, 1997). Importantly, the Egr-
1 binding element and the 5ʹ UTR are located in the region of the promoter that is absent 
from the ICP47 promoter used in the previous study by Russell and Tscharke (2016). 
Although much of the above information has been inferred based on in vitro systems using 
neuronal or non-neuronal cell lines, their relevance to ICP47 expression in the context of 
the viral genome in latently infected neurons in vivo is yet to be established. 
A further complication of this part of the HSV-1 genome is that the HSV-1 oriS region 
resides within a 90-bp sequence in the ICP22/47 promoter. The UL9 encoded origin 
binding protein (OBP) binds specific regions of oriS, and this sequence-specific binding of 
OBP is essential for activation of oriS mediated DNA replication (Elias et al., 1990; Wong 
and Schaffer, 1991; Nguyen-Huynh and Schaffer, 1998). While some of the cis-acting 
elements in the ICP22/47 promoter region were shown to strongly influence the origin 
function of oriS (Wong and Schaffer, 1991), a 62 bp deletion of the minimal OBP binding 
region in oriS only had a mild effect on gene expression in cell culture (Nguyen-Huynh and 
Schaffer, 1998). Summers and Leib drove a luciferase gene by ICP22/47 promoter with an 
intact OBP binding site or the promoter lacking this site. Although the deletion did not 
affect virus pathogenesis, virus replication or reactivation in mice, they found that the 
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removal of OBP binding site increased ICP47 promoter activity by two- to three-fold in 
cell culture indicating the likeliness of repressor function associated with this site (Summers 
and Leib, 2002). However, whether this OBP binding site has any repressor elements and 
whether they would inhibit gene expression during latency is not known. This literature is 
summarised in a map of the region up-stream of ICP47 (Figure 4.3).  
Using the ROSA26R/Cre reporter system, it was found that HSV-1 promoters of genes 
whose products are of immunological relevance were active in a subpopulation of neurons 
during the establishment of latency and also during latency (Russell and Tscharke, 2016). 
Nevertheless, there appears to be a discrepancy in the activation status of the ICP47 
promoter based upon either the position of the genome from where the expression cassette 
was placed or the promoter sequence and the potential regulatory elements present in the 
regions flanking the promoter. Given the potential scope of this reporter system to unravel 
the host and the viral factors contributing to the latency establishment and long-term 
stability of latency, we aimed to address the reason behind differential gene expression 
observed between the two studies. Therefore in this study, we set out to generate new 
recombinant viruses. The design of the promoters used to drive Cre in the newly 
constructed recombinant viruses are described in the following section. 
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Figure 4.3 Schematic of the HSV-1 genome expanded showing the cis-acting regulatory elements in the ICP47 promoter region. Location and 
orientation of region coding for ICP47, US11 and US10 (partial) are shown in grey arrows. The minimal promoter required for ICP47 expression and its 
orientation is indicated by the yellow arrow. The ICP47 promoter includes a copy of the oriS shown as orange box and the minimum oriS site of 62 bp is 
shown as a white box. In UL3-pa47min, the promoter used to drive Cre expression is the minimal promoter shown in yellow arrow without the minimum 
oriS site. The three red lines in the oriS site indicate the box I, box II and box III to which the OBP bind. The ICP47 transcription initiation site is located 
19 bp downstream of the TATA box shown in the orange line. An intron is located 5 to the ICP47 coding region and 3 to the promoter indicated by the 
blue box. The TATA box and the VP16 inducing complex binding motif (TAATGARAT) are shown as dark blue and light blue lines, respectively. The pink 
lines represent the sp1 binding motifs, which span the ICP47 promoter. Located within intron, indicated as green lines, are the reiterated Egr1 binding 
motifs. NFIII-binding site is indicated as dark red line situated 5 to the ICP47 promoter. 
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4.2 Results 
4.2.1 Design of recombinant HSV-1 viruses that express Cre under the 
ICP47 promoter 
We generated three recombinant viruses, UL27-pa47min, UL3-pa47 and UL3-pa47ΔoriS, 
that each expresses an eGFP-Cre fusion gene driven by different version of the ICP47 
promoter, from one of the two different ectopic locations.  
The three promoters include:  
a) pa47min, a minimal ICP47 promoter without oriS used by Russell and Tscharke (Figure 
4.4) 
b) pa47, a complete promoter comprising 869 bp nucleotide sequence upstream of ICP47 
translation initiation codon, with no deletion or modification (Figure 4.4). The promoter 
pa47 includes the previously annotated ICP47 minimal promoter (Gelman and Silverstein, 
1987), intron, 5′ UTR and the oriS site.  
c) pa47ΔoriS, a promoter comprising an 869 bp nucleotide sequence upstream of the 
ICP47 translation initiation codon with dinucleotide substitutions in OBP-binding site to 
disrupt the oriS function (Figure 4.4). Three defined sites of significant sequence homology 
called boxes I, II and III are located in the oriS site to which the OBP specifically interact 
(Elias and Lehman, 1988; Elias et al., 1990; Martin et al., 1991). The binding sites in each of 
these boxes were further narrowed down to 3 dinucleotides (Hernandez et al., 1991). OBP 
in collaboration with the single-stranded DNA binding protein (ICP8) bind these oriS sites 
resulting in an unwinding of supercoiled DNA and subsequently lead to activation of the 
replication process (Lee and Lehman, 1997; Makhov et al., 2003). Hernandez and 
colleagues showed that dinucleotide substitution mutation in any of these boxes cause a 
reduction in oriS-directed DNA replication and when all three sites were substituted 
simultaneously, the replication of an oriS containing plasmid was abolished entirely 
(Hernandez et al., 1991). Similar dinucleotide substitutions were made in the oriS site of 
pa47ΔoriS. 
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Figure 4.4 Design of ICP47 promoters to drive Cre expression from different loci. 
The orientation and relative location of minimal ICP47 promoter (yellow arrow), oriS 
region (orange and white boxes), intron region (blue box) and ICP47 gene (grey arrow) are 
depicted in the top stacks. The minimal promoter sequence is 499 bp. The distance from 
the start of the minimal promoter to the translation start site is 869 bp, which is referred to 
as “full-length ICP47 promoter” or “pa47”. To eliminate oriS function from the ectopic 
full-length ICP47 promoter, dinucleotide substitutions were created in box I, box II and 
box III of minimal oriS site. This promoter is referred to as “pa47ΔoriS” and the asterisks 
indicate the location of substitution mutations. The promoter “pa47min” used by Russell 
and Tscharke (2016) is the minimal ICP47 promoter without oriS site. Removal of oriS 
from ICP47 promoter is indicated as a rectangular box with diagonal stripes. 
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To test whether the neighbouring cis-elements are involved in regulating the minimal 
ICP47 promoter, two viruses were constructed. They are HSV-1 UL3-pa47 and HSV-1 
UL3-pa47ΔoriS, in which the promoters, pa47 and pa47ΔoriS, respectively, were inserted 
between UL3 and UL4 genes. To study the role of insertion loci in gene expression, activity 
of the original ICP47 promoter (pa47min) used by Russell and Tscharke (2016) was tested 
in the intergenic region between UL26 and UL27 by generating recombinant HSV-1 UL27-
pa47min. The viruses used in this chapter are described in Table 4.1. The following 
sections describe the generation and characterisation of each of these viruses. 
 
Table 4.1 List of recombinant HSV-1 viruses engineered to express eGFP-Cre 
controlled by the ICP47 promoter. 
Recombinant 
HSV-1 
Insertion locus Promoter  
Reference 
Ka47in ICP47 
Native ICP47 
promoter 
Chapter 3, section 
3.2.4.4.1 and Figure 3.14 
Ka47rescue ICP47 
Native ICP47 
promoter 
Chapter 3, section 
3.2.4.3.1 and Figure 3.14 
UL3-pa47min 
Intergenic region between 
UL3 and UL4  
pa47min 
Russell and Tscharke, 
2016 
UL27-pa47min 
Intergenic region between 
UL26 and UL27  
Pa47min 
Chapter 4, section 4.2.2 
and Figure 4.5 
UL3-pa47 
Intergenic region between 
UL3 and UL4  
pa47 
Chapter 4, section 4.2.3 
and Figure 4.7 
UL3-pa47ΔoriS 
Intergenic region between 
UL3 and UL4 
pa47ΔoriS 
Chapter 4, section 4.2.3 
and Figure 4.7 
 
4.2.2 Generation of HSV-1 UL27-pa47min 
One of the variables that could have contributed to the differential gene expression 
observed during latency is the insertion position of the gene cassette in the genome. In the 
previous study when the modified promoter pa47min driving Tdtomato reporter gene was 
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inserted into the intergenic region between UL26 and UL27, gene expression in DRG 
during lytic infection was comparable to that observed with HSV-1 UL3-pa47min (Russell 
and Tscharke, 2016). Therefore, it was concluded that the location of gene expression does 
not influence the promoter activity. However, activation of the ICP47 promoter during 
latency establishment and latency was not tested in the UL26-UL27 region. This locus has 
been used previously by others for heterologous gene expression and found that gene 
insertion in this locus does not affect the viral replication in vivo or the latent viral genome 
load (Balliet et al., 2007; Russell et al., 2015). To seek understanding of the influence of 
gene expression locus on promoter activation after lytic infection, recombinant HSV-1 
viruses that express the eGFP-Cre fusion gene under the control of the pa47min were 
engineered by inserting the transgene construct in the intergenic region between the genes 
UL26 and UL27. If pa47min could promote Cre-induced β-gal marking of neurons during 
latency establishment and latency from the UL26-UL27 locus (similar to pa47min in the 
UL3-UL4 locus), we could infer that the position of insertion may not be the underlying 
cause of the differential marking. For the generation of the virus, I employed CRISPR-Cas9 
genome editing techniques and transfection-infection methods as described in materials 
and methods (section 2.3.5). The double-stranded break was introduced in the intergenic 
region between UL26 and UL27 using Cas9-expressing plasmid, px330_ul26/7, containing 
the appropriate guide sequence. To direct the homology-mediated repair mechanisms, a 
linearised plasmid containing gene cassette comprising pa47min upstream of eGFP-Cre 
fusion gene was inserted between flanking regions homologous to the region of insertion in 
HSV-1 genome. The gene cassette was introduced such that transcription of the fusion 
gene occurred in the same orientation as that of the UL27 gene. The resultant recombinant 
virus was called UL27-pa47min (Figure 4.5 A). An RFLP analysis demonstrated that UL27-
pa47min displayed an expected pattern of DNA fragments (Figure 4.5 B). PCR 
amplification and sequencing confirmed the site of insertion of the expression cassette and 
orientation. Further, no difference was observed in the in vitro growth properties of the 
recombinant virus (Figure 4.6). 
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Figure 4.5 Construction of recombinant HSV-1 UL27-pa47min. (A) Diagram of the 
HSV-1 genome showing the typical arrangement of the unique and repeat regions. The 
green line represents the location of pa47min eGFP Cre cassette in the HSV-1 genome. 
Below is the expanded region showing the orientation of the inserted cassette. (B) RFLP 
analysis of the genome of the recombinant virus is shown. The viral genome was isolated 
from infected Vero cells and digested using restriction enzymes EcoRI, NheI or PsiI. The 
two images show the resolution of smaller DNA fragments (left) and larger fragments 
(right). The image on the left was captured first and after further electrophoresis to resolve 
the larger DNA fragments, the image on the right was taken. The blue arrows indicate the 
specific DNA fragments obtained because of modification introduced in the recombinant 
virus and sizes of the resultant fragments match the in-silico prediction. The yellow 
arrowheads point to the size of relevant fragments of molecular marker.  
A 
B 
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Figure 4.6 Multi-step replication kinetics of KOS and recombinant UL27-pa47min 
in Vero cells. Multi-step growth assay was performed as described in chapter 2 and viral 
titre was determined using a plaque assay at indicated time points. The experiment was 
conducted in triplicate. The error bars represent mean  SEM, which bars are obscured by 
the symbols.  
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4.2.3 Generation of UL3-pa47 and UL3-pa47ΔoriS 
To examine if the regulatory elements that reside in the region flanking ICP47 promoter or 
the oriS site are responsible for influencing marking of neurons during latency, two 
recombinant viruses, HSV-1 UL3-pa47 and HSV-1 UL3-pa47ΔoriS, were generated. In 
these viruses, a full-length copy of the ICP47 promoter was utilised to drive expression of 
an eGFP-Cre fusion gene located from the UL3-UL4 locus (see Figure 4.4 and Table 4.1). 
The ICP47 promoter driving eGFP-Cre fusion gene in UL3-pa47ΔoriS is similar to that of 
UL3-pa47 except for dinucleotide substitutions generated to disrupt the function of oriS 
(Figure 4.4). The rationale for constructing the UL3-pa47ΔoriS virus was to control for 
anomalies that may be introduced by adding an extra oriS sequence into the HSV-1 
genome. The gene cassette in both viruses was inserted between the UL3 and UL4 genes, 
with the orientation of the reporter cassette same as that of UL3 (Figure 4.7 A&B). The 
design of these viruses is similar to the HSV-1 UL3-pa47min used by Russell and Tscharke 
(2016). 
Restriction enzyme digestion using ScaI demonstrated that both UL3-pa47 and HSV-1 
UL3-pa47ΔoriS displayed similar DNA fragment arrays to that of the wild-type virus 
(Figure 4.8 A). This result was expected due to the absence of the ScaI site in the inserted 
gene cassette. Furthermore, the position and orientation of insertion of the reporter 
cassette were also confirmed by PCR amplification followed by sequence verification 
(Figure 4.8 B). We examined whether introducing reporter gene cassette and additional oriS 
into viral genome affect viral replication, using a multiple-step growth analysis (Figure 4.9). 
Wild-type KOS virus and the recombinant viruses (HSV-1 UL3-pa47 and HSV-1 UL3-
pa47ΔoriS) showed similar growth efficiencies and kinetics, suggesting that the virus 
replication was unaffected in these recombinant viruses.  
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Figure 4.7 Schematic representation of the HSV-1 UL3-pa47 and HSV-1 UL3-
pa47ΔoriS genomes. Diagrams of HSV-1 genomes showing the typical arrangement of 
the unique and the repeat regions. The green line represents the region of insertion of the 
(A) pa47- and (B) pa47ΔoriS- eGFP Cre cassette in the HSV-1 genome. The expanded 
region highlights the orientation of the inserted cassette and the flanking region. 
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Figure 4.8 Analysis of recombinant HSV-1 UL3-pa47 and HSV-1 UL3-pa47ΔoriS 
sequences by whole genome digestion and Sanger sequencing. (A) Viral DNA 
isolated from wild-type and the recombinant HSV-1 viruses were digested using ScaI, and 
the fragments were separated using agarose gel electrophoresis. The yellow arrowheads to 
the left of the gel image indicate the position of relevant marker fragments (in kbp). (B) 
The nucleotide sequence data of the oriS region of the wild-type strain KOS and the 
recombinant viruses are shown. The position of the dinucleotide substitutions made in 
UL3-pa47ΔoriS is highlighted in the image. 
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Figure 4.9 Multi-step replication kinetics of KOS, HSV-1 UL3-pa47 and HSV-1 
UL3-pa47ΔoriS viruses in Vero cells. Monolayers of Vero cells were infected at 0.01 
pfu/cell and multi-step growth curves were performed as described earlier (see section 
2.3.7.1). The amount of virus in infected cells was determined using plaque assays at the 
indicated time points. The experiment was conducted in triplicate. The results are shown as 
mean pfu/mL  SEM. The error bars are obscured by the symbols.  
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4.2.4 Replication of the recombinant viruses is not impaired in the skin 
and DRG 
To determine if insertion of the reporter gene cassettes altered virus replication in mice, 
groups of mice were infected with 1108 PFU/mL of wild-type or recombinant viruses, 
HSV-1 UL3-pa47 or HSV-1 UL3-pa47ΔoriS, on the left flank (see methods section 
2.3.10.1). After five days, 8 mm wide skin tissue sample, running from the dorsal to ventral 
mid-line surrounding the infection site, was surgically recovered and snap frozen. 
Additionally, ipsilateral DRG from spinal levels T5 to L1 were collected and snap frozen. 
The tissues were thawed and homogenised in culture media, and the amount of virus was 
determined using a plaque assay. The average virus titre in the skin and DRG was 
comparable between the wild-type and UL27-pa47min virus suggesting that insertion of 
pa47min eGFP Cre cassette into UL26 and UL27 intergenic region did not affect virus 
growth in vivo (Figure 4.10 A). Similarly, the difference in mean virus titre between the wild-
type HSV-1 KOS and the recombinants, HSV-1 UL3-pa47 or HSV-1 UL3-pa47ΔoriS, was 
not statistically significant (Figure 4.10 B). These results suggest that all three viruses have 
wild-type replication in vivo. 
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Figure 4.10 Growth analysis of HSV-1 KOS and recombinant viruses, HSV-1 UL27-
pa47min, HSV-1 UL3-pa47 and HSV-1 UL3-pa47ΔoriS, in mice. Mice were infected 
on the left flank by tattooing. Five days after infection, the skin and DRG were collected, 
homogenised and virus titre determined using plaque assay. (A) Amounts of KOS and 
UL27-pa47min in skin and DRG of mice are shown. The mean titres of the two viruses 
were not significantly different in both tissue types as assessed by unpaired t-test. (B) Virus 
titre of KOS, UL3-pa47, and UL3-pa47ΔoriS in skin and DRG of mice are shown. The 
means of the recombinant viruses were compared to the wild-type virus using one-way 
ANOVA with Dunnet’s multiple comparisons post-test. The differences were not 
statistically significant. The error bars in both graphs represent mean  SEM. 
A 
B 
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4.2.5 ICP47 follows the IE class of gene expression regardless of 
location or the promoter sequence 
ICP47 falls under the immediate-early (IE) category in the gene expression cascade and is 
expressed as early as one hour after infection (Harkness et al., 2014). Hence, in our 
recombinant viruses, eGFP expression was expected to follow the same IE kinetic class. 
To test whether in our recombinant viruses the reporter gene was expressed as an IE gene, 
we used an assay based on cycloheximide and actinomycin D (see section 2.3.8). 
Expression of IE genes does not require prior viral protein synthesis, but the E and L 
genes need IE proteins for their expression (Honess and Roizman, 1974). Addition of 
cycloheximide (CHX) to the culture media blocks the de novo protein synthesis in cells. 
Therefore, in the presence of CHX, only IE mRNA will be made and accumulate in 
infected cells. These IE mRNAs can then be translated to protein if the inhibition enacted 
by CHX is released. Replacing CHX by actinomycin D (AD) leads to a loss of further 
transcription and therefore blocks the synthesis of E and L gene products. The final 
outcome is that the only viral proteins that are made will be IE gene products. This CHX 
reversal (CHR) assay is commonly used to identify a promoter belonging to the IE class 
(Honess and Roizman, 1974; Barklie et al., 1977).  
Monolayers of Vero cells pre-treated with CHX were infected with wild-type virus or 
recombinant viruses expressing eGFP-Cre fusion gene controlled by various HSV-1 
promoters. A control with no drug treatment was included for each infection. The viruses, 
HSV-1 pICP0_eGC and HSV-1 gB_eGC, generated and tested by Russell and Tscharke 
(2016), were used here as control viruses. Expression of eGFP was noted in all the samples 
that were not treated with CHX or AD irrespective of the kinetic class of the promoter 
(Figure 4.11). Following the CHR process, reporter gene expression was observed in cells 
infected with HSV-1 pICP0_eGC, HSV-1 UL3-pa47min, HSV-1 Ka47in, Ka47rescue, 
UL27-pa47min, UL3-pa47 and UL3-pa47oriS. Whereas in cells infected with the HSV-1 
gB_eGC virus, in which the leaky-late gB promoter drive eGFP-Cre, we could not detect 
eGFP, confirming that CHX and AD were active. These results suggest that the ICP47 
promoter functions as an IE promoter regardless of the region from which it is expressed 
or the alterations in the promoter sequence. This was true for all recombinant viruses 
studied in this chapter. However, we can separate the promoters into two distinct classes 
on the basis of GFP-positive cell proportion. In one group, including pICP0_eGC, 
Ka47rescue and Ka47in, eGFP accumulated equally well in the presence or absence of 
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CHX. In the other group, which includes UL3-pa47min, UL27-pa47min, UL3-pa47 and 
UL3-pa47oriS, eGFP expressing cells were proportionately reduced from two to three-
fold in CHX treated cells compared to untreated cells. These data suggest that when the 
ICP47 promoter is situated at an ectopic location it functions differently to the native 
promoter, specifically it is less active under strict IE conditions in vitro.  
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Figure 4.11 IE characteristics of the ICP47 promoter are unaltered by promoter 
location in the genome or the lack of oriS and 5 UTR sequences. The promoter 
activity of each of the recombinant viruses under CHR (CHX/AD) or control (NT) 
conditions is shown. The histogram in grey represents the eGFP expression in cells 
infected with unmodified KOS, and the histogram in green represents the eGFP 
expression in cells infected with the recombinant virus. The viruses subjected to the CHR 
assay are indicated above each column. 
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4.2.6 Genomic loci may influence the activation of ICP47 promoter 
during latency  
We hypothesised that difference in promoter activation after lytic infection might be a 
consequence of varying genomic locations of reporter gene insertion or promoter 
sequences. If the observed differences could be attributed to location, we would anticipate 
that the β-gal marked neurons would not accumulate during latency if we alter the position 
of the gene cassette in the viral genome. To test this possibility, we constructed 
recombinant HSV-1 UL27-pa47min, which contains the eGFP-Cre fusion gene under 
control of pa47min, inserted into the UL26-UL27 locus (see section 4.2.2). We infected 
ROSA26R mice with this virus and enumerated the number of -gal producing neurons at 
various days after infection (Figure 4.2). Interestingly, we found that the number of marked 
neurons fell continuously and significantly from 5 to 20 days after infection and remained 
stable from 20 days onwards (Figure 4.12 A). Although the number of marked neurons did 
not increase beyond lytic infection, the number of DRG with marked neurons showed a 
slight, but not significant increase from 5 to 100 days after infection (Figure 4.12 B). When 
the modified ICP47 promoter, pa47min, was inserted into the UL3-UL4 locus, Cre 
marking of neurons continued to increase beyond lytic infection (Russell and Tscharke, 
2016). Whereas when the same promoter was inserted into an alternate gene expression 
locus UL26-UL27, it did not promote neuronal marking beyond lytic phase. Two possible 
reasons for the current observation are: the UL3-UL4 region contains a regulatory element 
that permits gene expression during latency or conversely, the UL26-UL27 region and 
ICP47 locus include suppressor elements that block the gene expression during latency.  
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Figure 4.12 The modified ICP47 promoter, pa47min, is repressed beyond lytic 
infection in the UL26-UL27 locus. Groups of ROSA26R mice (n=12) were infected 
with HSV-1 UL27-pa47min and culled at 5, 10, 20, 40 and 100 days after infection. DRG 
from T5 to L1 were excised from each mouse, stained with X-Gal staining buffer, mounted 
intact and used for enumerating large blue cells that represent β-gal marked neurons. (A) 
The graph shows the number of β-gal positive cells per mouse at the indicated times post-
infection. (B) The graph shows the number of DRG with at least one β-gal positive cell per 
mouse. (A&B) The results were pooled from three independent experiments each with at 
least two overlapping time points. The error bars represent mean ± SEM. The statistical 
significance was determined by comparing the mean at each time point to every other time 
point using one-way ANOVA with Bonferroni’s multiple comparisons post-test 
(***p<0.001, ****p<0.0001). 
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4.2.7 The UL3-UL4 intergenic region is permissive of full-length ICP47 
promoter activation 
To obtain a better understanding of current observations related to ICP47 promoter 
activation during the latency establishment phase and latency itself, we infected ROSA26R 
mice with HSV-1 UL3-pa47 or UL3-pa47ΔoriS. As described earlier in section 4.2.3, these 
viruses express the eGFP-Cre fusion gene controlled by the ICP47 promoter that 
encompasses the minimal promoter and the downstream sequence until the translation 
initiation site. Infection of ROSA26R mice with these viruses resulted in an initial decrease 
in the number of -gal producing neurons from days 5 to 10, followed by an upward trend 
from days 10 to 20 post-infection, however, the difference was not found to be statistically 
significant (Figure 4.13 and Figure 4.14). From 20 days after infection, the number of 
marked neurons continued to accumulate until the time of final examination (100 days). 
Comparison between the average numbers of β-gal marked neurons between 20 and 100 
days after infection revealed a significant increase across the HSV-1 UL3-pa47 and UL3-
pa47ΔoriS conditions. The number of neurons marked during lytic infection was 
comparable between all recombinants generated in this thesis in which the ICP47 promoter 
controlled Cre expression (Figure 4.15). However, neuronal marking was consistently 
documented during latency establishment phase (10 to 20 days) and latency (40 to 100 days) 
only when the reporter gene cassette was introduced into the region between the genes 
UL3 and UL4.  
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Figure 4.13 Use of the recombinant HSV-1 UL3-pa47 reveals that the UL3-UL4 
intergenic region induces Cre marking of neurons during latency. Groups of  
ROSA26R mice were infected with HSV-1 UL3-pa47 on the flank. DRG from T5 to L1 
were excised from each mouse on indicated days post-infection, stained with X-Gal, 
mounted intact and large blue cells were counted. The graphs show the number of  β-gal 
positive cells per mouse (A) and the number of DRG with at least one β-gal positive cell 
per mouse (B). (A&B) Each symbol represents a mouse (n=12) and error bar shows mean 
± SEM. The results were pooled from three independent experiments each with at least 
two overlapping time points. The means were compared at each time point and statistical 
significance was calculated using one-way ANOVA combined with Bonferroni’s multiple 
comparisons post-test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
A 
B 
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Figure 4.14 Recombinant HSV-1 UL3-pa47ΔoriS reveals that the UL3-UL4 
intergenic region induces Cre marking of neurons during latency. Groups of  
ROSA26R mice were infected with HSV-1 UL3-pa47ΔoriS on the flank. DRG from T5 to 
L1 were excised from each mouse on 5, 10, 20, 40- and 100-days post-infection, stained 
with X-Gal, mounted intact and large blue cells were counted. The graphs show the 
number of  β-gal positive cells per mouse (A) and the number of DRG with β-gal positive 
cells per mouse (B). Each symbol represents a mouse (n=12). The error bar shows mean ± 
SEM. The means were compared at each time point and statistical significance was 
calculated using one-way ANOVA combined with Bonferroni’s multiple comparisons post-
test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
 
A 
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4.2.8 Summary of the Cre-marking data 
The data from this chapter, summarised in Figure 4.15, suggest that changing the ectopic 
location from UL3-UL4 to UL26-UL27 altered the transcriptional behaviour of the ICP47 
promoter. On the one hand, in the UL3-UL4 locus, ICP47 promoter induced Cre-
mediated marking of new neurons beyond the lytic phase of infection. Additional neurons 
were marked regardless of whether the oriS, intron and 5 UTR were present in the 
promoter. On the other hand, in the UL26-U27 locus, the minimal ICP47 promoter did 
not induce marking of further neurons beyond the lytic infection, instead, the number of 
marked neurons dropped from days 5 to 20 and remained unaltered beyond 20 days. 
Furthermore, the number of neurons marked at each time point by the UL27-pa47min 
virus was similar to that seen following infection with the recombinant viruses that 
expressed Cre from the ICP47 promoter at the native locus (Ka47in and Ka47rescue). 
Together our data show that Cre marking of neurons beyond lytic infection is specific to 
the UL3-UL4 locus and suggests the regulatory elements present in the native ICP47 locus 
may not influence the accumulation of marked neurons. However, two major differences 
were noticed in marking between HSV-1 UL3-pa47min and HSV-1 UL3-pa47 or UL3-
pa47oriS. First, an inverse trend in marking was observed from 5 to 10 days after 
infection. Additionally, significantly more neurons were marked by pa47min compared to 
pa47 or pa47oriS at UL3-UL4 locus beyond 10 days after infection. Whether the cis-
acting elements in the full-length promoter play a role in the differential induction of Cre 
marking between these viruses is yet to be established.  
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Figure 4.15 Summary of β-gal marking of neurons in ROSA26R mice. The summary 
graph illustrates the number of β-gal+ cells per mouse at different time points when 
infected with the indicated viruses. The symbols represent the averages of β-gal+ cells 
across all mice for each recombinant virus. The error bar shows mean ± SEM.  
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4.3 Discussion 
In this chapter, we investigated the influence of a) potential regulatory elements in the 
ICP47 promoter and b) the location of gene expression on the promoter activation using 
the ROSA26R/Cre reporter mouse system. In a previous study, Proença and colleagues 
used this reporter mouse system to test lytic gene promoters representative of all kinetic 
classes (ICP0, ICP4, TK, gC, and VP16) by inserting reporter gene cassettes into US5 locus. 
At this position, none of the promoters induced detectable β-gal expression in previously 
unmarked neurons beyond 5 days (Proença et al., 2008, 2011). The results from this 
chapter demonstrate that ICP47 promoter was active beyond lytic infection when placed in 
the UL3-UL4 locus, however, placement at two other positions (ICP47 and UL26-UL27) 
resulted in no detectable promoter activity at this time. Given that ICP47 promoter 
activation was not detected in at least two alternate loci after 5 days in our study, and 
additionally no detectable activation was observed for other lytic promoters in the US5 
locus during latency (Proença et al., 2008, 2011), the most obvious conclusion is that UL3-
UL4 locus is more permissive for gene expression during latency. The ICP0 promoter was 
an exception, which, when allowed to drive Cre from UL3-UL4 locus, led to the number of 
marked neurons remaining stable after 20 days of infection (Russell and Tscharke, 2016). 
This finding indicates that the detectable level of promoter activation beyond lytic infection 
is not universal to all HSV-1 promoters in the UL3-UL4 locus.  
From viral transcriptome analysis of acutely infected TG neurons, it can be seen that UL3 
mRNA transcripts were produced but at a much lower level compared to the ICP47 
transcripts (Harkness et al., 2014). Using an IE-gene deficient mutant to establish persistent 
infection in neurons, Harkness and colleagues showed that transcription of genes was more 
pronounced at the joint regions of long, short and repeat segments of the genome. The 
expression level of the genes UL1 to UL5 at the TRL/UL joint region was higher 
compared to most genes of the long segment of the genome, yet, several folds lower than 
ICP47 (Harkness et al., 2014). Indeed, ICP47 is one of the few genes that was transcribed 
abundantly in TG neuron culture (Harkness et al., 2014). Notably, ICP47 transcripts were 
also detected in neurons harbouring the latent viral genome (Ma et al., 2014). However, in 
our current study, detectable ICP47 promoter activation did not occur beyond the lytic 
infection when the gene cassette was introduced in the native ICP47 location or an ectopic 
location (UL26-UL27 locus). It is possible that Cre expression still occurred from these loci 
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but at a level below that is required to mediate the effective genetic recombination at loxP 
sites and subsequent β-gal expression. In that case, the UL3-UL4 locus is peculiar in its 
ability to impact the activity of ICP47 promoter in the latent HSV-1 genome. To our 
knowledge, the issue of position-dependent gene expression in HSV-1 has not been 
previously demonstrated in vivo. 
The genes UL3 and UL4 are non-essential for virus replication in culture (Baines and 
Roizman, 1991). While UL3 and UL4 were shown to co-localise with ICP22 in the nucleus 
forming small dense nuclear bodies in cell culture (Jahedi et al., 1999; Xing et al., 2011; 
Zheng et al., 2011), the role of UL3 and UL4 in HSV-1 infection is currently unknown. 
Interestingly, the genes UL3 and UL4 are proximal to the LAT locus of the terminal repeat 
region of the HSV-1 genome (Stevens et al., 1987a). LATs are the most abundantly 
detectable transcripts during latency, expressed at least in one-third of the latently infected 
neurons at a given time (Stevens et al., 1987a; Mehta et al., 1995). The LAT transcription 
unit contains an upstream regulatory sequence comprising of a promoter and an enhancer 
element (Berthomme et al., 2000). In latent HSV-1 genomes, the LAT locus was shown to 
be enriched with histone H3 containing acetylated lysine residues (H3 K4, K9) and 
transcriptionally permissive dimethyl H3 K4 histones (Kubat et al., 2004). These data imply 
that the LAT region is transcriptionally active. The major LAT is transcribed anti-sense to 
ICP0 mRNA and these two genes exist as two copies, one located at IRL and the other 
copy at TRL segment of the genome (Spivack and Fraser, 1987; Stevens et al., 1987b). 
ICP27 (UL54) is located in the UL segment near the LAT locus in the IRL segment 
(McGeoch et al., 1988). Previous studies found that the IE genes, ICP0 and ICP27, bear 
acetylated histones in latently infected mouse DRG, although to a much lower extent than 
LAT region (Kubat et al., 2004). Similarly, in a rabbit model, latently infected TG showed 
transcriptionally permissive dimethyl H3 K4 histone marks not only on the LAT region but 
also to a lower extent on the ICP0 and ICP27 promoters (Giordani et al., 2008). Whether 
the acetylation extends from the LAT locus in the TRL region to the neighbouring genes 
(from UL1 to UL5) in the UL segment is unexplored. Given that the UL3-UL4 locus is 
near the LAT region, it is possible that the post-translational modification that supports 
active transcription is extended to the UL3-UL4 locus during latency, making it 
transcriptionally permissive. This would explain the observation of lytic gene promoter 
activation from the UL3-UL4 locus, particularly in ROSA26R mice where transient Cre 
expression is sufficient to mark the neurons with -gal expression. Further analysis is 
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required to determine whether transcription permissive histone modifications of the LAT 
region influence gene expression from the UL3-UL4 locus and in that case whether other 
lytic genes near the LAT loci such as ICP0, ICP4, UL54, and UL3 are expressed during 
latency.  
The LAT region is demarcated by the CTCCC boundary elements (CTRL1 and CTRL2) 
that bind CTCF proteins in latently infected neurons (Amelio et al., 2006). The binding of 
CTCF proteins to this region was shown to block enhancer activity from spreading to 
neighbouring genes (Amelio et al., 2006; Chen et al., 2007). Despite this enhancer blocking 
function, recent studies showed that CTCF has been associated with its ability to create 
chromatin loops and to mediate long-range genome interactions (Ohlsson et al., 2010; 
Kang et al., 2011; Tempera et al., 2011). CTCF-mediated chromatin looping and 
modulation of distal gene expression has been previously observed in Epstein-Barr virus 
(EBV) (Tempera et al., 2011; Chen et al., 2014). The HSV-1 genome is maintained as a 
circular episome in association with nucleosomes (Deshmane and Fraser, 1989) in which 
case the three-dimensional organisation of DNA may allow the LAT enhancer to regulate 
distal promoters leading to their activation. It is not known whether an interaction between 
the LAT enhancer and the promoter inserted into the UL3-UL4 locus occurs by chromatin 
reorganisation, however, currently, such a possibility cannot be excluded.  
Future experiments could be designed to test if the native UL3 or UL4 promoters induce 
Cre marking during and after the establishment of latency. For example, simultaneous 
expression of UL3 and Cre by the same native promoter is possible by insertion of an 
internal ribosomal entry site (IRES) or by introducing a self-cleaving small peptide called 
2A between the two genes (Hellen and Sarnow, 2001; Daniels et al., 2014; Ahier and 
Jarriault, 2014; Colussi et al., 2015). Whilst IRES allows translation of two open reading 
frames from one mRNA, the difference in expression level of genes inserted before and 
after IRES has been documented (Mizuguchi et al., 2000; Hennecke, 2001). This problem 
can be avoided by the use of 2A peptide. Introducing this small peptide sequence between 
two genes causes steric hindrance and ribosomal skipping during translation event, leading 
to co-expression of proteins at equal proportions (Szymczak et al., 2004; Ahier and Jarriault, 
2014; Liu et al., 2017). Thus, a recombinant HSV-1 co-expressing Cre with UL3 or UL4 
gene in a bi-cistronic manner in the native position would address if this region were prone 
to induce detectable Cre marking during latency. Because the gB and ICP6 promoters were 
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also active during latency in the UL3-UL4 locus, experiments could be conducted to 
determine if the promoters of gB and ICP6 at the native position are active during latency 
or whether their activation was specific to the UL3-UL4 locus. Such experiments may 
eventually lead to a broader understanding of lytic gene expression during latency. Given 
that ICP0 transcripts are detectable in latently infected neurons (Maillet et al., 2006), the 
lack of Cre marking by the ICP0 promoter in the UL3-UL4 locus could perhaps be due to 
the issue of sensitivity of the system. However, we cannot preclude the possibility that the 
ICP0 promoter carries a functional regulatory element that represses gene expression 
during and after the establishment of latency.  
At the UL3-UL4 locus both the full-length and the minimal ICP47 promoter induced 
detectable β-gal in previously unmarked neurons during the establishment and maintenance 
of latency. However, the number of neurons marked by pa47 or pa47ΔoriS was 
considerably less compared to that of the neurons marked by pa47min from 10 days after 
infection (Figure 4.15). This reduction in a number of visibly marked neurons implies that 
regulatory elements of a suppressive nature might be present in pa47 and pa47ΔoriS. 
Interestingly, the ICP47 intron region contains a cluster of CTCT motifs called CTRS3, 
which were shown to be occupied by CTCF proteins during latency (Amelio et al., 2006; 
Washington et al., 2018). Previous reports have shown that the CTCF proteins recruit 
diverse transcription factors to exert transcription activation, repression or enhancer-
blocking functions (Lutz et al., 2000; Chernukhin et al., 2007; Li et al., 2008). Consistent 
with this, a polycomb repressor complex (PRC) subunit called Suz12 was found to co-
localise with CTCF at CTRS3 on latent viral genomes (Cliffe et al., 2013b; Washington et 
al., 2018). The five-subunit complex, PRC2 causes epigenetic modification of the target 
gene leading to transcriptional repression. When reactivation was induced in latently-
infected mice, CTCF and Suz12 at CTSR3 were significantly reduced after 6 hours, most 
likely leading to transcription activation (Washington et al., 2018). This observation 
supports the idea that CTCF and PRC2 recruited through Suz12 may repress ICP47 gene 
expression during latency. Further, in the context of HCMV and MCMV infection, binding 
of CTCF with the intron of CMV major immediate early (MIE) gene was shown to cause 
repression of MIE gene (Martínez et al., 2014). The exact mechanism of transcriptional 
repression has not been established but it was suggested that CTCF may manipulate RNA 
polymerase II function in this case (Martínez et al., 2014). Since CTRS3 is also located on 
the ICP47 intron, a similar transcriptional dampening effect of the ICP47 gene is possible 
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during latency. This explains the differences in marking by the full-length and the intron-
less promoters. However, CTCF may not bind efficiently to CTRS3 at the ectopic location, 
explaining why the promoters, pa47 and pa47ΔoriS, still marked neurons during latency. 
However, these hypotheses are yet to be empirically tested. 
As demonstrated in this chapter, the local genomic environment in which a foreign gene is 
inserted can modulate gene expression. Similarly, a promoter taken out of the genomic 
context may act differentially compared to its functions at the native position. The data 
from the CHR assays support this hypothesis. Although inhibition of protein synthesis by 
CHX did not block ICP47 promoter activity at two ectopic locations, the level of reporter 
gene expression was considerably lower in these loci when compared to the native ICP47 
promoter. This suggests that the regulation of ICP47 promoter activity is more complex at 
the native locus. However, it is not surprising considering the complexity of the position at 
which ICP47 is located in the genome and the number of regulatory elements present in 
this region.  
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5 Investigation of inhibition of antigen presentation by ICP47 
on human and mouse cells 
5.1 Introduction 
In Chapter 3, the function of ICP47 was examined using a sensitive flow cytometry-based 
antigen presentation assay, where it became evident that ICP47 indeed inhibits antigen 
presentation in mouse cells. The in vivo data from chapter 3 showed that in a mouse model 
where the virus does not invade the CNS, removal of ICP47 did not affect the 
pathogenicity of the virus and its ability to establish or maintain latency. One possibility for 
the lack of phenotype is that perhaps the virus does not overcome CD8+ T cell immunity 
because the viral determinants are not sufficiently blocked from the presentation. Hence, 
the removal of ICP47 would not significantly affect pathogenesis. As a result, the role of 
ICP47 in vivo remains inconclusive. It is unknown a) how much more efficient ICP47’s 
inhibition of human TAP is compared to mouse TAP? b) whether the inhibition of TAP-
mediated peptide translocation would affect HSV-1 infection in humans? and c) whether all 
CD8+ T cell epitopes are equally inhibited? 
Historically, the effect of ICP47 on the cell surface presentation of pMHC-I was addressed 
indirectly using cytotoxic T cell lysis assays, which measure the level of killing of target cells 
by activated HSV-1 specific CD8+ T cells (Jugovic et al., 1998; Aubert et al., 2006). This 
method reveals differences in the CD8+ T cell response against HSV-1 infected human and 
mouse cells (Jugovic et al., 1998), however, it is not a strictly quantitative assay. The 
threshold for lysis depends on the density of the CD8+ T cell determinants on the cell 
surface and the quality of polyclonal or monoclonal CD8+ T cell population used for the 
analysis. Our antigen presentation assay detected the differences in the level of Kb-
SIINFEKL complex in the presence or absence of ICP47 on the surface of human and 
mouse cells. In mouse cells, the inhibition of antigen presentation was 44%, whereas in 
human cells presentation was reduced by 85% (see section 3.2.3 and Figure 3.8). However, 
this assay is based on relative quantification and it is limited in sensitivity by the 25D1.16 
monoclonal antibody. Further, the assay is limited to a single epitope and although 
expressed by a virus, it has been engineered and is thus not a natural product of infection. 
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Thus, these assays may not provide the full picture of the effect of ICP47 on the HSV-1 
immunopeptidome and on the presentation of individual HSV-1 peptides.  
To overcome these limitations, in this chapter, we set out to determine the impact of 
ICP47 on human and mouse TAP by determining the absolute number of HSV-1 peptides 
presented on human and mouse cells using mass spectrometry. For this, endogenously 
derived MHC I bound HSV-1 peptides were first identified from infected mouse cells 
using a conventional mass spectrometry approach known as liquid chromatography-
tandem mass spectrometry (LC-MS/MS) (see section 5.2.1.1 and Figure 5.2). Then, a 
subset of HSV-1 peptides presented on HSV-1 infected human and mouse cells were 
quantified by targeted MS (multiple reaction monitoring or MRM-MS) (see section 5.2.3 
and Figure 5.15). With this, we aimed to measure the extent to which ICP47 hindered 
antigen presentation, which in turn would allow us to make a robust comparison between 
the human and mouse cells. The workflow of the MS-based experiments used for the 
quantification of HSV-1 peptides is summarised in Figure 5.1. This was a collaborative 
project with the Immunoproteomics laboratory led by Professor Purcell at the Department 
of Biochemistry and Molecular Biology (Monash University, Melbourne). Infection of cells 
was carried out at ANU (Canberra) and the subsequent experiments were carried out at 
Monash University under the guidance of Dr. Nathan Croft. 
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Figure 5.1 Workflow of MS-based experiments to quantify the naturally presented 
HSV-1 peptides on human and mouse cells after infection with wild-type HSV-1 
(strain KOS) and ICP47 null mutant (HSV-1 Ka47∆). Broadly, the first step is to 
identify HSV-1 peptides naturally processed and presented on infected mouse (MC57G) 
cells using mass spectrometry (a). The next step is to perform absolute quantification of 
selected HSV-1 peptides using targeted mass spectrometry (b). 
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5.2 Results 
5.2.1 Identification of novel HSV-1 peptides using mass spectrometry 
The first objective of this chapter was to identify naturally presented HSV-1 peptides 
during infection. In a previous study, St Leger and colleagues suggested 376 potential CD8+ 
T cell epitopes in HSV-1. Of these predicted epitopes, only 19 peptides were recognised by 
CD8+ T cells (St Leger et al., 2011). It is possible that many HSV-1 epitopes on infected 
cells were missed by this study due to the highly stringent peptide selection process. For 
instance, they only considered peptides of 8 amino acids long for H-2Kb (Kb), peptides 
comprising 9 amino acids for H-2Db (Db) and a high cut-off was set for selection of 
peptides based on MHC I binding affinity. Moreover, they did not test whether all 376 
predicted epitopes were naturally presented on HSV-1 infected cells. Considering these 
limitations and to allow for a more extensive examination of the effect of ICP47 on antigen 
presentation, we chose to identify the diverse peptides that are naturally presented on 
HSV-1 infected cells. The strategy used for peptide identification, the quality of the 
immunopeptidome data, relationship between the HSV-1 peptides and their corresponding 
source proteins, and immunogenicity of the peptide identifications are presented in detail 
in the following sections.  
5.2.1.1 Peptide identification strategy 
Figure 5.2 summarises the workflow for the MS-based experiment used to identify the 
repertoire of MHC I bound HSV-1 peptides on mouse cells. The MC57G cell line was 
chosen for the discovery of MHC I bound peptides. Infecting MC57G cells with 
recombinant HSV-1 expressing eGFP at 5 pfu/cell for 6 hours yielded a maximal infection 
rate of about 95% as demonstrated using flow cytometry. These conditions were adopted 
to obtain optimal infection of cells for all mass spectrometry experiments. Overall, the 
peptide elution was performed on three biological replicates. MHC I bound peptide 
complexes were purified from MC57G cells infected with HSV-1 KOS or Ka47Δ using 
monoclonal antibody clone Y3 (anti-H-2Kb) or 28-14-8S (anti-H-2Db) immobilised on 
protein A sepharose resin. Uninfected cells were analysed in parallel as controls and are 
referred to as “mock-treated cells” from here on. To reduce the complexity of the peptides 
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and to increase the detection of low abundance peptides, the peptides were separated by 
high-performance liquid chromatography (HPLC) into multiple fractions based on relative 
hydrophobicity. The fractions were then analysed using HPLC coupled to a Q Exactive™ 
Plus (Thermo) mass spectrometer (LC-MS/MS). The resulting mass spectra were searched 
against a custom reference database of murine (Mus musculus) and HSV-1 proteomes using 
ProteinPilotTM (SCIEX) and PEAKS (Bioinformatics Solutions Inc.) software. The HSV-1 
protein database included a theoretical six-frame translation of HSV-1 KOS, as well as the 
annotated protein sequence of HSV-1 strain KOS (GenBank accession JQ673480), all 
appended to the UniProt reference proteome for Mus musculus. The resulting peptide 
sequence matches were subjected to a 5% false discovery rate. This methodology is robust 
and previously used for successful identification of a large number of mouse MHC I 
restricted vaccinia virus-derived peptides (Croft et al., In press) 
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Figure 5.2 Schematic of MS-based identification of the HSV-1 immunopeptidome. Following large-scale expansion and infection of cells with HSV-1, 
cell pellets were lysed (a) and pMHC-I complexes purified by immunoprecipitation using affinity columns (b). Subsequently, the pMHC-I complexes were 
dissociated by acid elution (c) and peptides, MHC I heavy chain and β-2-microglobulin were separated based on hydrophobicity by HPLC using a C18 
column (d). Fractions of interest were analysed by LC-MS/MS (e).  In this untargeted discovery phase, all eluting peptides are scanned for their intact m/z 
(mass over charge) and during each cycle of the instrument, the most intense precursor ions are subjected to fragmentation by collision-induced dissociation 
(CID). For identification of peptide sequences, the resulting mass spectra (f) are searched by the algorithms of ProteinPilot and PEAKS software, utilising a 
customised reference database combining both the mouse and HSV-1 proteomes (g).                                                            .
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5.2.1.2  General characteristics of HSV-1 immunopeptidome from MC57G cells 
A diverse set of host-derived peptides (n = 2,030) was identified from samples that were 
mock-treated, infected with wild-type HSV-1 (strain KOS) or with ICP47 null mutant 
(HSV-1 Ka47Δ) (Figure 5.3 A). Host peptides overlapped by 33% between mock-treated 
and HSV-1 infected samples. When HSV-1 infected samples were considered, the host 
peptides overlapped from 19% to 26% between any two replicates infected with wild-type 
HSV-1 and 26% to 29% overlap between any two replicates infected with ICP47 null 
mutant virus (Figure 5.3 B&C). While the majority of the peptides identified in each eluate 
were self-peptides, many distinct HSV-1 derived peptides were also identified (Figure 5.3 
A). As expected, HSV-1 peptides were found exclusively in the virus-infected samples and 
not in the mock-treated samples. Collectively, 75 unique peptides of viral origin were 
identified from the triplicate samples infected with HSV-1 KOS or HSV-1 Ka47Δ. 
However, only a minimal overlap of peptide identification was observed between the 
replicates (Figure 5.3 D & E). Table A-1 in the Appendix lists all the HSV-1 peptides 
identified in this study and their corresponding source proteins.  
Among the total HSV-1 peptides identified, 44 were exclusively eluted from Kb column 
and 25 were eluted only from Db column. Six peptides (UL5312-321, UL50353-371, UL40279-287, 
UL26613-621, UL23115-128, UL19482-495) were eluted from both the K
b and the Db columns. 
Based on the MHC I binding prediction, the peptides UL5312-321, UL40279-287 and UL26613-621 
showed a strong affinity to Db. The peptides UL50353-371, UL23115-128 and UL19482-495 have 
poor predicted binding affinity for both alleles, suggesting promiscuous MHC I binding. 
Four peptides, gB498-505, RRI822-829, ICP8171-178, and UL40279-287, from our peptide dataset were 
also previously described by other studies (Salvucci et al., 1995; St Leger et al., 2011; 
Wallace et al., 1999). The other 15 peptides discovered by St Leger et al. (2011) were not 
identified in our study. 
Overall, the length distribution of peptides eluted from Kb and Db columns were similar 
between the mouse (Figure 5.4 A) and HSV-1 -derived peptides (Figure 5.5 A). The Kb 
bound peptides peaked at 8 amino acids and Db bound peptides peaked at 9 amino acids 
for both the mouse and the HSV-1 derived peptides. This observation is consistent with 
predictions from previous structural studies (Falk et al., 1991; Young et al., 1994). Further, 
peptides of up to 19 amino acid residues were found, however, peptides more than 13 
amino acids long were relatively rare.  
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Falk and colleagues using crystal structure of MHC I molecules found that important 
anchor residues for H-2 allomorphs are at position 5 (p5) and at the carboxy-terminus (pΩ) 
of the peptides (Falk et al., 1991). We used WebLogo 3 (Crooks et al., 2004) to analyse the 
amino acid composition of the mouse and the HSV-1 peptides discovered in our study 
(Figure 5.4 B&C and Figure 5.5 B&C). The results from this analysis showed that in Kb 
bound octameric peptides, phenylalanine or tyrosine residues (F/Y) at the p5 anchor 
position and lysine or valine (L/V) at position p8 were enriched (Figure 5.4 B and Figure 
5.5 B). Of Db bound nonameric peptides, the asparagine residue (N) is enriched at the p5 
position and Leucine (L) at the p9 position, which are typical to the Db binders (Figure 5.4 
C and Figure 5.5 C). In HSV-1 peptide set, the p5 position of Db binders is also occupied 
by other amino acids such as serine (S), glycine (G), histidine (H), leucine (L) and threonine 
(T), which could be attributed to smaller sample size (n=12). Together, these data suggest 
that the host and the HSV-1 peptides identified in this study fit the expected characteristics 
of Kb and Db binders and support the quality of the workflow used here to identify MHC 
ligands.  
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Figure 5.3 Overview of MS identified host and HSV-1 peptides. (A) Proportional venn 
diagram depicting the overlap of peptides identified across three mock-treated (blue) and 
HSV-1 infected samples (brown). The HSV-1 derived peptide subset distinctly found in 
infected samples is shown as light-brown circle. (B) & (C) Venn diagram depicting the 
overlap of mouse peptides in the three samples infected with HSV-1 KOS represented as 
Wt-1, Wt-2 and Wt-3 and samples infected with HSV-1 Ka47Δ represented as mut-1, mut-
2 and mut-3. (D) & (E) shows the unique and overlapping HSV-1 peptides between three 
biological replicates. The sample identification is shown inside each circle. The number 
inside the circles shows the number of peptides identified in each subset.
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Figure 5.4 Overall characteristics of host immunopeptidome. Shown are pooled host 
peptide data from mock-treated, wild-type HSV-1 infected or ICP47 null mutant infected 
samples. (A) Length distribution of the host immunopeptidome is shown in the bar graph. 
(B) & (C) shows WebLogo 3 plots (Crooks et al., 2004) containing the amino acid 
composition of octameric peptides (n=474) eluted from Kb columns and nonameric 
peptides (n=311) eluted from Db columns, respectively. The position of amino acids is 
shown in the x-axis. Known anchor residues for Kb and Db haplotypes at various positions 
are listed below x-axis of each graph (information obtained from IEDB website). The 
overall height of the bar is proportional to the degree of sequence conservation at that 
position and the height of each amino acid is proportional to the frequency at which it 
occurs. The polar residues are indicated in green, neutral in purple, basic in blue, acidic in 
red and hydrophobic amino acids in black.  
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Figure 5.5 Overall characteristics of HSV-1 immunopeptidome. (A) Peptide length 
distribution of the Kb and Db immunopeptidome of HSV-1 from all infected samples. (B) 
& (C) shows WebLogo 3 plots (Crooks et al., 2004) containing the amino acid composition 
of octameric peptides (n=20) eluted from Kb columns and nonameric peptides (n=12) 
eluted from Db columns, respectively. The position of amino acids is shown in the x-axis. 
Known anchor residues for Kb and Db haplotypes at various positions are listed below each 
graph, respectively (information obtained from the IEDB website). The overall height of 
the bar is proportional to the degree of sequence conservation at that position and the 
height of each amino acid is proportional to the frequency at which it occurs. The polar 
residues are indicated in green, neutral in purple, basic in blue, acidic in red and 
hydrophobic amino acids in black.  
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5.2.1.3 Source proteins of HSV-1 peptides 
The 75 HSV-1 derived peptides identified in our study are derived from 31 different 
proteins, which are distributed along the HSV-1 genome (Figure 5.6 and Figure 5.7 A). 
These source proteins comprise 43% of the 72 HSV-1 proteins included in the HSV-1 
database used to search the MS/MS spectra. For 35.4% of source proteins, a single peptide 
was presented, however, nearly 46% of the peptides were derived from just seven proteins, 
which includes UL5, UL19, UL25, UL26, UL29, UL39 and US8 (Figure 5.7 A&B). This is 
in agreement with previous observations, which revealed that only a small proportion of 
self-proteome (4.8% by Hickman et al., 2003 and 13% by Hoof et al., 2012) to be 
represented by more than one peptide. Unequal distribution of CD8+ T cell determinants 
has also been noted for other viruses (Oseroff et al., 2008; Ternette et al., 2016; Croft et al., 
In press). For instance, a study conducted by Osseroff et al. (2008) showed that VACV 
epitopes represent only 50% of the viral proteins, of which, only six proteins give rise to 
five or more epitopes each. Several factors have been suggested to be responsible for 
determining which proteins are sampled for antigen-processing and MHC I mediated 
presentation. Some of these factors include mRNA level, the rate of translation, protein 
abundance and protein length (Reits et al., 2000; Khan et al., 2001; Fortier et al., 2008; 
Croft et al., 2013; Bassani-Sternberg et al., 2015). These factors are not independent but are 
related to each other (Hoof et al., 2012). For example, Hoof and colleagues (2012) noted an 
inverse correlation between protein length and protein abundance. They reasoned that 
smaller proteins have a greater chance of being represented in the immunopeptidome as 
they are supposedly translated at a higher rate (Hoof et al., 2012). In our study, we 
observed that the smallest source proteins, ICP47 with 88 amino acids, yielded three 
peptides, while the largest protein UL36 with 3100 amino acids resulted in a single peptide 
(Figure 5.7 A&C). However, overall the number of peptides derived from each protein was 
not significantly correlated to the length of the protein (Figure 5.7 C).  
Previous studies showed that the presentation of VACV epitopes coincides with the onset 
of protein synthesis (Croft et al., 2013). In our study, to test whether the timing of protein 
synthesis affects the sampling of HSV-1 proteome, we analysed the distribution of HSV-1 
peptides across various temporal classes of gene expression. The results showed that 60% 
(3 out of 5) of immediate early proteins, 50% (9 out of 18) of early proteins, 40% (12 out 
of 30) leaky late and 42% (7 out of 19) true late proteins are represented in the peptide set 
(Figure 5.8).  
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An explanation for the slightly, but not statistically significantly, low representation of late 
proteins in our peptide set is provided by a seminal study reported recently by Kulej and 
colleagues (2017) in which they performed a global proteome analysis in HSV-1 infected 
human foreskin fibroblast cells using mass spectrometry. They found that the IE proteins 
could be abundantly detected after 3 hours and early proteins after 6 hours of infection 
(Kulej et al., 2017a). Over 80% of the late proteins could be detected at 3 hours, however, 
the copy numbers of those proteins peaked only 9-12 hours after infection. Therefore, the 
infection time in our study may not be sufficient for the sampling of some late proteins. 
Acquiring proteomics data from our sample set would help analyse the correlation between 
the synthesis of late proteins and the immunopeptidome.  
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Figure 5.6 Schematic location of the naturally processed and presented HSV-1 derived peptides in the viral genome. The top figure shows the 
overall schematic of the HSV-1 genome. The bottom stack shows the relative position and orientation of HSV-1 coding sequences, which are depicted as 
grey arrows. The gene symbols are indicated below the grey arrows for reference. The pink lines indicate the position of LC-MS/MS identified HSV-1 
peptides. The image was generated using SnapGene® Viewer Version 3.3.4. 
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Figure 5.7 Analysis of the relationship between source protein and HSV-1 
immunopeptidome. (A) The number of distinct peptides from a given source protein was 
enumerated and graphed. Gene symbols of all the sampled proteins are indicated in the x-
axis. (B) The bar graph shows the grouping of source proteins based on a number of 
unique peptide sequences. (C) The association between the length of the source protein 
and the number of peptides derived from that protein is depicted as a scatter plot. The 
symbol in red represents the correlation for ICP47 protein (the shortest protein) and the 
symbol in green represents UL36 protein (the longest protein). Pearson’s correlation 
coefficient (r) and p values are shown.  
 
A 
B C 
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Figure 5.8 Distribution of source proteins based on the kinetic class of gene 
expression. After the infection of cells, HSV-1 genes express in an orderly fashion starting 
with immediate early (IE) genes followed by early (E) genes, then leaky late (L1) and true 
late (L2) genes. The graph shows the fraction of source proteins that fall under each kinetic 
class relative to the total HSV-1 proteins of that class. 
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5.2.1.4 Defining the immunogenicity of the novel HSV-1 peptides 
The immunogenicity of the HSV-1 peptides identified in this study was tested in mice 
using the intracellular cytokine staining (ICS) assay (see materials and methods section 
2.3.10.4) (Flesch et al., 2012). The peptides of eight to thirteen amino acids long identified 
using ProteinPilotTM program (46 peptides) were biochemically synthesised (GL Biochem 
(Shangai) Ltd.) and used for the analysis. To test these peptides, C57BL/6 mice were 
infected with HSV-1 KOS and after seven days, the splenocytes from these mice were 
stimulated in vitro using the synthetic peptides. Subsequently, the number of CD8+ T cells 
that could be restimulated with each of these peptides was enumerated by staining for 
intracellular IFN.  
Figure 5.9 shows the immunogenicity of all the peptides that triggered the CD8+ T cell 
response in more than one mouse. When the size of the response to a peptide is above the 
average of three times the standard deviation of negative controls in at least two of the 
eight mice tested, then the peptide was considered as an immunogenic peptide. Based on 
these criteria, an HSV-1 specific CD8+ T cell response was documented for a total of 11 
peptides (of 46 peptides tested). The immunodominant peptide gB498-505 derived from 
glycoprotein B showed the largest response in all eight mice tested. Previously identified 
epitopes ICP8171-178, RRI822-829 and UL40279-287, which also came up in our MS-based 
immunopeptidome analysis, showed a smaller response compared with the size of response 
reported by by St Leger and colleagues (2011). This is intriguing because the HSV-1 strain, 
mouse strain and the method used to determine the CD8+ T cell response are similar 
between the two studies. However, this observation is not peculiar to the current study 
because others in our laboratory have previously found similar differences (Spiering and 
Tscharke, unpublished). This suggests that the difference in outcome could be due to inter-
laboratory variability, including mouse sub-strain and perhaps microbiota differences. The 
remaining 7 epitopes UL40198-206, UL39451-461, UL39805-815, UL39956-964, UL37600-607, UL29605-613 
and UL5126-133 are newly identified in this study. Even though immediate early proteins were 
sampled in the peptidomic dataset, interestingly, only peptides derived from the proteins 
that belong to the early and the late kinetic classes were found to be immunogenic.  
A strong correlation has been suggested between the affinity with which a peptide bind to 
the MHC I and the immunogenicity of that peptide (Sette et al., 1994). Traditionally, the 
affinity between a peptide and MHC I is calculated by an inhibition assay in which the 
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peptide concentration required to cause 50% inhibition of the binding of a standard 
peptide is measured (IC50) (Sette et al., 1994). However, several prediction algorithms are 
also available. These are based on artificial neural networks (ANN) or the stabilised matrix 
method (SMM) in both cases informed by the sequences of large sets of known MHC I -
binding peptides and CD8+ T cell epitopes (Nielsen et al., 2003; Peters and Sette, 2005). 
These algorithms allow in silico prediction of affinity between a given peptide and an MHC 
I allomorph. These predicted values are well correlated with measured values for a large 
number of viral peptides (Croft et al., In press). The peptide binding affinity of the HSV-1 
peptides discovered in this study was predicted using ANN based algorithm at the Immune 
Epitope Database (IEDB) website (Nielsen et al., 2003). The predicted IC50 of peptides in 
our set ranged from 2.2 nM to nearly 50,000 nM (Figure 5.10 A). Interestingly, 
immunogenic HSV-1 peptides show a significantly higher binding affinity compared to the 
non-immunogenic ones (Figure 5.10 A). Previous studies suggested that IC50 of 500 nM is 
a reasonable threshold for predicting potential MHC I restricted immunogenic peptides 
(Sette et al., 1994; Paul et al., 2013). More than 80% of the CD8+ T cell epitopes identified 
in our study have a predicted IC50 of less than 500 nM. The remaining two epitopes 
UL39451-461 and UL39805-815 show a low predicted binding affinity (IC50 > 500 nM). Similarly, 
not all strong binders induced a CD8+ T cell response. When the relationship between the 
predicted MHC I binding affinity and the immunogenicity was analysed, no significant 
correlation was found (Figure 5.10 B). These data confirm previous findings that MHC I 
binding is a requirement for recognition by CD8+ T cells but it is not the only determinant 
of immunogenicity (Harndahl et al., 2012; Gilchuk et al., 2015). Of note, there is a 
significant association between the peptide length and the predicted IC50 (Figure 5.10 C). It 
appears that longer peptides (>10 amino acids) have significantly higher predicted IC50 and 
therefore lower binding affinity. Given that the peptides were detected by MS, they must 
bind MHC I with adequate affinity for presentation. Therefore, we speculate that the in-
silico analyses perform better for peptides of typical length for a given MHC I but are less 
able to predict the affinity of longer peptides.  
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Figure 5.9 CD8+ T cell response to identified HSV-1 peptides. The magnitude of 
HSV-1 peptide-specific CD8+ T cell responses, as measured by the ability to make IFN 
using in vitro restimulation assay is shown. The assay was conducted using splenocytes from 
HSV-1 infected mice 7 days after infection. Only the peptides that resulted in an 
immunogenic response in more than one mouse are shown. The dashed red line represents 
the average of 3 times the standard deviation (SD) of negative controls across 8 mice. Each 
symbol represents a mouse. Each closed circle shows a mouse when immunogenicity was 
detected above the threshold, which is 3 × SD above the average of negative controls. The 
error bars show mean  SD. The bars filled in green indicate the previously known 
epitopes (Salvucci et al., 1995; Wallace et al., 1999; St Leger et al., 2011) and the bars in 
pink show the epitopes identified in this study. I acknowledge Ms. Grace Patricia for 
contributing to the generation of the immunogenicity data. 
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Figure 5.10 Predicted binding affinity of HSV-1 derived peptides. (A) The MHC I 
binding affinity (IC50) of each peptide naturally presented by HSV-1 infected cells was 
predicted using the artificial neural network (ANN)-based alignment algorithm. The scatter 
plot shows the IC50 value of the non-immunogenic and immunogenic HSV-1 peptides 
identified in this study. The horizontal line represents the mean. The mean IC50 values of 
non-immunogenic and immunogenic peptides were compared using unpaired t-test with 
Welch’s correction. Asterisks show that the means are significantly different (p<0.0001). (B) 
The relationship between the proportion of peptide-specific CD8+ T cells and the 
predicted MHC I binding affinity score (IC50) is shown. (C) The relationship between the 
peptide length and the predicted MHC I binding affinity score (IC50) is shown. (B & C) 
Spearman linear correlation coefficient (r) and (p) value are indicated in the figure.  
 
A 
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5.2.2 The effect of ICP47 on the overall characteristics of the 
immunopeptidome 
The impact of ICP47 on the peptides identified from samples infected with HSV-1 KOS 
and HSV-1 Ka47Δ were analysed. Of all host and HSV-1 peptides identified in this study, 
35% and 41% were commonly found in samples infected with HSV-1 KOS and HSV-1 
Ka47Δ, respectively (Figure 5.11 A and Figure 5.12 A). Of the host-derived peptides, 24% 
were uniquely found in samples infected with HSV-1 KOS and 41% in samples infected 
with HSV-1 Ka47Δ (Figure 5.11 A). A similar proportion of unique HSV-1 peptides were 
detected in different sample types. Only 20% of the total HSV-1 peptides identified by MS 
were found exclusively in samples infected by HSV-1 KOS, but 39% of the peptides were 
exclusively found in samples infected by HSV-1 Ka47Δ (Figure 5.12 A). Together, these 
data suggest that ICP47 affects the repertoire of host- and HSV-1-derived pMHC-I on the 
cell surface. Furthermore, a proportion of 26% and 43% of the unique host-derived Kb-
bound peptides were detected in HSV-1 KOS and Ka47Δ samples, respectively (Figure 
5.11 B). Consistent to Kb peptides, relatively more host-derived Db bound peptides were 
exclusively found in HSV-1 Ka47Δ samples (29%) compared to samples infected with the 
wild-type virus (22%) (Figure 5.11 C). Of the total Kb bound HSV-1 peptides, 23%, and 
35% were found uniquely from wild-type and HSV-1 Ka47Δ infected samples, respectively 
(Figure 5.12 B). Similarly, 16% and 41% of the Db bound peptides were derived from the 
wild-type and Ka47Δ infected samples, respectively (Figure 5.12 C). Thus, when the 
peptides were sub-divided based on the MHC I allomorphs, an increased repertoire was 
observed for both allomorphs in the absence of ICP47.  
Analyses were next performed to check whether various characteristics of peptides affect 
the difference in the number of peptides identified between the two viruses. We 
investigated whether the distribution of peptide length is similar between HSV-1 KOS and 
Ka47Δ peptide sets. A majority of the peptides from the two peptide sets were found to 
have canonical length i.e., 8 amino acids for Kb binders and 9 residues for Db binders 
(Figure 5.13 A and B). Further, neither the host peptides nor the HSV-1 peptides showed a 
significant difference in the distribution of peptides across different lengths between the 
peptide sets (Figure 5.13 A&B).  
It has been shown that TAP selects peptides for translocation based on the amino acid 
composition of peptides (Momburg et al., 1994; Powis et al., 1992, 1996). While the amino- 
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and carboxy-terminal amino acid residues are critical for binding to TAP, the residues in 
between contributed less to the binding (Peters et al., 2003). To analyse the TAP 
dependency of peptides that are found in wild-type and Ka47Δ samples, a prediction 
matrix (Burgevin et al., 2008) was used to assess the contribution of each peptide residue 
towards the affinity to mouse TAP. TAP score was calculated for the host and HSV-1 
peptides by considering the first three amino-terminal and the carboxy-terminal residue of 
each peptide. Our analysis showed that TAP binding affinity of the peptides does not vary 
significantly between the peptides identified from HSV-1 KOS and HSV-1 Ka47Δ samples, 
for both the host (Figure 5.14 A) and the HSV-1 peptides (Figure 5.14 B).  
An analysis was performed to test whether the peptides identified from the two sample 
types showed a difference in MHC I binding affinity. Peptides with a range of IC50 values 
representing strong binders to non-binders were identified in both the peptide sets and the 
MHC I affinity was comparable between KOS-peptides and Ka47Δ-peptides (Figure 5.14 
C). Further, the kinetic class of proteins appears to have no role in the sampling of 
peptides in the presence or absence of ICP47 (Figure 5.14 D).  
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Figure 5.11 More host-derived MHC I-bound peptides were identified on cells 
infected with HSV-1 Ka47Δ compared to cells infected with HSV-1 KOS. (A) Venn 
diagram showing proportion of host-derived peptides identified exclusively in the HSV-1 
KOS infected samples, in HSV-1 Ka47Δ infected samples and the peptides commonly 
found in both sample types. (B) The proportion of Kb (left side) or Db-bound (right side) 
host-peptides exclusively found in HSV-1 KOS or HSV-1 Ka47Δ infected samples and 
those commonly identified between the two infected sample types are shown in the pie 
charts. The number of peptides identified in each subset is denoted as a percentage of total 
host-peptides bound to the corresponding MHC I allomorph.  
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Figure 5.12 More HSV-1 derived MHC I-bound peptides were identified on cells 
infected with Ka47Δ than with HSV-1 KOS. (A) The proportional Venn diagram shows 
the number of HSV-1-peptides identified exclusively in the HSV-1 KOS or HSV-1 Ka47∆ 
virus-infected samples and the subset of peptides common between the samples. (B) The 
proportion of Kb-bound (left side) and Db-bound (right side) HSV-1 peptides identified in 
samples infected with HSV-1 KOS, infected with HSV-1 Ka47Δ or common to the two 
infected sample types are shown in the pie charts. The number of peptides identified in 
each subset is denoted as a percentage of total host-peptides bound to the corresponding 
MHC I allomorph.  
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Figure 5.13 Length distributions of the MHC I -bound peptides detected in HSV-1 
KOS or Ka47Δ infected samples. (A) The number of host-peptides distributed across the 
different length of peptides is shown for HSV-1 KOS or Ka47Δ infected samples. (B) 
Similarly, all HSV-1-derived peptides identified in HSV-1 KOS or Ka47Δ infected samples 
were grouped based on the number of amino acid residues. (A&B) The graphs on the left 
side denote Kb-bound peptides and the graphs on the right represent Db bound peptides. 
The distribution of peptides with different amino acid residues was compared between the 
peptides derived from cells infected with HSV-1 KOS and cells infected with HSV-1 
Ka47∆ using two-way ANOVA Sidak’s multiple comparisons test. The differences are not 
statistically significant across any peptide length. 
 
B 
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Figure 5.14 Characterisation of immunopeptidome in mouse cells as a function of 
TAP inhibition by ICP47. (A) and (B) The TAP score was calculated by considering the 
three N-terminal residues and the C-terminal residue of MHC I bound peptides as 
described by Burgevin et al. (2008). According to the prediction matrix, smaller the score, 
higher the affinity towards TAP. The scatter plot shows the predicted TAP binding affinity 
of the host-derived peptides (A) and HSV-1-derived peptides (B) that were identified in 
HSV-1 KOS or Ka47Δ infected samples. (A) and (B) Each symbol represents a peptide 
and the horizontal lines represent mean. The p values were calculated using the unpaired t-
test. (C) Scatter plot shows the predicted binding affinity (IC50) of HSV-1 peptides from 
different samples. ANN algorithm was used to calculate the IC50 values. Each symbol 
represents a peptide and horizontal line represents mean. The p-value was calculated using 
the unpaired t-test. (D) Distribution of source proteins across the kinetic classes for 
peptides found in cells infected with HSV-1 KOS and Ka47Δ peptides. The p-value was 
calculated using two-way ANOVA. 
HSV-1 peptides 
A B 
C D 
Host peptides 
HSV-1 peptides 
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5.2.3 MS strategy for absolute quantification of MHC I bound HSV-1 
derived peptides 
The prime objective of this chapter was to estimate the efficiency by which ICP47 inhibits 
human and mouse TAP. Therefore, we employed a highly sensitive technique called MRM-
MS for absolute quantification of a subset of HSV-1 peptides naturally presented on 
infected cells (Figure 5.15). A key aspect of MRM-MS is that the user programs the MS to 
focus on selected peptide ions with particular target values. MRM is an experiment 
performed on an LC coupled triple quadrupole MS instrument. The eluted fractions from 
the LC are introduced into the MS instrument by electrospray ionisation (Figure 5.15 A). 
The first quadrupole (Q1) filters peptide ions based on the mass to charge ratio (m/z) and 
allows only peptide ions of interest (as programmed), to pass to the next quadrupole. In the 
second quadrupole (Q2), the peptide ion is fragmented by a process called collision-
induced dissociation (CID) (Figure 5.15 B). The fragmented product ions with a specific 
m/z values are again selected in the third quadrupole (Q3) and ultimately recorded by a 
detector. The predefined pairs of a given peptide ion in first quadruple and a 
corresponding product ion in the third quadruple is called an MRM transition. The main 
task during MRM-MS assay development is to select the transitions for the peptides of 
interest in order to optimise selectivity and sensitivity. The specificity of the transitions 
from precursor to product ion makes this technique more sensitive and allows targeted 
detection of even poorly abundant peptides within a complex sample. In conjunction with 
isotopic standards, this method can be used reliably to quantify multiple peptides with a 
sensitivity of one copy per cell (Croft et al., 2013).  
5.2.3.1 Peptide selection and optimisation of MRM assay 
A range of peptides with different binding affinities, immunogenicity and abundance were 
chosen for quantification. These included 15 Kb-restricted peptides from our peptide 
discovery dataset and two immunogenic peptides, RR1 (982-989) and ICP8 (876-883), 
identified by St Leger et al. (2011), which were not identified during our discovery 
experiments. Each of the chosen peptides was synthesised to incorporate a single isotopic 
(heavy) amino acid for use as standards. The newly synthesised labelled peptides for 
absolute quantification, commonly referred to as “AQUA peptides” (Gerber et al., 2003), 
are identical in sequence and thus, chemically identical to their native counterpart. However, 
the AQUA peptides can be easily distinguished by mass spectrometry due to the 7-10 Da 
(residue dependent) mass shift (Desiderio and Kai, 1983; Gerber et al., 2003).  
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The newly synthesised AQUA peptides were initially used for optimising the MRM assay 
conditions. In order to obtain high-resolution data on each peptide, its dominant precursor 
m/z and the nature of its fragmentation, a mixture of all peptides from Table 5.2 were 
analysed on a TripleTOF® 6600 system. Although this system is not a triple quadrupole, it 
uses the same collision cell as the QTRAP® 6500 LC-MS/MS system used for MRM-based 
quantification. This means that fragmentation information can be directly translated for 
quantification using QTRAP® 6500. Dominant Q1 precursors were selected, and the top 
five product ions were selected for each AQUA peptide. These were built into the 
transition list, which was then used to optimise collision energy and assess retention time. 
Then, the transitions of heavy peptides were used to generate a list of corresponding 
transitions for the native sequences (Lange et al., 2008). Table 5.1 and Table 5.2 detail the 
list of peptides for MRM, including information for all heavy and light sequences, the 
resultant mass shift, the dominant precursor m/z used and the selected transitions and 
optimal collision energy. Prior to the implementation of the method, ten-fold dilutions, 
ranging from 5 amoles to 500 fmoles, of the total AQUA peptide mixture were subjected 
to MRM-MS analysis in order to test the linearity and sensitivity of the optimised MRM 
assay. As shown in Figure 5.16, most peptides were measurable down to 50 amoles and the 
detection is linear over 50 amoles to 500 fmoles. Of the 17 AQUA peptides, two peptides 
(UL5300-307 and UL25304-311) were not detected by MRM analysis. It is likely that these two 
peptides did not undergo optimal separation by LC due to hydrophobicity, hence excluded 
from further analysis.  
5.2.4 Detection of endogenous peptides in infected samples 
MC57G or 293KbC2 cells (5 × 107) were infected with HSV-1 KOS or HSV-1 Ka47∆ for 
6 hours. Mock-infected cells were used as a control. The experiment was conducted in 
triplicates. The cells were snap frozen and then treated with mild lysis buffer followed by 
affinity purification of pMHC-I complexes. Until this point, the experimental steps are 
similar to that of the peptide discovery process shown in Figure 5.2. Then, a mixture of 
each AQUA peptide (Table 5.1; 50 fmoles per peptide) was spiked into the eluted pMHC-I 
complex followed by pre-fractionation using HPLC (Figure 5.15 A). The addition of 
AQUA peptides to the pMHC-I eluate provides for the losses during sample handling, thus, 
enabling precise quantification of peptides. Each of the fractions containing peptides was 
subjected to LC-MRM-MS analysis. The previously developed MRM assay (Section 5.2.3.1 
and Table 5.2) was used to simultaneously quantitate the 15 selected peptides in each 
Investigation of inhibition of antigen presentation by ICP47 on human and mouse cells 
207 
sample. Representative MRM transition peaks of gB498-505 are shown in Figure 5.17. The 
areas under the curve of each of the selected transitions were combined to obtain a sum 
peak area. The peptide abundance was calculated using the formula noted in the materials 
and methods chapter (Section 2.3.12.9). 
The native peptides were detected in the infected samples but not in the mock-treated 
samples. A total of 15 native peptides could be detected in the MC57G samples. Although 
detected at low level in two KOS-infected and two Ka47Δ-infected MC57G samples, the 
native peptide UL40279-287 (AAIENYVRF) was not detected in any of the 293KbC2 samples. 
Given that 293KbC2 cells display relatively low-level MHC I on their surface (Figure 3.4 A), 
it is possible that UL40279-287 is presented below detection level in 293KbC2 samples. This 
peptide was eliminated from further analysis only from 293KbC2 samples. Thus, in total, 
14 peptides were detected in the 293KbC2 samples. Further, some peptides were not 
detected in some replicates during the analysis. For instance, ICP8171-178 (INNTFLHL) and 
UL5126-133 (AQNMYAKL) were detected in only one of the replicates in 293KbC2 samples 
(infected with HSV-1 Ka47Δ) (Figure 5.19). However, this same peptide was found, in low 
abundance, in all six MC57G samples (Figure 5.19). Additionally, UL5126-133 was found in 
one replicate of KOS infected and two replicates of Ka47Δ infected MC57G samples 
(Figure 5.19). It is likely that in 293KbC2 cells these peptides were presented at levels close 
to the limit of detection of the instrument, and so were not found consistently in all 
replicates. Similarly, MRM transitions for the immunodominant peptide gB498-505 were 
present in all six MC57G samples (Figure 5.17 and Figure 5.18) and three replicates of 
293KbC2 infected with Ka47Δ, whereas it was either not detected or detected at a very low 
level in 293KbC2 cells infected with wild-type virus (Figure 5.17 and Figure 5.19). Peptides 
found in more than one replicate in each cell type were included for further analysis and an 
arbitrary value of 0.01 was added to all peptides to allow statistical testing despite some 
missing values. Because the peptides analysed in this study were detected from 50 amoles 
(Figure 5.16) and given that there were 5 × 107 viable cells in each sample, the limit of 
detection across our peptide set was determined to be 0.6 copies/cell. A value of 0.01 
copies/cell is well below the limit of detection and therefore, not expected to skew the 
statistical analysis. 
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Figure 5.15 Schematic representation of the targeted MRM MS method of peptide 
quantification. (A) MHC I bound peptides eluted from the immunoaffinity column are 
mixed with isotopically labelled standard AQUA peptides followed by pre-fractionation 
using RP-HPLC. The peptide fractions are then loaded on the triple quadrupole mass 
spectrometer coupled to LC. Here, the peptides undergo further separation by the LC and 
ionisation by electrospray. User-defined precursor ions are filtered in the first quadruple 
and the selected precursor ion is fragmented in the second quadruple upon collision with 
an inert gas. The fragmented ions are selected for detection in the third quadrupole. Precise 
quantification of endogenous peptides is achieved by comparing the signal intensities of the 
unlabelled endogenous (light) peptides and the corresponding isotopically labelled AQUA 
(heavy) peptides. (B) Nomenclature of peptide fragmentation by MS. The example 
precursor peptide “SSIEFARL”, which when fragmented would result in major product 
ions referred to as “b” ions when they retain N-terminal amino acids and “y” ions when 
they retain C-terminal amino acid. The number of amino acids retained in the product ion 
is shown as a subscript.  
B 
A 
Investigation of inhibition of antigen presentation by ICP47 on human and mouse cells 
209 
Table 5.1. List of heavy peptides used in MRM analysis. 
Peptide  Peptide 
sequence 
Isotope 
labelling  
M.W 
shift 
Epitope MS 
detection 
RR1982-989 FAPLFTNL F (13C9 15N)  10 Yes
# − 
ICP8876-883 GAINFINL F (13C9 15N)  10 Yes
# − 
RRI822-829 QTFDFGRL F (13C9 15N)  10 Yes
# + 
ICP8171-178 INNTFLHL F (13C9 15N)  10 Yes
# + 
gB498-505 SSIEFARL R (13C6 15N4)  10 Yes
# + 
UL40198-206 IAYLRTNNL R (13C6 15N4)  10 Yes + 
UL37600-607 TQIRFPAL R (13C6 15N4)  10 Yes + 
UL5126-133 AQNMYAKL A (13C3 15N)*2  8 Yes + 
UL39 451-461 VALDFGLTERL F (13C9 15N)  10 Yes + 
UL40279-287 AAIENYVRF F (13C6 15N4)  10 Yes
# +++ 
UL51155-163 AIAERALGL R (13C6 15N4)  10 No +++ 
US1198-205 INQLFRVL F (13C9 15N)  10 No +++ 
UL26361-370 VAYGPHGAGL A (13C3 15N)*2  8 No +++ 
UL5300-307 STFEHQKL F (13C9 15N)  10 No +++ 
UL5729-736 MGYTYTRV R (13C6 15N4)  10 No + 
ICP0748-755 GALDFRSL R (13C6 15N4)  10 No +++ 
UL25304-311 GRYEHGAL R (13C6 15N4)  10 No +++ 
Red font bold - the isotopically labelled amino acid residue  
M.W. is the abbreviation of molecular weight.  
#previously published epitopes (Salvucci et al., 1995; Wallace et al., 1999; St Leger et al., 
2011) 
Yes - The peptide is immunogenic in mice 
No - The peptide is non-immunogenic in mice 
Minus symbol (−) points to the peptides not identified by MS 
Plus symbol (+) points to the peptides identified by MS 
+++ denotes that the peptide was frequently detected by MS  
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Table 5.2 MRM transitions of HSV-1 derived peptides 
Peptide Heavy  Light 
 
Dwell time 
(ms) 
Optimum 
collision 
energy 
 Q1 m/z 
(charge) 
Q3 m/z (ion) Q1 m/z 
(charge) 
Q3 m/z (ion) 
RR1982-989 466.7689 783.4253 (b7-H2O)  461.7553 773.3981 (b7-H2O)  10 17.5 
669.3824 (b6-H2O)  659.3552 (b6-H2O)  10 17.5 
441.2496 (PLFT-H2O)  441.2496 (PLFT-H2O)  10 25.5 
358.2125 (PLF)  358.2125 (PLF)  10 29.5 
229.14 (b2)  219.1128 (b2)  10 21.5 
ICP8876-883 436.2587 740.4155 (b7)  431.2451 730.3883 (b7)  10 12.2 
496.2619 (b5-NH3)  486.2347 (b5-NH3)  10 20.2 
385.2299 (INF)  375.2027 (INF)  10 24.2 
272.1458 (NF)  262.1186 (NF)  10 28.2 
243.1921 (FI-28)  233.1648 (FI-28)  10 32.2 
RR1822-829 497.2645 865.4632 (y7)  492.2509 855.4359 (y7)  10 26.9 
764.4155 (y6)  754.3883 (y6)  10 26.9 
607.3198 (y5)  607.3198 (y5)  10 26.9 
345.2245 (y3)  345.2245 (y3)  10 30.9 
231.1557 (TF-28)  221.1285 (TF-28)  10 30.9 
ICP8171-178 491.2827 868.4741 (y7)  486.2691 858.4468 (y7)  10 22.6 
754.4311 (y6)  744.4039 (y6)  10 22.6 
640.3882 (y5)  630.361 (y5)  10 22.6 
269.1608 (y2)   269.1608 (y2)  10 30.6 
251.1503 (LH)   251.1503 (LH)  10 34.6 
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Peptide Heavy  Light 
 
Dwell time 
(ms) 
Optimum 
collision 
energy 
 Q1 m/z 
(charge) 
Q3 m/z (ion) Q1 m/z 
(charge) 
Q3 m/z (ion) 
gB498-505 466.7574 845.4755 (y7)  461.7533 835.4672 (y7)  10 21.5 
758.4435 (y6)   748.4352 (y6)  10 21.5 
645.3594 (y5)   635.3511 (y5)  10 21.5 
627.3488 (y5-H2O)   617.3406 (y5-H2O)  10 29.5 
516.3168 (y4)   506.3085 (y4)  10 25.5 
UL51155-163 462.281 735.4387 (b7)  457.2769 725.4304 (b7)  10 17.3 
 707.4438 (a7)   697.4355 (a7)  10 29.3 
 668.3965 (y6)   658.3883 (y6)  10 25.3 
 650.386 (y6-H2O)   640.3777 (y6-H2O)  10 25.3 
 539.3539 (y5)   529.3457 (y5)  10 21.3 
US1198-205 506.822 899.5526 (y7)  501.8084 889.5254 (y7)  10 27.3 
 785.5097 (y6)   775.4825 (y6)  10 23.3 
 657.4511 (y5)   647.4239 (y5)  10 23.3 
 544.3671 (y4)   534.3398 (y5)  10 27.3 
 228.1343 (b2)   228.1343 (b2)  10 23.3 
UL26361-370 475.2527 850.4297 (y9)  471.2456 842.4155 (y9)  10 25.9 
 775.3855 (y8)   771.3784 (y8)  10 21.9 
 612.3222 (y7)   608.3151 (y7)  10 21.9 
 388.1964 (y8+2)   386.1928 (y8+2)  10 21.9 
 136.0757 (Y)   136.0757 (Y)  10 33.9 
UL5300-307 500.2698 850.4271 (b7-H2O)  495.2562 840.3999 (b7-H2O)  10 31 
 811.4526 (y6)   801.4254 (y6)  10 23 
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Peptide Heavy  Light 
 
Dwell time 
(ms) 
Optimum 
collision 
energy 
 Q1 m/z 
(charge) 
Q3 m/z (ion) Q1 m/z 
(charge) 
Q3 m/z (ion) 
 740.3427 (b6)   730.3155 (b6)  10 27 
 680.358 (FEHQK)   670.3307 (FEHQK)  10 27 
 552.263 (FEHQ)   542.2358 (FEHQ)  10 31 
UL40 279-287 546.7892 950.497 (y7)  541.7851 940.4887 (y7)  10 25.1 
 837.4129 (y6)   827.4046 (y6)  10 25.1 
 708.3703 (y5)   698.362 (y5)  10 25.1 
 594.3274 (y4)   584.3191 (y4)  10 25.1 
 431.264 (y3)   421.2558 (y3)  10 25.1 
UL40198-206 544.3103 974.5293 (y8)  539.6357 964.5211 (y8)  10 24.9 
 957.5028 (y8-NH3)   947.4945 (y8-NH3)  10 24.9 
 903.4922 (y7)   893.4839 (y7)  10 28.9 
 740.4289 (y6)   730.4206 (y6)  10 28.9 
 627.3448 (y5)   617.3365 (y5)  10 24.9 
UL37600-607 478.2836 824.4653 (b7)  473.2795 814.457 (b7)  10 22 
 726.4536 (y6)   716.4454 (y6)  10 22 
 656.3754 (b5)   646.3671 (b5)  10 26 
 613.3696 (y5)   603.3613 (y5)  10 22 
 509.307 (b4)   499.2987 (b4)  10 38 
UL5126-133 473.7489 743.3878 (y6)  469.7418 739.3807 (y6)  10 21.8 
 498.2503 (MYAK)   494.2432 (MYAK)  10 21.8 
 409.154 (NMY)   409.154 (NMY)  10 33.8 
 335.2411 (y3)   331.234 (y3)  10 29.8 
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Peptide Heavy  Light 
 
Dwell time 
(ms) 
Optimum 
collision 
energy 
 Q1 m/z 
(charge) 
Q3 m/z (ion) Q1 m/z 
(charge) 
Q3 m/z (ion) 
 260.1969 (y2)   260.1969 (y2)  10 33.8 
UL39451-461 622.3591 960.5214 (y8)  617.3455 950.4942 (y8)  10 32.4 
 845.4945 (y7)   835.4672 (y7)  10 36.4 
 688.3988 (y6)   688.3988 (y6)  10 36.4 
 518.2933 (y4)   518.2933 (y4)  10 32.4 
 423.2509 (y7+2)   418.2373 (y7+2)  10 28.4 
UL5729-736 500.7434 869.4391 (y7)  495.7393 859.4308 (y7)  10 23 
 812.4176 (y6)   802.4094 (y6)  10 23 
 649.3543 (y5)   639.3461 (y5)  10 27 
 548.3066 (y4)    538.2984 (y4)  10 23 
 385.2433 (y3)   375.235 (y3)  10 23 
ICP0 748-755 444.7443 760.4227 (y6)  439.7402 750.4145 (y6)  10 20.6 
 647.3387 (y5)   637.3304 (y5)  10 20.6 
 532.3117 (y4)   522.3035 (y4)  10 24.6 
 419.2289 (ALDF-28)   419.2289 (ALDF-28)  10 36.6 
 314.1851 (FR)   304.1768 (FR)  10 36.6 
UL25304-311 456.7317 799.3721 (b7+H2O)  451.7276 789.3638 (b7+H2O)  10 25.1 
 710.3244 (b6)   700.3161 (b6)  10 21.1 
 653.303 (b5)   643.2947 (b5)  10 25.1 
 516.244 (b4)   506.2358 (b4)  10 37.1 
 391.1844 (b7+2)   386.1803 (b7+2)  10 25.1 
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Figure 5.16 Assessment of MRM limit of detection and quantification of each HSV-
1 AQUA peptide. The AQUA peptides were diluted across a ten-fold series (5 amoles to 
500 fmoles) and subsequently detected by MRM, with data showing the sum peak area of 
the total transitions for each peptide. Peptide quantity from 50 amoles (or 5 × 10-17 moles) 
could be detected for most peptides. Each data point represents mean ± SD. The goodness 
of fit (r2) value derived from the linear regression curve is shown for each peptide.  
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Figure 5.17 Detection of HSV-1 gB498-505 (SSIEFARL) in 293KbC2 and MC57G cells. 
Shown are the MRM transitions (y7, y6, y5, y5-18 and y4) for the peptide gB498-505 in the mock-
treated cells and the cells infected with HSV-1 KOS or HSV-1 Ka47∆. The left panel 
shows the transitions in 293KbC2 samples and the right panel shows transition peaks in 
MC57G samples. Results for AQUA and native peptide are shown in each panel for 
comparison. MRM transitions of AQUA peptides were detected in all samples. The results 
for the native peptide in mock-treated 293KbC2, mock-treated MC57G and HSV-1 KOS 
infected 293KbC2 samples were at background levels.  
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5.2.5  Quantification of endogenous HSV-1 peptides revealed the 
difference in ICP47 function between human and mouse cells 
5.2.5.1 Overview of quantification of HSV-1 peptides 
A total of 15 peptides were detectable in HSV-1 KOS and Ka47Δ infected MC57G 
samples. In 293KbC2 samples, only 9 peptides were above the detection limit in HSV-1 
KOS infected cells and 14 peptides were above the detection limit in Ka47Δ infected cells. 
However, only 12 peptides detected in Ka47Δ infected 293KbC2 cells were considered for 
further analysis due to reduced frequency of detection (refer to section 5.2.4). When 
detected, the peptides spanned a range of 0.9 to 6014 copies/cell in MC57G (Figure 5.18) 
compared to 0.6 to 1491.6 copies/cell in 293KbC2 cell line (Figure 5.19). In MC57G cells, 
the average number of peptide molecules varied from 2 molecules to 4350 molecules per 
cell across peptides in the absence of ICP47 (Figure 5.20 A). Relative to MC57G cells, the 
average peptide abundance was significantly less (p<0.0001) in 293KbC2 cells infected with 
Ka47Δ (Figure 5.20 C), ranging from nearly 4 to 1500 copies/cell (Figure 5.20 B). This 
observation is reflective of the previously observed relatively low cell surface MHC I 
observed in 293KbC2 cells compared to MC57G cells (Figure 3.4 A). The quantification of 
Kb bound HSV-1 peptides revealed that the removal of ICP47 significantly increased the 
overall abundance of the peptides presented on MC57G cells (Figure 5.20 A) and 
293KbC2 cells (Figure 5.20 B). This observation is in line with the previous finding 
(chapter 3, section 3.2.3) that demonstrated the ability of ICP47 to significantly hinder 
antigen presentation both in MC57G cells and in 293KbC2 cells. When the average peptide 
copies/cell was compared between the two cell lines infected with wild-type HSV-1, there 
was a significantly lower number of peptides in 293KbC2 cells compared to MC57G cells 
(Figure 5.20 D). This finding is consistent with the data presented in Chapter 3 (Figure 3.8). 
Together, these data suggest that the difference in copy number of peptides between 
293KbC2 and MC57G cells infected with HSV-1 KOS is largely due to the difference in 
efficiency at which ICP47 inhibit antigen presentation between the two cell lines. 
5.2.5.2 ICP47 severely impairs antigen presentation in human cells 
Analysis of the effect of ICP47 was performed at peptide level by comparing the peptide 
abundance between samples infected with HSV-1 KOS and HSV-1 Ka47Δ as paired 
samples in the same experiment (Figure 5.18 and Figure 5.19). Of the 15 Kb peptides 
examined in MC57G cells, we found a clear reduction in peptide copies for at least nine 
peptides in all three experiments infected with HSV-1 KOS compared to those infected 
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with HSV-1 Ka47Δ. The nine peptides include gB498-505, ICP8171-178, ICP8876-883, RR1982-989, 
RR1822-829, UL39451-461, UL40198-206, US1198-205 and UL40279-287 (Figure 5.18). Three peptides, 
UL5126-133, UL5729-736 and UL37600-607, showed diminished presentation in the presence of 
ICP47 in two experiments. In this case, the third pair was below the limit of sensitivity of 
the instrument. While the peptides ICP0748-755 and UL51155-163 were detected in all samples, 
the copy number was reduced in one experiment and increased in the other two 
experiments in HSV-1 KOS infected samples compared to samples infected with HSV-1 
Ka47Δ. Another peptide, UL26361-370 showed increased copy number in HSV-1 KOS 
infected samples compared to Ka47Δ infected samples in all three experiments. Of note, 
UL26361-370 was detected at low abundance, with copy number ranging from 0.9 to 4 
copies/cell across all samples (Figure 5.18). These data show that the presentation of 
peptides, ICP0748-755, UL51155-163 and UL26361-370, are not affected majorly by ICP47 in mouse 
cells compared to other peptides tested in this study.  
With 293KbC2 cell line, of the 14 peptides detected, 9 peptides including, gB498-505, ICP8876-
883, RR1982-989, RR1822-829, UL26361-370, UL40198-206, UL51155-163, UL5729-736, and US1198-205, were 
found to have reduced copy number in the presence of ICP47 in all three experiments 
(Figure 5.19). For three peptides, ICP0748-755, UL37600-607 and UL39451-461, quantification was 
observed only in 2 experiments and for peptides, ICP8171-178 and UL5126-133, quantification 
was possible in only one experiment. However, in all cases where a peptide was detectable 
in a sample infected with HSV-1 Ka47Δ, there was a reduction in the number of molecules 
presented on the wild-type HSV-1 infected sample. 
There are several observations that confirm the difference in efficiency at which ICP47 
affect antigen presentation in MC57G and 293KbC2 cells. Notably, the peptides gB498-505, 
ICP8876-883, RR1822-829, and UL39451-461 are immunogenic (Figure 5.9) (St Leger et al., 2011) 
and are presented at high abundance (100 to 10000 copies/cell) in the absence of ICP47, 
consistently in MC57G and 293KbC2 cells (Figure 5.18 and Figure 5.19). However, in 
wild-type HSV-1 infected MC57G cells, these immunogenic peptides are still presented at 
high copy numbers, whereas, a steep decline in abundance was observed for 293KbC2 
samples infected with the wild-type virus. Furthermore, in the presence of ICP47, 
293KbC2 samples showed peptide abundance at an average of 10 molecules or less for all 
14 peptides analysed (Figure 5.19 and Figure 5.21 A). Lack of direct correlation between 
the peptide copies presented between the KOS-infected and Ka47Δ-infected 293KbC2 
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cells (Figure 5.21 A) suggests that ICP47 severely impairs antigen presentation regardless of 
the maximum presenting capacity of a peptide in the absence of ICP47. Although the fold 
inhibition was variable across peptides in 293KbC2 cells, there was over ten-fold reduction 
in presentation of over 50% of the peptides (Figure 5.21 C). In comparison to 293KbC2 
cells, the inhibition of presentation by ICP47 is significantly less pronounced for MC57G 
cells, being just within a 5-fold range across all peptides (Figure 5.21 B&C). The effect of 
ICP47, although diminished in mouse cells, retains a similar effect across the peptides 
(Figure 5.21 C). Together, these results suggest that ICP47 impairs antigen presentation 
severely in human cells but only modestly in mouse cells, according to the two cell lines 
tested here. 
5.2.5.3 Level of inhibition of antigen presentation is variable between peptides  
On the one hand, the peptides, gB498-505, UL37600-607, UL39451-461, UL40198-206, and UL5729-736, 
are inhibited from presentation to near the detection limit by ICP47 in 293KbC2 samples 
(Figure 5.19). While on the other, the peptides ICP0748-755, RR1982-989, UL26361-370, and US1198-
205 are not inhibited to the same extent by ICP47 (Figure 5.19). These data suggest that 
ICP47 blocks certain peptides highly efficiently from translocation, while other peptides are 
not fully inhibited (Figure 5.21 C). The variability in the level of inhibition could be due to 
translocation of at least some peptides directly to ER independent of TAP (Norbury et al., 
2001) or an intrinsic feature of the peptide that may help to overcome TAP inhibition by 
ICP47. This theory is further supported by the significant association observed between 
the two cell lines with regard to the number of peptides presented in the absence of ICP47 
and the level of inhibition of antigen presentation by ICP47 (Figure 5.22 A&B). These 
results demonstrate that each peptide is influenced in a similar manner in both cell lines 
and therefore, the variation observed in both the abundance of peptides and inhibition by 
ICP47 is unlikely to be an artefact of a particular cell line. Hence, some of the factors that 
might explain the variability in inhibition by ICP47 across peptides are explored in the 
following sections. 
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Figure 5.18 Quantification of Kb-bound HSV-1 peptides on MC57G cells. For each 
peptide, the average copy number of peptide per cell was calculated from each sample. The 
graphs show the copies of peptide per cell in each replicate sample, which is either infected 
with Ka47 or with KOS. The trend line connecting the paired samples for each peptide 
indicates the increase or decrease in peptide abundance in the absence (HSV-1 Ka47) or 
presence of ICP47 (HSV-1 KOS) in an experiment. 
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Figure 5.19 Quantification of Kb-bound HSV-1 peptides on 293KbC2 cells. The 
abundance of selected HSV-1 peptides presented on 293KbC2 cells infected with HSV-1 
Ka47 or KOS was quantified using MRM-MS. The graphs show the copies/cell for the 
various peptides in every replicate sample. Each symbol represents a sample. The trend line 
connecting the paired samples for each peptide indicates the increase or decrease in peptide 
abundance in the absence (HSV-1 Ka47) or presence of ICP47 (HSV-1 KOS). 
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         A                MC57G        B                 293KbC2 
  
 
Figure 5.20 Overall effect of ICP47 on peptide abundance in MC57G and 293KbC2 
cells. (A) Summary of average peptide copies/cell quantified in MC57G cells infected with 
HSV-1 Ka47Δ or HSV-1 KOS. (B) Summary of average peptide copies/cell quantified in 
293KbC2 cells infected with HSV-1 Ka47Δ or HSV-1 KOS. (C) Comparison of peptide 
abundance between MC57G and 293KbC2 cells in the absence of ICP47. (D) Comparison 
of peptide abundance between the two cell lines infected with wild-type HSV-1. (A, B, C & 
D) The graphs show log10 transformed values. Each symbol represents a peptide and the 
peptides are colour coded for comparison between sample types. The horizontal line 
represents mean. The statistical significance was calculated using two-way ANOVA. 
****p<0.0001. 
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Figure 5.21 ICP47 severely impairs antigen presentation in 293KbC2 cells. (A) 
Analysis of correlation of the peptide copy number between KOS –infected and Ka47Δ –
infected 293KbC2 cells. (B) Analysis of correlation of the peptide copy number between 
KOS –infected and Ka47Δ –infected MC57G cells. (A&B) The average copy number of 
peptides determined in three independent experiments was used for correlation analysis. 
The statistical significance was determined using the Spearman rank correlation. The 
correlation coefficient (r) and p-value are shown. (C) The log10 ratio of an average number 
of peptide molecules detected on cells infected with HSV-1 KOS and on cells infected with 
HSV-1 Ka47Δ is shown for 293KbC2 and MC57G cell lines. Each symbol represents a 
peptide. The peptides are colour coded for comparison between sample types. The error 
bars represent geometric mean ± SD. Statistical significance (p=0.0001) was calculated 
using two-way ANOVA.  
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Figure 5.22 The abundance in the absence of ICP47 and level of inhibition of 
presentation of peptides by ICP47 show a significant correlation between 293KbC2 
and MC57G cell lines. (A) The relationship between human and mouse cell lines in 
copies of peptides per cell. For analysis, the average copy number of peptides found in 
samples infected with Ka47Δ was used. (B) The relationship between human and mouse 
cell lines in the level of inhibition of peptides by ICP47 is shown. The correlation analysis 
was performed using the log10 ratio of average peptide copies between cells infected with 
HSV-1 KOS and HSV-1 Ka47Δ. (A&B) The statistical significance was determined using 
the Spearman rank correlation. The correlation coefficient (r) and p-value are shown. 
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5.2.6  Analysis of factors influencing the variability in peptide 
abundance and ICP47 mediated inhibition of antigen presentation 
5.2.6.1 Association with ER-targeting signal sequence 
Alternative processing and presentation pathways occur in conjunction to the classical TAP 
mediated MHC I peptide presentation (Hammond et al., 1993; Snyder et al., 1997; Wölfel 
et al., 2000; Lautscham et al., 2003). A proportion of peptides that are translocated 
independently of TAP are derived from precursors containing ER-targeting signal 
sequences (Henderson et al., 1992; Wei and Cresswell, 1992). Signal sequences are 
composed of polar amino- and carboxy-termini flanking a small hydrophobic core 
sequence (Martoglio and Dobberstein, 1998). Signal sequence embedded peptide 
precursors including newly synthesised proteins are targeted to the ER membrane where 
the signal peptidase liberates the carboxy-terminus and the resultant peptide is further 
processed by signal peptide peptidases (Oliveira et al., 2013). Some peptide fragments 
resulting from this process are loaded onto MHC I in the ER. In our study, the source 
proteins of the quantified HSV-1 peptides were analysed for an embedded signal sequence 
using SignalP 4.1 server (Petersen et al., 2011). This program predicts the occurrence of 
signal sequence and the signal peptidase recognition site in the source protein. The 
prediction analysis showed that none of the source proteins of the specified peptides was 
predicted to contain a signal peptide sequence. However, it is possible that those peptides 
less responsive to ICP47 inhibition might use another unknown pathway whereby the 
peptides are loaded independently of the TAP. 
5.2.6.2 Hydropathicity of peptides 
Another possible explanation for the observed differences in the degree of inhibition of 
peptide transport by ICP47 was explored. In this context, a previous study demonstrated a 
relationship between the hydrophobicity of peptides and TAP-independent presentation 
(Lautscham et al., 2001). Using an EBV model, Lautscham et al. (2001) showed that the 
most hydrophobic epitopes were TAP-independent and suggested that high 
hydrophobicity is required and is sufficient for TAP-independent translocation of peptides 
to the ER. We tested the correlation between inhibition of peptide presentation and 
hydrophobicity of peptides. Further, since hydrophobicity may also affect the number of 
peptides transported, we analysed the relationship between hydrophobicity and abundance 
of peptides. 
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The hydropathicity of the quantified peptides was calculated based on the Hopp-Woods 
hydropathy score (Hopp and Woods, 1981). Peptides with smaller hydropathy score are 
considered to be more hydrophobic (Hopp and Woods, 1981). The hydropathicity of our 
peptides ranges from 0.1 to -1.0 (Table 5.3). Among the peptides that were highly inhibited 
in all three experiments, gB498-505, RR1822-829, and UL39451-461 have a relatively larger 
hydropathy score (-0.1 to 0) indicating that these peptides are relatively less hydrophobic 
(Table 5.3). However, for ICP8876-883, whose presentation was inhibited nearly 70-fold by 
ICP47, the total hydropathy score of -0.8 shows that this peptide might be relatively more 
hydrophobic. Similarly, for the peptides that are not subjected to absolute inhibition, a 
poor correlation to hydrophobicity was observed. For instance, when the peptides ICP0748-
755 and ICP8171-178 that are relatively less inhibited by ICP47 are considered, the former is less 
hydrophobic (hydropathy score -0.03) whereas the latter shows a large negative hydropathy 
score (-0.9) (Table 5.3). Overall, there was no significant correlation between the 
hydropathicity and ICP47 mediated TAP inhibition in the two cell lines (Figure 5.23 A) 
indicating that hydrophobicity is unlikely to explain the variable sensitivity of the peptides 
to inhibition of presentation by ICP47. 
5.2.6.3 TAP binding specificity 
The proteasomes and other cytosolic peptidases produce peptides that range in length 
from 2 to 25 amino acids (Nussbaum et al., 1998). From this peptide pool, TAP transports 
peptides based on length and the amino acid composition (Momburg et al., 1994; van 
Endert et al., 1994; Koopmann et al., 1996; Uebel et al., 1997). Peptides of lengths 8 to 16 
amino acids are preferred, however, peptides as long as 40 amino acids are also transported 
to a lesser extent (van Endert et al., 1994; Koopmann et al., 1996). Peptides longer than the 
optimum size are processed in the ER lumen before loading onto MHC I (Serwold et al., 
2002). Interestingly, the selection of peptides differs between human and mouse TAP 
(Momburg et al., 1994; Schumacher, 1994; van Endert, 1995; Burgevin et al., 2008). While 
mouse TAP prefers peptides with hydrophobic amino acids at the C-terminal end, human 
TAP selects peptides based on the amino acids at the first three N-terminal residues and 
the C-terminal residue (Uebel et al., 1997; Burgevin et al., 2008). Moreover, previous 
studies have demonstrated that the binding affinity to TAP is directly proportional to the 
transport and presentation of peptides (van Endert, 1995; Gubler et al., 1998).  
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Therefore, we tested whether the efficiency at which ICP47 inhibits antigen presentation 
correlates with the TAP binding affinity. The binding affinity of our peptide set towards 
human and mouse TAP was determined based on the prediction matrix developed by 
Burgevin et al., 2008 (Table 5.3). According to this matrix, the lower the score the higher 
the affinity of a peptide towards TAP. The analyses revealed a moderate but not statistically 
significant positive correlation (293KbC2, r  = 0.5477, p = 0.069; MC57G, r = 0.4829, p = 
0.070) between the level of inhibition of peptides and TAP score (Figure 5.23 B). This 
result suggests that peptides with higher predicted TAP binding affinity are likely to be 
more inhibited by ICP47 from the presentation on MHC I. Data from more peptides and 
empirical measurement of binding affinity is required to support this possibility.  
5.2.6.4 Peptide abundance 
Peptides that have high affinity towards TAP might be transported in high numbers into 
the ER. Further, as previously shown in Figure 5.18 and Figure 5.19, peptides are 
presented at varying abundance in the absence of ICP47. Therefore, it is plausible that 
peptide abundance might influence the level of inhibition of presentation. Our analysis 
showed that there is an apparent inverse correlation between peptide abundance and the 
level of inhibition but it did not reach statistical significance (293KbC2, r = -0.5664, p = 
0.05905; MC57G, r = -0.4607, p = 0.08607) (Figure 5.23 C). It is possible that the 
borderline correlation is simply due to a bigger window to measure the drop-in peptide 
number in case of high abundance peptides, especially considering our arbitrary value of 
0.01 copies per cell added to all samples. 
5.2.6.5 MHC I binding affinity and immunogenicity 
The peptides pre-selected by TAP are transported to the ER for selection by MHC I. The 
selection of peptides by Kb is relatively more stringent compared to TAP (Fremont et al., 
1992; Molano et al., 1998). In theory, it is unlikely that MHC I binding affinity would 
contribute to the differences in the level of peptide inhibition by ICP47. However, because 
the inhibition of TAP function results in increased retention of MHC I in ER (Townsend 
and Bodmer, 1989), it is possible that peptides with lower binding affinity to MHC I could 
be presented. Further, it is established that the higher the affinity of a peptide to MHC I, 
the more likely the pMHC-I is translocated to the surface and stably presented (Feltkamp 
et al., 1994; Sette et al., 1994; Assarsson et al., 2007). In case of limited peptide availability, 
even peptides with lower binding affinity might have a chance of being presented. 
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Therefore, we tested if there is a relationship between the differential inhibition of peptides 
by ICP47 and the predicted MHC I binding affinity or the immunogenicity of each peptide. 
The results showed that neither the binding affinity to MHC I (Table 5.3) (Figure 5.23 D) 
nor the immunogenicity appears to correlate with the peptide inhibition by ICP47 (Table 
5.3) (Figure 5.23 E).  
5.2.6.6 Influence of timing of gene expression  
At transcript level, ICP47 could be observed as early as 1 hour after infection and retained 
in the infected fibroblast cells for at least 24 hours (Harkness et al., 2014). Based on the 
above data, we expected that ICP47 would have a similar effect on peptides derived from 
proteins of all four kinetic classes. Therefore, the temporal relationship between the 
presentation of various HSV-1 peptides and ICP47 mediated inhibition of antigen 
presentation was analysed (Figure 5.24). In both the cell lines, IE peptides appear to be 
slightly less inhibited compared to the E and L peptides (Figure 5.24 A&C), however, with 
a small sample size (n = 2) it is not possible to reach a definitive conclusion. Statistical 
comparison amongst the peptides grouped based on temporal gene expression shows that 
there was no significant difference in the inhibition of peptides between the kinetic classes 
(Figure 5.24 B&D). Further, there is substantial variability in the inhibition level within E 
class, particularly in 293KbC2 cells, suggesting that even if expression time plays a role it 
cannot entirely explain the variability observed in peptide inhibition across all peptides.
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Table 5.3 Characteristics of Kb associated HSV-1 peptides  
Peptide Hydropathicitya TAP scoreb  Affinity to MHC I c 
(IC50 nm)  
% IFN (of 
CD8+) cellsd 
Ratio KOS:Ka47 (of average 
copies/cell) 
Human Mouse  293KbC2 (human) MC57G (mouse) 
gB498-505 0 -1 -1.3  2.29 11.4133 0.000752 0.20850725 
RR1982-989 -1.033333333 0 0.4  7.04 0.59145 0.122243 0.5744735 
RR1822-829 -0.111111111 -0.7 -1.3  7.99 0.41329 0.006464 0.45489471 
ICP8171-178 -0.933333333 0.3 -0.2  15.86 0.38454 - 0.63794576 
UL40198-206 -0.52 -1.3 -1.3  10.91 0.17704 0.009742 0.29638844 
ICP8876-883 -0.888888889 -0.7 -1.1  36.94 0.07478 0.0127 0.40840901 
UL37600-607 -0.422222222 -1.2 -1.3  17.03 0.06994 0.001232 0.80989466 
ICP0748-755 -0.033333333 -0.4 -0.6  498.68 0.05481 0.28894 1.11253151 
UL39451-461 -0.108333333 -1.5 -1.4  990.73 0.04666667 0.000032 0.37160359 
UL5126-133 -0.333333333 -1.1 -0.9  147.11 0.04242 - 0.52472487 
UL5729-736 -0.577777778 -0.6 -0.8  4.47 0.04 0.000075 0.40388286 
US1198-205 -0.666666667 0.0 -0.1  25.5 0 0.087033122 0.28175463 
UL26361-370 -0.645454545 -0.7 -0.7  87.33 0 0.227404567 0.66713888 
UL51155-163 -0.09 -1.3 -1.0  2036.19 0 0.083648693 1.71431281 
UL40279-287 -0.29 -2.2 -2.3  175.28 0.054805556 - 0.61231385 
aThe hydropathy score was alculated using the method of Hopp and Woods, 1981. 
bThe TAP score was calculated based on the prediction matrix developed by Burgevin et al., 2008. 
cMHC I binding affinity was predicted using ANN based algorithm at the Immune Epitope Database (IEDB) website (Nielsen et al., 2003) 
dThe immunogenicity of peptides in mice was determined as described in section 5.2.1.4. 
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Figure 5.23 Analysis of factors influencing peptide inhibition by ICP47. Spearman 
correlation coefficients were generated to test the correlation of level the inhibition of 
antigen presentation by ICP47 with (A) the Hopp-Woods hydropathy score, (B) TAP score, 
(C) abundance of peptides, (D) MHC I binding affinity, and (E) immunogenicity of 
peptides. Analysis for 293KbC2 cells is shown on the left panel (n=12 peptides) and for 
MC57G cells is shown on the right panel (n=15 peptides). The Spearman correlation 
coefficient (r) and p values are shown for each analysis.  
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Figure 5.24 Impact of ICP47 on antigen presentation is not influenced by the 
expression kinetics of the source protein. Inhibition of presentation of Kb specific 
HSV-1 peptides is shown for 293KbC2 cells (A) and MC57G cells (C). The graph plotted 
shows the log10 ratio of the average copies/cell (n=3) in samples infected with HSV-1 KOS 
and in samples infected with HSV-1 Ka47∆. Based on the expression of the source 
proteins, the peptides are classified as IE (green), E (pink) and L (yellow) class. Here, the 
genes expressed under early-late (1) and true-late (2) kinetics are grouped commonly as L. 
B & D shows the comparison of peptide inhibition among peptides from IE, E and L 
proteins. The differences between groups were not statistically significant based on the 
Kruskal-Wallis test by ranks and Dunn’s multiple comparison tests. 
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5.3  Discussion 
This chapter identified naturally presented HSV-1 peptides on infected MC57G cells using 
LC-MS/MS analysis. Seventy-five HSV-1 peptides were identified across six replicates of 
infected samples. This is the first report that lists the MHC I-bound peptides that are 
directly identified on HSV-1 infected cells. We tested forty-six MS identified HSV-1 
peptides for CD8+ T cell immunogenicity where, one-quarter of the peptides were found to 
be immunogenic, of which, 63% were newly discovered epitopes. For the remaining three-
quarters of the peptides presented on infected cells, no response was detected. This finding 
is in concordance with recent MS based immunopeptidomics studies, which indicated that 
despite the presentation of diverse pathogen-derived peptides on infected cells, CD8+ T 
cells recognise only a subset of these peptides during the in vivo infection (Johnson et al., 
2009; Gilchuk et al., 2013; Ternette et al., 2016). However, Croft and colleagues found 
more than 80% of the VACV peptides identified by LC-MS/MS were immunogenic, which 
is substantially a large proportion of epitopes compared to HSV-1 epitopes identified in 
this study (Croft et al., In press). There are several possibilities that could explain the 
discordance between the current study and the VACV data. First, it is possible that not all 
peptides identified by the database search algorithm ProteinPilot™ software will be true 
(Kapp and Schütz, 2007). Manual validation of our peptide set by comparing the mass 
spectra of endogenous peptides with that of the synthetic peptides can be used to rule out 
the possibility of false peptide identification. Second, cross-presentation is considered as 
the major CD8+ T cell-priming pathway during HSV-1 infection. While the peptide 
identification was performed using infected cells in vitro, these are unlikely to be a good 
model for a cross-presenting APC in mice. Finally, the detection limit of the ICS assay 
cannot be excluded from being responsible for the lack of immunogenic response to these 
peptides (Flesch et al., 2012). Nonetheless, this study has contributed to the finding of 
multiple novel immunogenic HSV-1 peptides in mice.  
A distinctly larger repertoire of peptides was identified from mouse cells infected with 
Ka47Δ compared to the wild-type virus. These data support other findings that ICP47 
inhibits mouse TAP and reduces peptide presentation (Chapter 3). However, the absolute 
quantification data, the limited peptide overlap amongst the replicates (see Figure 5.3) and 
the limited overlap with peptides detected by St Leger and colleagues (2011) suggest that 
the depth of sampling was a factor in peptide identification. For instance, some peptides 
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found exclusively in MC57G samples infected with just one virus, either wild-type virus or 
Ka47Δ, were detected in both sample types by the targeted MRM MS. Another observation 
is that two of the immunogenic peptides (RR1982-989 & ICP8876-883) discovered using a 
prediction algorithm by St Leger and colleagues (2011) but not found by our MS discovery 
run, were then detected using MRM MS in the MC57G samples. The LC-MS/MS method 
used for discovery was programmed such that if many peptides with similar m/z appear in 
an MS1 scan, then only the most abundant peptides are sampled and the less-abundant 
ones are often missed (Zhang et al., 2013). Further, a previously fragmented abundant 
peptide is excluded from repeated fragmentation for a specific time allowing identification 
of a broad range of sequences (Yates et al., 2009). Thus, the stochastic sampling of MS/MS 
presumably has lead to inconsistency in the identification of medium to low abundance 
peptides between replicates. This also explains why not all HSV-1 epitopes identified so far 
were detected by our method. By contrast, targeted MRM-MS focuses only on a small set 
of peptides with user-defined m/z values for precursor and fragment ions, which increases 
the reproducibility and sensitivity of detection. Therefore, a possible explanation for our 
observation is that the removal of ICP47 may have allowed the identification of some 
peptides, which might otherwise be presented below the detection limit of the current LC-
MS/MS workflow. Therefore, the smaller peptide identifications in KOS-infected samples 
is likely to be due to the effect of ICP47 on the number of peptides transported by mouse 
TAP.  
The major significance of this work lies in the provision of direct experimental evidence 
that demonstrates the highly efficient blockade of the human TAP by ICP47. Of the 14 
peptides detected by MRM MS, eight peptides were significantly inhibited from 
presentation in 293KbC2 cells by ICP47. Notably, the immunodominant peptide gB498-505 
and the subdominant peptides UL5729-736, UL37600-607, UL39451-461, and UL40198-206 are 
inhibited to below or close to the detection limit of the MRM-MS method, in all three 
replicates. Furthermore, all fourteen peptides were invariably detected at an average of 
fewer than 10 copies per cell in 293KbC2 cells infected by wild-type HSV-1 reflecting the 
effectiveness of ICP47 in blocking human TAP. The removal of ICP47 significantly 
improved the presentation of these peptides. This implies that the low copy number found 
in wild-type HSV-1 infected samples is due to the interference of TAP mediated 
translocation of peptides by ICP47 instead of 293KbC2 cells being inherently poor at 
Chapter 5 
234 
antigen presentation. To our knowledge, this is the first study to quantify the effect of a 
viral inhibitor of antigen presentation in human and mouse cells. 
Even though the overall abundance of peptides was significantly improved in the absence 
of ICP47, in MC57G cells the peptide copy number was not as markedly diminished by 
ICP47 compared to 293KbC2 cells. For instance, gB498-505 was inhibited by nearly 5-fold, 
but still presented at an abundance of about 350 copies on average per cell in the wild-type 
HSV-1 infected MC57G samples. In comparison, on 293KbC2 cells, gB498-505 was presented 
at an average of about 0.6 copies/cell, when infected by wild-type virus and 770 copies/cell, 
when infected by ICP47 null mutant. This explains, in significant part, why the removal of 
ICP47 did not affect any of the parameters of HSV-1 infection in our mouse model 
(Chapter 3). However, this conclusion comes with the caveat that the copies of 
immunogenic peptides presented on HSV-1 infected mouse primary skin epithelial cells or 
neurons have not been analysed and whether ICP47 affects antigen presentation in these 
primary mouse cells remains to be tested. Although direct evidence is lacking, an earlier in 
vivo study using a flank infection model showed that CD8+ T cells are sufficient to protect 
RAG-1-/- mice that lack both B cells and T cells from HSV-1 disease. Infection of RAG-1-/- 
mice with strain KOS resulted in neurological symptoms and death, whereas transfer of 
activated gB498-505 specific CD8
+ T cells abolished virus replication in DRG and reduced the 
skin lesion to a rate similar to that of immunocompetent C57BL/6 mice (van Lint et al., 
2004a). This indirect evidence shows that in mice, antigen presentation is not adequately 
inhibited by ICP47 and CD8+ T cells can provide effective control of the virus. 
With respect to a mechanistic explanation for the differences in ICP47’s degree of 
inhibition, although human and mouse TAP are homologous with more than 80% 
sequence similarity (Yewdell et al., 1993), the amino acid residues that interact with ICP47 
are not identical between the two species (Oldham et al., 2016b). A recent structural 
analysis shows that ICP47 interacts with the inner surface of TAP1 via amino acid residues 
of TMD4 and TAP2 interacts via TMD2, 3 and 6. While threonine (T) residue at position 
425 of human TAP2 (TMD6) form close contact with phenylalanine and tyrosine residues 
at position 11 and 22 of ICP47 (Oldham et al., 2016b), substitution of this T425 residue by 
alanine was shown to reduce the inhibitory function of ICP47 (Galocha et al., 1997). In 
mouse TAP2, the polar residue asparagine (N) replaces threonine at position 425. Based on 
the finding by Galocha et al. (1997), this T425N substitution is believed to disrupt the 
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interaction between mouse TAP and ICP47 (Galocha et al., 1997; Oldham et al., 2016a). 
The mechanistic changes associated with this substitution on peptide translocation upon 
ICP47 binding are not known. However, our peptide quantification data suggests that it 
does not entirely eliminate the interaction between ICP47 and mouse TAP but may explain 
the degree to which ICP47 can diminish peptide translocation by TAP. 
An unexpected finding from our data is that not every peptide was inhibited to the same 
extent. All quantified peptides were inhibited to less than 10 copies per 293KbC2 cell, 
however, some peptides were inhibited up to four-fold while others were inhibited over 
100-fold. The differential inhibition across peptides did not appear to significantly correlate 
with the hydrophobicity of peptides, TAP binding affinity, peptide abundance, MHC I 
binding affinity or immunogenicity. There is evidence to suggest that peptides can use 
TAP-independent mechanisms for presentation on MHC I (Lautscham et al., 2003; 
Weinzierl et al., 2007; Tey and Khanna, 2012a; Vigneron et al., 2018). Our analysis showed 
that the less inhibited peptides were not derived from signal sequences for direct entry into 
the ER. In line with this, Weinzierl and colleagues (2008) showed that not all peptides 
presented independently of TAP are associated with a signal sequence. Additionally, some 
of these TAP-independent peptides have low predicted MHC I binding affinity. They 
reasoned that in case of low supply of peptides to ER due to TAP deficiency, MHC I 
molecules are less stringent in their peptide selection and presentation (Weinzierl et al., 
2008). This might explain the lack of correlation between MHC I binding affinity and the 
level of inhibition observed in our study. Currently, the pathway by which the less inhibited 
peptides are transported to the ER for presentation is not known. It is also a possibility 
that these peptides are generated and loaded on MHC I in a vesicular compartment 
(Gromme et al., 1999; Tey and Khanna, 2012b; Vigneron et al., 2018). While cytotoxicity 
assays had suggested a complete shutdown of presentation by ICP47, our data demonstrate 
that when close to the limit of detection most peptides were still presented, albeit at 
extremely low levels.  
In summary, using cutting-edge mass spectrometry techniques, we quantified the effect of 
ICP47 on antigen presentation in human and mouse cell lines. An initial peptide 
identification MS method allowed us to discover 75 HSV-1 peptides naturally presented on 
infected mouse fibroblast cells. A subset of the HSV-1 immunopeptidome derived from 
the newly discovered set in this study and those previously found by others was then 
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chosen for absolute quantification using MRM MS. Using MRM multiplexing analysis, we 
successfully quantified 15 and 14 peptides in HSV-1 infected MC57G and 293KbC2 cells, 
respectively. The peptide quantification study allowed us to make two major observations. 
First, ICP47 inhibits mouse TAP mediated antigen presentation by up to five-fold, 
supporting our previous data. Second, human TAP is severely impaired in transporting 
peptides for MHC I mediated presentation in the presence of ICP47. This study is the first 
to directly quantify the unprecedented blockade on antigen presentation caused by ICP47 
during HSV-1 infection in human cells.  
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6 Discussion 
HSV-1, like other herpes viruses, has evolved extensive mechanisms to subvert host 
defence mechanisms, including, but not limited to, the generation of numerous immune 
evasion proteins. The work outlined in this thesis focuses on one such protein, ICP47, the 
prototypic TAP inhibitor that blocks peptide transport into ER lumen and subsequent 
loading onto MHC I molecules in humans. However, outside the context of human cells, 
ICP47 has been shown to a) elicit no detectable inhibition of MHC I in mouse cell lines, b) 
no or low binding to mouse TAP and c) poor inhibition of peptides transport via mouse 
TAP in biochemical assays (Ahn et al., 1996; Tomazin et al., 1996; Jugovic et al., 1998; 
Tomazin et al., 1998). In stark contrast to these in vitro findings, in vivo studies using mouse 
models demonstrated a significant role for ICP47 in CNS infection (Goldsmith et al., 1998; 
Burgos et al., 2006). The authors suggested that ICP47 has the capacity to prevent the 
recognition of infected neurons by CD8+ T cells; supported by the observation that 
infected mice develop lethal encephalitis as virus spreads to the CNS. These results raise 
concerns about the extrapolation of in vitro findings to in vivo situations. Furthermore, the 
discordance between these settings has remained unresolved for almost two decades, 
serving as a roadblock in understanding the importance of ICP47 during natural HSV 
infection. 
Recent studies have indicated that ICP47 is expressed from as early as 1 to 8 hours post-
infection both in a human embryonic lung fibroblast cell line and in primary mouse 
trigeminal neurons (Harkness et al., 2014). In another study, the ICP47 protein was found 
in abundance for as long as 15 hours after infection of human foreskin fibroblast cells 
(Kulej et al., 2017b). Besides its clear presence during acute infection, ICP47 transcripts 
were also found in a fraction of latently infected neurons (Ma et al., 2014), and a reporter 
gene driven by the ICP47 promoter expressed in a subset of latently infected neurons 
(Russell and Tscharke, 2016). These studies suggest that ICP47 might be relevant to other 
aspects of HSV-1 infection, for instance, latency and reactivation, in addition to its 
suspected role in infection of the CNS in mice. This prompted us to re-examine the 
functional significance of ICP47 with the overall aim of bridging the knowledge gap 
between the previous in vitro and in vivo studies.  
Chapter 3 focused on this broad aim. A set of ICP47 null mutants and appropriate control 
viruses were constructed on the genetic background of HSV-1 strain KOS. Using these 
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new sets of viruses, we investigated the function of ICP47 in different stages of the HSV 
life cycle in mice. First, using a flow cytometry-based antigen presentation assay, we 
determined that ICP47 is functional in mouse cells, but inhibits peptide presentation 
significantly more efficiently in human cells. Despite this, ICP47 was shown not to affect a) 
viral replication in the skin and DRG during acute infection, b) the HSV-1-specific CD8+ T 
cell response, c) the establishment of latency and maintenance of latency, d) the spread of 
the virus to distal DRG not directly innervating the infection site and e) the reactivation 
efficiency of the virus in mice. To further address the contradictory in vitro and in vivo data, 
the experiments discussed in Chapter 5 were performed. Here, we took a mass 
spectrometry approach to quantify HSV-1-derived peptides presented on infected human 
(293KbC2) and mouse (MC57G) cells. Using this approach, we found that ICP47 severely 
impairs antigen presentation in humans with detection of fewer than 10 molecules of most 
peptides. By contrast, on mouse cells, although significantly reduced, a considerable 
number of peptides were still presented in cells infected with ICP47 expressing virus. 
Immunological studies have previously suggested that CD8+ T cells are highly sensitive, 
and, that at least under specific in vitro conditions, recognition of a few pMHC-I complexes 
is sufficient to trigger a response (Sykulev et al., 1996). Therefore, the modest effect of 
ICP47 on antigen presentation in mice may mean that the virus-specific CD8+ T cells 
function effectively against infected cells similar to the condition in which there is no 
inhibitor present. This could explain the data from earlier in vitro studies as to why the 
HSV-1 infected mouse fibroblast cells were prone to specific lysis by CD8+ T cells, while 
the human fibroblast cells were not killed (Jugovic et al., 1998). In accordance with these 
data, in our in vivo model, removal of ICP47 affected neither acute HSV-1 infection nor its 
latency. Thus, the data from this study clarifies the difference between the human and 
mouse cells with respect to CD8+ T cell evasion at the molecular level. This study 
highlights need for a better model for understanding the consequence of immune evasion 
and antigen presentation during HSV-1 infection in humans.  
Mouse models of HSV infection have provided important insight into the immunobiology 
of HSV diseases. Many of the phenomenon involving CD8+ T cells observed in mouse 
models also occur in humans. For example, cross-presentation is established as the major 
pathway involved in the priming of CD8+ T cells during HSV-1 infection of mice (Allan et 
al., 2003, 2006; Bedoui et al., 2009; Whitney et al., 2017). In accordance with this, emerging 
evidence suggests that similar phenomena may occur in humans whereby dermal DCs 
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uptake antigens from epidermal LCs, which serve as the source of epitopes for priming 
CD8+ T cells (Bosnjak et al., 2005b; Kim et al., 2015). Both in the human cadaveric 
specimens and the mouse models, it was similarly found that HSV-specific CD8+ T cells a) 
infiltrate the infected mucocutaneous site and ganglia (Koelle et al., 1994b; Liu et al., 1996; 
Koelle et al., 1998; Araki-Sasaki et al., 2006; Verjans et al., 2007; Zhu et al., 2007, 2013b; 
van Velzen et al., 2013a), b) establish a local effector memory population at the initial 
infection site (Zhu et al., 2013b; Zaid et al., 2014), c) reside in ganglia next to the neurons 
harbouring HSV-1 genome and d) have the capacity to suppress reactivation through the 
secretion of IFN and other non-cytolytic factors (Khanna et al., 2003a; Verjans et al., 
2007). Thus, there is no doubt that mouse models are indispensable to HSV research and 
useful in untangling the intricacies of the immunological response to infection. However, 
our current study suggests that the evolutionary reason for the emergence of the CD8+ T 
cell evasion molecule ICP47 cannot be possibly explored using the existing mouse models. 
6.1 When does ICP47 function during HSV-1 infection in humans? 
The co-evolution of HSV and humans for thousands of years has caused viral existence to 
depend on two main processes; firstly, infecting the host and establishing latency, and, 
subsequently, spreading to a new host. Immune evasion genes, such as ICP47, may help in 
both of these processes.  
Based on animal model studies, it is well recognised that latency establishment occurs prior 
to mounting an adaptive immune response (Simmons and Nash, 1984; van Lint et al., 
2004b; Wakim et al., 2008). However, clearance of infectious virus is correlated with the 
appearance of CD8+ T cells at infection sites (Simmons and Tscharke, 1992; Koelle et al., 
1998; Speck and Simmons, 1998; Coles et al., 2002; van Lint et al., 2004b; Dobbs et al., 
2005). Perhaps, in humans, during acute HSV infection, ICP47 mediated CD8+ T cell 
evasion may allow the virus to disseminate in the infected epithelial tissue and assist in the 
establishment of a larger latent pool of virus. Data from this thesis and previous in vitro 
studies suggests that it is not possible to test the above hypothesis using the current murine 
models due to the inefficient functioning of ICP47 (Ahn et al., 1996; Jugovic et al., 1998; 
Tomazin et al., 1996, 1998).  
ICP47 may also drive transmission of HSV-1 through the human population by facilitating 
viral reactivation in latently infected ganglia. In humans that are seropositive for HSV-1 or 
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HSV-2 and in possession of an intact immune system, the virus spontaneously reactivates 
with frequent shedding episodes (Wald et al., 1997; Phipps et al., 2011; Tronstein et al., 
2011; Ramchandani et al., 2016). The duration of the episode varies from a few hours to 
several days (Johnston and Corey, 2016). Likewise, there is a profound heterogeneity in the 
amount of virus found in epithelia between successive episodes (Wald et al., 1997, 2000). 
For instance, during HSV-2 reactivation episodes, infiltrates of CD8+ T cells were found 
not only at sites of genital ulceration during recurrent genital herpes but also in intact 
epithelium during asymptomatic shedding (Zhu et al., 2007, 2013b). Schiffer and colleagues 
(2013) used mathematical modelling to analyse the influence of CD8+ T cells in the 
complex episodic nature of HSV-2 reactivation. These models show that density and 
spatial distribution of CD8+ T cells are factors which contribute to the differential 
containment of the reactivating virus, demonstrating that with high CD8+ T cell density the 
incidence of genital ulceration is low (Schiffer and Corey, 2013; Schiffer et al., 2009, 2018). 
Such detailed studies have yet to be conducted for HSV-1, however, frequent oral shedding 
observed in seropositive individuals suggests that a similar immune landscape may exist 
during recurrent HSV-1 infections. These studies point to the functional significance of 
CD8+ T cells in protection against recurrent disease. Furthermore, they imply that MHC I-
mediated antigen presentation and recognition of infected cells occur at the level of 
mucosal epithelium. We speculate that ICP47 does not completely protect the infectious 
virus from elimination by CD8+ T cells, it may increase the duration of shedding episodes, 
consequently increasing the chance of viral dissemination.  
At the neuronal level, direct observations of reactivation in human ganglia are not possible 
due to lack of access to such tissues. However, frequent viral shedding in the genital tract 
or oral mucosa suggests that complete sets of viral proteins are synthesised in at least some 
neurons during latency, which subsequently lead to viral DNA replication, transport of 
virion components via axons and release of assembled virions at the peripheral site (Wald 
et al., 1997; Phipps et al., 2011; Tronstein et al., 2011; Ramchandani et al., 2016). 
Furthermore, permanent retention of activated HSV-1-specific effector memory CD8+ T 
cells within the trigeminal ganglia reflected the frequent stimuli received from cognate 
pMHC-I complexes expressed on latently infected neurons (Verjans et al., 2007; van 
Velzen et al., 2013a). Despite substantial viral activity and presence of functional virus 
specific CD8+ T cells in ganglia, these CD8+ T cells appeared to be unable to entirely 
contain recurrent viral shedding. Results from chapter 5 provide a possible explanation for 
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this occurrence. Our results showed that ICP47 is able to block antigen presentation 
almost completely in human cells. Thus, if ICP47 is expressed even in a few neurons in 
which the virus attempts to reactivate, evasion of those neurons from CD8+ T cell 
recognition can lead to virion production and emergence at the mucosal epithelium. 
However, there appears to be a fine balance between reactivation and long-term 
persistence of the virus. A reactivation episode only lasts for a short time, from 2 to 12 
hours in case of asymptomatic shedding and a few days for symptomatic shedding (Mark et 
al., 2008). One possible explanation for virus clearance during recurrent infection is that 
CD8+ T cells recognise HSV-1 peptides presented via TAP-independent pathways. In 
Chapter 5, we found that although ICP47 blocks peptide presentation almost entirely in 
human cells, the level of inhibition was variable across peptides. This suggests that the 
peptides that are relatively less inhibited by ICP47 might use alternate peptide presentation 
pathways in addition to the TAP-mediated presentation pathway. 
Two non-classical antigen presentation pathways have been described so far, both of which 
include transport via the trans-Golgi network and endosomal pathways. An endopeptidase 
furin, that is normally involved in the maturation of secreted proteins in trans-Golgi 
network (Thomas, 2002), is capable of generating peptides that can bind to MHC I (Gil-
Torregrosa et al., 1998; Lu et al., 2004; Medina et al., 2009). Furin cleaves a protein or a 
polypeptide C-terminally to substrate recognition motifs Arg-X-X-Lys and Arg-X-Lys or 
Arg-Arg (Hosaka et al., 1991). While further trimming of the cleavage product by 
exopeptidases is necessary for loading on to MHC I (Gil-Torregrosa et al., 1998), currently 
little information is available on this process. Furthermore, TAP is essential for a functional 
conventional peptide-loading complex (Owen and Pease, 1999; Momburg and Tan, 2002), 
in which case how these peptides are loaded onto MHC I in this secretory-route is still 
unclear. Nevertheless, furin-mediated secretory antigen-processing pathways have been 
shown to co-exist with the conventional TAP-mediated pathway (Medina et al., 2009). The 
peptides can also be generated by the lytic proteases in vacuolar compartments, such as 
endosomes (Gromme et al., 1999). These peptides may encounter endosomally-located 
MHC I molecules recycled from the cell surface, which are subsequently assembled and 
transported to the cell surface for presentation to CD8+ T cells. A melanoma vaccine 
epitope pMEL209-217 was recently shown to be potentially presented via the endosomal 
pathway on TAP-deficient cells at levels recognised by CD8+ T cells (Vigneron et al., 2018). 
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Similarly, the vacuolar pathway has been shown to mediate presentation of an 
endogenously derived epitope from HCMV protein UL138 (Tey and Khanna, 2012b). In 
addition to these pathways, peptides that associate with ER-targeting signal sequences 
(Anderson et al., 1991; Bacik et al., 1994) or that are highly hydrophobic in nature 
(Lautscham et al., 2003) can enter the ER without the assistance of TAP. These are loaded 
on to MHC I molecules by the conventional PLC.  
Although alternate antigen presentation pathways exist, the lack of components dedicated 
to antigen processing and presentation in the vacuolar and secretory routes explain the 
rarity of these peptides. In concordance with this, peptides not affected by ICP47 have 
been shown to be presented at low abundances, irrespective of the presence of ICP47. 
Based on our data in Chapter 5, it is possible that TAP-independent HSV-1 peptides are 
generated in the human population. Particularly, several variants of human MHC I (HLA) 
show different levels of TAP dependency in humans. For example, peptide presentation by 
HLA-1 A2, -A23, -B7, -B8, -B35, -B57 and -B4405 molecules can load peptides 
independent of TAP (Henderson et al., 1992; Wei and Cresswell, 1992; Neisig et al., 1996; 
de la Salle et al., 1997; Geng et al., 2018). Whereas TAP is essential for loading of HLA-A1, 
-A3, -A11, -A24, -B15, -B27, and -B4402 (Grandea et al., 1995; de la Salle et al., 1997; 
Zernich, 2004; Thammavongsa et al., 2006; Hillen et al., 2008). Moreover, several TAP-
independent self-peptides were identified in TAP-deficient cell lines using mass-
spectrometric approaches (Weinzierl et al., 2008; Lorente et al., 2013). CD8+ T cells may 
effectively control infection when there are a sufficient number of TAP-independent 
immunogenic peptides displayed on the infected cells. Therefore, identification of TAP-
independent HSV-1 peptides in the human population that can elicit an immune response 
would help to understand if the host immune system has alternate ways to strike back and 
clear HSV-1 infection. 
6.2 Does ICP47 block reactivation in mice? 
For HSV to reactivate and emerge in peripheral tissues, there are several potential hurdles 
to overcome, including chromatin re-organisation of the latent episome, sufficient levels of 
gene expression, synthesis of viral proteins, DNA replication, transport of virion 
components via axons to nerve endings, assembly and release of virus particles to the 
periphery, and infection of epithelial cells. However, in mice, low levels of lytic mRNA can 
be detected in neurons harbouring the latent HSV-1 genome (Deatly et al., 1987; Gordon 
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et al., 1988; Kramer and Coen, 1995; Maillet et al., 2006; Ma et al., 2014). Curiously, this is 
accompanied by the detection of viral proteins in neurons during latency (Feldman et al., 
2002b). Collectively, these studies suggest that in mice, the virus is capable of overcoming 
some of the early hurdles of reactivation, yet unable to generate infectious virion particles. 
It could potentially be due to the biphasic nature of HSV-1 reactivation (Kim et al., 2012a). 
Reactivation begins with the transient reversal of gene silencing and simultaneous 
transcription of genes from all three kinetic classes. VP16, synthesised during phase I, is 
believed to elevate the lytic transcript levels in phase II, leading to reactivation of the virus 
(Kim et al., 2012a). It is possible that the presentation of viral antigens, via MHC I 
molecules, occurs at phase I, and leaves cells exposed to CD8+ T cell detection. At least 
two potential mechanisms have been described that are employed by CD8+ T cells to 
curtail reactivation in the early phase. Firstly, IFN was shown to dampen the transcription 
of lytic genes and reduce early viral replication (Liu et al., 1996, 2001; Decman et al., 2005). 
Secondly, granzyme B, released by CD8+ T cells, promotes degradation of ICP4, which is a 
transcriptional trans-activator of early and late genes (Knickelbein et al., 2008). This may 
explain, at least in part, why infectious virus is seldom observed in mice after the 
establishment of latency. 
In our mouse model, a similar efficiency of reactivation between wild-type HSV-1 and 
ICP47 null virus was observed. In contrast, upon incorporation of genes, MCMV m152 or 
HCMV US11, encoding potent inhibitors of antigen presentation into HSV-1, there was 
enhanced capacity for reactivation upon UV exposure of the latently-infected mice (Orr et 
al., 2007). Together these results support the idea that in mice, reactivation of the wild-type 
virus is impeded at an early stage, due to the incomplete functioning of ICP47. Conceivably, 
in humans ICP47-mediated blocking of antigen presentation allows the virus to evade 
detection, thus providing the opportunity for subsequent reactivation. Previous in vitro 
studies demonstrated that ICP47 is less effective in blocking rabbit TAP (Jugovic et al., 
1998). However, in experimentally infected rabbits spontaneous reactivation and peripheral 
shedding is frequent (Laibson and Kibrick, 1969; Berman and Hill, 1985; Hill et al., 1986, 
1987, 1997, 2012). This suggests that there are other factors, viral or host, which may also 
contribute to reactivation.  
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6.3 Alternate models for evaluating the function of ICP47 
Searching for an alternate in vivo model in which ICP47 is fully functional is necessary to 
better understand the host-viral interaction with respect to CD8+ T cell immunity. The 
study by Jugovic et al. (1998) showed that the fibroblast cells from pigs, dogs or non-
human primates, such as owl monkeys and chimpanzees, were resistant to lysis by virus-
specific CD8+ T cells after infection with HSV-1. While they may be suitable animal 
models for investigating how ICP47 influences HSV infection, they have not been explored 
extensively in HSV research and possess a number of ethical and practical pitfalls. Another 
potential candidate, Rhesus Macaques, could be useful in the HSV context, as they are 
already used for studying genital herpes and manifest clinical symptoms similar to humans 
(Crostarosa et al., 2009; Fan et al., 2017). However, the availability of such animal resources 
and the associated technical difficulties limit their use. An immortalised cell line HD10.6 
derived from human dorsal root ganglia was recently established as an in vitro model for 
HSV-1 latency and reactivation (Raymon et al., 1999; Thellman et al., 2017). Such in vitro 
models could potentially be useful to elucidate the function of ICP47 during latency and 
reactivation. However, as this simplified cell culture system lacks essential immunological 
components and the supporting environment of an intact ganglion, the physiological 
relevance of the results derived would still require in vivo validation. 
Mouse models can be enlightening due to extensive information provided on host-virus 
interactions and the current wealth of tools available for dissecting the mouse immune 
response. However, the effect of ICP47 on the function of human TAP is far more 
profound compared to mouse TAP. Previously, it has been shown that ICP47 interacts 
only with TAP (Hill et al., 1995). TAP1 and TAP2 can be substituted interchangeably 
between mice and humans without the loss of function of these proteins (Yewdell et al., 
1993; Seliger et al., 1998; Ritz et al., 2001). Thus, differences observed in ICP47 functioning 
between mice and humans are likely due to sequence discrepancies in TAP1 and TAP2 
protein sequences, which share a homology of 74% and 84%, respectively, between the 
two species. Therefore, a genetically humanised mouse model, where the mouse TAP1/2 is 
functionally replaced by human TAP1/2 would be ideal to study the impact of ICP47 
during the acute infection, latency and reactivation. Such a model is currently being 
generated in our laboratory (Tscharke et al., Unpublished). Future experiments can focus 
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on defining the outcome of ICP47 and human TAP interaction using the recombinant 
viruses generated in the current study and the humanised TAP mice.  
The efficiency of inhibition of antigen presentation by ICP47 could be determined by 
infection of primary fibroblasts derived from the humanised TAP mice and quantifying 
HSV-1 derived peptides using mass spectrometry. If the human TAP in these transgenic 
mice functions as expected, the efficiency of TAP inhibition by ICP47 should be similar to 
that seen in the results observed in chapter 5 for 293KbC2 cells. Humanised TAP mice 
could also be used as a robust model to determine the effect of ICP47 on HSV-1 
pathogenesis. If ICP47 blocks the visibility of infected cells from CD8+ T cells during acute 
infection, it might be reflected as a delay in resolution of lesion induced by flank infection 
or perhaps, as a delay in clearance of infectious virus in appropriate tissues or both. Further, 
in this model the contribution of ICP47 in the establishment of latency can be determined 
by quantifying the latent genome load. Humanised TAP mice could potentially be used to 
determine the role of CD8+ T cells in blocking HSV-1 reactivation. This could be 
accomplished by measuring infectious virus in ex vivo cultured DRG isolated from latently 
infected mice or by using in vivo reactivation methods described by others. Humanised TAP 
mice crossed on to the ROSA26R mice would allow detection of even subtle differences in 
the ability of HSV-1 (expressing Cre recombinase) to spread and express genes when it is 
able to block TAP expression with the same efficiency as in human cells. Furthermore, 
transgenic humanised mice in possession of human HLA molecules have already been 
generated by others (Kievits et al., 1987; Ureta-Vidal et al., 1999; Cheuk et al., 2002) and are 
beginning to contribute to HSV research (Dervillez et al., 2013; Srivastava et al., 2015). 
Therefore, a mouse model that expresses human TAP in addition to various HLA I alleles 
could enable the discovery of novel TAP-independent epitopes, and providing a more 
faithful preclinical environment to investigate new therapeutics. 
6.4 Redundancy in immune system 
The evolutionary significance of various herpesvirus immunomodulatory proteins has been 
extensively explored, however, no definitive in vivo function has been assigned to many of 
those that interfere with antigen presentation (Yewdell et al., 1993; Verweij et al., 2015). 
Lack of suitable in vivo models is often responsible for this impediment. One exception to 
this is MCMV, which has the advantage of being studied in its natural host. MCMV 
encodes three proteins that interfere with different stages of antigen processing and 
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presentation, causing a significant down-modulation of surface MHC I in vitro (Pinto and 
Hill, 2005). However, in mouse models, deletion of all three immune evasion genes from 
MCMV did not have a biologically significant impact on viral fitness (Gold et al., 2004). 
This observation supplements data from patients who have defective antigen presentation 
pathways. For instance, humans with defects in TAP1, TAP2 or both, develop normal 
levels of functional CD4+ T cells, but have significantly less surface MHC I and reduced 
numbers of CD8+ T cells (Donato et al., 1995; de la Salle et al., 1994, 1999, 2002; Johnston 
and Corey, 2016; Law-Ping-Man et al., 2018). Furthermore, in TAP-deficient individuals 
the number of  T cells was enhanced, whilst levels of B cells, NK cells and NKT cells 
were comparable to individuals with functional TAP (Moins-Teisserenc et al., 1999; Gadola 
et al., 2000). TAP-deficient patients often develop recurrent bacterial lung infections 
leading to a condition known as bronchiectasis. Another manifestation of TAP deficiency 
is the development of skin ulcers on the face, arms and legs. However, TAP-deficient 
patients can fight viral infections as efficiently as healthy individuals (de la Salle et al., 1994; 
Donato et al., 1995; Moins-Teisserenc et al., 1999; Law-Ping-Man et al., 2018). The data 
suggest it is possible that other immune cells contribute to protection against viral 
infections. A previous report by de la Salle and colleagues (1997) showed that in TAP-
deficient patients, CD8+ T cells, although present in low numbers, retain a broad repertoire 
of TCRs. This observation was further supported by the discovery of EBV-specific CD8+ 
T cells in TAP-deficient patients and EBV-specific TAP-independent epitopes throughout 
the human population (de la Salle et al., 1997; Lautscham et al., 2001, 2003). Collectively, 
these observations suggest that the redundant function of other immune cells, TAP-
independent antigen presentation and the function of residual CD8+ T cells may provide 
effective anti-viral immunity in humans with defective TAP. Thus, in other populations, 
where the immune system is intact, ICP47 may not have a significant biological impact due 
to the redundant immune cell function. However, ICP47 might significantly enhance the 
virulence in immunocompromised individuals. It might also increase shedding and 
therefore transmission in a manner that is subclinical, as noted above, providing selective 
pressure to keep this gene in the HSV genome. 
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6.5 Location in HSV-1 genome plays a major role in gene 
expression  
In Chapter 3, by focussing on the impact of ICP47 expression during latency using the 
ROSA26R/Cre reporter mouse system, we uncovered that the activity of the ICP47 
promoter in vivo was strikingly different in its native location compared to an ectopic 
location. We probed this further in Chapter 4 by generating new recombinant viruses. The 
results from these chapters collectively showed that the activity of an HSV-1 lytic promoter 
is different at different locations and gene expression depends on the type of promoter and 
the genomic position.  
The phenomenon by which the local genomic region influences the expression of the 
inserted gene is called “position effect”. It has been described in various organisms from 
yeast to humans, and diverse mechanisms have been demonstrated to cause this effect 
(Baker, 1968; Kleinjan and van Heyningen, 1998, 2005; De and Babu, 2010). This includes, 
but is not limited to, the loss or gain of essential cis-regulatory elements, juxtaposition of 
the gene with an enhancer element of another gene, chromatin architecture, epigenetic 
regulation, post-translational modification of histones or association of non-histone 
proteins, such as polycomb group proteins (Kleinjan and van Heyningen, 2005; De and 
Babu, 2010; Tchasovnikarova et al., 2015; Kellum and Schedl, 1991). Akhtar and colleagues 
developed a high throughput method for parallel monitoring of reporters inserted at 
different locations of the mouse genome. The study demonstrated that an enhancer has the 
potential to influence gene expression with an average distance of 20 Kbp. In addition, at 
distinct genomic locations, gene expression can differ by 1000 fold (Akhtar et al., 2013). In 
a similar high throughput study, latent HIV genomes were found to integrate further away 
from enhancers in host genome compared to the non-latent HIV genomes, which 
highlights the chromosomal context for the regulation of HIV latency (Chen et al., 2017). 
Position dependent gene expression has been found even in simple prokaryotic genomes, 
such as bacteria and fungi (Zhao and Peeters, 2003; Bryant et al., 2014; Sauer et al., 2016; 
Bilyk et al., 2017). Although this phenomenon has not yet been explicitly investigated in 
HSV-1, it has been described in other viruses such as coronavirus, hepatitis C virus and 
vaccinia virus (Coupar et al., 2000; Haan et al., 2003; Jopling et al., 2008). Typically, the 
HSV genome exists in the host nucleus as an autonomous circular episome (Strang and 
Stow, 2005). Previous studies have found that during the active lytic state, nucleosome 
deposition preferentially occurred at specific sites in the HSV-1 genome (Kent et al., 2004; 
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Lacasse and Schang, 2010; Oh et al., 2015). However, in neurons, the latent HSV-1 genome 
is associated with regularly spaced nucleosomes and utilises host epigenetic repression to 
restrict viral gene expression (Efstathiou et al., 1986b; Mellerick and Fraser’, 1987; 
Deshmane and Fraser, 1989). Other than viral factors, the regulatory mechanisms that 
influence the expression of host genes are also applicable to HSV-1. Hence, it is plausible 
that the location dependent gene expression that we observed in our study is due to the 
position effect. A thorough genome-wide analysis of gene expression at various loci during 
lytic and latent infection is necessary to draw a definitive conclusion.  
6.6 Conclusion 
Most experimental models are not without inadequacies or unexpected features. ICP47 in 
this thesis highlights two specific shortcomings: a) species-specific effects on viral genes 
and b) position-specific effects on viral gene expression. The work presented in this thesis 
showed that ICP47 is not an effective immunomodulator in a mouse model where HSV is 
confined to the peripheral nervous system. This may be attributed to an insufficient 
blockade of mouse TAP as compared to the human equivalent. Further, the data presented 
here demonstrated that the same gene expressed from different loci within the HSV-1 
genome had signiﬁcant effect of insertion site and suggest that the local genomic context is 
critical for HSV-1 gene expression. Due to these features, we suggest future models 
attempt to more faithfully recapitulate ICP47-mediated HSV-1 pathogenesis in humans. 
Overall, these limitations can be considered hurdles to research, but alternatively as 
opportunity for deeper understanding of virus biology. 
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Appendix 
Table A - 1 MHC I bound HSV-1 derived peptides eluted from virus infected MC57G cells  
Gene symbol  
(peptide 
position) 
Peptide sequences 
MHC I 
allele 
(H-2) 
$MHC I 
binding 
affinity 
(IC50) 
Kinetic 
class 
Samples 
found in 
 #Immunogenicity 
Gene / 
Source protein 
 %IFNγ+  
(of CD8+) 
cells 
Number 
of mice 
positive 
RRI822-829 *QTFDFGRL K
b 7.99 E 
3 × KOS, 
3 × Ka47Δ 
 
0.41 8 
UL39 (RR1) 
Ribonucleoside-diphosphate 
reductase large subunit  
US1198-205 INQLFRVL K
b 25.5 IE 
3 × KOS, 
3 × Ka47Δ 
 
0 0 
US1 (ICP22) 
Transcriptional regulator  
gB498-505 *SSIEFARL K
b 2.29 L1 
3 × KOS, 
3 × Ka47Δ 
 
11.41 8 out of 8 
UL27 (gB) 
Envelope glycoprotein B 
UL40279-287 *AAIENYVRF K
b/Db 
102.2 (Db), 
175.28 (Kb) 
E 
3 × KOS, 
3 × Ka47Δ 
 
0.05 6 out of 8 
UL40 
Ribonucleoside-diphosphate 
reductase small subunit  
UL26613-621 AAHVDVDTA K
b/Db 
848.39 (Db), 
31503 (Kb) 
L1 
3 × KOS, 
3 × Ka47Δ 
 
0 0 
UL26 
Capsid scaffolding protein  
US899-110 YAPPAPSATGGL D
b 27331 L1 
3 × KOS, 
2 × Ka47Δ 
 
0 0 
US8 
Envelope glycoprotein E 
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Gene symbol  
(peptide 
position) 
Peptide sequences 
MHC I 
allele 
(H-2) 
$MHC I 
binding 
affinity 
(IC50) 
Kinetic 
class 
Samples 
found in 
 #Immunogenicity 
Gene / 
Source protein 
 %IFNγ+  
(of CD8+) 
cells 
Number 
of mice 
positive 
UL26483-495 GAVTSLQQELAHM K
b/Db 
12483 (Db), 
12854 (Kb) 
L1 
2 × KOS, 
3 × Ka47Δ 
 
0 0 
UL26 
Capsid scaffolding protein 
UL29605-613 TIITNREAL D
b 183.45 E 
2 × KOS,   
2 × Ka47Δ 
 
0.07 2 out of 8 
UL29 
Major DNA-binding protein 
UL26331-339 ASHYNQLVA D
b 879.48 L1 
2 × KOS,   
2 × Ka47Δ 
 
0 0 
UL26 
Capsid scaffolding protein 
UL51155-163 AIAERALGL K
b 2036.19 L1 
2 × KOS,   
2 × Ka47Δ 
 
0 0 
UL51 
Tegument protein UL51 
RL1136-144 VTAEHLARL K
b 42.65 L1 
1 × KOS,   
3 × Ka47Δ 
 
NA NA 
RL1 (ICP34.5) 
Neurovirulence factor   
UL26361-370 VAYGPHGAGL K
b 87.33 L1 
2 × KOS,   
2 × Ka47Δ 
 
0 0 
UL26 
Capsid scaffolding protein 
US8349-358 ASPQHSGLYL K
b/Db 
5475 (Kb), 
1529 (Db) 
L1 
1 × KOS,   
2 × Ka47Δ 
 
0 0 
US8 
Envelope glycoprotein E 
UL3101-109 FMVSSIDEL D
b 68.64 L2 3 × Ka47Δ 
 
NA NA 
UL3 
Nuclear phosphoprotein  
UL5300-307 STFEHQKL K
b 40.75 E 
1 × KOS,   
2 × Ka47Δ 
 
0 0 
UL5 
DNA replication helicase  
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Gene symbol  
(peptide 
position) 
Peptide sequences 
MHC I 
allele 
(H-2) 
$MHC I 
binding 
affinity 
(IC50) 
Kinetic 
class 
Samples 
found in 
 #Immunogenicity 
Gene / 
Source protein 
 %IFNγ+  
(of CD8+) 
cells 
Number 
of mice 
positive 
UL5213-221 AALERTLGL K
b 524.28 E 
1 × KOS,   
2 × Ka47Δ 
 
NA NA 
UL5 
DNA replication helicase 
US7372-383 PTTSTPTPPLLV K
b 25189.24 L1 
1 × KOS,  
2 × Ka47Δ 
 
NA NA 
UL7 
Envelope glycoprotein I 
US249-56 VVVRPANL K
b 28.56 L2 
1 × KOS,   
2 × Ka47Δ 
 
0 0 US2 
UL29324-332 LALESIVSM D
b 1259.36 E 2 × Ka47Δ 
 
NA NA 
UL29 
Major DNA-binding protein 
US1241-51 RTAVHDPERPL D
b 16284.92 IE 2 × KOS 
 
0 0 
US12 (ICP47) 
TAP transporter inhibitor  
UL19947-955 HTIQNGDYF D
b 59.08 L1 2 × KOS 
 
NA NA 
UL19 
Major capsid protein 
MCP1251-1263 SYGDLLYNGAYHL D
b 12483.37 L1 
1 × KOS,   
1 × Ka47Δ 
 
0 0 
UL19 
Major capsid protein 
UL25255-263 RAPVTFGDL D
b 7839.28 L2 
1 × KOS,   
1 × Ka47Δ 
 
0 0 
UL25 
Capsid vertex component 2 
US23-11 VVVVNVMTL D
b 92.37 L2 2 × Ka47Δ  NA NA US2 
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Gene symbol  
(peptide 
position) 
Peptide sequences 
MHC I 
allele 
(H-2) 
$MHC I 
binding 
affinity 
(IC50) 
Kinetic 
class 
Samples 
found in 
 #Immunogenicity 
Gene / 
Source protein 
 %IFNγ+  
(of CD8+) 
cells 
Number 
of mice 
positive 
UL25338-346 STHVNPDGV D
b 1285.35 L2 
1 × KOS,   
1 × Ka47Δ 
 
NA NA 
UL25 
Capsid vertex component 2 
UL3899-109 AALIGSPRHHL D
b 13479.26 L2 
1 × KOS,   
1 × Ka47Δ 
 
0 0 
UL38 
Triplex capsid protein 1 
UL535-15 RSLQHLSTVVL D
b 5080.85 L2 
1 × KOS,   
1 × Ka47Δ 
 
NA NA 
UL53 
Envelope glycoprotein K 
UL5610-617 RAFDFKQL K
b 19.15 E 
1 × KOS,   
1 × Ka47Δ 
 
NA NA 
UL5 
DNA replication helicase 
ICP0748-755 GALDFRSL K
b 498.68 IE 
1 × KOS,   
1 × Ka47Δ 
 
0 0 
RL2 (ICP0) 
Ubiquitin E3 ligase  
UL25304-311 GRYEHGAL K
b 5291.01 L2 
1 × KOS,   
1 × Ka47Δ 
 
0 0 
UL25 
Capsid vertex component 2 
UL32384-391 VAPRFAQF K
b 13.02 L2 
1 × KOS,   
1 × Ka47Δ 
 
0 0 
UL32 
Packaging protein  
UL362139-2147 SSPEHIYTF K
b 1161.84 L2 
1 × KOS,   
1 × Ka47Δ 
 
0.03 1 out of 8 
UL36 
Large tegument protein 
deneddylase  
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Gene symbol  
(peptide 
position) 
Peptide sequences 
MHC I 
allele 
(H-2) 
$MHC I 
binding 
affinity 
(IC50) 
Kinetic 
class 
Samples 
found in 
 #Immunogenicity 
Gene / 
Source protein 
 %IFNγ+  
(of CD8+) 
cells 
Number 
of mice 
positive 
UL22562-570 TNADLRTAL K
b 2507 L2 
1 × KOS,   
1 × Ka47Δ 
 
0 0 
UL22 
Envelope glycoprotein H  
UL50353-371 
DAEAPPSERGTGG
FGSTGI 
Kb/Db NA E 
1 × KOS,   
1 × Ka47Δ 
 
NA NA 
UL50 
Deoxyuridine 5'-triphosphate 
nucleotidohydrolase 
UL39956-964 HGLRNSQFV D
b 56.9 E 1 × Ka47Δ 
 
0.05 3 out of 8 
UL39 
Ribonucleoside-diphosphate 
reductase large subunit 
UL52655-663 AAVQLLFPA D
b 641.65 E 1 × KOS 
 
NA NA 
UL52 
DNA primase  
UL13114-123 TAPPSSPSHI D
b 10876.3 E 1 × Ka47Δ 
 
0 0 
UL13 
Tegument serine/threonine 
protein kinase 
UL39805-815 SGVCNLGSVNL D
b 1866.7 E 1 × Ka47Δ 
 
0.05 3 out of 8 
UL39 
Ribonucleoside-diphosphate 
reductase large subunit 
UL29104-114 DPSTQAPNLTR D
b 48793.25 E 1 × Ka47Δ 
 
0 0 
UL29 
Major DNA-binding protein  
UL23115-128 EDAAVVMTSAQIT D
b 3072.46 E 1 × Ka47Δ  NA NA UL23 
 314 
Gene symbol  
(peptide 
position) 
Peptide sequences 
MHC I 
allele 
(H-2) 
$MHC I 
binding 
affinity 
(IC50) 
Kinetic 
class 
Samples 
found in 
 #Immunogenicity 
Gene / 
Source protein 
 %IFNγ+  
(of CD8+) 
cells 
Number 
of mice 
positive 
M Thymidine kinase 
UL26237-245 AGIAGHTYL D
b 314.78 L1 1 × KOS 
 
NA NA 
UL26 
Capsid scaffolding protein 
UL26611-621 SSAAHVDVDTA D
b 13285.1 L1 1 × Ka47Δ 
 
0 0 
UL26 
Capsid scaffolding protein 
UL2755-66 APPALGAAPTGD D
b 46885.06 L1 1 × KOS 
 
0.04 1 out of 8 
UL27 
Envelope glycoprotein B 
UL19482-495 
EAANPYGAYVAAP
A 
Db 38438.89 L1 1 × Ka47Δ 
 
NA NA 
UL19 
Major capsid protein 
UL25255-264 RAPVTFGDLL D
b 3276.16 L2 1 × Ka47Δ 
 
0.04 1 out of 8 
UL25 
Capsid vertex component 2 
UL344-54 GAALASPAQPL D
b 4493.89 L2 1 × Ka47Δ 
 
0 0 
UL3 
Nuclear phosphoprotein 
UL5729-736 MGYTYTRV K
b 4.47 E 1 × Ka47Δ 
 
0.04 1 out of 8 
UL5 
DNA replication helicase 
ICP8171-178 *INNTFLHL K
b 15.86 E 1 × Ka47Δ 
 
0.38 8 out of 8 
UL29 (ICP8) 
Major DNA-binding protein I 
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UL5126-133 AQNMYAKL K
b 147.11 E 1 × KOS 
 
0.042 4 out of 8 
UL5 
DNA replication helicase 
UL30816-823 SVYGFTGV K
b 6.11 E 1 × Ka47Δ 
 
NA NA 
UL30 
DNA polymerase catalytic 
subunit 
UL40198-206 IAYLRTNNL K
b 10.91 E 1 × Ka47Δ 
 
0.18 8 out of 8 
UL40 
Ribonucleoside-diphosphate 
reductase small subunit  
UL29639-647 RNFKFRDGL K
b 27.41 E 1 × Ka47Δ 
 
0 0 
UL29 
Major DNA-binding protein  
UL52292-300 TSFAAITRF K
b 403.45 E 1 × Ka47Δ 
 
0 0 
UL52 
DNA primase  
UL50277-285 PGHVCAFFV K
b 22627.87 E 1 × KOS 
 
0 0 
UL50 
Deoxyuridine 5'-triphosphate 
nucleotidohydrolase 
UL13118-126 SSPSHILTL K
b 136.13 L1 1 × Ka47Δ 
 
NA NA 
UL13 
Tegument serine/threonine 
protein kinase 
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UL42467-475 ASPGAFSAF K
b 711.63 E 1 × Ka47Δ 
 
NA NA 
UL42 
DNA polymerase processivity 
factor 
UL2993-103 SVYVFHGGRHL K
b 12.31 E 1 × Ka47Δ 
 
0 0 
UL29 
Major DNA-binding protein  
UL39451-461 VALDFGLTERL K
b 990.73 E 1 × Ka47Δ 
 
0.05 5 out of 8 
UL39 
Ribonucleoside-diphosphate 
reductase large subunit  
UL3027-39 AGPRGAGPGPPPC K
b 43341.72 E 1 × KOS 
 
0 0 
UL30 
DNA polymerase catalytic 
subunit 
UL2993-105 SVYVFHGGRHLDP K
b 27.62 E 1 × KOS 
 
NA NA 
UL29 
Major DNA-binding protein 
UL23 
CNLPPGWSRPTSPP
Q 
Kb NA E 1 × KOS 
 
NA NA 
UL23 
Thymidine kinase 
UL52835-850 
PACGRLLPVFVIPPA
C 
Kb NA E 1 × KOS 
 
NA NA 
UL52 
DNA primase  
US1244-52 VHDPERPLL K
b 11599.26 IE 1 × KOS 
 
0 0 
US12 (ICP47) 
TAP transporter inhibitor  
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US1273-85 RTGGTVTDSPRNP K
b 43598.04 IE 1 × KOS 
 
NA NA 
US12 (ICP47) 
TAP transporter inhibitor  
UL37600-607 TQIRFPAL K
b 17.03 L1 1 × Ka47Δ 
 
0.07 3 out of 8 
UL37 
Inner tegument protein  
UL37233-240 EGLRFLAL K
b 489.74 L1 1 × KOS 
 
0.041 1 out of 8 
UL37 
Inner tegument protein  
US8459-466 KGPTYIRV K
b 196.95 L1 1 × Ka47Δ 
 
NA NA 
US8 
Envelope glycoprotein E 
US1054-61 GNPEYREL K
b 1659.04 L1 1 × Ka47Δ 
 
NA NA 
US10 
Virion protein  
UL1966-73 SLVRFLEL K
b 198.85 L1 1 × Ka47Δ 
 
NA NA 
UL19 
Major capsid protein 
US812-22 GVCVVSCLAVT K
b 26655.16 L1 1 × Ka47Δ 
 
0 0 
US8 
Envelope glycoprotein E 
UL27867-877 GTSALLSAKVT K
b 21523.39 L1 1 × KOS 
 
0.037 1 out of 8 
UL27 
Envelope glycoprotein B 
UL4645-55 EGLLSAAVGAL K
b 29150.54 L1 1 × KOS 
 
NA NA 
UL46 
Tegument protein  
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UL53175-182 LQYPYTKI K
b 168.03 L1 1 × Ka47Δ 
 
0 0 
UL53 
Envelope glycoprotein K  
UL32171-178 AAFEFVYV K
b 14.46 L2 1 × Ka47Δ 
 
NA NA 
UL32 
Packaging protein 
UL5312-321 RQSENVLTYL Kb/Db 
963.74 (Db), 
23102 (Kb) 
E 1 × Ka47Δ 
 
NA NA 
UL5 
DNA replication helicase  
*Previously found by St Leger et al., 2011 
$MHC I binding affinity was predicted using ANN 4.0 algorithm from IEDB analysis resource. For peptides comprising more than 14 amino acids, it is not 
possible to obtain IC50 value, hence denoted NA. 
#Immunogenicity of 46 peptides were tested in eight C57BL/6 mice. The peptides for which the immunogenicity was not tested is denoted as NA.  
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Figure A-1 HSV-1 genome sequence showing the cis-acting regulatory elements in the ICP47 promoter region. The grey arrows show the location 
and orientation of region coding for ICP47, US11 and US10. The yellow arrow indicates the location and orientation of the minimal promoter required for 
ICP47 expression. The minimum oriS site of 62 bp is shown as a white box. The three red arrows in the oriS site indicate the box I, box II and box III to 
which the OBP bind. The green box shows the intron that is located 5 to the ICP47 coding region and 3 to the promoter. The blue box shows the TATA 
box and the blue arrow show the VP16 inducing complex binding motif (TAATGARAT). The pink arrows represent the sp1 binding motifs, which span the 
ICP47 promoter. Located within intron, indicated as blue arrows, are the reiterated Egr1 binding motifs. NFIII-binding site is indicated as dark red line 
situated 5 to the ICP47 promoter. 
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